Title 2 U.S. Code of Federal Regulations Part 200 (Uniform Guidance) Reports for the Year Ended June 30, 2021

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

TABLE OF CONTENTS

| | Page |
|--|-------|
| INDEPENDENT AUDITORS' REPORT | 1–2 |
| CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2021 AND 2020: | |
| Consolidated Balance Sheets | 3 |
| Consolidated Statements of Operations and Changes in Net Assets | 4–5 |
| Consolidated Statements of Cash Flows | 6 |
| Notes to Consolidated Financial Statements | 7–34 |
| SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2021 | 35–45 |
| NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2021 | 46 |
| REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS | 47–48 |
| REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON THE SCHEDULE OF EXPENDITURES OF FEDERAL REQUIRED BY THE UNIFORM GUIDANCE | 49–50 |
| SCHEDULE OF FINDINGS AND QUESTIONED COSTS | 51-52 |



Deloitte & Touche LLP

50 W 5th Street Suite 200 Cincinnati, OH 45202-3789 USA

Tel: +513 784 7100 Fax: +513 784 7204 www.deloitte.com

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees Children's Hospital Medical Center and Affiliates: Cincinnati, Ohio

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Children's Hospital Medical Center and Affiliates ("Cincinnati Children's and Affiliates"), which comprise the consolidated balance sheets as of June 30, 2021 and 2020, and the related consolidated statements of operations and changes in net assets and of cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cincinnati Children's as of June 30, 2021 and 2020, and the consolidated results of their operations and their consolidated cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated September 30, 2021 on our consideration of Cincinnati Children's internal control over financial reporting and our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on Cincinnati Children's internal control over financial control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Cincinnati Children's internal control over financial reporting and compliance.

Deloitte ? Touche LLP

September 30, 2021

Consolidated Balance Sheets June 30, 2021 and 2020 (dollars in thousands)

| | 2021 | 2020 |
|--|--|--|
| CURRENT ASSETS: | | |
| Cash and cash equivalents | \$ 274,863 | \$ 274,854 |
| Marketable securities | 1,352,918 | 1,028,382 |
| Cash, cash equivalents and marketable securities | 1,627,781 | 1,303,236 |
| Patient receivables, net | 506,944 | 417,654 |
| Other receivables | 140,916 | 134,337 |
| Inventories and prepaid expenses | 74,042 | 47,202 |
| Total current assets | 2,349,683 | 1,902,429 |
| ASSETS LIMITED AS TO USE - Funds in trust | 31,250 | 100,469 |
| PROPERTY AND EQUIPMENT, | 1,403,713 | 1,310,805 |
| net of accumulated depreciation | 1,403,713 | 1,510,805 |
| GOODWILL | 8,154 | - |
| OPERATING LEASE RIGHT-OF-USE ASSETS | 16,485 | 14,802 |
| PENSION BENEFIT ASSET | 171,709 | - |
| OTHER LONG-TERM ASSETS | 48,651 | 52,330 |
| INTEREST IN NET ASSETS OF SUPPORTING ORGANIZATIONS | 4,545,670 | 3,425,051 |
| Total assets | \$8,575,315 | \$6,805,886 |
| CURRENT LIABILITIES: Accounts payable and accrued expenses Current portion of long-term debt and lease obligations Commercial paper Bonds payable subject to remarketing, net Total current liabilities | \$ 410,481 28,815 100,000 91,640 630,936 | \$ 332,100 26,509 100,000 96,774 555,383 |
| ACCRUED PENSION BENEFIT LIABILITY | _ | 78,931 |
| | 22,184 | 20,666 |
| SELF-INSURANCE RESERVES | 22,104 | 20,000 |
| LONG-TERM DEBT: | | |
| Tax-exempt bonds payable | 340,776 | 358,965 |
| Taxable bonds payable | 595,946 | 397,180 |
| Notes payable | - | 6,000 |
| Finance lease obligations | 51,647 | 52,250 |
| Operating lease obligations | 14,242 | 12,978 |
| OTHER LONG-TERM LIABILITIES | 54,976 | 51,117 |
| Total liabilities | 1,710,707 | 1,533,470 |
| COMMITMENTS AND CONTINGENCIES (Note 11) | - | - |
| NET ASSETS: | | |
| Without donor restrictions | 2,100,516 | 1,655,768 |
| With donor restrictions | 4,764,092 | 3,616,648 |
| Total net assets | 6,864,608 | 5,272,416 |
| Total liabilities and net assets | \$8,575,315 | \$6,805,886 |
| | | |

See accompanying notes to consolidated financial statements.

Consolidated Statements of Operations and Changes in Net Assets For the Years Ended June 30, 2021 and 2020 (dollars in thousands)

| | 2021 | 2020 |
|---|-------------|-------------|
| OPERATING REVENUES, GAINS AND OTHER SUPPORT: | | |
| Net patient service revenue | \$2,226,690 | \$2,060,167 |
| Net assets released from restriction used for operations- | | |
| Grant revenue | 202,492 | 186,594 |
| Other restricted net assets used to support operations | 109,627 | 104,907 |
| Other revenue | 207,082 | 220,386 |
| Total operating revenues, gains and other support | 2,745,891 | 2,572,054 |
| OPERATING EXPENSES: | | |
| Salaries | 1,258,656 | 1,205,925 |
| Employee benefits | 347,711 | 324,118 |
| Supplies, drugs and other | 469,344 | 430,167 |
| Purchased services | 252,208 | 249,333 |
| Depreciation | 138,638 | 130,347 |
| Utilities | 18,401 | 19,177 |
| Interest | 23,249 | 24,627 |
| Total operating expenses | 2,508,207 | 2,383,694 |
| Operating income | 237,684 | 188,360 |
| NONOPERATING GAINS: | | |
| Net investment return | 85,743 | 47,673 |
| Net benefit gain other than service cost | 1,682 | 4,594 |
| Net nonoperating gains | 87,425 | 52,267 |
| Revenue and gains in excess of expenses and losses | 325,109 | 240,627 |
| OTHER CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS: | | |
| Receipts from supporting organizations | 3,757 | 3,475 |
| Net assets released from restrictions used for purchase of property | , | , |
| and equipment | 4,031 | 968 |
| Transfers to supporting organizations | (37,181) | (108,625) |
| Pension and post-retirement health liability adjustment | 149,032 | (80,752) |
| Increase in net assets without donor restrictions | \$ 444,748 | \$ 55,693 |

Consolidated Statements of Operations and Changes in Net Assets For the Years Ended June 30, 2021 and 2020 (dollars in thousands)

| | 2021 | 2020 |
|---|-------------|-------------|
| NET ASSETS WITH DONOR RESTRICTIONS: Contributions and investment income- | | |
| Grant receipts | \$ 202,702 | \$ 186,761 |
| Gifts, contributions and other income | 140,273 | 125,605 |
| | 342,975 | 312,366 |
| Net assets released from restriction- | | |
| Grant expenditures | (202, 492) | (186,594) |
| Net assets with donor restrictions used to support operations | (109,627) | (104,907) |
| Net assets with donor restrictions used for purchase of property | | |
| and equipment | (4,031) | (968) |
| | (316,150) | (292,469) |
| Gain (loss) in interest in net assets of supporting organizations | 1,120,619 | (1,888) |
| Increase in net assets with donor restrictions | 1,147,444 | 18,009 |
| | | |
| INCREASE IN NET ASSETS | 1,592,192 | 73,702 |
| NET ASSETS, beginning of year | 5,272,416 | 5,190,063 |
| Cumulative effect of adoption of ASU 2016-02 | - | 8,651 |
| ADJUSTED NET ASSETS, beginning of year | 5,272,416 | 5,198,714 |
| NET ASSETS, end of year | \$6,864,608 | \$5,272,416 |

See accompanying notes to consolidated financial statements.

Consolidated Statements of Cash Flows For the Years Ended June 30, 2021 and 2020 (dollars in thousands)

| | 2021 | 2020 |
|---|--------------|-----------------|
| CASH FLOWS FROM OPERATING ACTIVITIES: | | |
| Increase in net assets | \$ 1,592,192 | \$ 73,702 |
| Adjustments to reconcile increase in net assets to net cash provided by operating activities- | •)) - | • • • • • • • • |
| Depreciation and amortization | 135,955 | 128,714 |
| Loss on disposal of property and equipment | 1,563 | 3,550 |
| Proceeds from sale of donated securities | 2,176 | 2,285 |
| Receipts from supporting organizations | (3,757) | (3,475) |
| Contributions to supporting organizations | 37,181 | 108,625 |
| Contributions restricted for purchase of property and equipment | (4,031) | (968) |
| (Gain) loss in interest in net assets of supporting organizations | (1,120,619) | 1,888 |
| Unrealized and realized gains on marketable securities, net | (50,232) | (24,811) |
| (Gain) loss on interest rate swap | (3,066) | 6,022 |
| (Increase) decrease in receivables | (95,869) | 22,446 |
| Increase in inventories and prepaid expenses and other assets | (23,161) | (3,845) |
| (Increase) decrease in pension benefit asset | (250,640) | 99,930 |
| Increase in accounts payable and accrued expenses, net | 71,877 | 20,179 |
| Decrease in operating lease obligations | (2,097) | (2,353) |
| Increase (decrease) in self-insurance reserves and other long-term liabilities | 8,443 | (1,397) |
| Net cash provided by operating activities | 295,915 | 430,492 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | | |
| Expenditures for property and equipment | (220,455) | (239,876) |
| Acquisition of pediatric primary care practices | (8,583) | - |
| Purchases of marketable securities | (1,484,503) | (2,186,563) |
| Sales and maturities of marketable securities | 1,208,023 | 2,131,953 |
| Cash withdrawn from funds in trust | 1,391 | 3,670 |
| Cash invested in funds in trust | (8,526) | (14,987) |
| Net cash used in investing activities | (512,653) | (305,803) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | | |
| Issuance of bonds and notes payable | 200,000 | 200,000 |
| Repayment of bonds, notes payable, and finance lease obligations | (30,214) | (35,651) |
| Contributions restricted for purchase of property and equipment | 4,031 | 968 |
| Receipts from supporting organizations | 3,757 | 3,475 |
| Contributions to supporting organizations | (37,181) | (108,625) |
| Net cash provided by financing activities | 140,393 | 60,167 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (76,345) | 184,856 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, beginning of year | 359,247 | 174,391 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, end of year | \$ 282,902 | \$ 359,247 |
| SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES: | | |
| | ¢ 20.002 | ¢ 77.770 |
| Capital expenditures in accounts payable and accrued expenses | \$ 29,882 | \$ 23,378 |
| Acquisition of property through finance leases | \$ 5,793 | \$ - |
| Acquisition of property through operating leases | \$ 3,906 | \$ 3,575 |

See accompanying notes to consolidated financial statements.

(1) <u>Accounting Policies</u> –

(a) <u>Basis of Consolidation</u> – Children's Hospital Medical Center (Cincinnati Children's), River City Insurance Limited (River City), CHMC Community Health Services Network (CHSN), Burnet Ave LLC (Burnet), TSHCH LLC (TSHCH), DTPM2 LLC (DTPM2), BACE Properties LLC (BACE) and Avondale Rentals LLC (Avondale Rentals), which are under common management, are included in the accompanying consolidated financial statements and are collectively referred to as Cincinnati Children's. Intercompany transactions and balances have been eliminated.

Cincinnati Children's is an Ohio not-for-profit corporation providing pediatric healthcare services, education, and related research. River City is a captive insurance company and a wholly owned subsidiary of Cincinnati Children's. CHSN is a wholly owned subsidiary of Cincinnati Children's whose purpose is to manage primary care practices in a community setting. Burnet, TSHCH, DTPM2, BACE and Avondale Rentals are wholly owned subsidiaries of Cincinnati Children's whose purpose is to hold land.

(b) <u>Supporting Organizations</u> – The Children's Hospital (TCH) and Convalescent Hospital Fund for Children (CHFC) are both Ohio not-for-profit corporations that provide financial support to Cincinnati Children's. Effective March 19, 2021, CHFC changed the name of The Convalescent Hospital for Children and Orphan Asylum (CHCOA) to the Convalescent Hospital Fund for Children.

The TCH and CHFC purpose clauses both specify the support of Cincinnati Children's as the organization's sole purpose. Additionally, certain endowment funds of these supporting organizations are restricted by the donors for specific operating purposes of Cincinnati Children's. As such, the assets of TCH and CHFC are recorded in Cincinnati Children's consolidated financial statements as an increase in Interest in Net Assets of Supporting Organizations and an increase in Net Assets with Donor Restrictions. Changes in the fair value of Interest in Net Assets of Supporting Organizations are recorded as a Gain in Interest in Net Assets of Supporting Organizations in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

The majority of receipts are from TCH and CHFC donor-restricted endowment funds or are other receipts that are designated by the supporting organizations' Boards of Trustees for specific operating purposes. The receipts are reflected in Gifts, contributions and other income with donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Upon spending, such funds are reflected in Other restricted net assets used to support operations in the Consolidated Statements of Operations and Changes in Net Assets.

Other receipts are from TCH as designated by the supporting organization's Board of Trustees to provide general support. The receipts are reflected in Receipts from supporting organizations without donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

(c) <u>Support Received from Supporting Organizations</u> – TCH and CHFC provide annual support to Cincinnati Children's through transfers of dividend and interest earnings on investments, net of investment management fees, administrative expenses, and donor-required income reinvestments.

The Supporting Organizations' respective Boards of Trustees may also make certain pledges of principal without donor restriction in support of key projects or initiatives at Cincinnati Children's. In January 2020, CHFC's Board of Trustees made a gift in the amount of \$36,000 to support the construction of a new facility at the College Hill Campus and programmatic support of Cincinnati Children's *Pursuing our Potential in Mental Health* initiative. The agreement has certain criteria that represent donor-imposed conditions that must be overcome before Cincinnati Children's is entitled to the assets promised. A contribution of \$1,855 was made for the year ended June 30, 2021. The receipts are reflected in Gifts, contributions and other income with donor restrictions and in Net assets used for purchase of property and equipment in the Consolidated Statements of Operations and Changes in Net Assets.

The following table details transfers between Cincinnati Children's and Supporting Organizations in the Consolidated Statements of Operations and Changes in Net Assets:

| | 2021 | 2020 |
|---|------------|-----------|
| Transfers of net assets with donor restrictions included in Gifts, contributions and other income: | | ¢ 00.074 |
| Cincinnati Children's from TCH | \$ 103,074 | \$ 88,274 |
| Cincinnati Children's from CHFC | 6,280 | 3,867 |
| Total | 109,354 | 92,141 |
| Transfers of net assets without donor restrictions included in Receipts from (Transfers to) supporting organizations: | | |
| Cincinnati Children's from TCH | 3,757 | 3,475 |
| Cincinnati Children's to TCH (1) | (37,181) | (108,625) |
| Total | (33,424) | (105,150) |
| Receivables at June 30 | | |
| Cincinnati Children's from TCH (2) | - | 10,587 |
| Total | \$ - | \$ 10,587 |

(1) The purpose of this transfer is to establish funds designated to support divisional activities and strategic priorities.

- (2) This receivable relates to an expected payment upon the maturity of a life insurance policy. The policy matured in fiscal year 2021, and proceeds were transferred to Cincinnati Children's.
- (d) <u>Revenue Recognition</u> The following revenue streams are subject to the revenue recognition guidance in Accounting Standards Codification No. 606 (ASC 606) "Revenue from Contracts with Customers":

| | 2021 | 2020 |
|-----------------------------|-------------|-------------|
| Net patient service revenue | \$2,226,690 | \$2,060,167 |
| Other revenue | 207,082 | 220,386 |
| | \$2,433,772 | \$2,280,553 |

Net Patient Service Revenue

Cincinnati Children's net patient service revenue generally relates to contracts with patients in which the performance obligations are to provide health care services to patients. As patients simultaneously receive and consume the benefits of health care provided by Cincinnati Children's, the performance obligations meet the criteria to be satisfied over time. Net patient service revenue is recorded as services are provided. Payment for such services is due between thirty to forty-five days from payer receipt of claim. Consideration for patient service revenue is variable. Agreements with payers typically provide for payments at amounts less than established charges.

Effective January 1, 2021, Cincinnati Children's signed an agreement with an Ohio Medicaid managed care company in which performance obligations are to stand-ready to provide care for approximately 130,000 children. The performance obligation to stand-ready is satisfied over time. Cincinnati Children's is reimbursed under a variable capitation methodology for hospital services. All physician and home care services are reimbursed based on provider fee schedules. The hospital services are reimbursed through a variable capitation payment which represents the amount remaining after payment has been made for (a) Cincinnati Children's physician services, (b) Cincinnati Children's home care services, (c) services provided to members by facilities outside the Cincinnati Children's network, and (d) an actuarially determined accrual for incurred but not reported claims (see Note 1h). Under delegation agreements, Cincinnati Children's receives fixed payments to perform the required medical management, care management and care coordination functions. Medicaid managed care organizations retain risk for payments to providers. The amount of net patient service revenue recorded in fiscal year 2021 under this arrangement is \$103,836.

Laws and regulations concerning government programs, including Medicaid and Medicare, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from related programs. There can be no assurance that regulatory authorities will not challenge Cincinnati Children's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon Cincinnati Children's. In addition, the contracts Cincinnati Children's has with third party payers also provide for retroactive audit and review of claims. At June 30, 2021, Cincinnati Children's has settled all Medicaid cost reports through 2016 and all Medicare cost reports through 2019.

Settlements with third party payers for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of estimated transaction price for providing patient care. These settlements are based on the terms of the payment agreement with the payer, correspondence from the payer, and Cincinnati Children's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Estimated settlements are adjusted in future periods as adjustments become known based on new information or as years are settled and no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in transaction price were not material in fiscal years 2021 and 2020.

Generally, patients who are covered by third party payers are responsible for related deductibles and coinsurance, which vary in amount. Cincinnati Children's also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or law, from standard charges. Cincinnati

Children's estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by established contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of change.

Consistent with Cincinnati Children's mission, care is provided to patients regardless of their ability to pay. Therefore, Cincinnati Children's has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances. The implicit price concessions included in estimating the transaction price represent the difference between the amounts billed to patients and the amounts Cincinnati Children's expects to collect based on its collection history with those patients.

Patients who meet Cincinnati Children's criteria for charity care are provided care without charge or at amounts less than established rates. Amounts determined to qualify as charity care are not reported as net patient service revenue.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, Cincinnati Children's has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the fiscal year. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the fiscal year. The performance obligations for these contracts are generally completed when patients are discharged, which generally occurs shortly after the end of the fiscal year.

In both fiscal years 2021 and 2020, substantially all of net patient service revenue is derived from thirdparty payment programs (Medicaid, insurance companies and various managed care agreements). Cincinnati Children's classifies its patients by payer. The following table disaggregates Cincinnati Children's net patient service revenue by payer categories for the fiscal year ended June 30, 2021 and 2020:

| | | 2021 | | 2020 |
|----------------------------------|-----|-------------|-----|-------------|
| Commercial insurers | 1% | \$ 22,266 | 2% | \$ 41,203 |
| Managed care | 63% | 1,402,815 | 65% | 1,339,108 |
| Government (HMO and third party) | 28% | 623,473 | 25% | 515,042 |
| International | 4% | 89,068 | 3% | 61,805 |
| Specialty contracts ¹ | 3% | 66,801 | 4% | 82,407 |
| Self-pay | 1% | 22,267 | 1% | 20,602 |
| | _ | \$2,226,690 | | \$2,060,167 |

The following details the percentage of accounts receivable by payer category as of June 30, 2021 and 2020:

| | 2021 | 2020 |
|----------------------------------|------|------|
| Commercial insurers | 2% | 3% |
| Managed care | 63% | 57% |
| Government (HMO and third party) | 20% | 22% |
| International | 7% | 9% |
| Specialty contracts ¹ | 7% | 7% |
| Self-pay | 1% | 2% |

¹ Specialty contracts are single case agreements or contracts for specialty services, such as transplants.

Other Revenue

Cincinnati Children's other revenue generally relates to contracts with external organizations in which the performance obligations are to provide research services or other various fee-for-service arrangements outside the scope of healthcare services. Relief funds received as a result of the Coronavirus Aid, Relief, and Economic Security (CARES) Act are also included in other revenue. See Note 1(s) for further discussion on the COVID-19 Pandemic.

Revenue from industry contracts and certain government contracts is earned based on performance obligations to provide research services to the external organizations. License and royalty revenue relates to contracts with other organizations in which our performance obligations are to provide intellectual property to the organization. Revenue is also earned for various other contracted fee-for-service arrangements where services are performed for external organizations outside the scope of healthcare services for Cincinnati Children's patients. Performance obligations for industry and government contracts, license and royalty contracts, and various other fee-for-service arrangements are satisfied over time. Consideration is fixed based on contracted price, and there is no significant variable consideration related to these agreements.

- (e) <u>Graduate Medical Education</u> Cincinnati Children's receives Federal graduate medical education funding. Other revenue of \$11,188 and \$10,832 was recognized for the years ended June 30, 2021 and 2020, respectively.
- (f) <u>Tax Exempt Status</u> Cincinnati Children's and CHSN are recognized by the Internal Revenue Service as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code as charitable organizations qualifying under Section 501(c)(3). River City is a captive insurance company and has no income tax obligations. Burnet, TSHCH, DTPM2, BACE and Avondale Rentals are limited liability corporations whose income is taxable to Cincinnati Children's. The income tax provisions recorded in the accompanying consolidated financial statements are immaterial for the years ended June 30, 2021 and 2020.

Cincinnati Children's accounts for income taxes in accordance with Accounting Standards Codification Topic (ASC) 740 "Income Taxes". It is Cincinnati Children's policy to classify the expense related to interest and penalties, if any, to be paid on underpayments of income taxes within other expenses. There were no material penalties or interest recognized in fiscal years 2021 and 2020.

Fiscal years 2018 through 2021 are subject to examination by both the Federal and State tax jurisdictions.

- (g) <u>Cash Equivalents</u> Cash equivalents consist primarily of money market investments (including money market mutual funds) and demand deposits. Money market investments have maturities of 90 days or less at the time of purchase. Cash is held primarily in two financial institutions.
- (h) <u>Inventories and Prepaid Expenses</u> Inventories consist primarily of medical supplies and pharmaceuticals and are valued on an average cost method.

As part of Cincinnati Children's variable capitation agreement, reimbursement is reduced by an actuarially determined estimate for incurred but not reported claims. Cincinnati Children's recorded incurred but not reported claims of approximately \$21,107 for the year ended June 30, 2021. The estimate is recorded as an increase in prepaid expenses and an increase in accounts payable and accrued expenses.

(i) <u>Marketable Securities</u> – Cincinnati Children's accounts for its investments under ASC 958-320 "Not-for-Profit Entities – Investments – Debt Securities" and ASC 958-321 "Not-for-Profit Entities – Investments – Equity Securities." Cincinnati Children's carries its marketable securities at fair value with unrealized gains and losses included in investment income in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

At June 30, 2021 and 2020, Cincinnati Children's marketable securities included 19% and 20% in U.S. Treasury securities, respectively.

(j) <u>Property and Equipment</u> – Property and equipment are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, ranging from three to forty years, as follows:

| Land Improvements | 3-25 years |
|-------------------------------------|------------|
| Buildings and Building Improvements | 5-40 years |
| Equipment | 3-25 years |

Cincinnati Children's evaluates long-lived assets under the provisions of ASC 360 "Property Plant and Equipment." During fiscal years 2021 and 2020, Cincinnati Children's did not incur any losses related to impairment of property and equipment.

- (k) <u>Goodwill</u> Goodwill is the excess of the purchase price over the fair value of the net assets of an entity acquired. Cincinnati Children's acquired the assets of a pediatric primary care practice, resulting in goodwill of \$8,583 in fiscal year 2021, and elected to apply the accounting alternatives available for not-for-profit entities. Goodwill is amortized over a 10-year period and tested for impairment when a triggering event occurs. During fiscal year 2021, \$429 of amortization expense and no impairment losses were recognized.
- (1) Leases Cincinnati Children's leases property and equipment under finance and operating leases. Cincinnati Children's determines if an arrangement is a lease at inception. Right-of-use assets and lease obligations are recognized for leases with terms greater than 12 months based on the net present value of the future minimum lease payments over the lease term at commencement date. When readily determinable, Cincinnati Children's uses the interest rate implicit in the lease to determine the present value of future minimum lease payments. However, most of Cincinnati Children's leases do not have a readily determinable implicit interest rate. For these leases, Cincinnati Children's uses a collateralized incremental borrowing rate based on the period and cash payment stream comparable with that of each lease. The right-of-use asset and lease obligations include a value for options to extend a lease if it is reasonably certain that the option will be exercised.

The current portion of operating lease obligations is included in the current portion of long-term debt and lease obligations and the non-current portion is separately stated as operating lease obligations on the consolidated balance sheets. The related right-of-use assets are included in operating lease right-ofuse assets on the consolidated balance sheets. Operating lease expense is recognized on a straight-line basis over the lease term and is included in purchased services in the consolidated statements of operations and changes in net assets. The current portion of finance lease obligations is included in current portion of long-term debt and lease obligations and the non-current portion is separately broken out as finance lease obligations on the consolidated balance sheets. The related finance lease right-of-use assets are included in property and equipment, net on the consolidated balance sheets. Finance lease right-of-use assets are amortized using the straight-line method over the shorter period of the lease term or the estimated useful life of the property or equipment. Such amortization expense is included in depreciation in the consolidated statements of operations and changes in net assets.

(m) <u>Costs of Borrowing</u> – Interest incurred on borrowed funds, net of interest earned on restricted bond funds, during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. In fiscal years 2021 and 2020, Cincinnati Children's capitalized \$11,013 and \$6,201 of interest related to construction in progress, respectively. Total cash paid for interest was approximately \$33,655 and \$30,130 and in fiscal years 2021 and 2020, respectively.

Deferred bond issuance costs and issuance premiums are amortized using the effective interest method over the period the related obligation is outstanding.

- (n) <u>Interest Rate Swap Agreement</u> In fiscal year 2020, Cincinnati Children's entered into an interest rate swap agreement to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. The swap agreement is measured at fair value and recognized in the Consolidated Balance Sheets within other long-term liabilities. Cincinnati Children's recognizes gains and losses from the changes in fair value of the interest rate swap agreement as non-operating gains and losses within net investment return on the Consolidated Statements of Operations and Changes in Net Assets.
- (o) <u>Net Asset Classifications</u> Cincinnati Children's reports its financial position and activities according to the following net asset classifications:

<u>Net assets without donor restrictions</u> – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objective of the organization are classified as net assets without donor restrictions. These net assets may be used at the discretion of management of Cincinnati Children's.

<u>Net assets with donor restrictions</u> – Net assets subject to stipulations imposed by donors or supporting organizations are classified as net assets with donor restrictions. Some restrictions are temporary in nature; those restrictions will be met by fulfilling a certain purpose or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the principal be maintained in perpetuity.

(Continued on next page)

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Net assets with donor restrictions are comprised of the following:

| | 2021 | 2020 |
|--|-------------|-------------|
| Subject to expenditure for specified purpose: | | |
| Clinical | \$ 40,342 | \$ 36,377 |
| Research | 93,558 | 89,846 |
| Education | 16,493 | 15,344 |
| General Administration and Other | 44,831 | 23,366 |
| | 195,224 | 164,933 |
| Subject to expenditure for specified purpose, held at supporting organizations: | | |
| Research | 15,507 | 11,874 |
| Education | 1,144 | 876 |
| General Administration and Other | 4,604 | 3,526 |
| | 21,255 | 16,276 |
| Subject to expenditure based on Board discretion of the | 2 2 2 2 1 1 | 1 (10 105 |
| supporting organization, held at supporting organizations | 2,202,814 | 1,648,127 |
| | 2,202,814 | 1,648,127 |
| Investment in perpetuity, the income from which is expendable for specified purpose, held at Cincinnati Children's: | | |
| Clinical | 917 | 381 |
| Research | 17,929 | 12,803 |
| Education | 1,352 | 999 |
| General Administration and Other | 3,000 | 1,893 |
| | 23,198 | 16,076 |
| Investment in perpetuity, the income from which is expendable for specified purpose, held at supporting organizations: | | |
| Clinical | 46,872 | 34,946 |
| Research | 2,099,458 | 1,589,092 |
| Education | 91,815 | 70,207 |
| General Administration and Other | 81,498 | 60,430 |
| | 2,319,643 | 1,754,675 |
| Subject to appropriation and expenditure when a specified event occurs: | | |
| Upon death of insured party | 1,958 | 16,561 |
| | 1,958 | 16,561 |
| Total net assets with donor restrictions | \$4,764,092 | \$3,616,648 |

(Continued on next page)

- (p) <u>Revenue and Gains in Excess of Expenses and Losses</u> The Consolidated Statements of Operations and Changes in Net Assets subtotals operating revenues, gains and other support, operating expenses and nonoperating gains as Revenue and gains in excess of expenses and losses. Other changes in net assets without donor restrictions are receipts from and transfers to supporting organizations, pension and postretirement health liability adjustments, and net assets released from restrictions used for purchase of property and equipment, which are excluded from Revenue and gains in excess of expenses and losses.
- (q) <u>Use of Estimates</u> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
- New Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (r) (ASU) 2016-02 Leases. ASU 2016-02 introduces a new lessee model that brings substantially all lease obligations and assets onto the balance sheet. Most of the existing lessor principles are retained, but ASU 2016-02 aligns many of those principles with the FASB's new revenue guidance. Cincinnati Children's adopted ASU 2016-02 on July 1, 2019. Cincinnati Children's elected the transition package of practical expedients available in ASU 2016-02 whereby, upon adoption, an entity need not reassess expired or existing contracts to determine whether the contracts are or contain leases or to determine lease classification. Cincinnati Children's additionally elected the short-term lease recognition exemption, a practical expedient which permits a lessee not to recognize on its balance sheet assets and liabilities related to leases whose lease term is twelve months or less. The impact of adoption on the consolidated financial statements on July 1, 2019 resulted in an increase in other noncurrent assets to record right-of-use assets and an increase in other current and noncurrent liabilities to record lease obligations for operating leases of approximately \$13,748 representing the present value of remaining lease payments of the operating leases. Additionally, Cincinnati Children's recorded a credit to beginning net assets without restriction of \$8,651 for the year ended June 30, 2020. The adoption of ASU 2016-02 did not have a material impact on the consolidated statements of operations and changes in net assets or consolidated statements of cash flows.

In August 2018, the FASB issued ASU 2018-13 *Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement.* The ASU improves the effectiveness of the notes to financial statements through changes to disclosure requirements for fair value measurement. The ASU is effective for fiscal years beginning after December 15, 2019 with retrospective application. Cincinnati Children's adopted the standard for the year ended June 30, 2021, and there was no significant impact to the consolidated financial statements as a result of adoption.

In August 2018, the FASB issued ASU 2018-15, *Intangibles—Goodwill and Other (Topic 350): Internal-Use Software.* This standard aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years beginning after December 15, 2020, which means that it will be effective for Cincinnati Children's in the fiscal year beginning July 1, 2021. Cincinnati Children's is currently evaluating the impact that this standard will have on its consolidated financial statements and will adopt the provisions upon the effective date.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets.* This ASU changes the presentation and disclosure requirements for not-for-profit entities to increase transparency about

contributed nonfinancial assets. The ASU is effective for annual periods beginning after June 15, 2021, and interim periods within annual periods beginning after June 15, 2022, with early adoption permitted. Cincinnati Children's is currently evaluating the impact that this standard will have on its consolidated financial statements and will adopt the provisions upon the effective date.

In March 2021, the FASB issued ASU 2021-03, *Intangibles—Goodwill and Other (Topic 350):* Accounting Alternative for Evaluating Triggering Events. The standard allows not-for-profit entities with an accounting alternative to evaluate the facts and circumstances as of the end of each reporting period to determine whether a triggering event exists and, if so, whether it is more likely than not that goodwill is impaired. An entity that elects this alternative is not required to monitor for goodwill impairment triggering events during the reporting period. The ASU is effective on a prospective basis for fiscal years beginning after December 15, 2019. Cincinnati Children's adopted ASU 2021-03 effective July 1, 2020. Adopting ASU 2021-03 had no impact on the consolidated financial statements.

(s) <u>COVID-19 Pandemic</u> – An order was issued by the Ohio Department of Health, effective Wednesday, March 18, 2020, that required all non-essential or elective surgeries and procedures that utilized personal protective equipment ("PPE") be cancelled. As a result of this order, Cincinnati Children's experienced a decline in patient volumes which significantly affected financial results for fiscal year 2020. This order was rescinded effective April 30, 2020. On May 1, Cincinnati Children's began its "Responsible Recovery for Kids" plan, which included the rescheduling of previously cancelled procedures and reopening outpatient clinics in a gradual, thoughtful, and safe manner. Cincinnati Children's experienced a significant decline in inpatient days, outpatient visits and surgical cases during the period the order was in effect. The financial impact of these declines are reflected in the Consolidated Statement of Operations and Changes in Net Assets for fiscal year 2020.

The Coronavirus Aid, Relief, and Economic Security ("CARES") Act was passed by Congress on March 27, 2020 to aid organization and individuals with the economic impacts of COVID-19. Cincinnati Children's received \$50,000 and \$42,404 in relief funds from the Department of Health and Human Services in fiscal years 2021 and 2020, respectively. Relief funds are recorded as other revenue in the Operating revenues, gains and other support section of the Consolidated Statements of Operations and Changes in Net Assets for the years ended June 30, 2021 and 2020.

In addition to the distribution of relief funds, the CARES Act also included electable payroll tax credits and deferrals. Cincinnati Children's elected to delay payment of the employer portion of the Social Security payroll taxes on wages paid from March 27, 2020 through December 31, 2020 in the amount of \$45,656. Half of the total deferred amount is required to be paid by December 31, 2021 and the remaining portion is due by December 31, 2022. At June 30, 2021, deferred payroll taxes of \$22,828 are included in Other Long-Term Liabilities, and \$22,828 are included in Accounts payable and accrued expenses on the Consolidated Balance Sheets. At June 30, 2020, deferred payroll taxes totaled \$17,013 in Other Long-Term Liabilities.

A payroll tax credit was also available under the CARES Act for employers that continued to pay their employees while experiencing significant declines in operations caused by government orders or mandates associated with the response to the COVID-19 pandemic. The available credit was determined by the amount of eligible wages and healthcare benefits paid to non-working employees. Cincinnati Children's recognized total credits \$10,566 in fiscal year 2020, which is reflected as a reduction in the respective Salaries and Employee benefits expenses in the Consolidated Statements of Operations and Changes in Net Assets. No such credits were recognized in fiscal year 2021.

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(2) Liquidity and Availability –

Financial assets available for general expenditure within one year of the balance sheet date consist of the following:

| | 2021 | 2020 |
|--|-------------|-------------|
| Amounts available for general expenditure | | |
| Cash and cash equivalents | \$ 274,863 | \$ 274,854 |
| Marketable securities | 1,352,918 | 1,028,382 |
| Patient receivables, net | 506,944 | 417,654 |
| Other receivables | 140,916 | 134,337 |
| | 2,275,641 | 1,855,227 |
| Less: Board-designated assets | 100,000 | - |
| Financial assets available for general expenditure | \$2,175,641 | \$1,855,227 |

Cincinnati Children's has cash and cash equivalents, marketable securities (more fully described in Note 4), patient receivables and certain other receivables which are liquid and available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the quantitative information above. During fiscal 2021, the Board of Trustees designated \$100,000 from net assets without donor restrictions to be used to support Cincinnati Children's community pillar of the *Pursuing Our Potential Together* strategic plan. Cincinnati Children's has other assets limited to use for professional liability, self-insurance health care and debt service, as well as perpetual endowments with donor restrictions. These assets limited to use, which are more fully described in Notes 4 and 6, are not available for general expenditure within the next year and are not reflected in the amounts above.

Cincinnati Children's has \$192,165 in outstanding obligations for which liquid funds must be available for payment in the event of a failed remarketing. Cincinnati Children's maintains certain balances in cash and investments and has access to a \$100,000 line of credit, as discussed in more detail in Note 9.

Additionally, Cincinnati Children's is required to maintain certain liquidity ratios as outlined in bond covenants. As of June 30, 2021 and 2020, Cincinnati Children's was in compliance with all such covenants.

Cincinnati Children's forecasts its future cash flows and monitors liquidity on an ongoing basis.

(3) <u>Reconciliation of Cash, Cash Equivalents, and Restricted Cash</u> -

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statement of Cash Flows for the fiscal years ending June 30, 2021 and 2020:

| | 2021 | 2020 |
|--|--------------------|---------------------|
| Cash and cash equivalents | \$274,863 8,039 | \$274,854 84,393 |
| Restricted cash included in other long-term assets Total cash, cash equivalents, and restricted cash shown in the | 0,057 | 04,375 |
| statement of cash flows | \$282,902 | \$359,247 |

(4) Fair Value Measurements –

Cincinnati Children's accounts for its assets and liabilities under ASC 820 "Fair Value Measurements." As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three broad levels, which are described below:

Level 1: Quoted Prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. These include quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are a few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Unobservable inputs, developed using Cincinnati Children's estimates and assumptions, which reflect those that the market participants would use. Such inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Determining where an asset or liability falls within the hierarchy depends on the lowest level input that is significant to the fair value measurement as a whole. In determining fair value, Cincinnati Children's utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in the assessment of fair value.

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2021.

| | Level 1 | Level 2 | Level 3 | Total |
|---|-----------|-----------|---------|-------------|
| Marketable Securities: | | | | |
| U.S. Government and agency securities | \$ - | \$370,368 | \$ - | \$ 370,368 |
| Foreign bonds | - | 46,067 | - | 46,067 |
| Municipal bonds | - | 9,347 | - | 9,347 |
| Common stock | 239,044 | - | - | 239,044 |
| Corporate obligations | - | 471,451 | - | 471,451 |
| Bond mutual funds | 25,086 | - | - | 25,086 |
| Total marketable securities measured in the fair value hierarchy | 264,130 | 897,233 | - | 1,161,363 |
| Full discretion fixed income | | | | 191,555 |
| | 264,130 | 897,233 | | 1,352,918 |
| Assets Limited As To Use: | | | | |
| Money market mutual funds | 9,088 | - | - | 9,088 |
| Common stock | 22,162 | - | - | 22,162 |
| | 31,250 | - | _ | 31,250 |
| Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets): | | | | |
| Common stock | 8,116 | _ | - | 8,116 |
| Mutual funds: | 0,110 | | | 0,110 |
| Money market | 1,203 | - | _ | 1,203 |
| Equity | 950 | - | - | 950 |
| International equity | 587 | - | - | 587 |
| Bond | 972 | - | - | 972 |
| Lifecycle | 3,384 | - | - | 3,384 |
| Variable annuities | - | 208 | - | 208 |
| Guaranteed insurance contract | - | | 469 | 469 |
| | 15,212 | 208 | 469 | 15,889 |
| Derivative Investments (included in Other-Long-term Liabilities): | 10,212 | | | |
| Interest rate swap agreement | _ | (2,956) | _ | (2,956) |
| Total investments at fair value | \$310,592 | \$894,485 | \$469 | \$1,397,101 |
| i otar myestments at fair value | φJ10,572 | ψ074,405 | ψτυγ | ψ1,577,101 |

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2020.

| Marketable Securities: | | | | Total |
|--|-----------|-----------|---------|-------------|
| Marketable Securities. | | | | |
| U.S. Government and agency securities | \$ - | \$352,525 | \$ - | \$352,525 |
| Foreign bonds | - | 31,853 | - | 31,853 |
| Municipal bonds | - | 8,338 | - | 8,338 |
| Common stock | 118,316 | - | - | 118,316 |
| Corporate obligations | - | 374,481 | - | 374,481 |
| Total marketable securities measured in the fair value hierarchy | 118,316 | 767,197 | - | 885,513 |
| Full discretion fixed income | | | | 82,952 |
| High yield corporate | | | | 50.017 |
| obligations | | | | 59,917 |
| | 118,316 | 767,197 | | 1,028,382 |
| Assets Limited As To Use: | | | | |
| Money market mutual funds | 84,527 | - | - | 84,527 |
| Common stock | 15,942 | | | 15,942 |
| | 100,469 | | | 100,469 |
| Deferred Compensation Plans (included in Other Receivables and | | | | |
| Other Long-term Assets): | | | | |
| Common stock | 5,967 | - | - | 5,967 |
| Mutual funds: | | | | |
| Money market | 286 | - | - | 286 |
| Equity | 956 | - | - | 956 |
| International equity | 384 | - | - | 384 |
| Bond | 776 | - | - | 776 |
| Lifecycle | 3,916 | - | - | 3,916 |
| Variable annuities | - | 101 | - | 101 |
| Guaranteed insurance | | | 1 7 7 7 | 1 727 |
| contract | - | - | 1,737 | 1,737 |
| = | 12,285 | 101 | 1,737 | 14,123 |
| Derivative Investments (included in Other-Long-term Liabilities): | | | | , |
| Interest rate swap agreement | - | (6,022) | - | (6,022) |
| Total investments at fair value | \$231,070 | \$761,276 | \$1,737 | \$1,136,952 |

The valuation methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in different fair value measurement at the reporting date.

The carrying amount and fair value of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.

Cincinnati Children's uses quoted market prices in active markets to determine the fair value of common stock and mutual funds; such items are classified as Level 1 in the fair value hierarchy.

Cincinnati Children's primarily bases fair value for investments in fixed income securities, including U.S. government securities, municipal bonds and corporate obligations on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate). Consideration is also given to the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy.

Cincinnati Children's interest rate swap agreement (Note 14) is a derivative instrument valued using the income approach, which uses market inputs to discount future cash flows to a single present amount based on market expectations.

Cincinnati Children's investment in High Yield Corporate Obligations is an investment in a limited liability company whose investment objective is to achieve superior fixed income returns on invested funds through exposure to higher quality, less volatile, high yield debt securities. As set forth in the LLC agreement, the LLC will dissolve on March 29, 2040, but may dissolve earlier under certain conditions. Any Investing Member may elect to withdraw, in whole or in part from the LLC on the last business day of any month or at such other date, as determined by the manager. The High Yield Corporate Obligations is measured at fair value using the net asset value per share practical expedient.

Cincinnati Children's investment in Full Discretion Fixed Income is an investment in a limited liability company whose investment objective is to invest in marketable and non-marketable securities with issue and industry diversification. As set forth in the LLC agreement, the LLC will dissolve on May 22, 2047, but may dissolve earlier under certain conditions. Any Investing Member may elect to withdraw, in whole or in part from the LLC if the Member notifies of intent to withdraw sixty calendar days in advance. The Full Discretion Fixed Income is measured at fair value using the net asset value per share practical expedient.

The guaranteed insurance contract is recorded based on discounted cash flows, which is an approximation of fair value, and is classified as Level 3 based on time restrictions for redemption.

Activity and transfers into and out of Level 3 and the reasons for those transfers are as follows:

| <u>2021</u> | Guaranteed Insurance Contracts |
|-------------|--------------------------------|
| Purchases | \$132 |
| Issues | - |
| <u>2020</u> | Guaranteed Insurance Contracts |
| Purchases | \$257 |
| Issues | - |

Cincinnati Children's policy is to recognize transfers in and out as of the actual date of the event or change in circumstances that caused the transfer. For the years ended June 30, 2021 and 2020, there were no material transfers in or out of Levels 1, 2 or 3.

(5) Losses on the Provision of Uncompensated Care –

In accordance with its mission and purpose, Cincinnati Children's maintains a policy of providing medically necessary services to pediatric patients within its primary service area regardless of ability to pay. This primary service area has been defined to include the four counties in Ohio, three counties in Kentucky and one county in Indiana that geographically surround Cincinnati. Under certain circumstances, Cincinnati Children's accepts patients from outside the primary service area regardless of their ability to pay. Cincinnati Children's defines uncompensated care as services rendered to patients whose families' annual income or net worth falls

below certain minimum standards. As such, losses absorbed by Cincinnati Children's in rendering services to patients who are covered under governmental programs which are designed to aid low-income families (primarily the Medicaid program) are considered uncompensated care.

The following information summarizes uncompensated care provided during the years ended June 30, 2021 and 2020:

| CHARGES | 2021 | 2020 |
|---|-------------|-------------|
| Charges under Medicaid and other entitlement programs | \$1,982,947 | \$1,877,045 |
| Charity care not eligible for Medicaid assistance, at established | | |
| charges | 24,580 | 29,606 |
| Other uncollectible self-pay, at established charges | 19,442 | 27,404 |
| Total Medicaid, charity care and other uncollectible self-pay charges | \$2,026,969 | \$1,934,055 |
| COSTS/LOSSES | | |
| Estimated costs to provide uncompensated care | \$ 851,532 | \$ 817,078 |
| Reimbursement from Medicaid programs | (611,230) | (493,257) |
| Losses on the provision of uncompensated care | (240,302) | (323,821) |
| Funds received from HCAP and tax levy | 31,463 | 31,039 |
| Losses on provision of uncompensated care net of HCAP and tax levy | \$(208,839) | \$(292,782) |

The 2021 and 2020 cost amounts reflected in the tables above are calculated using cost to charge ratios calculated from preliminary cost reports because the current year cost report is not yet available. Management does not believe the use of preliminary data would have a material impact on the amounts calculated above.

(6) Funds in Trust -

Cincinnati Children's has certain funds, which are invested and held in trust for various specified purposes. Funds are carried at fair value with unrealized gains and losses included in net investment return in the accompanying Consolidated Statements of Operations and Changes in Net Assets. The amounts of such funds, at carrying value, and the specified purposes for which such funds may be used, are set forth below:

| | June 30, | | |
|--|----------|-----------|--|
| | 2021 | 2020 | |
| Self-insurance Funds- | | | |
| Professional liability | \$ 159 | \$ 160 | |
| Employee health and workers' compensation | 140 | 140 | |
| Bond interest and principle escrow funds | 7,740 | 6,960 | |
| Endowment funds held in perpetual trust | 23,211 | 16,076 | |
| Bond proceeds held in trust for construction project | - | 77,133 | |
| | \$31,250 | \$100,469 | |

Consolidated Financial Statements

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(7) Property and Equipment –

Property and equipment consists of the following:

| | June 30, | | |
|-------------------------------------|-------------|-------------|--|
| | 2021 | 2020 | |
| Land | \$ 42,158 | \$ 42,142 | |
| Land improvements | 31,645 | 32,038 | |
| Buildings and building improvements | 1,610,173 | 1,599,462 | |
| Equipment | 693,081 | 678,044 | |
| Construction in progress | 416,644 | 273,169 | |
| | 2,793,701 | 2,624,855 | |
| Accumulated depreciation | (1,389,988) | (1,314,050) | |
| Property and equipment, net | \$1,403,713 | \$1,310,805 | |

(8) Professional Liability -

Cincinnati Children's insurance program includes a self-insured retention for losses arising out of healthcare professional liability claims. The current self-insured retention for asserted claims is \$10,000 (\$25,000 in aggregate). Cincinnati Children's regularly purchases excess healthcare professional liability insurance on a claim made basis at varying levels.

The actuarial present value of expected costs (including incurred, but not reported claims) for the healthcare professional liability program of \$22,184 and \$20,939 for 2021 and 2020, respectively, has been accrued in the accompanying Consolidated Balance Sheets. Accrued healthcare professional liability losses have been discounted at a rate of 4% at June 30, 2021 and 2020. The costs of Cincinnati Children's healthcare professional liability program, including premiums paid for excess re-insurance, legal fees, settlements, judgments, and other administrative costs are included in Supplies, Drugs and Other in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Accrued losses funding levels are actuarially determined based on management's estimation of potential outstanding loss liabilities, payout patterns, and various other assumptions, and then adjusted to reflect its best estimate of the present value of expected costs for the healthcare professional liability claims. Healthcare professional liability expense was \$5,359 and \$12,309 for fiscal years 2021 and 2020, respectively.

Consolidated Financial Statements

For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

(9) <u>Debt</u> –

Debt at June 30, 2021 and 2020 is summarized as follows:

| | 2021 | 2020 |
|---|-----------|-----------|
| Series 2018BB commercial paper, variable interest (0.04% | | |
| to 0.08% at June 30, 2021), taxable | \$100,000 | \$100,000 |
| Bonds payable: | | |
| Series 2011, 2.18% due through 2023 | 8,480 | 16,555 |
| Series 2014S, 3.0% to 5.0% due through 2034, net of | | |
| unamortized premium of \$2,662 in 2021 and \$3,437 in | | |
| 2020 | 92,029 | 98,324 |
| Series 2014T, 4.268% due 2044, taxable | 297,804 | 297,708 |
| Series 2016X, 5.00%, due through 2032, net of unamortized | | |
| premium of \$8,744 in 2021 and \$9,540 in 2020 | 59,937 | 60,687 |
| Series 2016Y, 2.853% due 2026, taxable | 99,558 | 99,472 |
| Series 2018Z*, variable interest (0.03% at June 30, 2021), | | |
| due through 2037 | 36,012 | 38,029 |
| Series 2018AA*, variable interest (0.03% at June 30, 2021), | | |
| due through 2037 | 55,627 | 58,745 |
| Series 2019CC, 5.0% due through 2049, net of unamortized | | |
| premium of \$60,360 in 2021 and \$62,793 in 2020 | 194,715 | 197,099 |
| Series 2020DD, 2.82% due 2051, taxable | 198,585 | - |
| Notes Payable: | 6.000 | |
| Term Note Payable, 2.20% due 2022 | 6,000 | 12,000 |
| Total | 1,148,747 | 978,619 |
| Less: | | |
| Current portion of bonds and notes payable | (20,385) | (19,700) |
| Commercial paper notes | (100,000) | (100,000) |
| Bonds payable subject to remarketing, net | (91,640) | (96,774) |
| Bonds payable and notes payable - long-term | \$936,722 | \$762,145 |
| | | |

- - - -

*Denotes variable rate bonds subject to remarketing agreements

(a) <u>Bonds Payable</u> – Cincinnati Children's has pledged gross revenues to secure the payment of 2011, 2014S, 2014T, 2016X, 2016Y, 2018Z, 2018AA, 2019CC, and 2020DD bonds. Cincinnati Children's is bound by certain financial covenants included in the bond indentures, direct placement agreements, and related agreements, including a requirement to maintain a minimum Debt Service Coverage Ratio.

The 2018Z and 2018AA tax-exempt bonds are subject to mandatory tender purchase seven days after notice from bondholders and may be remarketed. If the bonds are not remarketed, Cincinnati Children's must repay the bonds. The 2018Z and 2018AA bonds are classified as current liabilities in bonds payable subject to remarketing, net in the accompanying Consolidated Balance Sheets. The interest rates on the 2018Z and 2018AA variable rate bonds are reset weekly by a rate-setting agent.

(b) <u>Commercial Paper</u> – The Series 2018BB taxable commercial paper was issued in the original aggregate principal amount of \$100,000 and outstanding at any one time in a principal amount not to exceed \$100,000. The Notes shall mature no later than May 15, 2048. The commercial paper notes have a maximum maturity period of 270 days and are resold at maturity. In the event the notes have not been resold, Cincinnati Children's must repay the notes. The 2018BB commercial paper is classified as current liabilities in the accompanying Consolidated Balance Sheets. The interest rates on the 2018BB commercial paper are reset with each remarketing by a rate-setting agent.

(c) <u>Future Debt Maturities</u> – The following is a schedule of future debt maturities, excluding discounts/premiums and deferred issuance costs:

| 2022 | \$ 212,550 |
|------------|-------------|
| 2023 | 9,125 |
| 2024 | 9,060 |
| 2025 | 9,510 |
| 2026 | 9,750 |
| Thereafter | 833,835 |
| | \$1,083,830 |

(d) <u>Line of Credit</u> – In June 2020, Cincinnati Children's entered into a 1-year agreement for a line of credit of \$100,000. The line of credit agreement was amended in June 2021 to extend the maturity date to June 2024. The line of credit bears interest at the greater of the Daily Reset LIBOR Rate or 0.50%, plus 50 basis points. In the event LIBOR is no longer available, the line of credit bears interest at the daily SOFR rate, plus an adjustment spread. There were no draws on the line of credit during fiscal year 2021 or 2020.

(10) Employee Benefit Plans -

Cincinnati Children's maintains non-contributory retirement plans covering substantially all employees. Among these plans is a defined benefit plan where benefits are based on a formula which reflects years of service and salary levels. Cincinnati Children's funding policy for its defined benefit plan meets the funding standards established by the Employee Retirement Income Security Act of 1974 (ERISA).

Cincinnati Children's investment strategy with respect to pension assets is designed to achieve a moderate level of overall portfolio risk in keeping with desired risk objective, which is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Cincinnati Children's adopted an Investment Policy that adjusts allocations between return-seeking assets and liability-hedging assets based on the funded status of the Plan and prevailing yields. As the funded ratio improves, allocations to liability-hedging assets increase accordingly.

Cincinnati Children's seeks to maintain diversified portfolios and has adopted allocation targets within the return-seeking and liability hedging portfolios as follows:

| Return-Seeking Allocation: | Min - Target -Max |
|---|-------------------|
| Global Equity | 60% - 70% - 80% |
| Private Equity | 5% - 10% - 15% |
| Private Real Estate | 5% - 10% - 15% |
| Multi-Asset Credit | 5% - 10% - 15% |
| Opportunity Allocation | 0% - 0% - 10% |
| Liability-Hedging Allocation: | |
| Long Credit | 50% - 75% - 100% |
| STRIPS (Long Duration Treasury Instruments) | 0% - 25% - 50% |

In order to maintain the portfolio's actual asset allocation in line with the target allocations specified above, rebalancing will occur periodically. As of June 30, 2021, Cincinnati Children's has made \$126,400 in funding commitments in eleven investment partnerships of which \$81,340 has been funded. Additionally, Cincinnati Children's has made \$72,500 in funding commitments in nine real estate investment partnerships of which \$67,620 has been funded. It is anticipated that these commitments will be funded from liquid investments of the plan.

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Cincinnati Children's defined benefit plan investment allocation at the actuarial measurement date of June 30, 2021 and 2020 by asset category is as follows:

| | 2021 | 2020 |
|-----------------------------|--------|--------|
| Cash and cash equivalents | 1.7% | 1.8% |
| Corporate bonds | 13.6% | 16.4% |
| Government bonds | 1.8% | 1.1% |
| Investment Partnerships: | | |
| Equity | 4.0% | 4.0% |
| Bond | 0.8% | 6.4% |
| Real estate | 2.4% | 2.9% |
| Commingled Investment Funds | | |
| Equity | 18.7% | 35.8% |
| Bond | 40.0% | 19.3% |
| Government | 17.0% | 12.3% |
| | 100.0% | 100.0% |

At June 30, 2021, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

| | Level 1 | Level 2 | Level 3 | Total |
|--|----------|-----------|---------|-------------|
| Cash and cash equivalents | \$29,579 | \$ - | \$ - | \$ 29,579 |
| Corporate bonds | - | 239,259 | - | 239,259 |
| Government bonds | | 31,870 | | 31,870 |
| Total assets in the fair value hierarchy | 29,579 | 271,129 | | 300,708 |
| Investments measured at net asset value ¹ : | | | | |
| Investment Partnerships: | | | | |
| Equity | - | - | - | 70,552 |
| Bond | - | - | - | 14,348 |
| Real Estate | - | - | - | 42,696 |
| Commingled Investment Funds: | | | | |
| Equity | = | = | = | 327,271 |
| Bond | = | = | = | 702,807 |
| Government | <u> </u> | <u>=</u> | | 297,274 |
| Total assets at fair value | \$29,579 | \$271,129 | \$ - | \$1,755,656 |

(Continued on next page)

¹ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the balance sheet.

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

At June 30, 2020, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

| | Level 1 | Level 2 | Level 3 | Total |
|--|----------|-----------|----------|-------------|
| Cash and cash equivalents | \$25,999 | \$ - | \$ - | \$ 25,999 |
| Corporate bonds | - | 239,216 | - | 239,216 |
| Government bonds | _ | 15,899 | _ | 15,899 |
| Total assets in the fair value hierarchy | 25,999 | 255,115 | - | 281,114 |
| Investments measured at net asset value ¹ : | | | | |
| Investment Partnerships: | | | | |
| Equity | - | - | - | 58,171 |
| Bond | - | - | - | 92,715 |
| Real Estate | - | - | - | 42,510 |
| Commingled Investment Funds: | | | | |
| Equity | Ξ | = | = | 520,228 |
| Bond | Ξ | = | = | 280,657 |
| Government | <u> </u> | <u> </u> | <u> </u> | 178,829 |
| Total assets at fair value | \$25,999 | \$255,115 | \$ - | \$1,454,224 |

The fair values of Level 1 investments are based on quoted prices in active markets. The fair value for investments in fixed income securities, including U.S. government securities and corporate obligations, is based on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate) and considers the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy. Investments in partnerships – U.S. equities, real estate, and bonds – are valued using the net asset value reported by the managers of the funds and as supported by the unit prices of actual purchase and sale transactions. The investments in investment partnerships generally are associated with liquidation restrictions that may range from 91 days to the life of the fund (up to fifteen years) and may require redemption penalties. Commingled investment funds are private funds for institutional investors valued at net asset value. The commingled funds primarily invest in actively traded equity mutual funds, bond mutual funds, and US Treasury STRIPS with daily liquidity and no lockup period.

There were no transfers between levels in fiscal year 2021 or fiscal year 2020.

The following table reflects the weighted average assumptions utilized to determine benefit obligations:

| | 2021 | 2020 |
|--|-------|-------|
| Discount rate used to determine actuarial present value of the | | |
| projected benefit obligation | 3.27% | 3.33% |
| Assumed rate of increase in compensation levels | 3.50% | 3.50% |
| Long-term rate of return | 5.50% | 5.50% |

¹ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the balance sheet.

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The following table sets forth the funded status of the plan and amounts recognized in the accompanying Consolidated Balance Sheets as of June 30, 2021 and 2020, utilizing actuarial measurement dates as of June 30, 2021 and 2020.

| | 2021 | 2020 |
|---|-------------|-------------|
| Change in projected benefit obligation: | | |
| Projected benefit obligation at beginning of year | \$1,533,155 | \$1,338,263 |
| Service cost | 71,800 | 60,340 |
| Interest cost | 49,725 | 50,425 |
| Other actuarial loss | 33,202 | 167,618 |
| Benefits paid | (103,935) | (83,491) |
| Projected benefit obligation at end of year | \$1,583,947 | \$1,533,155 |
| Change in plan assets: | | |
| Fair value of plan assets at beginning of year | \$1,454,224 | \$1,359,262 |
| Actual gain on plan assets | 233,567 | 141,893 |
| Employer contributions | 171,800 | 36,560 |
| Benefits paid | (103,935) | (83,491) |
| Fair value of plan assets at end of year | 1,755,656 | 1,454,224 |
| Funded status | 171,709 | (78,931) |
| Net accrued pension benefit asset (liability) in Consolidated Balance Sheets | \$ 171,709 | \$ (78,931) |

For the Retirement Plan, the overall actuarial loss in plan obligation of approximately \$33 million is primarily attributable to a decrease in the discount rate between June 30, 2020 and June 30, 2021. The discount rate decrease of 6 basis points resulted in an increase in benefit obligation of approximately \$20 million.

In 2021 and 2020, the mortality tables utilized by actuaries to value the pension liability were updated based on current experience. The impact of the change in mortality assumptions is included in other actuarial loss in fiscal years 2021 and 2020.

Amounts included in Unrestricted Net Assets but not yet recognized in pension cost consist of:

| | 2021 | 2020 |
|--------------------------|-----------|-----------|
| Net actuarial loss | \$317,248 | \$477,831 |
| Net prior service credit | (77,041) | (88,792) |
| | \$240,207 | \$389,039 |

The table below reflects the following weighted average assumptions utilized to determine benefit costs were:

| | 2021 | 2020 |
|--|-------|-------|
| Discount rate used to determine benefit costs | 3.33% | 3.86% |
| Assumed rate of increase in compensation levels | 3.50% | 3.50% |
| Expected long-term rate of return on plan assets | 5.50% | 5.50% |

The Cincinnati Children's expected long-term rate of return on plan assets is based on the expected average returns based on the portfolio mix of plan assets and is reassessed on an annual basis.

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Net periodic pension cost for 2021 and 2020 related to the defined benefit plan consisted of the following components:

| | 2021 | 2020 |
|--------------------------------------|----------|----------|
| Service cost | \$71,800 | \$60,340 |
| Interest cost | 49,725 | 50,425 |
| Return on plan assets | (76,121) | (72,312) |
| Amortization of prior service credit | (11,751) | (11,751) |
| Recognized net actuarial loss | 36,339 | 29,357 |
| Net periodic pension cost | \$69,992 | \$56,059 |

Based on preliminary estimates, we do not expect any required fiscal year 2021 contributions for the qualified defined benefit plan under the current funding regulations.

The accumulated benefit obligation for the pension plan was \$1,504,250 and \$1,462,649 at June 30, 2021 and 2020, respectively.

Cincinnati Children's estimated benefit payments in each of the next five fiscal years and in aggregate for the five fiscal years thereafter are as follows:

| 2022 | \$75,570 |
|-----------|----------|
| 2023 | 74,960 |
| 2024 | 76,977 |
| 2025 | 78,612 |
| 2026 | 80,065 |
| 2027-2031 | 427,085 |

All other retirement plans maintained by Cincinnati Children's are defined contribution plans. Cincinnati Children's contributions to these plans are generally based on ten percent of salaries up to established ERISA limits. Total expense, net of forfeitures, related to these other plans was approximately \$27,581 and \$25,862 in fiscal years 2021 and 2020, respectively.

Cincinnati Children's provides individual nonqualified deferred compensation benefits to key employees with varying terms. Accounts are participant-directed, and the amounts are at a substantial risk of forfeiture and revert back to the Cincinnati Children's if the employee does not meet certain criteria as established by the plan. The amount of deferred compensation income and expense recognized in fiscal years 2021 and 2020 was \$1,358 and \$175, respectively. The current portion of plan accounts are included in Other receivables with a corresponding liability in Accounts payable and accrued expenses on the Consolidated Balance Sheets. The long-term portion of plan accounts are included in Other long-term liability in Other long-term liabilities on the Consolidated Balance Sheets.

The following table displays the nonqualified deferred compensation plans assets and liabilities as of June 30, 2021 and 2020:

| | 2021 | 2020 |
|------------------------------|----------|----------|
| Current portion | \$ 307 | \$ 2,640 |
| Long-term portion | 15,582 | 11,483 |
| Total assets and liabilities | \$15,889 | \$14,123 |

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

The postretirement benefit obligations, included within other long-term liabilities, as of June 30, 2021 and 2020 were as follows:

| | 2021 | 2020 |
|---|---------|---------|
| Change in benefit obligation: | | |
| Benefit obligation at beginning of year | \$1,514 | \$1,756 |
| Interest cost | 26 | 48 |
| Actuarial gain | (101) | (41) |
| Benefits paid | (223) | (249) |
| Benefit obligation at end of year | \$1,216 | \$1,514 |

Amounts included in Unrestricted Net Assets but not yet recognized in postretirement cost consist of:

| | 2021 | 2020 |
|------------------------|---------|---------|
| Net actuarial loss | \$1,108 | \$1,402 |
| Net prior service cost | (51) | (144) |
| | \$1,057 | \$1,258 |

The above table reflects the following weighted average assumptions to determine postretirement obligations:

| | 2021 | 2020 |
|---------------|-------|-------|
| Discount rate | 1.88% | 1.84% |

Net periodic cost for 2021 and 2020 related to the postretirement benefits consisted of the following components:

| | 2021 | 2020 |
|--|-------|---------|
| Interest cost | \$ 26 | \$ 48 |
| Amortization of unrecognized net gain and prior service credit | 100 | (362) |
| | \$126 | \$(314) |

For fiscal years 2021 and 2020, the discount rate used to determine the net periodic postretirement costs was 1.84% and 2.98%, respectively.

Cincinnati Children's expects to make the future benefit payments, which reflect expected future service, as appropriate. The following benefit payments are expected to be paid over each of the next five years and five fiscal years thereafter:

| | Payments |
|-----------|----------|
| 2022 | \$188 |
| 2023 | 169 |
| 2024 | 150 |
| 2025 | 132 |
| 2026 | 115 |
| 2027-2031 | 372 |

(11) Commitments and Contingencies -

- (a) <u>Litigation</u> Cincinnati Children's is engaged from time to time in a variety of litigation and regulatory compliance matters in addition to professional and general liability matters. Management assesses the probable outcome of unresolved litigation and records estimated reserves consistent with ASC No. 450, "Contingencies." After consultation with legal counsel, management believes that all such currently existing matters will be resolved without material adverse impact to the consolidated financial position or results of operations of Cincinnati Children's.
- (b) <u>Laws and Regulations</u> The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations guide the healthcare industry in many domains such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient service, and Medicare and Medicaid fraud and abuse to name a few. Compliance with these laws and regulations, specifically those relating to the Medicare and Medicaid programs, is complex and can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time. Management believes that Cincinnati Children's is in compliance, in all material respects, with fraud and abuse as well as other applicable government laws and regulations. Cincinnati Children's has recorded reserves for routine regulatory compliance issues and believes these reserves are adequate to cover any potential repayment of previously billed and collected revenue from patient service.
- (c) <u>Capital Commitments</u> In fiscal year 2018, Cincinnati Children's entered into agreements to build and equip a 633,000 square foot clinical building and renovate 146,000 square feet of existing space. Construction commenced in fiscal year 2018. In fiscal year 2020, Cincinnati Children's Board of Trustees approved expanding the renovation scope to a total of 285,000 square feet. Cincinnati Children's has spent approximately \$460,782 through June 30, 2021 and expects to spend an additional \$237,221 in conjunction with the construction project. The new building will be completed in fiscal year 2022, and the renovation will be completed in fiscal year 2024.

In fiscal year 2020, Cincinnati Children's Board of Trustees approved construction of a replacement facility at the College Hill campus which provides inpatient and outpatient mental health services. The facility is anticipated to be approximately 175,000 square feet. Cincinnati Children's spent \$6,846 through June 30, 2021 and expects to spend an additional \$92,154 in conjunction with the construction project. The replacement facility is projected to be completed in fiscal year 2024.

In fiscal year 2020, Cincinnati Children's Board of Trustees approved the construction of a new ambulatory facility on the eastside of Cincinnati. This project will consolidate two smaller leased facilities into one larger owned facility. Cincinnati Children's spent \$49 through June 30, 2021 and expects to spend an additional \$34,951. The new facility is projected to be completed in fiscal year 2025.

Cincinnati Children's has entered into agreements with general contractors for several new construction projects, renovation projects, equipment, and information system technology projects. Cincinnati Children's has committed to spend approximately \$21,928 in connection with current active projects as of June 30, 2021. The projects are expected to be completed primarily in fiscal year 2022.

(d) <u>Funding Commitments</u> – The Board of Trustees of Cincinnati Children's approved revocable commitments for up to \$20,000 in non-recourse loans to Uptown Consortium Inc. Cincinnati Children's has provided \$17,867 of funding in relation to these commitments through June 30, 2021. Management does not anticipate any additional funding. These funds are used to invest in commercial and residential

projects in the uptown area. During fiscal year 2021, none of the loans were repaid. Cincinnati Children's expects to receive an additional \$5,000 related to the loans.

(e) <u>Investment Commitments</u> – Cincinnati Children's has made commitments to invest \$25,000 in five limited partnerships that focus on investing in venture capital funds or provide venture capital for companies in the high-growth sectors of the economy, including life sciences, information technology, advanced manufacturing, and healthcare. Cincinnati Children's has made commitments to invest \$12,294 in nine limited liability companies that focus on investing in early-stage venture capital funds regionally and nationally with the goals of making the Cincinnati region the place for entrepreneurs and investors to launch new ideas and driving capital into scalable technology companies in southwest Ohio. Investment values are included in Other Assets in the Consolidated Balance Sheets. Cincinnati Children's occasionally receives distributions from these investments which reduce investment values.

The following displays the amounts funded and investment values at June 30, 2021 and 2020:

| 2021 | Funded | Value |
|---|----------|----------|
| Investment in Limited Partnerships | \$20,349 | \$ 8,075 |
| Investments in Limited Liability Corporations | 9,324 | 13,263 |
| Total | \$29,673 | \$21,338 |
| 2020 | Funded | Value |
| Investment in Limited Partnerships | \$19,076 | \$8,841 |
| Investments in Limited Liability Corporations | 7,958 | 8,540 |
| Total | \$27,034 | \$17,381 |

(12) <u>Leases</u> –

Cincinnati Children's leases certain property and equipment. Cincinnati Children's determines if an arrangement is a lease at inception of a contract.

The following table presents expenses recorded related to lease arrangements for the years ended June 30, 2021 and 2020:

| | 2021 | 2020 |
|---------------------------------------|----------|----------|
| Operating lease expense | \$ 2,765 | \$ 3,236 |
| Finance leases: | | |
| Amortization of right-of-use assets | 6,698 | 6,556 |
| Interest on finance lease obligations | 1,955 | 1,915 |
| Short-term and variable lease expense | 4,994 | 4,494 |
| Total lease expense | \$16,412 | \$16,201 |

Other information related to leases for the years ended June 30, 2021 and 2020 is as follows:

Supplemental cash flow information

Cash paid for amounts included in the measurement of lease liabilities:

| | 2021 | 2020 |
|--|----------|----------|
| Operating cash flows from operating leases | \$ 2,097 | \$ 2,353 |
| Financing cash flows from finance leases | 5,319 | 5,621 |

Consolidated Financial Statements For the Years Ended June 30, 2021 and 2020, respectively (dollars in thousands)

Weighted average remaining lease term (in years)

| | 2021 | 2020 |
|--------------------------------|-------|-------|
| Operating leases | 7.4 | 8.0 |
| Finance leases | 10.5 | 11.8 |
| Weighted average discount rate | | |
| | 2021 | 2020 |
| Operating leases | 3.27% | 3.61% |
| Finance leases | 3.34% | 3.41% |

The aggregate future lease payments for operating and finance leases as of June 30, 2021 are as follows:

| | Operating | Finance |
|--|-----------|----------|
| 2022 | \$ 3,055 | \$ 7,705 |
| 2023 | 3,081 | 7,078 |
| 2024 | 3,005 | 6,331 |
| 2025 | 2,684 | 6,331 |
| 2026 | 1,691 | 5,829 |
| Thereafter | 5,594 | 35,499 |
| Total lease payments | 19,110 | 68,773 |
| Present values: | | |
| Current lease liabilities | 2,548 | 5,882 |
| Long-term lease liabilities | 14,242 | 51,647 |
| Total lease liabilities | \$16,790 | \$57,529 |
| Difference between undiscounted cash flows | | |
| and discounted cash flows | \$ 2,320 | \$11,244 |

(13) <u>Functional Expenses</u> – The cost of providing Cincinnati Children's services are summarized on a functional basis in the following tables. Accordingly, certain costs have been allocated among functions. Such allocations are determined by management on an equitable basis. The expenses that are allocated include the following:

| Expense | Method of Allocation | | |
|-------------------|----------------------|--|--|
| Employee benefits | Full Time Equivalent | | |
| Depreciation | Square footage | | |
| Utilities | Square footage | | |

The following presents expenses by both their nature and function for the year ended June 30, 2021:

| | | | | | Management | |
|---------------------------|-------------|-----------|-----------|-------------|-------------|-------------|
| | Clinical | Research | Education | Fundraising | and General | TOTAL |
| | | | | | | |
| Salaries | \$ 814,088 | \$186,686 | \$57,395 | \$4,159 | \$196,328 | \$1,258,656 |
| Employee benefits | 204,106 | 51,114 | 11,822 | 1,043 | 79,626 | 347,711 |
| Supplies, drugs and other | 367,962 | 38,150 | 1,936 | 427 | 60,869 | 469,344 |
| Purchased services | 86,164 | 42,605 | 2,258 | 720 | 120,461 | 252,208 |
| Depreciation | 82,628 | 28,282 | 139 | 416 | 27,173 | 138,638 |
| Utilities | 10,967 | 3,754 | 18 | 55 | 3,607 | 18,401 |
| Interest | - | - | - | - | 23,249 | 23,249 |
| | \$1,565,915 | \$350,591 | \$73,568 | \$6,820 | \$511,313 | \$2,508,207 |
| | | | 22 | | | |

| | Clinical | Research | Education | Fundraising | Management and General | TOTAL |
|------------------------------|-------------|-----------|-----------|-------------|---------------------------|-------------|
| | Cinical | Research | Education | Funuraising | and General | IUIAL |
| Salaries | \$ 771,653 | \$182,646 | \$54,929 | \$4,236 | \$192,461 | \$1,205,925 |
| Employee benefits | 189,805 | 46,366 | 14,763 | 1,254 | 71,930 | 324,118 |
| Supplies, drugs and other | 333,008 | 32,113 | 3,266 | 581 | 61,199 | 430,167 |
| Purchased services | 83,223 | 43,344 | 2,422 | 568 | 119,776 | 249,333 |
| Depreciation | 78,555 | 27,553 | 116 | 349 | 23,774 | 130,347 |
| Utilities | 11,557 | 4,054 | 17 | 51 | 3,498 | 19,177 |
| Interest | - | | | | 24,627 | 24,627 |
| | \$1,467,801 | \$336,076 | \$75,513 | \$7,039 | \$497,265 | \$2,383,694 |

The following presents expenses by both their nature and function for the year ended June 30, 2020:

(14) Interest Rate Swap Agreement –

In August 2019, Cincinnati Children's entered into a 10-year interest rate swap agreement in which Cincinnati Children's and the counterparty agree to exchange the difference between fixed rate and variable rate interest amounts calculated by reference to specified notational principal amounts during the agreement period. The objective is to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. Parties to interest rate swap agreements are subject to market risk for changes in interest rates and risk of credit loss in the event of nonperformance by the counterparty.

The following table summarizes the general terms of Cincinnati Children's fixed payment swap agreement as of June 30, 2021:

| Expiration | Countornauty | Interest Data Daid | Interest Data Dessived | Notational |
|-------------|---------------------------|---|-----------------------------------|--|
| Expiration | Counterparty | Kate r alu | Interest Kate Keceiveu | Amount |
| August 2029 | Fifth Third Bank | 1.38% | 1 1 | \$92,165,000 |
| | Expiration August 2029 | ExpirationCounterpartyAugust 2029Fifth Third Bank | Expiration Counterparty Rate Paid | Expiration Counterparty Rate Paid Interest Rate Received |

(15) Subsequent Events -

Management reviewed subsequent events through September 30, 2021, the date the consolidated financial statements were issued, noting no changes are required to the consolidated financial statements or footnotes.

Children's Hospital Medical Center and Affiliates Supplementary Schedule of Expenditure of Federal Awards For the Year Ended June 30, 2021

| | Gov Branch | Award Title | Pass-Through Grantor | Subrecipient Name | Indentifying | Federal Grant Number | CFDA | Sub Exp | Fed Exp | Total Exp |
|------------------------------|--|---|--|---|--|--|--|---------------------------------------|---|--|
| Department of Defense | Military Medical Research and Developmer | Ionic Mechanisms of Resistance to | | | Number | W81XWH1710378 | 12.420 \$ | - \$ | 59,372.00 \$ | 59,372.0 |
| | | Stathmin phosphorylation as a Therapeutic Benefit of Hsp90 Inhibition | University of Cincinnat | University of Cincinnat | 011138-002 | W81XWH1710601 W81XWH1710666 | 12.420 12.420 | - \$ 46,726.00 \$ | 5,087.00 216.085.00 | 5,087.0 262.811.0 |
| | | Mechanisms of acute pain gene | Biotechnology HPC Software Application | onivolaty of onionniat | 5161 | W81XWH1720024 | 12.420 | - \$ | 122,458.00 | 122,458. |
| | | Neurofibromatosis Clinical Consor | University of Alabama-Birminghan | Ohio State University | 000516840-004-T001 | W81XWH1720037 W81XWH1810269 | 12.420 12.420 | - \$ | 6,900.00 238,176.00 | 6,900. 271,271. |
| | | A Novel and Rapid System to C Novel Neuroimaging Assessments | | Onio State University | | W81XWH1810269 W81XWH1810615 | 12.420 | 33,095.00 \$ - \$ | 238,176.00 | 2/1,2/1. 31,373. |
| | | Surviving and Thriving in the | | | | W81XWH1810677 | 12.420 | - \$ | 294,766.00 | 294,766. |
| | | Roleof hepatocyte-derived extracellula Development of Virtual Surger | | | | W81XWH1910038 W81XWH1910043 | 12.420 12.420 | - \$ | 31,023.00 103,537.00 | 31,023. 103,537. |
| | | A Novel FANCD2-Chromatin Bound | | | | W81XWH1910262 | 12.420 | - \$ | 194,922.00 | 103,537. 194,922. |
| | | Single cell analyses of NF1 p | | | | W81XWH1910816 | 12.420 | - \$ | 272,689.00 | 272,689. |
| | | Immune-Schwann cell signaling | | | | W81XWH2010116 | 12.420 | - \$ | 129,457.00 | 129,457. |
| | | Antioxidant Therapy with N-Act Merlin-ASPP2 Tumor Suppressor | | | | W81XWH2010139 W81XWH2010377 | 12.420 12.420 | - \$ - \$ | 221,085.00 160,526.00 | 221,085. 160,526. |
| | | Inflammatory vigor in heterog | | | | W81XWH2010392 | 12.420 | - \$ | 218,923.00 | 218,923.0 |
| | | Inflammatory vigor in heterog Identification of cellular he | | | | W81XWH2010393 W81XWH2010443 | 12.420 12.420 | - \$ | 180,338.00 70,588.00 | 180,338. 70,588. |
| | | The Influence of Social, Educa | Vanderbilt University Medical Cente | | VUMC84410 | W81XWH2010445 | 12.420 | - o - S | 109,016.00 | 109,016. |
| | | Mitochondrial ALR protein def | , | | | W81XWH2010477 | 12.420 | - \$ | 445,530.00 | 445,530. |
| | | Rational Targeting Oncogenic I The role of mitochondria in bo | University of Wisconsin-Madison | | 000000812 | W81XWH2010616 W81XWH2010689 | 12.420 12.420 | - \$ | 124,483.00 88,986.00 | 124,483. 88,986. |
| | | Evaluating the therapeutic pc | | | | W81XWH2010870 | 12.420 | - \$ | 49,771.00 | 49,771.0 |
| | | MBio DARPA Phase II | MBio Diagnostics, Inc. | | IS0000364 | 140D6318C0027 | 12.RD | - \$ | 2,228.00 | 2,228. |
| | | DoD/GEIS project on MDRO globa | Georgetown University Medical Cente | | 411640_GR411625-CCH | MHT001119R0019 Medical Research and Developr | 12.RD | - \$ | 3,378,522.00 | 1,203.0 3,458,343.0 |
| | | | | | wintary i | | | ., | | |
| | | | | | | Department of Defe | ense Total | 79,821.00 | 3,378,522.00 | 3,458,343.0 |
| Department of Educatior | Education Research, Development and Disseminatio | Longitudinal Evaluation of the Impac | Virginia Commowealth Universit | | FP00000519-SA001 | R305A160126 | 84.305 | - | 1,971.00 | 1,971.0 |
| | | Longitudinal Evaluation of SI | | | Education Resear | R305A200028 ch, Development and Dissemina | 84.305 ation Tota | | 218,210.00 220,181.00 | 218,210.0 220,181.0 |
| | | | | | | | | | | |
| | Research in Special Education | Sluggish Cognitive Tempo: Examining it Teaching Academic Success Ski | | | | R305A160064 R324A180053 | 84.324 84.324 | | 148,998.00 324,853.00 | 148,998.0 324,853.0 |
| | | reading roadenie oddeese on | | | | Research in Special Educa | | | 473,851.00 | 473,851.0 |
| | | | | | | | | | | |
| | | | | | | Department of Educa | ition Total | - | 694,032.00 | 694,032.0 |
| Department of Justice | Crime Victim Assistance | VOCA Mayerson 2020 | | | | 2020-VOCA-132924253 | 16.575 | - | 76,047.00 | 76,047.0 |
| | | VOCA Joining Forces 2020 | | | | 2020-VOCA-132924265 | 16.575 | - | 263,430.00 | 263,430.0 |
| | | VOCA Forensic RN 2020 VOCA Mayerson 2021 | | | | 2020-VOCA-132924224 2021-VOCA-133916106 | 16.575 16.575 | | 52,709.00 188.827.00 | 52,709. 188.827. |
| | | VOCA Forensic RN 2021 | | | | 2021-VOCA-133916112 | 16.575 | - | 77,251.00 | 77,251.0 |
| | | | | | | Crime Victim Assista | ance Total | - | 658,264.00 | 658,264.0 |
| | Edward Byrne Memorial Justice Assistance Grant Program | BJA Police Response Training | The Arc of The United States INC | | BJA Police Response Rid | BJA Police Response Ridd | 16.738 | - | 33,537.00 | 33,537.0 |
| | | | | | | I Justice Assistance Grant Prog | gram Tota | - | 33,537.00 | 33,537.0 |
| | | | | | | Department of Just | stice Total | - | 691,801.00 | 691,801.0 |
| National Science Foundation | Biological Sciences | NSF/MCB-BSF:Quantitative analysis and mo | d | University of Cincinnat | | 1715822 | 47.074 | 19,210.00 | 114,323.00 | 133,533.0 |
| | | | | | | Biological Scier | nces Total | 19,210.00 | 114,323.00 | 133,533.0 |
| | Engineering Grants | Accelerating Understanding o | Onu Technology, Inc | University of Cincinnat | 2028008 NSF | 2028008 NSF | 47.041 | 7,015.00 | 11,685.00 | 18,700.0 |
| | | | | | | Engineering Gr | ants Total | 7,015.00 | 11,685.00 | 18,700.0 |
| | | | | | | | | | | |
| | | | | | | National Science Founda | tion Total | 26,225.00 | 126,008.00 | 152,233.0 |
| Department of Energy | | Joint Faculty Agreement No. JF | University of Cincinnat | | 012385-003 | National Science Founda | ation Total 81.RD | 26,225.00 | 126,008.00 76,719.00 | 76,719.0 |
| Department of Energy | | Joint Faculty Agreement No. JF | University of Cincinnat | | 012385-003 | | 81.RD | 26,225.00 - - | | |
| | Occupant Protection Regional Coordinatio | Joint Faculty Agreement No. Jf Occupant Protection Regional Coorr | University of Cincinnat Ohio Department of Healt! | | 012385-003 03130014BB0421 | 4000173601 Department of En 03130014BB0421 | 81.RD ergy Total 20.616 | 26,225.00 - - - - | 76,719.00 76,719.00 27,021.00 | 76,719.0 76,719.0 27,021.0 |
| Department of Transportation | | Occupant Protection Regional Coord | | | | 4000173601 Department of En 03130014BB0421 Department of Transporta | 81.RD ergy Total 20.616 ation Total | - - - - | 76,719.00 76,719.00 27,021.00 27,021.00 | 76,719.0 76,719.0 27,021.0 27,021.0 |
| | Occupant Protection Regional Coordinatio | Occupant Protection Regional Coord | | University of Cincinnat | | 4000173601 Department of En 03130014BB0421 Department of Transporta R01AG053498 | 81.RD ergy Total 20.616 ttion Total 93.866 | 26,225.00 - - - 16,477.00 | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 | 76,719.0 76,719.0 27,021.0 27,021.0 541,067.0 |
| Department of Transportation | | Occupant Protection Regional Coord | | University of Cincinnat | | 4000173601 Department of En 03130014BB0421 Department of Transporta | 81.RD ergy Total 20.616 ation Total | - - - - | 76,719.00 76,719.00 27,021.00 27,021.00 | 76,719.0 76,719.0 27,021.0 27,021.0 |
| Department of Transportation | | Occupant Protection Regional Coort Metabolic alterations in age-asso Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu | | University of Cincinnat | | 4000173601 Department of Em 03130014880421 Department of Transporta R01AG053498 R01AG053605 R01AG063967 R21AG057983 | 81.RD ergy Total 20.616 ttion Total 93.866 93.866 93.866 93.866 | - - - - | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 351.201.00 594,082.00 105,818.00 | 76,719.0 76,719.0 27,021.0 27,021.0 541,067.0 351,201.0 594,082.0 105,818.0 |
| epartment of Transportation | | Occupant Protection Regional Coord Metabolic alterations in age-asso Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu IL-31 Regulation of Immuropati | Ohio Department of Healt | University of Cincinnat | 03130014BB0421 | 4000173601 Department of Enc 03130014B80421 Department of Transporta R01AG053498 R01AG053967 R21AG057983 R21AG057983 R21AG057983 | 81.RD ergy Total 20.616 tion Total 93.866 93.866 93.866 93.866 93.866 93.866 | - - - - | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 351,201.00 594,082.00 105,816.00 49,138.00 | 76,719. 76,719. 27,021. 27,021. 541,067. 351,201. 594,082. 105,816. 49,136. |
| epartment of Transportation | | Occupant Protection Regional Coort Metabolic alterations in age-asso Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu | Ohio Department of Healt | University of Cincinnat | 03130014BB0421 | 4000173601 Department of Em 03130014880421 Department of Transporta R01AG053498 R01AG053605 R01AG063967 R21AG057983 | 81.RD ergy Total 20.616 ttion Total 93.866 93.866 93.866 93.866 | - - - - | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 351.201.00 594,082.00 105,818.00 | 76,719. 76,719 . 27,021. 541,067. 351,201. 554,062. 105,816. 49,136. 33,589. |
| epartment of Transportation | | Occupant Protection Regional Coorr Metabolic alterations in age-asso Role of lockistal muscle asimin Novel mechanism of insettina A novel Research Infrastructu IL-31 Regulation of Immunopati Casua Role of Mitochondrial I Mechanisms in Lamin A functior A Novel Research Infrastructu | Ohio Department of Healt | University of Cincinnat | 03130014BB0421 | 4000173601 Department of En 03130014880421 Department of Transports R0140609305 R0140609305 R0140609305 R0140609503 R2140059503 R2140059633 R21400597803 | 81.RD 20.616 100 Total 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 | - - - - | 76,719.00 76,719.00 27,021.00 524,500.00 351,201.00 354,082.00 105,516.00 49,136.00 33,589.00 86,151.00 231,026.00 | 76,719. 76,719. 27,021. 54,1087. 351,201. 594,082. 105,816. 49,336. 33,589. 86,151. 231,026. |
| epartment of Transportation | | Occupant Protection Regional Coord Metabolic alterations in age-asso Role of skeletal muscle stem (Novel Research Infrastructu L-31 Regulation of Immunopatt Causal Role of Mitochondrial [Mechanism in Lamin A function | Ohio Department of Healt | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 | 4000173601 Department of Enc 03130014880421 Department of Transporta R014C053496 R014C053963 R214C055963 R214C0559633 R214C055933 R214C055933 R214C055933 R214C055933 R214C055933 R214C055933 R214C055933 R214C055933 R214C055933 R214C055933 R214C05798 R214C05798 R2140778 R2140778 R2140778 | 81.RD 20.616 33.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 | - - - - | 76,719.00 76,719.00 27,021.00 524,590.00 351,201.00 554,082.00 105,816.00 33,589.00 88,151.00 231,026.00 283,006.00 | 76,719. 76,719. 27,021. 27,021. 541,067. 351201. 554,082. 105,816. 49,136. 33,589. 86,151.1 231,026. 288,006.1 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coord Metabolic alterations in age-asso Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu L-S1 Regulation of Immunopat Causal Role of Mitochondrial E Mechanism in Lamin A functior A Novel Research Infrastructu Homeostasis and function of ri | Ohio Department of Healt | | 03130014BB0421 TUL-HSC-556566-18/19 | 4000173601 Department of Enc 03130014880421 Department of Transporta R014C0639408 R014C0639607 R214C0659633 R214C0659633 R214C0659633 R214C0614008 R33AC067963 R33AC067963 R55AC0614008 R55AC0614008 R55AC0614008 R55AC061408 | 81.RD 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 | - | 76,719.00 76,719.00 27,021.00 524,590.00 351,201.00 105,816.00 33,589.00 86,151.00 231,028.00 231,028.00 231,028.00 235,006.00 285,006.00 | 76,719. 76,719. 27,021. 541,067. 351,201. 594,082. 105,816. 49,136. 33,889. 86,151. 231,026. 288,006. 2,260,074. |
| epartment of Transportation | | Occupant Protection Regional Coorr Metabolic alterations in age-asso Role of skeletal muscle stem i Novel mechanism of intestin A statistic statistical and the A statistical and the statistical Casas Role of Milochondrial [Mechanisms in Lamin A functior A Novel Research Infrastructu Homeostasis and function of ri Immunological identity redefined b | Ohio Department of Healt | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 | 4000173601 Department of Em 03130014880421 Department of Transporta R0143053498 R0143053695 R0143053695 R0143053695 R0143059635 R0143059635 R0143059635 R0143059635 R0143059635 R014305963 R014305965 R014505965 R014505965 R014505965 R014505965 R014505965 R014505965 R014505965 R014505965 R014505 | 81.RD 20.616 tition Total 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 | | 76,719.00 76,719.00 27,021.00 524,590.00 351,201.00 105,816,00 40,516,50 26,151,00 286,151,00 286,151,00 286,151,00 286,151,00 286,151,00 286,151,00 286,151,00 286,152,00 607,258,00 | 76,719.0 76,719.0 76,719.1 27,021.0 541.067,7 541.067,7 541.067, 351.021,1 544.002, 594.002, 594.002,2 594.002,2 594.002,2 255,0006,2 516,245,0 616,245,0 |
| Department of Transportation | Aging Research | Occupant Protection Regional Coord Metabolic alterations in age-asso Role of skeletal muscle stem (Novel Research Infrastructu L-31 Regulation of Immunopati Causal Role of Mitochondrial E Mechanism in Lamin A functior A Novel Research Infrastructu Homeostasis and function of ri Immunological identity redefined b Matemal microchimerism trans | Ohio Department of Healt | | 03130014BB0421 TUL-HSC-556566-18/19 | 4000173601 Department of Enc 03130014880421 Department of Transporta R01406059065 R01406059067 R2140605963 R2140605963 R2140605963 R2140605963 R214061408 R0140131080 P141131080 P141131080 | 81.RD 20.616 tion Total 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | - | 76,719.00 76,719.00 27,021.00 524,590.00 351,201.00 105,816.00 33,589.00 231,026.00 231,026.00 231,026.00 607,258.00 607,258.00 63,409.00 | 76,719.1 76,719.1 27,021.1 27,021.1 54,067.1 351,201.1 594,082.1 105,816.4 49,136.4 33,589.4 86,151.1 231,026.4 243,006.4 245,006.4 245,006.4 54,006.4 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coord Metabolic alterations in age-asso Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu L-31 Regulation of Immunopati Causal Role of Mitochondrial E Mechanisms in Lamin A functior A Novel Research Infrastructu Homeostasis and function of ri Immunological identity redefined b Maternal microchimerism trans Epithelial antigen presentatii ORMDL3 Regulation of Dendritic Cells | Ohio Department of Healt! Tulane University Tulane University | | 03130014880421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 | 4000173601 Department of Enc 03130014880421 Department of Transporta R01406059005 R01406059005 R0140605903 R2140605903 R2140605903 R2140605903 R214061408 R014131080 F3241451814 F324147591 F324147591 | 81.RD argy Total 20.616 100 Total 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 93.855 93.855 | - | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 351,201.00 105,816.00 33,589.00 231,026.00 231,026.00 231,026.00 607,258.00 63,499.00 67,041.00 162.00 | 76,719. 27,021. 27,021. 54,067. 54,067. 55,002. 105,816. 49,136. 33,569. 86,151. 231,026. 268,004. 235,0074. 61,245. 63,409. 67,041. 162. 163. 162. 163. 1 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coorr Metabolic alterations in age-asso Rökel of skeletal muscle stem (Novel Research Infrastructu L-31 Regulation of Immunopatil Causal Role of Minchondrial E Metabolic Minchondrial E A Novel Research Infrastructu Homeostasis and function of rr Immunological identity redefined b Maternal microchimerism trans Epithelial antigen presentali ORMDL3 Regulation of Dendritic Cells A concept for Gene Therapy fo | Ohio Department of Healt | | 03130014BB0421 TUL-HSC-556566-18/19 | 4000173601 Department of Em 03130014880421 Department of Transports R01AG053498 R01AG05905 R01AG | 81.RD argy Total 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 arch Total 93.855 93.855 93.855 93.855 93.855 | - | 76,719.00 76,719.00 27,021.00 524,590.00 351,201.00 534,082.00 105,816,00 9,21,026,00 9,21,026,00 22,83,006,00 2,243,597,800 607,258,00 607,258,00 607,258,00 607,258,00 607,258,00 162,00 172,00 162,000 162,000 162,000 162,000 | 76,719, 77,721, 27,021, 541,067, 541,075,075,075,075,075,075,075,075,075,075 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coorr Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu Li-31 Regulation of Immunopati Causal Role of Mitochondrial E Mechanism in Lamin A functior A Novel Research Infrastructu Homeostasis and function of r Immunological identity redefined b Maternal microchimerism trans Epithelial antigen presentatii ORMDL3 Regulation of Candritic Cells A concept for Gene Therapy fo Regulation of Gastrointestina | Ohio Department of Healt! Tulane University Tulane University | University of Cincinnat | 03130014880421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 | 4000173601 Department of En 03130014880421 Department of Transportz R0140699605 R0140699605 R0140699605 R014069963 R21406059833 R21406059833 R264020983 R264020984 R3340695470 R3840694775 R204147551 R304126875 P3040505410 R304059888 | 81.RD argy Total 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 93.855 93.855 93.855 93.855 | | 76,719.00 76,719.00 27,021.00 524,580.00 554,580.00 105,816.00 49,136.00 23,589.00 33,589.00 243,026.00 243,026.00 243,026.00 243,026.00 57,041.00 16,536.00 19,536.00 306,579.00 | 76,719. 76,719.1 27,021 54,1067,735 54,1067,735 54,002,105,816,1 49,136,4 33,584,0 24,000,74,1 61,6245,2 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 61,6245,400,74,1 71,6245,400,74,1 71,6245,400,74,1 71,6245,400,74,1 71,6245,400,74,1 71,6245,400,74,1 71,6245,400,74,1 71,6245,400,74,1 71,6245,400,74,1 71,6245,400,745,400 |
| Department of Transportation | Aging Research | Occupant Protection Regional Coorr Metabolic alterations in age-asso Rökel of skeletal muscle stem (Novel Research Infrastructu L-31 Regulation of Immunopatil Causal Role of Minchondrial E Metabolic Minchondrial E A Novel Research Infrastructu Homeostasis and function of rr Immunological identity redefined b Maternal microchimerism trans Epithelial antigen presentali ORMDL3 Regulation of Dendritic Cells A concept for Gene Therapy fo | Ohio Department of Healt! Tulane University Tulane University | | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 | 4000173601 Department of Em 03130014880421 Department of Transports R01AG053498 R01AG05905 R01AG | 81.RD argy Total 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 arch Total 93.855 93.855 93.855 93.855 93.855 | - | 76,719.00 76,719.00 27,021.00 27,021.00 554.4580.00 105.816.00 105.816.00 105.816.00 105.816.00 233.0580.00 233.0580.00 233.056.00 234.006.00 2,243.597.00 607.258.00 63.408.00 63.408.00 63.408.00 63.408.00 63.7579.00 305.579.00 305.579.00 | 76,719, 77,721, 27,021, 541,067, 541,075,075,075,075,075,075,075,075,075,075 |
| Department of Transportation | Aging Research | Occupant Protection Regional Coorr Metabolic alterations in age-asso Role of skeletal muscle stem (Novel Research Infrastructu Li-31 Regulation of Immunopati Causal Role of Mitochondrial (Mechanisms in Lamira A function A Novel Research Infrastructu Homeostass and function of r Immunological identity redefined b Maternal microchimerism trans Egithielia antigen presentatii ORMDL3 Regulation of Dendritic Cells A concept for Gene Therary to Regulation of Gastrointestina Egidemiologic Impact of HPV vi GM-CSF-Induced Metal Sequestri | Ohio Department of Healt! Tulane University Tulane University | University of Cincinnat | 03130014880421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 | 4000173601 Department of Em 03130014880421 Department of Transports R01AG053498 R01AG059805 R21AG059805 | 81.RD 20.616 ttion Total 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 93 | | 76,719.00 76,719.00 27,021.00 524,590.00 351,201.00 534,862.00 105,816.00 33,589.00 24,015.00 24,006.00 24,006.00 24,006.00 60,7258.00 67,741.00 67,741.00 67,7536.00 306,579.00 375,052.00 19,237.00 | 76,719, 77,713, 27,021, 541,067, 351,201, 105,816,4 49,136,4 49,136,4 49,136,4 28,006,1 28,006,1 28,006,1 28,006,1 28,006,1 105,251,5 615,245,5 615,2 |
| Department of Transportation | Aging Research | Occupant Protection Regional Coorr Metabolic alterations in age-asso Role of skeletal muscle stem i Market and the stem in the stem A hoved Research Infrastructul L-31 Regulation of Immunopati Casal Role of Mitochondrial E Mechanisms in Lamin A functior A hovel Research Infrastructu Homeostasis and function of re Immunological identity redefined b Matemal microchimerism trans Epithelia altigen presentation of Dendritic Cells ARMDL3 Regulation of Dendritic Cells Apequiation of Gastronitesha Epidemiologic Impact of HPV Vi GM-CSF-Induced Metal Sequestri Role df 62AP in Regulation Infram | Ohio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 | 4000173601 Department of Em 03130014880421 Department of Transporta R014069369 R014069365 R014069365 R014069365 R014069365 R014069365 R014069583 R054059783 R054059783 R054059783 R054059783 R05405985 R05405983 R05405985 R0555985 R0555985 R0555985 R0555985 R0555985 | 81.RD rgy Total 20.616 tion Total 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 93.855 93.855 93.855 93.855 | | 76,719.00 76,719.00 27,021.00 27,027.00 524.580,00 105,816,00 105,816,00 105,816,00 105,816,00 105,816,00 231,026,00 231,026,00 234,093,00 607,258,00 63,409,00 67,041,00 105,757,00 305,577,00 | 76,719.1 76,719.1 27,021.1 541,007.7 541,007.7 541,007.1 540,002.2 105,816.1 49,186.1 35,569.4 68,151.1 231,026.1 288,006.4 53,409.4 616,245.1 63,409.4 67,041.1 105,65 105,577.4 105,65 105,577.4 105,65 105,577.4 105,65 105,577.4 105,657.4 105,577.4 105,657.4 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coorr Metabolic alterations in age-asso Role of skeletal muscle stem (Novel Research Infrastructu Li-31 Regulation of Immunopati Causal Role of Mitochondrial (Mechanisms in Lamira A function A Novel Research Infrastructu Homeostass and function of r Immunological identity redefined b Maternal microchimerism trans Egithielia antigen presentatii ORMDL3 Regulation of Dendritic Cells A concept for Gene Therary to Regulation of Gastrointestina Egidemiologic Impact of HPV vi GM-CSF-Induced Metal Sequestri | Ohio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 | 4000173601 Department of Em 03130014880421 Department of Transports R01AG053498 R01AG059805 R21AG059805 | 81.RD 20.616 ttion Total 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 93 | | 76,719.00 76,719.00 27,021.00 524,590.00 351,201.00 534,862.00 105,816.00 33,589.00 24,015.00 24,006.00 24,006.00 24,006.00 60,7258.00 67,741.00 67,741.00 67,7536.00 306,579.00 375,052.00 19,237.00 | 76,719, 77,713, 27,021, 541,067, 351,201, 105,816,4 49,136,4 49,136,4 49,136,4 28,006,1 28,006,1 28,006,1 28,006,1 28,006,1 105,251,5 615,245,5 615,2 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coorr Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu Li-31 Regulation of Immunopati Causal Role of Mitochondrial (Mechanisms in Lamira A function A Novel Research Infrastructu Homeostass and function of r Immunological identity medefined b Maternal microchimerism trans Egithielia antigen presentati ORMD13 Regulation of Dendritic Cells A concept for Gene Theray to Regulation of Gastrointestina Epidemiologic Impact of HPV Vi GMC-GS-Induced Metal Sequestr Role of BCAP In Regulating Inflamm Lcitruling and anti-Uberculosis host | Ohio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi University of Cincinnat | University of Cincinnat | 03130014880421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 | 4000173601 Department of Em 03130014880421 Department of Transports R01AG053498 R01AG059805 R01AG059805 R01AG059805 R01AG059805 R01AG059805 R01AG059805 R01AG059805 R01AG059805 R01AG059805 R01A102695 R01A102695 R01A102695 R01A110259 R01A1102505 R01A1102605 R01A1122002 | 81.RD 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 351,201.00 536,402.00 105,816,00 33,589,00 231,026,00 231,026,00 231,026,00 60,728,00 60,728,00 60,728,00 60,728,00 60,728,00 122,00 375,022,00 19,237,00 (22,838,00) 223,370,00 | 76,719. 77,719. 27,021. 541,067. 541,067. 541,067. 351,201. 544,062. 105,816. 443,136. 443,136. 33,569. 230,000. 230,000. 230,000. 230,000. 448,646. 19,237. (22,838. 19,237. (22,838. 19,237. (22,838. 19,237. (22,838. 19,237. (22,838. 19,237. (22,838. 19,237. (22,838. 19,237. (22,837. (22,837. (22,837. (22,837. (22,837. (22,837. (22,837. (22,837. (22,837. (22,837. (22,837. (22,837. (23,837. |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coorr Metabolic alterations in age-asso Role of skeletal muscle stem i Network and the stem of the stem of the stem A reverse field of the stem of the stem Causal Role of Mitochondrial f Mechanisms in Lamin A functor A lovel Research Infrastructu Homeostasis and function of re Immunological identity redefined b Maternal microchimerism trans Epithelial antigen presentatia ORMDL3 Regulation of Dendritic Calls A concept for Gene Therapy to Regulation of Gastrointestina Epidemiologic Impact of HPV vi CM-CSF-Induced Metal Sequestri Role ARCAP in Regulating Inflamm L-citrulline and anti-tuberculosis host Maternal Regulatory T oll antigen-specific Instate Mechanisms Reg of Memory TH17 A novel lacit acid bacteria | Ohio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 | 4000173601 Department of Em 03130014880421 Department of Transportar R0142683980 R0142683980 R0142683980 R0142683980 R0142683980 R01426878 R01408983 R01408983 R01408983 R01408983 R01408983 R014128675 R0141042895 R0141042895 R0141106289 R01411055 R0141106289 R01411055 R0141106289 R01411255 R0141116688 R01411255 R0141116688 R01411255 R014111255 R014111255 R014111255 R014112565 R014112565 R014112565 R014112565 R014112565 R014112565 R014112565 R014112565 R014112565 R01411257 R014112565 R01411257 R01411257 R0141123176 R01412 | 81.RD 20.616 33.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 505,452,010 354,452,00 105,462,00 105,462,00 105,462,00 105,4589.00 288,006,00 228,006,00 67,258,00 67,258,00 67,258,00 67,258,00 119,257,00 306,579,300 306,579,300 306,579,300 306,579,300 306,579,300 306,579,300 307,5062,00 119,237,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 228,3370,00 235,3350,00 235,3350,00 235,3350,00 235,3350,00 235,3350,00 235,3350,00 235,3350,00 235,350,00 235,350,00 235,350,0 | 76,719. 27,021. 27,021. 54,1067. 54,1067. 54,1067. 54,1067. 54,1067. 54,1067. 54,106. 288,006. 288,006. 54,009. 56,041. 10,258. 53,409. 54,049. 54,049. 55,031. 10,228. 54,059. 55,031. 55,0 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coord Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu Li-31 Regulation of Immunopati Causal Role of Minochondrial E Mechanisms in Lamira A Introitor A Novel Research Infrastructu Homeostassis and function of r Homeostassis and function of r Maternal microchimerism trans Epithelia Indigen presentatia ORMDL3 Regulation of Dendritic Cells A concept for Gene Therapy to Regulation of Gastrointestina Epidenia (joc Impact of HV V si GM-CSF-Induced Metal Sequestra Role of BCAP In Regulating Inflamm L-dirtuing and anti-Uberculosis hoad Maternal Regulatory T cell antigen-speci Innate Mechanisms Reg of Memory THI 2 | Ohio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi University of Cincinnat | University of Cincinnat | 03130014880421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 | 4000173601 Department of Em 03130014880421 Department of Transporter R0142083480 R0142083480 R0142083980 R0142083980 R014208983 R014208983 R014008983 R014008983 R01410898 R014108 R014108280 R0141108280 R0141108280 R0141108280 R0141108280 R0141108280 R0141108280 R0141108280 R0141108280 R014112376 R01412376 R0141237 | 81.RD 20.616 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 76,719.00 27,021.00 524,590.00 916,516.00 146,516.00 146,516.00 146,516.00 235,026.00 236,006.00 67,041.00 67,258.00 67,258.00 667,258.00 667,258.00 112,257,00 337,505,200 122,370,00 235,370,00 245,370,000 245,370,00025,370,000 245,370,0000000000000000000000000000000000 | 76,719. 77,719. 27,021. 54,107. 55,107. 55, |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coorr Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu Li-31 Regulation of Immunopati Causal Role of Mitochondrial (Mechanisms In Lamira A function A Novel Research Infrastructu Homeostasis and function or In Immunological Identity medefined b Maternal microchinewism tarins Egithelia region presentatio (RMIDL3 Regulation of Danrittic Cells A concept for Cenno Therary Io Regulation of Gastrointestina Epithemiogic Impact of HPV vi CMC-95-Induced Metal Sequestri Role of BCAP in Regulating Inflamm L-dirtuine and anti-uberculosis host Maternal Regulatory T cell antigen-speci Innate Mechanisms Reg of Memory THT A novel lactic acid bacteria-based nor Functional immuno tolerance to nor Dendritic cell KL2PNotch Axis and Thic Rola de Regulation of TX | Chio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi University of Cincinnat | University of Cincinnat | 03130014880421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011836-003 R01A1123661 | 4000173601 Department of Enc 03130014880421 Department of Transporter R01AG053498 R01AG053965 R21AG05963 R21AG05963 R21AG05963 R21AG05963 R21AG05963 R21AG05963 R21AG05963 R21AG05963 R21AG05963 R21AG05963 R01AG05963 R01A102695 R01A102695 R01A1102695 R01A1102695 R01A1102695 R01A1122657 R01A1226657 R01A1226657 R01A1226657 R01A1226657 R01A1226657 R01A1226657 R01A1226657 R01A1226657 R01A1226657 R01A1226815 R01A1226657 R01A1226657 R01A1226815 R01A1226657 R01A122667 R01A12667 R01A1267 R01A1267 R01A1267 R01A1 | 81.RD 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 355,201.00 105,816.00 33,589.00 23,1026.00 23,1026.00 23,1026.00 64,409.00 67,641.00 67,241.00 162,00 305,579.00 375,062.00 102,283.00 3375,062.00 3375,000 3375 | 76,719. 76,719. 27,021. 541,067. 554,062. 105,816. 49,136. 33,589. 88,151. 231,026. 248,006. 248,007. 2,260,074. 616,245. 62,040. 63,007. 248,074. 19,237. (28,83,370. 19,237. (28,3370. 556,031. 19,237. (28,3370. 557,352. 448,646. 19,237. (28,3370. 557,352. 448,646. 19,237. (28,3370. 557,352. 47,741. 386,637. 27,369. 67,2210. (27,210. (2 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coorr Role of skeletal muscle stem r Novel mechanism of intestina A Novel Research Infrastructual Cause Part of Microbiothy and Cause A Novel Research Infrastructual Cause Park of Microbiothy A Novel Research Infrastructual Horhanisms in Lamin A functior A Novel Research Infrastructual Horhanisms in Lamin A function Research Infrastructual Control (Cause Control (Cause Cause) (Cause Control (Cause A concept for Gene Therapy to Regulation of Gastrontestina Epidemiologic Impact of HPV Vs Chief of GAP In Regulatory Tool antigen-sper Infrastructual Cause Cause Infrastructual Maternal Regulatory Tool antigen-sper Innate Mechanisms Reg of Memory TH17 A novel Incidic acid bacteria-based nor Dendritic Cal (KL-2P) Noth Axis and Tho Role and Regulatory Tool (Cals LP) in Chik Role and Regulator) of TSLP in Chik | Chio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi University of Cincinnat | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A1123661 R01A1128818 | 4000173601 Department of Em 03130014880421 Department of Transporter R01430053408 R0143005905 R0143005905 R0143005905 R0143005905 R0143005905 R0143005905 R01441008 R0144104598 R0141131285 R0141192875 R014128176 | 81.RD 20.616 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 76,719.00 27,021.00 524,590.00 351,201.00 1534,046.00 163,616.00 163,616.00 235,026.00 238,006.00 63,409.00 67,258.00 63,409.00 67,258.00 63,409.00 337,052.00 19,253,00 336,579.00 (22,538,00) 235,352.00 19,253,00 235,352.00 19,253,00 235,352.00 19,253,00 255,3741.00 355,352.0 | 76,719) 77,7191 27,0211 541,067 351,201 144,106 351,201 144,106 351,201 144,106 144,106 144,002 144,002 144,002 144,002 144,002 144,002 144,002 144,002 144,002 145 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coorr Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructu Li-31 Regulation of Immunopati Causal Role of Mitochondrial (Mechanisms In Lamira A function A Novel Research Infrastructu Homeostasis and function or In Immunological Identity medefined b Maternal microchinewism tarins Egithelia region presentatio (RMIDL3 Regulation of Danrittic Cells A concept for Cenno Therary Io Regulation of Gastrointestina Epithemiogic Impact of HPV vi CMC-95-Induced Metal Sequestri Role of BCAP in Regulating Inflamm L-dirtuine and anti-uberculosis host Maternal Regulatory T cell antigen-speci Innate Mechanisms Reg of Memory THT A novel lactic acid bacteria-based nor Functional immuno tolerance to nor Dendritic cell KL2PNotch Axis and Thic Rola de Regulation of TX | Chio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi University of Cincinnat | University of Cincinnat | 03130014880421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A1123661 R01A1128618 R01A1126818 R01A1120103 R01A1120103 R01A1120103 | 4000173601 Department of Em 03130014880421 Department of Transporter R01430053408 R0143053905 R0143053905 R0143053905 R0143053905 R014305905 R014305905 R014305905 R0144154184 R034125675 R01411045808 R0144125675 R01411045808 R014110205 R014110205 R014110205 R014110205 R014110205 R0141122561 R01412361 R014123621 R014123621 R014123621 R014123621 R014123621 R014123621 R014123621 R014123621 R014123621 R014123621 R014123621 R014123621 R01413033 R01413013 R01413013 R0141239 R01413013 R0141239 R01413013 R01413013 R01413013 R01413013 R0141239 R0141239 R0141239 R01413013 R0 | 81.RD 20.616 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 76,719.00 27,021.00 27,021.00 351,201100 351,201100 364,802.00 36,889.00 36,889.00 37,889.00 2243,897.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 306,579.00 305,579.00 375,062.00 119,237.00 324,377.00 324,377.00 324,377.00 325,237.00 325,237.00 327,241.00 327,00 347,741.00 327,241.00 327,241.00 327,00 347,741.00 327,241.00 327,241.00 327,00 347,741.00 327,241.00 327,241.00 327,00 347,741.00 327,3450.00 347,741.00 347,745,745,745,745,745,745,745,745,745,7 | 76,719. 76,719. 27,021. 541,067. 351,201. 544,062. 105,816. 34,0589. 36,589. 36,589. 27,800. 27,800. 27,800. 44,548. 61,245. 63,409. 67,041. 19,536. 306,579. 448,646. 19,237. (22,83,370. 562,031. 37,741. 37,741. 37,759. |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coord Metabolics alternatives in age-asso Role of kolotati muscles assemits Novel mechanism of insettin L-31 Regulation of insettinuch L-31 Regulation of Inmunopati Causal Role of Mitochondrial I Mechanisms in Lamin A functior A I word Research Infrastructu Homeostasis and function of r Immunological identity medefined b Maternal microchimerism trans Epithelia adingen presentariliati Colle A concept for Gamo Tharagy fo Regulation of Gastrontestina Epithelia Regulatory T call anigen-spec Infrastructure and Infrastructures Role of BCAP In Regulating Inflamm L-citrulline and anit-luberculosis host Maternal Regulatory T call anigen-spec Innate Mechanisms Reg of Memory Th17 A novel lacic acid bacteria based nor Functional Immune Iolerance to nor Functional Immune Iolerance to nor Role of Acidos in cosinophilic astim Role of Acidos in cosinophilic astim Role and Regulation T calls in Chil Role and Regulation T calls in Chil Role and Regulation T calls in Chil Role and Regulation of TSL in Chil | Chio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi University of Cincinnat Ohio State Universit University of Cincinnat University of Cincinnat University of Cincinnat Northwestern University Medical Schoor | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A1123661 R01A1126818 R01A1126818 R01A1130692 | 4000173601 Department of Lane 3130014880421 Department of Transportar 80140609405 80140609405 80140609405 80140609405 80140609405 80140609405 801401408 8034065470 8034065470 8034065470 80340155 803405410 80341140565 803405410 8034114055 8034014104709 80141140588 8014114058 | 81.RD 20.616 33.866 33.866 33.866 33.866 33.866 33.866 33.866 33.866 33.865 33.855 | | 76,719.00 76,719.00 27,021.00 27,021.00 524,580.00 351,201.00 354,082.00 365,861.00 33,589.00 365,861.00 233,0580.00 363,0580.00 363,059.00 375,062.00 375,062.00 375,062.00 375,062.00 375,062.00 375,370.00 363,370.00 376,371,00 376,371,00 377,2741.00 377,3741.00 377,374 | 76,719 76,719 27,021 27,021 54,1057 55,1201 55,4022 105,816 49,136 33,589 86,151 231,025 2280,007 2280,074 61,025 238,005 2280,074 61,025 305,579 305,579 305,579 315,352 448,84646 448,846 448,846 448,84646 448,846 448,84646 448,846 448,84646,846 448,84646 448,846 448,84646 448,846 448,84646 448,846 448,84646 448,846 448,84646 448,846 448,84646 448,84646 448,846 448,84646 448,84646 448,84646 448,846 448,84646 448,84646 448,84646 448,84646 468,84646 468,84646 468,84646 468,84646 468,84646,846 468,84646,846 468,84646,846 468,84646,846 468,84646,846 468,84646,846 468,84646,846 468,84646,846 468,84646,846 468,84646,846 468,84646,846 468,84646,846 468,846,84646,846 468,846,84646,846,84646,846,846,84646,846,846,846,84 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coord Robel of Skeletal muscle stem (Novel mechanism of Intestina A Novel Research Infrastructul L-31 Regulation of Immunopail Ocusal Robe of Mimim Antinal for Robel Research Infrastructul Homeostasis and function of rr A Novel Research Infrastructul Homeostasis and function of rr Movel Research Infrastructul Homeostasis and function of rr Robel antigen presentati ORMDL3 Regulation of Dendritic Colls A concept for Gene Therapy to Regulation of Gastrointestina Epidenialogic Impact of HVV ki CMI-CSF-Induced Metal Sequestri Robel of BCAP in Regulating Inflarm Lotituling and anti-Ubercalis in host Maternal Regulatory T cell antigen-speci Innata Mechanisms Reg of Memory TH17 A Shot of BCAP in Regulating Inflarm Lotituling of KL:25Piord Net Asia and Tri- Dendritic OKL:25Piord KAS and Tri- Robe and Regulation of TSLP in Chik Robe and Roberg Sudy-Food Metary Outcomes ForRWARD Study-Food Metary Outcomes ForRWARD Study-Food Metary Outcomes | Chio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi University of Cincinnat University of Cincinnat Diversity of Cincinnat Diversity of Cincinnat Diversity of Cincinnat Diversity of Cincinnat | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A1123661 R01A1123661 R01A11236818 R01A161250 CCHMC R01A112369-S001 | 4000173601 Department of Em 03130014880421 Department of Transporter R01430053408 R0143053905 R0143053905 R0143003905 R0143003905 R0143003905 R0143003905 R014131000 R0141145184 R014128675 R014110269 R014110269 R014110229 R014110229 R014110229 R014110229 R014110229 R0141122575 R014122675 R014126 | 81.RD 20.616 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 351,201100 105,818,00 36,589.00 231,026.00 231,026.00 234,009.00 67,258.00 67,258.00 67,258.00 67,258.00 67,258.00 67,258.00 306,579.00 305,579.00 337,052.00 119,257.00 562,031.00 347,741.00 347,741.00 347,741.00 347,741.00 347,741.00 377,022.10.00 377,2210.00 377,2210.00 377,2210.00 377,2210.00 377,7210.00 377,7210.00 377,7210.00 377,7210.00 377,7210.00 377,7210.00 377,7210.00 377,7210.00 377,7210.00 377,700 377,7210.00 377,7210.00 377,7210.00 377,720 377,7210.00 377,72 | 76,719 77,79 27,021 27,021 541,067 541,067 541,067 541,067 541,067 541,067 541,067 541,067 240,077 612,245 63,409 67,041 162,245 63,409 67,041 162,245 63,409 67,041 19,237 (22,83,770 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 562,012,3570 57,750 50,355 55,421 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coord Metabolic alterations in age-asso Role of skeletal muscle stem i Metabolic alterations in age- Role of Michonol (International Construction 1-31) Regulation of Immunopati Casal Role of Michonondrial E Mechanisms in Lamin A functior A Novel Research Infrastructu Homeostasis and function of re Immunological identity redefined b Maternal microchimerism trans Epithelia attigen presentation ORMDL3 Regulation of Dendritic Cells Appuident of Carlon Phage Regulatory Carlon Dendritic Cells Appuident of Carlon Phage Epithelia Information of Dendritic Cells Appuident of Carlon Phage Epithelia Information of TSU Role of BCAP in Regulating Inflamm L-citrulline and anti-tuberculosis host Maternal Regulatory T cell antigen-spec Innate Mechanisms Reg of Memory TH17 A novel lacit caid bacteria-based nor Functional immune tolerance to nor Dendritic cell KL2PNotch Nots and Th2 Role and Regulation of TSLP in Chin Wing Antiboly optightmed maint Forward Reparite prediction of Forward Reparite prediction Forward Reparite prediction of Forward Reparite prediction of Forward Reparite prediction for Forward Reparite prediction of Forward Reparite prediction of Forward Reparite prediction of Forward Reparite prediction of Forward Reparite prediction for SLP in Chin Reparite Prediction of FSLP in Chin Reparite Prediction of TSLP in Chin Reparite Reparite Prediction of Forward Reparite prediction of Forward Reparite Prediction of TSLP in Chin Reparite Prediction of TSLP in Ch | Chio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi University of Cincinnat Ohio State Universit University of Cincinnat University of Cincinnat University of Cincinnat Northwestern University Medical Schoor | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A1123661 R01A1126818 R01A1126818 R01A1130692 | 4000173601 Department of Lane 3130014880421 Department of Transportar 80140609365 80140609365 80140609365 80140609365 8014063963 8214063963 82340639783 825401408 83340639783 8254014756 80141414586 801411414586 80141141668 80141141668 80141141668 80141141668 80141141668 80141141668 80141141668 80141141668 80141141668 80141141668 80141141668 801411416 | 81.RD 20.616 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 76,719.00 27,021.00 27,021.00 524,580.00 105,816.00 48,1380.00 231,025.00 231,025.00 243,006.00 2,243,097.00 607,258.00 607,258.00 305,757.00 307,578.00 305,757.00 30 | 76,719 77,747 27,021 27,021 54,1057 55,021 55,021 55,022 2280,074 616,245 63,409 67,041 15,553 30,557 30,557 30,577 30,577 35,307 55,217,366 67,214 35,327,3 |
| partment of Transportation | Aging Research | Occupant Protection Regional Coor Netabolic alterations in age-asso Role of skeletal muscle stem i Net in Mark State State (State And State State) And State State State State And State State State State And State State State And State State State And State State State State | Chio Department of Healt Tulane University Tulane University University of North Carolina at Chapel Hi University of Cincinnat University of Cincinnat University of Cincinnat University of Cincinnat University of Cincinnat University of Cincinnat Northwestern University Medical Schoc Phor Physical Medical Schoc Phor Physi | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01Al123661 R01Al126818 R01Al126818 R01Al126818 R01Al132692 A180-655-5001 R01Al139126 | 4000173601 Department of Enc 03130014880421 Department of Transporter R01430039005 R0143003905 R0143003905 R0143003905 R0143003905 R0143003905 R014103020 R0141102020 R0141102020 R0141102202 R0141102202 R0141102202 R0141102202 R014112256 R014112256 R014112266 R01411236 R01411236 R01411236 R01411236 R01411236 R01411236 R01411326 R0141326 R014136 | 81.RD 20.616 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 351,201.00 534,682.00 105,816,00 353,587,00 27,243,587,00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 607,258.00 712,210,00 335,152,200 47,741,00 272,210,00 273,210,00 273,200 273,200 273,200 273,200 273,200 273,200 273,200 273,200 273,200 274,200 274,200 274,200 274,200 274,200 274,200 274,200 274,200 274,200 274,200 275,200 275,200 275,200 275,200 275,200 275,200 275,200 275,200 275, | 76,719 77,79 27,021 541,067 541,067 541,067 541,067 541,067 351,201 541,067 351,201 2285,000 2,285,000 2,285,000 67,041 162,53 562,037 19,253 300,579 448,654 19,237 (22,858 235,370 562,031 351,352 235,370 562,031 357,352 27,250 562,031 357,352 27,250 562,031 357,352 27,250 562,031 357,352 27,250 562,031 357,352 27,250 562,031 357,352 27,250 562,031 357,352 27,250 57,253 57,753 57,753 57,553 55,5421 22,8588 55,5421 22,8588 55,5421 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coord Role of skeletal muscle stem (Novel mechanism of intestina A Novel Research Infrastructul LL-31 Regulation of Immunopatil Causal Role of Minochondrial E Marken and Statistical Statistical A novel Research Infrastructul LL-31 Regulation of Immunopatil Causal Role of Minochondrial E Marken and Statistical Statistical A novel Research Infrastructul Homeostasis and function of r Maternal microchimerism trans Epithelial antigen presentati ORMDL3 Regulation of Dendritic Cells A concept for Gene Therapy to Regulation of Gastrointestina Epidenilogic Impact of HV vis CMA-CSF-Induced Metal Sequestri Role of BCAP in Regulating Inflamm L-dituling and anti-Ubercalosis host Maternai Regulatory T cell antigen-speci Innate Mechanisms Reg of Memory THT2 A novel lactic acid bacteria-based nor Functional Immuno tolerance to nor Dendritic cell KL-ENOtot A Den Mito Role of McOS Induced Metal Sequestri Role of BCAP in Regulating Inflamm L-distructional Immuno tolerance to nor Dendritic cell KL-ENOtot A Den Mito Role of McOS Induced Metal Metary Outcomes Forward genetic prediction and Role of Mitorobime in Northoration Eratif Reference Suppreservolet against FORWARD Study-Food Metary Outcomes Forward genetic prediction and Role of Metary Outcomes A Role of TET1 in ainvarge uptithe | Chio Department of Healt Tulane University Tulane University Univ of North Carolina at Chapel Hi University of Cincinnat University of Cincinnat Diversity of Cincinnat Diversity of Cincinnat Diversity of Cincinnat Diversity of Cincinnat | University of Cincinnat Indiana University University of California | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A1123661 R01A1123661 R01A11236818 R01A161250 CCHMC R01A112369-S001 | 4000173011 | 81.RD 20.616 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | 16,477.00 | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 351,201.10 534,082.00 105,816,00 335,415,00 335,415,00 335,415,10 637,025,00 607,258,00 67,041,00 67,041,00 67,041,00 67,041,00 67,041,00 19,237,00 19,237,00 (22,838,00) 375,052,00 19,237,000 562,031,00 27,363,00 572,360,00 335,352,00 47,741,00 77,241,400 77,241,400 77,241,400 77,241,400 77,241,400 77,241,400 77,241,400 77,241,400 77,241,00 55,273,000 55,273, | 76,719 76,749 27,021 541,067 541,067 541,067 541,067 541,067 541,067 541,067 541,067 541,067 27,007 27,8007 27,8007 27,8007 27,8007 448,646 19,237 19,237 448,646 19,237 19,253 147,741 386,637 27,356 67,041 19,253 147,741 386,637 27,356 67,041 19,253 19,253 19,253 19,257 19,257 10, |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coor Role of skeletal muscle stem i Net of skeletal muscle stem i Net of skeletal muscle stem i Net of the stem i And one st | Chio Department of Healt! Lulane University Lulane University University of Cincinnat Chio State University University of Cincinnat Northwester University Medical Schoc The Reports of the Univ of Californi Wake Forest University Health Science: University of Cincinna-Davit | University of Cincinnat | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A123661 R01A123661 R01A126818 R01A130123 A18-0558-5001 R01A139126 SUBK00011618 | 4000173001 | 81.RD 20.616 31.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.865 93.85593.855 93.855 93.855 93.85593.855 93.855 93.855 93.85593.855 93.855 93.85593.855 93.855 93.85593.855 93.855 93.85593.855 93.85593.855 93.855 93.85593.855 93.855 93.85593.855 93.85593.855 93.85593.855 93.85593.855 93.85593. | | 76,719.00 76,719.00 27,021.00 524,520,00 351,221,00 354,250,00 354,250,00 355,250,00 355,250,00 355,350,00 355,350,00 367,258,00 375,062,00 375,062,00 375,062,00 375,062,00 375,352,00 355,370,0 | 76,719 77,797 27,021 541057 551201 5512000 5512000 55120000000000 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coort Metabolic alterations in age-asso Röte of skeletal muscle stem (Novel Research Infrastructul L-31 Regulation of Immunopatil Causal Role of Minochondinal E Mechanisms in Lamin A Hunchon A hove Research Infrastructul L-31 Regulation of Immunopatil Causal Role of Minochondinal E Methemissis and function of r Homos Research Infrastructul A hove Research Infrastructul A mono Research Infrastructul Research Infrastructul A mono Research Infrastructul Research Infrastructul A mono Research Infrastructul Research Infrastructul Research Infrastructul CMMDL3 Regulation of Dendritic Cells A concept for Gene Therapy Io Regulation of Gastrointestina Epidemiologic Impact of HPV Vs GM-CSF-Induced Metal Sequestri Role of BCAP In Regulating Inflamm L-ditruling and anti-Ubercalisis host Maternai Regulatory T cell antigen-speci Innate Mechanisms Reg of Memory TH17 A novel lactic acid bacteria-based nor Functional Immune tolerance to nor Dendritic cell KLF2Notch Axis and Th2 Role of MCDS Study-Food Metagy Outcomes Forward pretic prediction and Regulation Of TSD Study-Food Metagy Outcomes Forward preteil prediction and Role of Microbiome in Neonati Early life factors, gene-envi Translational Regulation of Cl SLGMA3 regulation of Cl SLGMA3 regulation of Study-Food Antery Othemation Role of Microbiome in Neonati Early B Progesterone induced Immune mi | Chio Department of Heatt Tulane University Tulane University University of North Carolina at Chapel Hi University of Cincinnat University of Cincinnat | University of Cincinnat Indiana University University of California | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A1123661 R01A1126818 R01A1126818 R01A1126818 R01A112585001 R01A112585001 R01A1139126 SUBK00011618 A20-04945001 | 4000173011 Department of Em 03130014880421 Department of Transporter R0140059305 R014005905 R014005905 R014005905 R014005905 R014005905 R01401590 R01401590 R01401490 R01400 R01400 R01400 R01400 R01400 R01 | 81.RD 20.616 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | 16,477.00 | 76,719.00 76,719.00 27,021.00 27,021.00 524,590.00 351,201.00 534,082.00 105,816,00 33,581.00 92,205,00 27,80,006,00 27,80,006,00 27,80,006,00 27,80,006,00 27,80,006,00 27,80,006,00 375,052,00 375,052,00 375,052,00 375,052,00 375,052,00 375,052,00 375,052,00 375,052,00 335,352,00 47,741,00 27,369,00 562,031,00 56 | 76,719 27,021 27,021 541,067 541,067 541,067 351,201 105,816 431,156 33,517 2,260,074 2,260,074 102,278,0079 2,260,074 102,278,0079 448,674 102,278 102,278,0079 448,674 102,278 102,278,0079 448,674 102,278 103,557 27,350 562,031 351,352 47,741 386,637 27,350 562,031 351,352 47,741 386,637 27,350 552,512 47,741 386,637 27,350 552,512 47,742 355,5421 22,580,672 100,557 51,522 43,755 33,575 53,577 22,580 53,577 53,577 53,577 53,577 54,521 55,5421 53,577 53,577 54,521 54,521 54,521 55,5421 53,577 53,577 53,577 53,577 53,577 54,521 54,522 55,5421 53,577 53,577 53,577 53,577 54,522 54,522 54,522 54,522 55,522 54,522 55,525 55,522 55,525 55,522 55,525 55,522 55,525 55,522 55,525 55,522 55,525 55,55 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coor Metabolis alterations in age-asso Role of kolvital muscle asimn i Novel mechanism of intestina A lovel Research Infrastruchu L-31 Regulation of Inmunopati Causal Role of Mitcchondrial I Mechanisms in Lamin A functior A lovel Research Infrastruchu Homeostasis and function of re Immunological identity redefined b Metamial microchinensism trans Egidemiologic Impact of Motion Collis A concept for Gene Therapy to Regulator of Castronitestina Epidemiologic Impact of HPV vis GM-CSF-Induced Metal Sequestri Role of BCAP In Regulating Inflamm L-citruline and anti-luberculosis host Matemia Regulatory T cells A novel Regulatory T cells A novel Regulatori of Dentritic Cells A concept for Gene Therapy to Regulatori of Castronitestina Epidemiologic Impact of HPV vis GM-CSF-Induced Metal Sequestri Role of BCAP In Regulating Inflamm L-citruline and anti-luberculosis host Matemia Regulatory T cells Role of Aclos in essinghilic astim Wimy antibody isolypes protect agains FORWARD Study-Food Allergy Outcomes Forward peulation of Stophage Provent Regulation of Cells and Matemia Regulation of Cells SLCABA Regulation of Cell SLCABA Regulation of Cell SLCABA Regulation of Cell SLCABA Regulation of Cell SLCABA Regulation of Cell Progesterone induced immune m Role of Allocol incologies protect agains Provend Regulation of Cells SLCABA Regulation of Cell SLCABA Regulation of Cells COVID-19 regesterone induced immune m Role of Succession of IgE Targeting natural killor cells | Chio Department of Healt! Lulane University Lulane University University of Cincinnat Chio State University University of Cincinnat Northwester University Medical Schoc The Reports of the University Medical Schoc The Reports of the University Medical Schoc The Reports of the University Chio State University Chio State University Chio Schoc Chio State University Chio Schoc Chio Chio Schoc Chio Chio Chio Chio Chio Chio Chio Chio | University of Cincinnat Indiana University University of California | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A123661 R01A123661 R01A126818 R01A130123 A18-0558-5001 R01A139126 SUBK00011618 | 4000173601 | 81.RD 20.816 33.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.865 93.855 | 16,477.00 | 76,719.00 76,719.00 27,021.00 27,021.00 524,580.00 105,816,00 49,136,00 23,0589.00 38,151.00 23,026,00 230,026,00 230,026,00 230,026,00 230,026,00 230,026,00 230,026,00 230,026,00 230,026,00 306,579.00 305,579 | 76,719 76,719 27,021 27,021 541,057 551,201 554,022 100,5816 4,91,363 33,589 88,6151 2,283,002 2,285,007 4,285,007 4,45,646 445,646 445,646 445,646 445,646 445,646 445,646 445,646 445,646 445,646 445,646 439,053 55,5370 562,214 439,053 55,5421 22,5888 6,612,015 55,5421 22,5888 6,612,015 55,5421 25,5888 6,612,015 55,5421 25,5888 6,612,015 55,5421 25,5888 6,612,015 55,5421 25,5888 6,612,015 55,5421 25,5888 6,612,015 55,5421 25,5888 6,612,015 55,5421 25,5888 6,612,015 55,5421 25,5888 6,612,015 55,5421 25,5888 6,612,015 55,5421 25,5888 6,612,015 7,512,015 7,512,01 |
| epartment of Transportation | Aging Research | Occupant Protection Regional Coor Metabolic alterations in age-asso Role of skeletal muscle stem r Novel mechanism of intestin A. 11 Regulation of Immunopati Causal Role of Mitochondrial [Mechanisms in Lamin A functior A lovel Research Infrastructu Homeostasis and function of r Immunological identity redefined b Maternal microchimerism trans Epithelial antigen presentati ORMDL3 Regulation of Dendritic Cells A concept for Gene Therapy to Regulation of Gastrontestina Epidenial citica antibaction antibactor Causal Rodon Kotal Sequestr Role of CAP in Regulation for HPV Vi CM-CSF-Induced Metal Sequestr Role of CAP in Regulation for HPV Vi CM-CSF-Induced Metal Sequestr Role of CAP in Regulation for Strongen Lottruline and anti-tuberculosis host Maternal Regulatory T cell antigon-spec- Innate Mechanisms Reg of Memory TH17 A novel lacic acid bacteria-based nor Functional immune tolerance to nor Dendritic cold host in Seriophilic asthm Wimpy antibody isotypes protect agains FORWARD Study-Food Altergy Outcomes Forward genetic prediction ant Role of Microbomia in Neonata Englemistional Regulation of Gastron Surgenson and the strongen antibactor Role of TET In anivary epithe Progenstence in duced Immune m COVID-19 Progenstence induced Immune m Readit, alse suppression of Igi | Chio Department of Heatt Tulane University Tulane University University of North Carolina at Chapel Hi University of Cincinnat University of Cincinnat | University of Cincinnat Indiana University University of California | 03130014BB0421 TUL-HSC-556566-18/19 TUL-HSC-556566-18/19 5119391 011636-003 R01A1123661 R01A1126818 R01A1126818 R01A1126818 R01A112585001 R01A112585001 R01A1139126 SUBK00011618 A20-04945001 | 4000173001 | 81.RD 20.616 20.616 93.866 93.866 93.866 93.866 93.866 93.866 93.866 93.865 93.855 | | 76,719.00 77,719.00 27,021.00 524,590.00 354,2510 354,2510 354,2510 354,2520 354,2520 355,2520 355,2520 355,2520 306,579.300 306,579.300 307,505 306,579.300 306,579.300 306,579.300 306,579.300 306,579.300 307,505,00 323,370.00 323,370.00 323,370.00 355,352.00 355,352.00 355,352.00 355,357.00 355,357.00 355,357.00 355,357.00 355,377.80,00 355,778.00 357,77 | 76,719. 27,021 27,021 541067 551201 564022 105.816 49,136 33,559 86,151 231026 2280,074 616245 64,400 64 |

| | An experimentally-refined, dy | - | | | R01AI153442 | 93.855 | - | 97,154.00 | 97.154.00 |
|---|---|---|--|--|---|--|--|---|---|
| | Proteasome targeting for allo Defining the role of Gimap5 in T cell dif | University of Pennsylvania | | 580121 | R01AI154932 R21AI131050 | 93.855 93.855 | | 134,349.00 99,661.00 | 134,349.00 99,661.00 |
| | Mech of LRBAmediatedcontrol of CTLA4 | | | | R21AI132822 | 93.855 | - | 114.00 | 114.00 |
| | The molecular analysis of Gab. Obesity, Metabolic Syndrome ar | | | | R21AI135380 R21AI139829 | 93.855 93.855 | - | 23,306.00 194,930.00 | 23,306.00 194,930.00 |
| | Single cell analysis of transp Targeted manipulation of the E | | University of Cincinnat | | R21AI142264 R21AI142266 | 93.855 93.855 | 19,998.00 | 118,850.00 10.609.00 | 138,848.00 10,609.00 |
| | Therapeutic target discovery Copper tolerance and homeosta | | University of Cincinnat | | R21AI142704 R21AI143467 | 93.855 93.855 | 55,366.00 | 119,624.00 58,117.00 | 119,624.00 113,483.00 |
| | Genetics of organ-specific lup | | University of Cincinnat | | R21AI145304 | 93.855 | 6,541.00 | 134,989.00 | 141,530.00 |
| | Preserving T cell / antigen p Preconceptual paternal enviro | | | | R21AI148612 R21AI152100 | 93.855 93.855 | - | 126,404.00 155,554.00 | 126,404.00 155,554.00 |
| | Reconstituting the oligogeni Genetic ancestry differences | | University of Cincinnat | | R21AI152575 R21AI157363 | 93.855 93.855 | 4,344.00 | 204,335.00 4,050.00 | 208,679.00 4,050.00 |
| | Volume Expansion in Children v Comparison of high dose flu va | University of Calgary Vanderbilt University Medical Cente | | 1R34AI136783-01A1 VUMC83193 | R34AI136783 R34AI150532 | 93.855 93.855 | | 3,182.00 39,270.00 | 3,182.00 39,270.00 |
| | A Nanoparticle-Based Multivale | valuerbiit University wedical Cente | Virginia Tech | V0INIC63193 | R56AI148426 | 93.855 | 19,427.00 | 126,114.00 | 145,541.00 |
| | An experimentally-refined, dy Pathogenesis and therapeutic targeting | | | | R56AI153442 T32AI118697 | 93.855 93.855 | - | 242,935.00 124,925.00 | 242,935.00 124,925.00 |
| | Gene therapy for SCID-X1 with Gene Regulation as a Foundation for Aut | Children's Hospital Bostor | Stanford University. | GENFD0001865408 | U01AI125051 U01AI130830 | 93.855 93.855 | - 19,680.00 | 2,187.00 520,324.00 | 2,187.00 765,479.00 |
| | Gene Regulation as a Foundation for Aut | | The Scripps Research Institute | | 00141100030 | 33.033 | 51,749.00 | 0.00 | 103,413.00 |
| | | | University of Colorado University of Nebraska Medical Cente | | | | 157,364.00 16,362.00 | - | |
| | COVID-19 Exosomes and the Immune Resp Impact of the Initial Influen: | o Stanford University | Emory University | 62502353-128779 | COVID-19 U01AI135950-03S1 U01AI144673 | 93.855 93.855 | 756,709.00 | 3,961.00 3,471,577.00 | 3,961.00 4,939,271.00 |
| | | | Fundacion para la salud y la Educacio University of Cincinnat | | | | 108,720.00 602,265.00 | - | |
| | COVID-19 Epidemiology and Immi Dynamic regulatory network mo | Icahn School of Medicine at Mount Sina | University of Cincinnat | 0255-E053-4609 | COVID-19 U01AI144673-02S1 U01AI150748 | 93.855 93.855 | 56,250.00 | 1,286,163.00 430,670.00 | 1,342,413.00 430,670.00 |
| | Atopic dermatitis: mechanisms | Idami octoor or wedicine at would one | | 0200-2000-4000 | U01AI152034 | 93.855 | | 149,806.00 | 149,806.00 |
| | Multi-omics of the Frequent Ex Epithelial Genes in Allergic Inflammatio | | | | U01AI159087 U19AI070235 | 93.855 93.855 | - | 21,626.00 1,413,091.00 | 21,626.00 1,413,091.00 |
| | COVID-19 Epithelial Genes in Allergic COVID-19 Epithelial Genes in Allergic | | | | COVID-19 U19AI070235-14S1 COVID-19 U19AI070235-15S1 | 93.855 93.855 | - | 12,359.00 398,660.00 | 12,359.00 398,660.00 |
| | Airway inflammation and airway monito | University of California San Dieg | University of Cincinnati. | U19AI070535 | U19AI070535 | 93.855 | 9,977.00 | 39,522.00 | 49,499.00 |
| | Consortium of Eosinophilic Gastro | | Ann & Robert H Lurie Children's Hosp Arkansas Children's Hospita | ita | U54AI117804 | 93.855 | 10,461.00 23,407.00 | 480,804.00 | 1,058,796.00 |
| | | | Baylor College of Medicine Children's Hospital of Philadelphi | | | | 20,031.00 80,405.00 | - | |
| | | | Mount Sinai School of Medicine | | | | 12,886.00 | - | |
| | | | Northwestern University University of California | | | | 96,928.00 13,520.00 | - | |
| | | | University of Colorado University of Illinois at Chicago | | | | 161,615.00 91.00 | - | |
| | | | University of North Carolina-Chapel Hi University of Pennsylvani: | l . | | | 81,892.00 41,385.00 | - | |
| | | | University of Utah | | | | 6,857.00 | | |
| | | | Vanderbilt University Medical Cente Wake Forest Univ School of Medicine | | | | 23,935.00 4,579.00 | - | |
| | COVID-19 HEROs-Consortium of Eosinophil Extension of clinical data st | ic | University of Colorado | | COVID-19 U54AI117804-06S1 UH2AI145837 | 93.855 93.855 | 42,979.00 | 171,829.00 215.396.00 | 214,808.00 215,396.00 |
| | International Maternal Pediat | Johns Hopkins School of Medicine | | PTCL02 FY20ITN385 | UM1AI068632 | 93.855 | - | 3,881.00 | 3,881.00 |
| | Pre-SUNBEAM Skin Tape Transcr Inner City Asthma Consortium (| Benaroya Research Institute at Virginia Mas University of Wisconsin-Madison | NU | UM1AI114271 | UM1AI109565 UM1AI114271 | 93.855 93.855 | - | 18,929.00 705,880.00 | 18,929.00 705,880.00 |
| | COVID-19 Inner City Asthma Consortium S Vaccine and Treatment Evaluar | University of Wisconsin-Madison | Nationwide Childrens Hospita | 000000639 | COVID-19 UM1AI114271-06S1 UM1AI148372 | 93.855 93.855 | - 15,587.00 | 80,825.00 699,237.00 | 80,825.00 714,824.00 |
| | COVID-19 Vaccine and Treatment Evaluat | | Nationwide Childrens Hospita | | COVID-19 UM1AI148372-01S1 | 93.855 | 15,587.00 | 2,659,907.00 | 2,659,907.00 |
| | COVID-19 Vaccine and Treatment Evaluat Leadership Group for an Infec | Emory University | | UM1AI148684 | COVID-19 UM1AI148372-02S1 UM1AI148684 | 93.855 93.855 | - | 37,644.00 59,981.00 | 37,644.00 59,981.00 |
| | New Horizons In The Preventior CISA Clinical Vaccine Safety Evaluation | Johns Hopkins University | University of Cincinnat University of Cincinnat | 2004813187 | UM2AI130836 200-2012-53661 | 93.855 93.RD | 43,018.00 69,098.00 | 337,210.00 436,082.00 | 380,228.00 505,180.00 |
| | Human Adenovirus Infection and Dis | Children's Hospital of Philadelphia | University of Ontenniat | HHSN272201600014C | HHSN272201600014C | 93.RD | - | 87,423.00 | 87,423.00 |
| | Nitazoxanide in Acute and Chronic Nor Vaccine and Treatment Eval Units (VTEU | Northwestern University Medical Schoo | | SP0033779 60044358 | HHSN272201600016C HHSN272201300016I | 93.RD 93.RD | - | 168,444.00 1,653,599.00 | 168,444.00 1,653,599.00 |
| | | | | Allergy, Immun | ology and Transplantation Resea | | 3,158,411.00 | 25,598,400.00 | 28,756,811.00 |
| Arthritis, Musculoskeletal and Skin Diseases Researc | Elucidating the mechanisms of Monocyte and macrophage polarizatio | | | | F32AR077396 | 93.846 | - | 28.341.00 | 28,341.00 |
| | Behavioral Interventions and Long Tern Cincinnati Rheumatic Diseases Res | | | | K08AR072075 | | - | | |
| | | | Prigham and Waman's Heapita | | K08AR072075 K24AR056687 | 93.846 93.846 | | 157,289.00 5,882.00 | 157,289.00 5,882.00 |
| | Pediatric musculOskeletal and | | Brigham and Women's Hospita | | K08AR072075 K24AR056687 P30AR070549 P30AR076316 | 93.846 93.846 93.846 93.846 | 11,129.00 | 157,289.00 5,882.00 739,391.00 432,410.00 | 5,882.00 750,520.00 432,410.00 |
| | Pediatric musculOskeletal and Neuromuscular Intervention Targete Deciphering mechanisms of myol | Mayo Clinic | Brigham and Women's Hospita | CHI-263812-01 | K08AR072075 K24AR056687 P30AR070549 | 93.846 93.846 93.846 | | 157,289.00 5,882.00 739,391.00 | 5,882.00 750,520.00 |
| | Pediatric musculOskeletal and Neuromuscular Intervention Targeter | Mayo Clinic | Children's Hospital Bostor | CHI-263812-01 | K08AR072075 K24AR056687 P30AR070549 P30AR076316 R01AR055563 | 93.846 93.846 93.846 93.846 93.846 93.846 | 11,129.00 - 97,886.00 | 157,289.00 5,882.00 739,391.00 432,410.00 61,754.00 | 5,882.00 750,520.00 432,410.00 61,754.00 |
| | Pediatric musculOskeletal and Neuromuscular Intervention Targete Deciphering mechanisms of myol | Mayo Clinic | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente | CHI-263812-01 | K08AR072075 K24AR056687 P30AR070549 P30AR076316 R01AR055563 R01AR068286 | 93.846 93.846 93.846 93.846 93.846 93.846 | 11,129.00 97,886.00 129,249.00 123,463.00 | 157,289.00 5,882.00 739,391.00 432,410.00 61,754.00 425,886.00 | 5,882.00 750,520.00 432,410.00 61,754.00 425,886.00 |
| | Pediatric musculOskeletal and Neuromuscular Intervention Targete Deciphering mechanisms of myol | Mayo Clinic | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University | CHI-263812-01 | K08AR072075 K24AR056687 P30AR070549 P30AR076316 R01AR055563 R01AR068286 | 93.846 93.846 93.846 93.846 93.846 93.846 | 11,129.00 97,886.00 129,249.00 123,463.00 17,744.00 124,620.00 | 157,289.00 5,882.00 739,391.00 432,410.00 61,754.00 425,886.00 | 5,882.00 750,520.00 432,410.00 61,754.00 425,886.00 |
| | Pediatric musculOskeletal and Neuromuscular Intervention Targete Deciphering mechanisms of myol | Mayo Clinic | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University | CHI-263812-01 | K08AR072075 K24AR056687 P30AR070549 P30AR076316 R01AR055563 R01AR068286 | 93.846 93.846 93.846 93.846 93.846 93.846 | 11,129.00 97,886.00 129,249.00 123,463.00 17,744.00 124,620.00 79,491.00 | 157,289.00 5,882.00 739,391.00 432,410.00 61,754.00 425,886.00 | 5,882.00 750,520.00 432,410.00 61,754.00 425,886.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targete Deciphering mechanisms of myd Multi-site Randomized Clinical Trial of FI' | Mayo Clinic | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita | CHI-263812-01 | K08AR072075 K24AR05687 P30AR070549 P30AR070516 R014R05563 R014R05286 R014R05286 R014R071301 | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 97.886.00 129.249.00 123.463.00 17,744.00 124.620.00 79.491.00 14,410.00 | 157289.00 5,882.00 739.391.00 432.410.00 61,754.00 425.886.00 810,450.00 | 5,882.00 750,520.00 432,410.00 61,754.00 425,886.00 1,397,313.00 357,125.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targeten Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of Fl' In vivo role of the fibroblast in muscula Transcription Factor Genetic Complement in Human Lupus: De | Mayo Clinic Nationwide Children's Hospita | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita | CHI-263812-01 700165-0519-00 | K08AR072075 K24AR05687 P30AR070549 P30AR070549 R014R05563 R014R05563 R014R05286 R014R070474 R014R071301 R014R077228 | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 11,129.00 97,886.00 129,249.00 123,463.00 17,744.00 124,620.00 79,491.00 14,410.00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,886,00 810,450,00 | 5,882.00 750.520.00 432,410.00 61,754.00 425,886.00 1,397,313.00 357,125.00 455,093.00 11,010.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FI' In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GSK3 beta study in patients w Identifying neural pathophysis | | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelon; | | K08AR072075 K24AR056687 P30AR070549 P30AR070540 R01AR05563 R01AR05563 R01AR05286 R01AR070474 R01AR071301 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR073795 | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 11, 129, 00 129, 249, 00 129, 249, 00 123, 243, 00 17, 774, 00 124, 620, 00 79, 460, 00 14, 410, 00 14, 410, 00 42, 775, 00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,886,00 810,450,00 | 5,882.00 750.520.00 432,410.00 425,586.00 1,397,313.00 357,125.00 455,093.00 11,010.00 252,612.00 329,045.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FI In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GSK3 biets study in patients w | | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi | | K08AR072075 K24AR05687 P30AR070549 P30AR070516 R01AR05563 R01AR071301 R01AR071301 R01AR071301 R01AR073228 R01AR073311 R01AR073379 | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 11, 129,00 97, 886,00 129,249,00 123,463,00 17,744,00 124,620,00 79,491,00 14,410,00 | 157,289.00 5,882.00 739,391.00 432,410.00 61,754.00 810,450.00 810,450.00 | 5,882.00 750.520.00 432,410.00 61,754.00 425,886.00 1,397,313.00 357,125.00 455.093.00 11,010.00 252,612.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FI' In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GSK3 beta study in patients w Identifying neural pathophysis | | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Nationwide Childrens Hospita Ohio State University Universitat De Barcelon; Children's Hospital of Philadelphi Duke University Johns Hospita University | | K08AR072075 K24AR056687 P30AR070549 P30AR070540 R01AR05563 R01AR05563 R01AR05286 R01AR070474 R01AR071301 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR073795 | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 11, 129,00 97, 886,00 129,249,00 123,463,00 17,744,00 124,620,00 79,491,00 14,410,00 42,775,00 7,771,00 12,923,00 6,573,00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,886,00 810,450,00 | 5,882.00 750.520.00 432,410.00 425,586.00 1,397,313.00 357,125.00 455,093.00 11,010.00 252,612.00 329,045.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FT In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GSK3 blast study in patients w Identifying neural pathophysis Epigenetic Determinants Influr Neuroplastic Mechanisms for th | | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University | | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR05563 R01AR071301 R01AR071301 R01AR071301 R01AR0713228 R01AR073379 R01AR073379 R01AR073857 R01AR075857 | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 11, 129,00 97,886,00 129,249,00 123,463,00 17,744,00 124,620,00 79,441,00 14,410,00 44,2775,00 7,771,00 12,923,00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,886,00 810,450,00 10,450,003,00 455,000 455,00 | 5,882.00 750.520.00 432,410.00 61,754.00 425,886.00 1,397,313.00 357,125.00 455.093.00 11,010.00 252,612.00 329,045.00 502,940.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FI' In vivo role of the fibroblast In muscula Transcription Factor Genetics Complement In Human Lupus: De GSKS beta study in patients w Identifying neural pathophysis Epigenetic Determinants Influr | | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University | | K08AR072075 K24AR056887 P30AR070549 P30AR070549 R01AR055653 R01AR07474 R01AR071301 R01AR071301 R01AR073228 R01AR073311 R01AR073379 R01AR073379 R01AR0735657 R01AR078657 | 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 93.846 | 11, 129,00 17, 286,00 129,249,00 123,463,00 17,744,00 124,620,00 79,441,00 14,410,00 44,2775,00 7,771,00 6,573,00 6,573,00 37,048,00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,886,00 810,450,00 | 5,882.00 750,520.00 432,410.00 61,754.00 425,886.00 1,397,313.00 455,083.00 455,083.00 11,010.00 252,612.00 329,045.00 502,940.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FI' In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GKG bate study in patients w Identifying neural pathophysi Epigenetic Determinants Influe Neuroplastic Mechanisms for th Improving Bediatric Lupus Neph Improving delivery of therape Electrical Coupling of Circula | | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelont Children's Hospital of Philadelphi Johns Hopkina University Stanford University University of Cincinnat Salk Institute | | K08AR072075 K24AR05687 P30AR070549 P30AR070549 R01AR0705416 R01AR071301 R01AR071301 R01AR071301 R01AR0713228 R01AR071328 R01AR073379 R01AR073567 R01AR077657 R01AR077657 | 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 33.846 | 11, 129,00 97,886,00 129,249,00 123,463,00 17,744,00 124,620,00 79,491,00 14,410,00 44,2775,00 7,771,00 42,273,00 6,573,00 37,048,00 9,156,00 9,835,00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 810,450,00 810,450,00 810,450,00 11,010,00 252,612,00 286,271,00 286,271,00 286,271,00 286,271,00 285,844,00 358,444,00 327,178,00 | 5,882.00 760.520.00 432,410.00 61,774.00 425,886.00 1,397,313.00 11,010.00 11,010.00 11,010.00 52,240.00 502,940.00 502,940.00 358,444.00 358,444.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FI' In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GSK3 beta study in patients w Identifying neural pathophysis Epigenetic Determinants Influ Neuroplastic Mechanisms for th Improving delivery of therape Electrical Coupling of Cincula Real-Time Sensorimotor Feedbac | Nationwide Children's Hospita | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University Stanford University University of Cincinnat | 700165-0519-00 | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR055653 R01AR071301 R01AR071301 R01AR071301 R01AR0713228 R01AR073311 R01AR073313 R01AR073557 R01AR075153 R01AR075153 R01AR076153 R01AR076151 R01AR076153 | 33.846 | 11, 129,00 17, 286,00 123,249,00 123,463,00 17,744,00 124,620,00 79,441,00 14,410,00 14,410,00 14,410,00 14,42,775,00 7,771,00 12,923,00 6,573,00 9,748,00 9,748,00 9,748,00 9,748,00 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 810,450,00 810,450,00 810,450,00 1,01,00 455,093,00 11,010,00 252,612,00 266,270,00 438,622,00 121,186,00 358,444,00 358,444,00 127,136,00 186,684,00 | 5,882.00 750.520.00 432,410.00 61,754.00 425,886.00 1,397,313.00 357,125.00 455.083.00 359,045.00 359,045.00 3502,940.00 130,843.00 62,881.00 358,444.00 358,444.00 358,444.00 231,157.00 |
| | Pediatric musculOskeletal anc Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FI' In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GKG bate study in patients w Identifying neural pathophysi Epigenetic Determinants Influe Neuroplastic Mechanisms for th Improving Bediatric Lupus Neph Improving delivery of therape Electrical Coupling of Circula | | Children's Hospital Bostor Children's Mercy Hospital Connecticut Childrens Medical Cente Emory University Nationwide Children Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University Stanford University University of Cincinnat Salk Institute University of Cincinnat. | 700165-0519-00 3210940919-XX UH22HQ67688 Hildemai | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR05563 R01AR071301 R01AR071301 R01AR071301 R01AR0713228 R01AR073228 R01AR073311 R01AR073379 R01AR073557 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR07571 | 33.846 | 11, 129,00 97,886,00 129,249,00 123,243,00 17,744,00 124,450,00 79,491,00 14,410,00 14,410,00 1,771,00 1,775,00 1,7 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,886,00 810,450,00 810,450,00 1,754,00 455,093,00 11,010,00 252,612,00 252,612,00 252,612,00 252,612,00 252,612,00 252,612,00 252,612,00 12,1887,00 62,684,00 135,684,00 135,684,00 135,684,00 135,684,00 135,684,00 135,684,00 135,694,00 1 | 5,882.00 750.520.00 432,410.00 61,774.00 425,886.00 1,397,313.00 357,125.00 455.093.00 11,397,313.00 322,042.00 322,042.00 322,042.00 326,043.00 62,881.00 338,444.00 136,871.00 136,871.00 136,500 14,323.00 |
| | Pediatric musculOskeletal and Neuromusculoskeletal and Meuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FI' In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GSK3 bela study in patients w Identifying neural pathophysis Epigenetic Determinants Influe Neuroplastic Mechanisms for H Improving Pediatric Lupus Neph Improving Pediatric Capute Real-Time Sensortmotor Feedbac The Child-Centered Outcomes in Prac PEARL: Pathway Exploration and | Nationwide Children's Hospita Children's Hospital of Philadelphi | Children's Hospital Bostor Children's Mercy Hospital Connecticut Childrens Medical Cente Emory University Nationwide Children Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University Stanford University University of Cincinnat Salk Institute University of Cincinnat. | 700165-0519-00 3210940919-XX UH22HQ67688 Hildemai | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR070540 R01AR071301 R01AR071301 R01AR071301 R01AR073228 R01AR073228 R01AR073228 R01AR073311 R01AR073313 R01AR073379 R01AR073557 R01AR075153 R34R0716151 R34R0716151 R34R070160 U1AR076153 R34R0771 R01AR076153 R34R07701 U1AR076989 U1AR076989 | 33.846 | 11, 129,00 17, 286,00 123,249,00 123,463,00 17,744,00 124,620,00 79,441,00 14,410,00 14,410,00 14,410,00 14,42,775,00 7,771,00 12,923,00 6,573,00 9,748,00 9,748,00 9,748,00 9,748,00 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 14,450,000 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,286,00 810,450,00 - - - - - - - - - - - - - | 5,882.00 750.520.00 432,410.00 61,754.00 425,886.00 1,397,313.00 357,125.00 445,093.00 11,010.00 329,045.00 329,045.00 329,045.00 329,045.00 329,045.00 329,045.00 352,240.00 138,844.00 138,844.00 138,844.00 138,8471.00 231,157.00 135,00 14,323.00 6,161,774.00 |
| Assistance Programs for Chronic Disease Prevention and Contin | Pediatric musculOskeletal and Neuromuscular Intervention Targete Deciphering mechanisms of myd Multi-site Randomized Clinical Trial of FT In vivo role of the fibroblast in muscula Transcription Factor Genetica Complement in Human Lupus: De GSK3 beta study in patients w Identifying neural pathophysis Epigenetic Determinants Influ Neuroplastic Mechanisms for th Improving Pediatric Lupus Nept Improving Pediatric Lupus Nept Improving Pediatric Lupus Nept Improving Of Circula Real-Time Sensorimotor Feedbac The Child-Centered Outcomes in Prax | Nationwide Children's Hospita Children's Hospital of Philadelphi | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University Johns Hopkins University University of Cincinnat University of Cincinnat. | 700165-0519-00 3210940919-XX UH2AR067888 Hildeman Arthritis, Musculoo | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR05563 R01AR05563 R01AR071301 R01AR071301 R01AR071301 R01AR073228 R01AR073228 R01AR073311 R01AR073379 R01AR073557 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR075153 R01AR07571 | 33.846 33.846 33.846 33.846 33.846 93.846 | 11, 129,00 97,886,00 129,249,00 123,243,00 17,744,00 124,450,00 79,491,00 14,410,00 14,410,00 1,771,00 1,775,00 1,7 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,886,00 810,450,00 810,450,00 1,754,00 455,093,00 11,010,00 252,612,00 252,612,00 252,612,00 252,612,00 252,612,00 252,612,00 252,612,00 12,1887,00 62,684,00 135,684,00 135,684,00 135,684,00 135,684,00 135,684,00 135,684,00 135,694,00 1 | 5,882.00 750.520.00 432,410.00 61,774.00 425,886.00 1,397,313.00 357,125.00 455.093.00 11,397,313.00 322,042.00 322,042.00 322,042.00 326,043.00 62,881.00 338,444.00 136,871.00 136,871.00 136,500 14,323.00 |
| Assistance Programs for Chronic Disease Prevention and Contin Biomedical Research and Research Trainin | Pediatric musculOskeletal and Neuromusculoskeletal and Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FI' In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GSK3 bela study in patients w Identifying neural pathophysis Epigenetic Determinants Influ Neuroplastic Mechanisms for th Improving Pediatric Lupus Negh Improving delivery of therape Electrical Coupling of Circula Real-Time Sensorimotor Feedbac The Child-Centered Outcomes in Prac PEARL: Pathway Exploration and SEARCH tor Diabetes in Youth Registry Mouse and Guinea Pig Models for Cyte | Nationwide Children's Hospita Children's Hospital of Philadelphi | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University Johns Hopkins University University of Cincinnat University of Cincinnat. | 700165-0519-00 3210940919-XX UH22AR067888 Hildeman Arthritis, Musculos stance Programs for Chro | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR070541 R01AR071301 R01AR071301 R01AR0713228 R01AR073228 R01AR073228 R01AR073379 R01AR073379 R01AR073379 R01AR073557 R01AR075153 R01AR075657 R01AR075657 U10AR075657 U10AR075695 U10AR05695 U10AR057695 U10AR05695 U10AR05695 U10AR05695 U10AR05695 U10AR05769 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR057695 U10AR0576 U10AR0576 U10AR0576 U10AR0576 U10AR0576 U10AR0576 | 33.846 33.846 33.846 33.846 33.846 33.846 93.846 | 11, 129,00 97,886,00 129,249,00 123,243,00 17,744,00 124,450,00 79,491,00 14,410,00 14,410,00 1,771,00 1,775,00 1,755,00 1,7 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,886,00 810,450,00 - - - - - - - - - - - - - | 5,882.00 750,520.00 432,410.00 41,754.00 425,886.00 1,397,313.00 357,125.00 455,093.00 11,010.00 252,612.00 353,045.00 502,940.00 62,681.00 358,444.00 136,871.00 136,871.00 136,871.00 14,323,00 6,161,774.00 180,756.00 |
| | Pediatric musculOskeletal and Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FT In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement In Human Lupus: De GSK3 beta study in patients w Identifying neural pathophysis Epigenetic Determinants Influr Neuroplastic Mechanisms for th Improving Pediatric Lupus Neph Improving Sensormotor Feedbac The Child-Centred Outcomes in Prac FEARL: Pathway Exploration and SEARCH tor Diabetes in Youth Registry Mouse and Guinea Pig Models for Cyb | Nationwide Children's Hospita Children's Hospital of Philadelphi | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationa University Dio State Uni | 700165-0519-00 3210940919-XX UH22AR067888 Hildeman Arthritis, Musculos stance Programs for Chro | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR0705416 R01AR071301 R01AR071301 R01AR071328 R01AR073228 R01AR073311 R01AR073311 R01AR073379 R01AR07357 R01AR07357 R01AR07657 U10AR07657 U10AR07657 U10AR07657 U10AR07673 U10AR07673 U10AR07673 U10AR07673 U10AR07679 U10AR07679 U10AR07679 U10AR07679 U10AR07679 U10AR07679 U10AR0768 Seketetal and Skin Diseases Resea U10AR0768 Seketetal and Skin Diseases Resea U10AR0768 Seketetal and Skin Diseases Resea U10AR0768 | 33.846 33.856 33.856 | 11, 129,00 17, 286,00 123,249,00 123,248,00 17,744,00 124,620,00 79,441,000 144,410,00 442,775,00 7,771,00 6,573,00 9,156,00 9,835,00 43,022,00 1,451,00 768,546,00 | 157,289.00 5,882.00 739,391.00 432,241.00 61,754.00 425,268.00 810,450.00 810,450.00 11,010.00 225,217.20 286,271.00 286,271.00 286,271.00 121,887.00 62,681.00 388,444.00 127,136.00 143,523.00 130,756.00 130,756.00 720,147.00 132,761.00 | 5,882.00 750.520.00 432,410.00 61.7754.00 425,886.00 1,397,313.00 357,125.00 455,093.00 11,010.00 252,612.00 358,444.00 358,444.00 358,444.00 358,444.00 136,847.10 231,157.00 14,323.00 6,101,774.00 180,756.00 182,766.00 |
| | Pediatric musculOskeletal and Neuromusculoskeletal and Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FT In vivo role of the fibroblast In muscula Transcription Factor Genetic Complement In Human Lupus: De GSK3 beta study in patients w Identifying neural pathophysis Epigenetic Determinants Influr Neuroplastic Mechanisms for th Improving Pediatric Lupus Neph Improving delivery of therape Electrical Coupling of Circuia Real-Time Sensorimotor Feedbac The Child-Centered Outcomes in Prac PEARL: Pathway Exploration and SEARCH for Diabetes in Youth Registry Mouse and Guinea Pig Models for Cyh The Role of Olfactomedin 4 in Septic Mechanisms governing context-r Reid FU | Nationwide Children's Hospita Children's Hospital of Philadelphi | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationa University Dio State Uni | 700165-0519-00 3210940919-XX UH22AR067888 Hildeman Arthritis, Musculos stance Programs for Chro | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR0705416 R01AR070474 R01AR071301 R01AR071301 R01AR073228 R01AR073228 R01AR073311 R01AR073311 R01AR073379 R01AR073557 R01AR07455 R01AR076151 R01AR076151 R01AR07676 R01AR07676 U19AR067987 U19AR067987 U19AR067987 U19AR06788 U118DP006134 onic Disease Prevention and Con HH5NR7200003 K00SH11229 R01AK1755 | 33.846 33.859 33.859 | 11, 129,00 17, 286,00 123,249,00 123,248,00 17,744,00 124,620,00 79,441,000 144,410,00 442,775,00 7,771,00 6,573,00 9,156,00 9,835,00 43,022,00 1,451,00 768,546,00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,386,00 810,450,00 425,386,00 810,450,00 425,386,00 11,010,00 225,212,00 225,212,00 225,212,00 225,212,00 225,212,00 121,887,00 127,136,00 127,136,00 127,136,00 135,00 14,42,33,00 186,684,00 135,00 14,423,00 180,755,00 190,755,00 180,75 | 5,882.00 750.520.00 432,410.00 61.754.00 425.886.00 1,397.313.00 357.125.00 455.093.00 11.010.00 252,612.00 359.045.00 502.940.00 130.845.00 136.847.100 231,157.00 14,323.00 6,017,776.00 180,756.00 182,756.00 182,2756.00 182,2756.00 182,2756.00 |
| | Pediatric musculOskeletal and Neuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FT In vivo role of the fibroblast in muscula Transcription Factor Genetic Complement In Human Lupus: De CGKS beta study in patients w Identifying neural pathophysis Epigenetic Determinants Influr Neuroplastic Mechanisms for tt Improving Pediatric Lupus Nept Improving Bediatric Lupus Nept Improving Colling of Circuit Real-Time Bensorimotor Feedbac The Child-Centered Outcomes in Prac PEARL: Pathway Exploration and SEARCH for Diabetes in Youth Registry Mouse and Guinae Pig Models for Cyt The Role of Olfactomedin 4 in Septic Mechanisms governing context-f Reid Olfu, Tethenin, and Sig Biochemical and Computational Analysis Mechanisms of Homeodomain Tran | Nationwide Children's Hospita Children's Hospital of Philadelphi | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University Johns Hopkins University University of Cincinnat. University of North Carolina-Chapel H University of North Carolina-Chapel H University of North Carolina-Chapel H University of Wisconsin System University of Cincinnat. | 700165-0519-00 3210940919-XX UH22AR067888 Hildeman Arthritis, Musculos stance Programs for Chro | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR0705416 R01AR071301 R01AR071301 R01AR071301 R01AR073228 R01AR073311 R01AR073313 R01AR073313 R01AR073557 R01AR076151 R01AR076153 R01AR076151 R01AR076151 R01AR076151 R01AR076151 R01AR076151 R01AR076151 R01AR076151 R01AR07675 U104R065925 U104R06 | 33.846 33.856 33.859 33.859 33.859 | 11, 129,00 17, 288,00 123,249,00 123,248,00 17,744,00 124,420,00 79,441,00 144,410,00 144,410,00 144,410,00 144,4775,00 7,771,00 12,223,00 6,573,00 9,835,00 43,022,00 1,451,00 112,609,00 30,830,00 50,752,00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,2686,00 810,450,00 1,754,00 455,093,00 11,010,00 252,612,00 266,270,00 121,687,00 122,687,00 122,687,00 122,687,00 135,00 135,00 14,432,300 136,084,00 136,084,00 136,084,00 136,084,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,094,00 136,00 | 5,882.00 750.520.00 432,2410.00 61.754.00 425.886.00 1,387.313.00 357.125.00 455.093.00 11.010.00 252.612.00 359.045.00 502.940.00 130.843.00 62.281.00 358.444.00 358.444.00 358.444.00 136.871.00 231.157.00 14.323.00 6,101.774.00 180.756.00 182.756.00 182.2756.00 182.2756.00 182.2756.00 182.2756.00 182.2756.00 |
| | Pediatric musculOskeletal and Neuromuscular Intervention Targete Deciphering mechanisms of myd Multi-site Randomized Clinical Trial of FT In vivo role of the fibroblast In muscula Transcription Factor Genetic Complement In Human Lupus: De GSK3 beta study in patients w Identifying neural pathophysis Epigenetic Determinants Influe Neuroplastic Mechanisms for If Improving Pediatric Lupus Negh Improving Pediatric Lupus Negh Improving Pediatric Lupus Negh Real-Time Sensormotor Feedbac The Child-Centered Outcomes in Prac PEARL: Pathway Exploration and SEARCH for Diabetes in Youth Registry Mouse and Guinea Pig Models for Cyt The Role of Uffactomadin 4 in Septic Mechanisms of Homeodomain Tran Studies of Weal-Dependent Intercellulai | Nationwide Children's Hospita Children's Hospital of Philadelphi | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Nationwide Childrens Hospita Ohio State University University of Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University University of Cincinnat. University of Cincinnat. University of North Carolina-Chapel H Ansert Pennington Biomedical Research Cent | 700165-0519-00 3210940919-XX UH22AR067888 Hildeman Arthritis, Musculos stance Programs for Chro | K08AR072075 K02AR05687 P30AR070549 P30AR070546 R01AR070546 R01AR071301 R01AR071301 R01AR071474 R01AR0713228 R01AR073228 R01AR073228 R01AR073379 R01AR073379 R01AR073379 R01AR073379 R01AR073585 R01AR075857 R01AR075857 R01AR075857 U13AR076857 U13AR07697 U13AR07697 U13AR07897 U13AR07897 U13AR07897 U13AR07897 U13AR07897 U13AR07897 U13AR07897 U13AR07897 U13AR07897 U13AR07897 U13AR07897 R01AR0771 R01AR0771 R01AR0771 R01AR07757 R01AR0775 R01AR0771 R01AR0775 R01AR0771 R01AR07897 U13AR08925 U13AR07897 U13AR08925 U13AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0771 R01AR0780 R01AR0771 R01AR0771 R01AR0780 R01AR0771 R01AR0780 R01AR0771 R01AR0780 R01AR0771 R01AR0780 R01AR0771 R01AR0780 R01AR0780 R01AR0771 R01AR0780 R01AR0770 R01AR0780 R01AR0770 R01AR0780 R01AR0770 R01AR0780 R01AR0770 R01AR0780 R01AR0770 R01AR0770 R01AR0780 R01AR0770 R01AR070 R01AR | 33.846 33.859 33.859 33.85933.859 | 11, 129,00 129,249,00 129,249,00 129,249,00 129,248,00 17,744,00 128,248,00 17,744,00 128,248,00 14,410,00 42,775,00 7,7771,00 12,129,20 42,775,00 7,771,00 9,156,00 9,156,00 1,451 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 810,455,00 810,455,003 0 455,805,003 0 455,003,00 455,003,00 455,003,00 438,625,003 0 438,625,003 121,687,00 62,681,00 338,644,00 127,136,00 126,2681,00 338,444,00 127,136,00 126,2681,00 338,444,00 127,136,00 14,523,00 186,658,00 180,755, | 5,882.00 750,520.00 432,410.00 61,754.00 425,886.00 1,397,313.00 357,125.00 455,093.00 11,010.00 252,812.00 329,045.00 502,240.00 136,871.00 136,871.00 14,323.00 14,323.00 14,323.00 14,323.00 14,323.00 14,323.00 14,323.00 14,323.00 14,323.00 14,323.00 14,323.00 14,323.00 14,325.00 12,355.00 12,3 |
| | Pediatric musculOskeletal and Neuromuscular Intervention Targete Deciphering mechanisms of myd Multi-site Randomized Clinical Trial of FT In vivo role of the fibroblast in muscula Transcription Factor Genetics Complement in Human Lupus: De GSK3 beta study in patients w Identifying neural pathophysis Epigenetic Determinants Influe Neuroplastic Mechanisms for th Improving Pediatric Lupus Neph Improving Selivery of therape Real-Time Sensorimotor Feedbac The Child-Centred Outcomes in Prac PEARL: Pathway Exploration and SEARCH for Diabetes in Youth Registry Mouse and Guinea Pig Models for Cy6 The Role of Offactomedin 4 in Septic Mechanisms governing context- Biochemical and Computatian Analysi Mechanisms of Homeodomain Tran Studies of Welai-Dependent Intercollulau DNA Damage Response Pathways | Nationwide Children's Hospita Children's Hospital of Philadelphi | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University Johns Hopkins University University of Cincinnat. University of North Carolina-Chapel H University of North Carolina-Chapel H University of North Carolina-Chapel H University of Wisconsin System University of Cincinnat. | 700165-0519-00 3210940919-XX UH22AR067888 Hildeman Arthritis, Musculos stance Programs for Chro | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR070540 R01AR071301 R01AR071301 R01AR071474 R01AR0713228 R01AR073228 R01AR073228 R01AR073379 R01AR073379 R01AR073379 R01AR073379 R01AR073379 R01AR073379 R01AR0735857 R01AR075857 R01AR075857 U19AR069525 U19AR07397 U19AR069525 U19AR069525 U19AR0695 R014124299 R0141125 R0141150475 R0141150475 R0141150475 R0141150475 R0141150475 R0140079428 R0140079428 R0140079428 R0140079428 R0140079428 R0140079428 R0140079428 R0140079428 R0140079428 R0140079428 R0140079428 R014007945 R014007945 R014007945 R014007947 R01400797 R0140077 R01400797 R01400797 R0140077 R0140007 R0140077 R0140007 R0140077 R0140007 R014000007 R01400000000000000000000000000000000000 | 33.846 33.855 33.855 33.855 33.855 33.855 33.855 33.855 33.855 33.85533.855 33.855 33.855 33.85533.855 | 11, 129,00 17, 288,00 129,249,00 123,463,00 17,744,00 124,462,00 79,481,00 14,41,00 44,2775,00 7,771,00 12,223,00 6,573,00 9,835,00 43,022,00 1,451,00 112,609,00 1,451,00 112,609,00 30,830,00 50,752,00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 40,558,00 810,450,00 1,754,00 40,558,00 357,125,00 357,125,00 357,125,00 357,125,00 357,125,00 357,125,00 357,125,00 358,244,00 122,161,00 228,270,00 121,168,00 14,323,00 152,761,00 252,562,00 | 5,882.00 750.520.00 432,410.00 61.754.00 425,886.00 1,397,313.00 357,125.00 455.093.00 11,010.00 252,812.00 329,045.00 502,240.00 132,697.100 233,045.00 3358,444.00 3358,444.00 3358,444.00 1356,971.00 14,323.00 6,101,774.00 110,756.00 1152,761.00 1152,766.00 1152,766.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1152,776.00 1153,776.00 1153,776.00 1153,776.00 111,776.00 |
| | Pediatric musculOskeletal and Neuromusculoskeletal and Meuromuscular Intervention Targete Deciphering mechanisms of myol Multi-site Randomized Clinical Trial of FT In vivo role of the fibroblast in muscula Transcription Factor Genetics Carlos Control (1997) Carlos (19 | Nationwide Children's Hospita Children's Hospital of Philadelphi Feinstein Institute for Medical Researci | Children's Hospital Bostor Children's Mercy Hospita Connecticut Childrens Medical Cente Emory University Indiana University Nationwide Childrens Hospita Ohio State University Universitat De Barcelons Children's Hospital of Philadelphi Duke University Johns Hopkins University Johns Hopkins University University of Cincinnat. University of North Carolina-Chapel H University of North Carolina-Chapel H University of North Carolina-Chapel H University of Wisconsin System University of Cincinnat. | 700185-0519-00 3210940919-XX UH2AR087688 Hildeman Arthritis, Musculot stance Programs for Chri te | K08AR072075 K02AR05687 P30AR070549 P30AR070549 R01AR0705416 R01AR071301 R01AR071301 R01AR071301 R01AR073228 R01AR073311 R01AR073313 R01AR073313 R01AR073313 R01AR073557 R01AR075153 R01AR075151 R01AR075151 R01AR075151 R01AR075151 R01AR075151 R01AR075151 R01AR075151 R01AR075151 R01AR07575 U192AR065255 U192AR065255 U192AR065255 U192AR065255 U192AR065255 U192AR065255 U192AR065255 U192AR065255 U192AR06525 U192AR06525 U192AR06525 R01AI1515 | 33.846 33.846 33.846 33.846 33.846 93.859 93.859 93.859 93.859 93.859 | 11, 129,00 17, 288,00 129,249,00 123,463,00 17,744,00 124,462,00 79,481,00 14,41,00 44,2775,00 7,771,00 12,223,00 6,573,00 9,835,00 43,022,00 1,451,00 112,609,00 1,451,00 112,609,00 30,830,00 50,752,00 | 157,289,00 5,882,00 739,391,00 432,410,00 61,754,00 425,2686,00 810,450,00 425,2686,00 810,450,00 455,093,00 11,010,00 225,212,00 226,270,00 438,622,00 121,487,00 126,274,00 126,274,00 127,136,00 135,00 14,323,00 180,756,00 190,756,00 190,756,00 191,736,00 1 | 5,882.00 750.520.00 432,410.00 61,754.00 425,886.00 1,387,313.00 455,083.00 455,093.00 11,001.00 252,612.00 359,045.00 502,940.00 130,843.00 62,681.00 358,444.00 136,871.00 231,157.00 143,523.00 143,523.00 180,756.00 180,756.00 180,756.00 182,756.00 182,756.00 182,756.00 182,756.00 182,756.00 182,756.00 182,756.00 182,756.00 |

| | G-CSF in Human Severe Congenita Viral and Cellular Determinan | | | | R01GM110628 R01GM111027 | 93.859 93.859 | - | 33.00 2,308.00 | 33.00 2,308.00 |
|---|---|---|--|--|--|---|--------------------------|---|---|
| | Regulatory Mechanisms Governing Age-Depenedent Mechansims of Me | | | | R01GM111987 R01GM115973 | 93.859 93.859 | - | 1,842.00 393,301.00 | 1,842.00 393,301.00 |
| | Endocytic Trafficking and Cell Signaling Epigenetic Regulation of Gene Expres | The University of Texas Southwestern | | 0001239 | R01GM120196 R01GM122776 | 93.859 93.859 | - | 132,979.00 124,613.00 | 132,979.00 124,613.00 |
| | Epigenetic Regulation of Gene Expres Elucidating the Mechanism of Precision | University of California-Davi: | | A21-3093-S001 | R01GM122776 R01GM122956 | 93.859 93.859 | - | 12,319.00 271,146.00 | 12,319.00 271.146.00 |
| | Role of STAT3 in sepsis-induced ad Applying common variant gene | Vanderbilt University Medical Cente | | VUMC 77403 | R01GM126551 R01GM130791 | 93.859 93.859 | - | 277,349.00 43,344.00 | 277,349.00 43,344.00 |
| | Functional characterization o Death-Seq. a Method for Genom | Validoloik onivoloky modolal oonte | Ohio State University | 1011011100 | R01GM134731 R21GM135634 | 93.859 93.859 | 39,336.00 | 304,707.00 | 344,043.00 126,776.00 |
| | A Synthetic Approach for Bacte | University of Cincinnat | | 013094-002 | R21GM137321 | 93.859 | - | 11,865.00 | 11,865.00 |
| | Growing Community Change Rese: WE ENGAGE via Data and Stories to | University of Cincinnat | Miami University | 011577-004 | R25GM129234 R25GM129808 | 93.859 93.859 | 48,278.00 | 11,858.00 149,953.00 | 11,858.00 205,867.00 |
| | Macrophage regulation of the sperr | | University of Cincinnat | | R35GM119458 | 93.859 | 7,636.00 | 319,400.00 | 319,400.00 |
| | Sepsis from Bedside to Bench to Bedside | | Children's Hospital Med Center of Akr Children's Hospital Oakland | 01 | R35GM126943 | 93.859 | 1,500.00 1,500.00 | 494,525.00 | 518,947.00 |
| | | | Childrens Hospital of Orange Count Children's Hospital of Philadelphi | | | | 500.00 5,000.00 | - | |
| | | | Indiana University Stanford University | | | | 6,500.00 500.00 | - | |
| | | | University of Florida Vanderbilt University Medical Cente | | | | 2,500.00 6,422.00 | - | |
| | Molecular Analysis of priman Host Response to Trauma Resea | University of Cincinnat | | 1016094 | R35GM131875 T32GM847828 | 93.859 93.859 | - | 324,520.00 54,219.00 | 324,520.00 54,219.00 |
| | | | | | medical Research and Res | earch Training Tota | 343,643.00 | 5,888,853.00 | 6,232,496.00 |
| Blood Diseases and Resources Research | Sickle Cell Anemia, Splenic Pa The racial disparity in plate | | | | K23HL153763 R00HL136784 | 93.839 93.839 | | 156,512.00 236,211.00 | 156,512.00 236,211.00 |
| | Role of FA Proteins in Hematopolesi: Mechanisms of granulocyte home | | Imporial College of Science Technolog | ~ | R01HL076712 R01HL122661 | 93.839 93.839 | 1,617.00 | 265,394.00 463,213.00 | 265,394.00 464,830.00 |
| | Chronic thrombus ablation with Cellular crosstalk in hematopoietic micr | The University of Chicago | Imperial College of Science Technolog University of Michigar | FP066598-A | R01HL133334 R01HL136529 | 93.839 93.839 93.839 | 5,889.00 | 45,166.00 312,443.00 | 45,166.00 318,332.00 |
| | Normal and Pathological Hematopoietic | | Oniversity of Michigan | | R01HL141418 | 93.839 | | 381,448.00 | 381,448.00 |
| | Small molecules targeting Rho/ The roles of mDia2 in hematop | Northwestern University Medical Schoo | | 60055894 CCH | R01HL147536 R01HL148012 | 93.839 93.839 | - | 688,516.00 80,213.00 | 688,516.00 80,213.00 |
| | Linking Endotypes and Outcome: MIDAS: Microangiopathy, Endoti | Children's Hospital of Philadelphia The Ohio State University Research Fru | | 3201710624 60078812 | R01HL148054 R01HL148247 | 93.839 93.839 | - | 62,380.00 82,042.00 | 62,380.00 82,042.00 |
| | The role of mitochondria in he The Role of Erythroblastic Is | | The Feinstein Institute Medical Resea | rcl | R01HL151654 R01HL152099 | 93.839 93.839 | 200,131.00 | 143,297.00 429,945.00 | 143,297.00 630,076.00 |
| | Defining human hematopoletic (Decoding innate immune signaling in | | | | R21HL150678 R35HL135787 | 93.839 93.839 | - | 94,524.00 863,691.00 | 94,524.00 863,691.00 |
| | Improving outcomes in CF patie Cincinnati Cntr of Excellence in Hemoglo | Dartmouth College | | R1069 | R56HL139846 U01HL117709 | 93.839 93.839 | - | 9,502.00 574.00 | 9,502.00 574.00 |
| | Realizing Effectiveness Across Continents | | Baylor College of Medicine CEFA/Centre Hospitalier Monkole | | U01HL133883 | 93.839 | 15,512.00 68,506.00 | 263,122.00 | 660,707.00 |
| | | | Hospital Pediatrico David Bernardin Mbale Regional Referral Hospita | | | | 105,557.00 118,977.00 | - | |
| | | | University of Oxford The Feinstein Institute Medical Resea | rel | | | 44,539.00 25,963.00 | : | |
| | Darbepoetin Trial to Improve F | University of Utał | University Health Networl | 10053175-02 | U01HL136318 | 93.839 | 18,531.00 | 19,230.00 | 19,230.00 |
| | Sickle Cell Improvement, Enhal | Medical College of Wisconsir | | U01HL143477 | U01HL143477 Blood Diseases and Resou | 93.839 | 605,222.00 | 6,896.00 4,604,319.00 | 6,896.00 5,209,541.00 |
| Cancer Biology Research | The Role of CHAF1B in Maintair | | | _ | R00CA230314 | 93 396 | | 250,710.00 | 250.710.00 |
| cance, biology rescarer | Exploiting proteotoxic stress in therap Hemostatic Factors Drive Prostate Cancer | | | | R01CA193549 R01CA193678 | 93.396 93.396 | : | 34,122.00 274,192.00 | 34,122.00 274,192.00 |
| | A rapid spontaneous murine model c Coagulation factors modifiers of the color | | University of Miam | | R01CA196658 R01CA204058 | 93.396 93.396 | 3,537.00 | 87,384.00 261,496.00 | 90,921.00 261.496.00 |
| | Leukemia stem cell polarity and differe | | | | R01CA204895 | 93.396 93.396 93.396 | - | 454,154.00 | 454,154.00 |
| | Mechanisms coupling DEK to oncogenesi: FA pathway activities in norm: | | | | R01CA218072 R01CA223790 | 93.396 | - | 426,609.00 427,631.00 | 426,609.00 427,631.00 |
| | The role of transcription elor New activities of the human DE | | University of Kentucky | | R01CA234038 R01CA239605 | 93.396 93.396 | 17,544.00 | 599,020.00 415,127.00 | 599,020.00 432,671.00 |
| | Defining genetic and metaboli Patho-Genetic Analysis of Inv: | University of Cincinnat | Massachusetts General Hospital | 012828-002 | R01CA239697 R01CA240317 | 93.396 93.396 | 66,707.00 | 262,366.00 340,642.00 | 262,366.00 713,614.00 |
| | Modeling myelodysplasi: | | University of Utah Johns Hopkins University | | R01CA253981 | 93.396 | 306,265.00 31,261.00 | 143,525.00 | 174,786.00 |
| | Infectious pressures on cell c Pathogenic Role of FoxI1 Hep: | | | | R21CA257984 R37CA225807 | 93.396 93.396 | - | 9,634.00 341,094.00 185,399.00 | 9,634.00 341,094.00 |
| | Therapeutic insights through patient | | | | R50CA211404 Cancer Bio | 93.396 logy Research Total | 425,314.00 | 185,399.00 4,513,105.00 | 185,399.00 4,938,419.00 |
| Cancer Cause and Prevention Researc | Addressing ELSI issues in unregulated | University of Louisville | | ULRF16-1486-01 | R01CA207538 | 93.393 | - | 10,367.00 | 10,367.00 |
| | Instructive role of MLL fusion protein: Research Into Visual Endpoints | The University of Chicago Vanderbilt University Medical Cente | | R01CA215504 VUMV67585 | R01CA215504 R01CA225005 | 93.393 93.393 | - | 335,754.00 21,701.00 | 335,754.00 21,701.00 |
| | Unbiased identification of sp Strenghening epidermal defense | | | | R01CA226802 R01CA228113 | 93.393 93.393 | - | 446,450.00 329,000.00 | 446,450.00 329,000.00 |
| | Increasing HPV Vaccination Ra | | | | R21CA238170 Cancer Cause and Preven | 93.393 ntion Research Total | | 204,128.00 1,347,400.00 | 204,128.00 1,347,400.00 |
| Cancer Detection and Diagnosis Research | Integrated Informatic and Expl | University of Pennsylvania | | 577035 | R01CA227485 | 93.394 | - | 433,545.00 | 433,545.00 |
| | Detection and characterization Redefining hemophagocytic lymp | | University of Cincinnat | | R21CA240664 R21CA256390 | 93.394 93.394 | 71,314.00 | 103,793.00 90,916.00 | 175,107.00 90,916.00 |
| | | | | Ca | ancer Detection and Diagr | | 71,314.00 | 628,254.00 | 699,568.00 |
| Cancer Research Manpower Tota | Patient Preferences and Adherence in Targeting MBNL1-mediated alte | | Seattle Children's Hospita | | K07CA200668 K08CA237753 | 93.398 93.398 | 4,745.00 | 134,065.00 34,672.00 | 138,810.00 34,672.00 |
| | Pathways to Cancer Therapeutic: Post-Graduate Hematology/Oncology | University of Cincinnat University of Cincinnat | | 1016448 1016321 | T32CA117846 T32CA236764 | 93.398 93.398 | - | 158,926.00 58,018.00 | 158,926.00 58,018.00 |
| | | | | | | rch Manpower Total | 4,745.00 | 385,681.00 | 390,426.00 |
| Cancer Treatment Research | Transporters and hematopoietic toxicit Linked regulation of tumor angiogenesis | St Jude's Children's Hospita | | R01CA194206 | R01CA194206 R01CA207068 | 93.395 93.395 | - | 30,319.00 346,413.00 | 30,319.00 346,413.00 |
| | Mechanism of non-oncogene addictio Targeting TET1 signaling to treat acute | City of Hope | | R01CA211614 | R01CA211594 R01CA211614 | 93.395 93.395 | - | 494,013.00 65,937.00 | 494,013.00 65,937.00 |
| | Innovative Pain and Symptom M (PQ10) Role of Gut Microbiota | University of California The University of Texas Southwestern | | 2018-3581 R01CA231303 | R01CA222012 R01CA231303 | 93.395 93.395 | - | 14,524.00 200,501.00 | 14,524.00 200,501.00 |
| | Targeted Inhibition in Leukerr Co-targeting S6 and TAM kinas | University of Cincinnat | | 12653-002 | R01CA237016 R01CA239657 | 93.395 93.395 | - | 364,403.00 16,827.00 | 364,403.00 16,827.00 |
| | | · · · · · · · · · · · · · · · · · · · | | | R01CA250516 R21CA229930 | 93.395 93.395 | - | 555,280.00 182,993.00 | 555,280.00 182,993.00 |
| | Mechanism of Therapy in high- | | | | | | | | |
| | Mechanism of Therapy in high- Targeted Inhibition in Triple COG NCTN Network Group Operat | Children's Hospital of Philadelphi: St. Jude's Children's Hospita | | 2U10CA180886 U24CA055727 | U10CA180886 | 93.395 93.395 | - | 193,771.00 | 193,771.00 150 138 00 |
| | Mechanism of Therapy in high- Targeted Inhibition in Triple | Children's Hospital of Philadelphia St Jude's Children's Hospita St Jude's Children's Hospita | | 2U10CA180886 U24CA055727 110068210-7947557 | U10CA180886 U24CA055727 7 UM1CA081457 | 93.395 93.395 | | 193,771.00 150,138.00 74,437.00 | 150,138.00 74,437.00 |
| Cardiovascular Diseases Research | Mechanism of Therapy in high- Targeted Inhibition in Tripk COG NCTN Network Group Operat Childhood Cancer Survivor Stud The Pediatric Brain Tumor Cons | St Jude's Children's Hospita | | U24CA055727 | U10CA180886 U24CA055727 7 UM1CA081457 Cancer Treatr | 93.395 | - | 193,771.00 150,138.00 | 150,138.00 |
| Cardiovascular Diseases Research | Mechanism of Therapy in high- Targeted Inhibition in Tright COG NCTN Network Group Operat Childhood Cancer Survivor Study The Pediatric Brain Tumor Cons Cardiovascular Impact of Gata4 Loss Nr21fa suppresses bulbous arte | St Jude's Children's Hospita | | U24CA055727 | U10CA180886 U24CA055727 7 UM1CA081457 Cancer Treatr F30HL137239 F31HL147399 | 93.395 93.395 nent Research Total 93.837 93.837 | - | 193,771.00 150,138.00 74,437.00 2,689,556.00 3,317.00 34,344.00 | 150,138.00 74,437.00 2,689,556.00 3,317.00 34,344.00 |
| Cardiovascular Diseases Research | Mechanism of Therapy in high- Targeted Inhibition in Tright COG NCTN Network Group Operat Chilchood Cancer Survivor Study The Pediatric Brain Tumor Cons Cardiovascular Impact of Gata4 Loss Nr2f1a suppresses bulbous arte Prox1 and oscillatory shear s Nr2f1a promotes artial mainte | St Jude's Children's Hospita | | U24CA055727 | U10CA180886 U24CA055727 7 UM1CA081457 Cancer Treatr F30HL137239 F31HL147399 F31HL150935 F31HL152600 | 93.395 93.395 nent Research Total 93.837 93.837 93.837 93.837 93.837 | | 193,771.00 150,138.00 74,437.00 2,689,556.00 3,317.00 34,344.00 28,188.00 40,627.00 | 150,138.00 74,437.00 2,689,556.00 3,317.00 34,344.00 28,188.00 40,627.00 |
| Cardiovascular Diseases Research | Mechanism of Therapy in high- Targeted Inhibition in Tright COG NCTN Network Group Operat Childhood Cancer Survivor Stud The Pediatric Brain Tumor Cons Cardiovascular Impact of Gata4 Loss N271a suppresses bulbous arte Proxt and oscillatory shear s | St Jude's Children's Hospita | | U24CA055727 | U10CA180886 U24CA055727 UM1CA081457 Cancer Treatr F30HL137239 F31HL147399 F31HL150935 | 93.395 93.395 nent Research Total 93.837 93.837 93.837 | | 193,771.00 150,138.00 74,437.00 2,689,556.00 3,317.00 34,344.00 28,188.00 | 150,138.00 74,437.00 2,689,556.00 3,317.00 34,344.00 28,188.00 |

| A genetic and molecular appro- Therapeutic Response Evaluation and A | | | | K08HL143177 K23HL128885 | 93.837 93.837 | - | 154,476.00 177,868.00 | 154,476.00 177,868.00 |
|--|--|---|--|--|--|--|---|---|
| Uncovering compensatory mecha | | | | R00HL135258 | 93.837 | - | 137,506.00 | 137,506.00 |
| Dissecting the role of novel Molecular pathways controlling | | | | R00HL141630 R01HL060562 | 93.837 93.837 | - | 341,313.00 403,237.00 | 341,313.00 403,237.00 |
| Thrombospondin 4 regulates ada | | | | R01HL105924 | 93.837 | - | 436,537.00 | 436,537.00 |
| Venous Malformations (VM): A M Targeted, Highly Sensitive, Nr | | | | R01HL117952 R01HL119747 | 93.837 93.837 | - | 95,375.00 11,648.00 | 95,375.00 11,648.00 |
| Childhood CV Risk and Adult CVD Ou | | Universit of Turku | | R01HL121230 | 93.837 | 27,324.00 | 827.00 | 138,760.00 |
| | | University of Iowa University of Minnesota | | | | 8,316.00 102,293.00 | 0 | |
| Functional Impact of Col18a1/Endostatir | Johns Hopkins School of Medicine | University of Minnesola | JHU;R01HL132153 | R01HL132153 | 93.837 | 102,293.00 | 37,101.00 | 37,101.00 |
| Hippo Signaling in Heart Developmer | | | | R01HL132211 | 93.837 | - | 276,907.00 | 276,907.00 |
| Unraveling ancestry and environmenta Paracrine hypothesis underlying cardiac | Temple University School of Medicine | University of Cincinnat | R01HL132391 | R01HL132344 R01HL132391 | 93.837 93.837 | 25,561.00 | 294,514.00 60,251.00 | 320,075.00 60,251.00 |
| Molecular examination of mitochondria | | University of California | | R01HL132831 | 93.837 | 1,357.00 | 164,117.00 | 165,474.00 |
| Targeting pathologic G-protein signaling Role of Collagen COL22A1 in intracra | | Indiana University | | R01HL133695 R01HL134815 | 93.837 93.837 | 720.00 | 462,799.00 63,145.00 | 462,799.00 63.865.00 |
| Clinical and mechanistic role | Johns Hopkins School of Medicine | , | R01HL135114 | R01HL135114 | 93.837 | - | 64,689.00 | 64,689.00 |
| Regulatory mechanisms of adult cardi Autologous Cardiomyocytes from Mas | University of Cincinnat | | UC;R01HL136025 | R01HL135848 R01HL136025 | 93.837 93.837 | | 339,464.00 10,074.00 | 339,464.00 10,074.00 |
| Molecular mechanisms of atrial develo | | | | R01HL137766 | 93.837 | - | 300,610.00 | 300,610.00 |
| Circadian Rhythms and Interna Retinoic acid-dependent epigenetic and | University of Massachusetts, Amhers | | 19-010568 A00 | R01HL138551 R01HL141186 | 93.837 93.837 | - | 320,582.00 356,789.00 | 320,582.00 356,789.00 |
| Cela1 in Lung Development and Diseas | | | | R01HL141229 | 93.837 | - | 555,082.00 | 555,082.00 |
| Familial hypercholesterolemi Predictive Molecular Markers | Columbia University Medical Cente | | 7(GG012850-01) | R01HL141823 R01HL142210 | 93.837 93.837 | - | 20,769.00 414,109.00 | 20,769.00 414,109.00 |
| Cardiac fibroblasts in postna | | | | R01HL142210 | 93.837 | | 530,120.00 | 530,120.00 |
| Mechanisms of Congenital Heart Valv | I la la constanta de Martena de La constante | | 100000077 | R01HL143881 | 93.837 | - | 382,876.00 | 382,876.00 |
| HDL compostion/function and ca Molecular mechanisms underlyir | University of Washington | | UWSC10977 | R01HL144558 R01HL144774 | 93.837 93.837 | | 39,033.00 503,951.00 | 39,033.00 503,951.00 |
| Characterizing the formation : | University of Texas Southwestern | | R01HL144793 | R01HL144793 | 93.837 | - | 27,677.00 | 27,677.00 |
| MRI Phenotyping of Early BPD ; Impact of Well-Timed vs. Mis-I | | University of Wisconsin System | | R01HL146689 R01HL147915 | 93.837 93.837 | 144,111.00 | 556,966.00 319,980.00 | 701,077.00 319,980.00 |
| Novel Methods to Grow the Imp | | | | R01HL147957 | 93.837 | - | 560,321.00 | 560,321.00 |
| Ultrasound-Mediated Controllec Accelerating research to advar | University of Cincinnat | Brigham and Women's Hospita | 012268-003 | R01HL148451 R01HL151604 | 93.837 93.837 | 8,808.00 | 68,915.00 146,345.00 | 68,915.00 489,181.00 |
| resoluting research to dava | | Children's Hospital Bostor | | 10112101004 | 00.001 | 230,338.00 | - | 400,101.00 |
| Endothelial subpopulations in | | Vanderbilt University Medical Cente | | R01HL156270 | 93.837 | 103,690.00 | 125,256.00 | 125,256.00 |
| Lipoprotein Interactions in th | | | | R01HL157260 | 93.837 | - | 47,664.00 | 47,664.00 |
| National Biological Sample and Dat Pediatric REPLAcement of the F | Children's Hospital of Philadelphia | | 3201202621 | R24HL105333 R34HL142142 | 93.837 93.837 | - | 4,728.00 15,523.00 | 4,728.00 15,523.00 |
| Effect of dietary approaches c | Johns Hopkins School of Medicine | | R56HL139620 | R56HL139620 | 93.837 | - | 29,511.00 | 29,511.00 |
| Understanding Cardiovascular Disease | | | | T32HL125204 T35HL113229 | 93.837 93.837 | - | 301,920.00 | 301,920.00 |
| Cincinnati Children's Summer Med Student Administrative Coordinating Cr | | Children's Hospital Bostor | | U01HL131003 | 93.837 | 113,092.00 | 20,251.00 4,353,986.00 | 20,251.00 5,687,255.00 |
| 5 | | Children's Hospital of Philadelphia | | | | 120,949.00 | - | |
| | | Columbia University Harvard College | | | | 96,635.00 242,618.00 | - | |
| | | J David Gladstone Institutes | | | | 72,634.00 | - | |
| | | Mount Sinai School of Medicine The Feinstein Institute Medical Resear | rel | | | 33,794.00 22,491.00 | | |
| | | University of California | 10 | | | 345,236.00 | - | |
| | | University of Utah Yale University | | | | 259,191.00 26,629.00 | - | |
| Multicenter Interventional Lymphangi | University of Cincinnat | raio onivolotij | U01HL131755 | U01HL131755 | 93.837 | - | 78,148.00 | 78,148.00 |
| | University of California San Dieg | | | | | | 48.053.00 | 48,053.00 |
| Lung Map submission with UC Sa Role of Epithelial XAP in Alw | | | 125063615 | U01HL148867 | 93.837 | | | |
| Role of Epithelial YAP in Alve Data Coordinating Center for PHN | University of Maryland (Baltimore New England Research Institutes | University of Cincinnat | 1701192 U24HL135691 | U24HL134763 U24HL135691 | 93.837 93.837 | 30,863.00 | 5,477.00 243,702.00 | 5,477.00 274,565.00 |
| Role of Epithelial YAP in Alve Data Coordinating Center for PHN A cloud-based decision suppor | University of Maryland (Baltimore | University of Cincinnat | 1701192 | U24HL134763 U24HL135691 U54HL119810 | 93.837 93.837 93.837 | 30,863.00 3,448.00 | 5,477.00 243,702.00 31,474.00 | 5,477.00 274,565.00 34,922.00 |
| Role of Epithelial YAP in Alve Data Coordinating Center for PHN | University of Maryland (Baltimore New England Research Institutes | University of Cincinnat University of Cincinnat Indiana University | 1701192 U24HL135691 | U24HL134763 U24HL135691 | 93.837 93.837 93.837 93.837 | 30,863.00 | 5,477.00 243,702.00 | 5,477.00 274,565.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PH A cloud-based decision suppor Pediatric Heart Network Prairieland Con | University of Maryland (Baltimore New England Research Institutes | University of Cincinnat | 1701192 U24HL135691 | U24HL134763 U24HL135691 U54HL119810 UG1HL135678 Cardiovascular Disea | 93.837 93.837 93.837 93.837 93.837 ses Research Total | 30,863.00 3,448.00 179,402.00 | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,917.00 | 5,477.00 274,565.00 34,922.00 399,615.00 16,683,417.00 |
| Role of Epithelial YAP in Alw Data Coordinating Geneter for PHH A cloud-based decision suppor Pediatric Heart Network Prairieland Con Child Health Research Career Develo Surviving and Thriving in th | University of Maryland (Baltimore New England Research Institutes | University of Cincinnat | 1701192 U24HL135691 | U24HL134763 U24HL135691 U54HL135691 UG1HL135678 Cardiovascular Disea: K12HD028827 K23HD094855 | 93.837 93.837 93.837 93.837 93.837 ses Research Total 93.865 93.865 | 30,863.00 3,448.00 179,402.00 | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,917.00 463,891.00 178,334.00 | 5,477.00 274,565.00 34,922.00 399,615.00 16,683,417.00 463,891.00 178,334.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHt A cloud-based decision suppor Pediatric Heart Network Prairieland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke | University of Maryland (Baltimore New England Research Institutes | University of Cincinnat Indiana University | 1701192 U24HL135691 | U24HL134763 U24HL135691 U54HL138691 UG1HL135678 Cardiovascular Disea: K12HD028827 K23HD094855 K23HD094855 K23HD101416 | 93.837 93.837 93.837 93.837 ses Research Total 93.865 93.865 93.865 93.865 | 30,863.00 3,448.00 179,402.00 2,199,500.00 | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,917.00 463,891.00 178,334.00 127,776.00 | 5,477.00 274,565.00 34,922.00 399,615.00 16,683,417.00 463,891.00 178,334.00 127,776.00 |
| Role of Epithelial YAP in Alw Data Coordinating Genetre for PHH A cloud-based decision support Pediatin Heart Network Prainteinand Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache | University of Maryland (Baltimore New England Research Institutes | University of Cincinnat Indiana University Columbia University | 1701192 U24HL135691 | U24HL134763 U24HL136691 U54HL136691 U54HL139810 UG1HL139578 Cardiovascular Disea: K12HD028827 K23HD094855 K23HD101416 P01HD093363 | 93.837 93.837 93.837 93.837 93.837 93.865 93.865 93.865 93.865 93.865 | 30,863.00 3,448.00 179,402.00 2,199,500.00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,397,00 463,891,00 178,334,00 127,776,00 1,034,137,00 | 5,477,00 274,565,00 34,922,00 399,615,00 463,891,00 178,334,00 127,776,00 1,354,448,00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHH A cloud-based decision suppor Pediatric Heart Network Prairienand Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc | University of Maryland (Baltimore New England Research Institutes | University of Cincinnat Indiana University Columbia University University of Central Missour | 1701192 U24HL135691 | U24HL134763 U24HL136591 U54HL119810 U31HL135678 Cardiovascular Disea K12HD028827 K23HD094855 K23HD101416 P01HD093363 P01HD103133 | 93.837 93.837 93.837 93.837 93.837 93.865 93.865 93.865 93.865 93.865 93.865 | 30,863.00 3,448.00 179,402.00 2,199,500.00 310,311.00 10,000.0 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,977,00 463,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 | 5,477,00 274,565,00 399,615,00 16,683,417,00 463,891,00 178,334,00 127,776,00 1,354,448,00 9,548,00 |
| Role of Epithelial YAP in Alw Data Coordinating Genetre for PHH A cloud-based decision support Pediatin Heart Network Prainteinand Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache | University of Maryland (Baltimore Newe England Research Institute: Cleveland Clin Lerner Col of Med of CWRI | University of Cincinnat Indiana University Columbia University | 1701192 U24HL135691 1232-Sub | U24HL134763 U24HL136691 U54HL136691 U54HL139810 UG1HL139578 Cardiovascular Disea: K12HD028827 K23HD094855 K23HD101416 P01HD093363 | 93.837 93.837 93.837 93.837 93.837 93.865 93.865 93.865 93.865 93.865 | 30,863.00 3,448.00 179,402.00 2,199,500.00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,397,00 463,891,00 178,334,00 127,776,00 1,034,137,00 | 5,477,00 274,565,00 34,922,00 399,615,00 463,891,00 178,334,00 127,776,00 1,354,448,00 |
| Role of Epithelial YAP in Alw Data Coordinating Geneter for PHH A cloud-based decision support Pediatris Heart Network Prainteiand Con Child Health Research Carser Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Pediatris HIVAIDS Cohort Stuc Xenbas: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis b | University of Maryland (Baltimore New England Research Institute Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo | University of Cincinnat Indiana University Columbia University University of Central Missour | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 | U24HL134763 U24HL136501 U54HL135578 Cardiovascular Disea K12HD028827 K23HD094855 K23HD10416 P01HD103133 P01HD103133 P01HD103133 P11HD064556 PL1HD10159 R01HD055651 | 93.837 93.837 93.837 93.837 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30,863.00 3,448.00 179,402.00 2,199,500.00 310,311.00 10,000.0 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,917,00 463,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 623,504,00 270,805,00 4,7771,00 | 5.477.00 274,565.00 349,922.00 399,615.00 16,683,417.00 463.891.00 178,334.00 127,776.00 1,354,448.00 9,548.00 1,473,151.00 270,805.00 4,771.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHH A cloud-based decision suppor Pediatric Heart Network Prairieland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis b Molecular signaling in uterinor eceptivit | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRL Harvard Medical Schoo RTI Internationa | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L | U24HL134763 U24HL135691 U37HL135691 UG1HL135678 Cardiovascular Disea K12HD028827 K23HD04855 K23HD01416 P01HD093363 P01HD103133 P01HD064566 PL1HD101059 R01HD06551 R01HD065524 | 93.837 93.837 93.837 93.837 93.837 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30,863,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,891,00 178,334,00 1,034,137,00 9,548,00 623,504,00 270,805,00 4,771,00 279,301,00 | 5,477.00 274,565.00 34,922.00 399,875.00 18,683,417.00 463,891.00 178,334.00 1,354,448.00 9,548.00 1,473,151.00 270,805.00 4,771.00 279,301.00 |
| Role of Epithelial YAP in Alw Data Coordinating Geneter for PHH A cloud-based decision support Pediatris Heart Network Prainteiand Con Child Health Research Carser Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Pediatris HIVAIDS Cohort Stuc Xenbas: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis b | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRL Harvard Medical Schoo RTI Internationa | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L | U24HL134763 U24HL136501 U54HL135578 Cardiovascular Disea K12HD028827 K23HD094855 K23HD10416 P01HD103133 P01HD103133 P01HD103133 P11HD064556 PL1HD10159 R01HD055651 | 93.837 93.837 93.837 93.837 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30.863.00 3.448.00 179.402.00 2.199,500.00 310.311.00 10.000.00 849,647.00 - - 1.559.00 2.107.00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,917,00 463,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 623,504,00 270,805,00 4,7771,00 | 5.477.00 274,565.00 349,922.00 399,615.00 16,683,417.00 463.891.00 178,334.00 127,776.00 1,354,448.00 9,548.00 1,473,151.00 270,805.00 4,771.00 |
| Role of Epithelial YAP in Alw Data Coordinating Geneter for PHH A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIVAIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Og Prenatal Genetic Diagnosis br Molecular signaling in uterine receptivit Impact of Emergency Departmen | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) | U24HL134763 U24HL136691 U54HL136691 U51HL135578 Cardiovascular Disea K12HD08825 K23HD094855 K23HD014465 P01HD03833 P01HD03333 P01HD03333 P01HD035651 R01HD058551 R01HD05851 R01HD058524 R01HD071915 | 93.837 93.837 93.837 93.837 93.855 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30,863,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 1,589,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,917,00 463,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 623,564,00 270,806,00 4,7771,00 279,301,00 152,025,00 | 5,477.00 274,565.00 389,615.00 18,683,417.00 463,881.00 1763,334,00 1,354,448,00 9,548,00 1,473,151.00 2470,805.00 4,771.00 279,301.00 196,081.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHN A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Developmental Mechanisms of trache Research State State State Xenbase: The Xenoparis Indevelopmental Melecular signaling in uterine receptivit Impact of Emergency Departmen Long-Term Outcomes of Interver A Conditive Test Battery for | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRL Harvard Medical Schoo RTI Internationa | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgan Children's National Medical Cente University of Michigar Washington University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L | U24HL134763 U24HL136691 U54HL1385078 Cardiovascular Disea K12HD02827 C34D094855 K23HD094855 K23HD101416 P01HD03383 P01HD103333 P01HD103133 P01HD035561 R01HD056551 R01HD056551 R01HD076159 R01HD076189 | 93.837 93.837 93.837 93.837 93.855 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30,863,00 3,448,00 179,402,00 2,199,590,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,917,00 463,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 270,805,00 270,805,00 279,301,00 152,025,00 9,3,619,00 | 5,477.00 274,565.00 389,615.00 18,683,417.00 18,683,417.00 1,354,480.00 9,584.00 1,477,151.00 2,70,805.00 1,477,151.00 2,70,805.00 1,96,081.00 9,954.00 9,954.00 9,954.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHH A cloud-based decision suppor Pediatric Heart Network Prairienad Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis b Molecular signaling in ustrine receptivit Impact of Emergency Departmen Long-Term Outcomes of Interver A Cognitive Test Battery for Bone Mineral Accretion in Young Childre | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRL Harvard Medical Schoo RTI Internationa Columbia University Medical Cente | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC | U24HL134763 U24HL136501 U54HL135578 Cardiovascular Disea K12HD028827 K23HD094855 K23HD101416 P01HD093363 P01HD103435 R01HD064556 R01HD065651 R01HD065561 R01HD06524 R01HD074579 R01HD074579 R01HD074579 R01HD074579 | 93.837 93.837 93.837 93.837 93.845 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30.863.00 3.448.00 179.402.00 2.199,500.00 310.311.00 10.000.00 849,647.00 - - 1.559.00 2.107.00 | 5,477,00 243,702,00 31,474,00 220,213,00 463,891,00 178,334,00 1,27,776,00 1,034,137,00 9,548,00 623,504,00 270,805,00 4,771,00 279,301,00 152,025,00 9,954,00 93,619,00 97,056,00 | 5,477.00 274,565.00 34,922.00 399,615.00 18,683,417.00 463,891.00 178,334.00 1,354,448.00 9,548.00 1,473,151.00 270,805.00 4,771.00 279,301.00 196,081.00 9,954.00 93,619.00 152,867.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHN A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Developmental Mechanisms of trache Research State State State Xenbase: The Xenoparis Indevelopmental Melecular signaling in uterine receptivit Impact of Emergency Departmen Long-Term Outcomes of Interver A Conditive Test Battery for | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRL Harvard Medical Schoo RTI Internationa Columbia University Medical Cente | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphia San Diego State University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC | U24HL134763 U24HL136691 U54HL1385078 Cardiovascular Disea K12HD02827 C34D094855 K23HD094855 K23HD101416 P01HD03383 P01HD103333 P01HD103133 P01HD035561 R01HD056551 R01HD056551 R01HD076199 | 93.837 93.837 93.837 93.837 93.855 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30,863,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 449,647,00 1,569,00 2,107,00 40,360,00 55,817,00 1,195,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,917,00 463,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 270,805,00 270,805,00 279,301,00 152,025,00 9,3,619,00 | 5,477.00 274,565.00 389,615.00 18,683,417.00 18,683,417.00 1,354,480.00 9,584.00 1,477,151.00 2,70,805.00 1,477,151.00 2,70,805.00 1,96,081.00 9,954.00 9,954.00 9,954.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHN A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc Xenbase. The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal aregulary begartimen Image of Emergency Departmen Long-Term Outcomes of Interver A Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5b in 167-1 Production and An Intervention to Reduce SHS Exposure | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgan Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State Universit | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC | U24HL134763 U24HL135601 U54HL135671 Cardiovascular Diseat K12HD02827 K23HD094855 K23HD094855 K23HD101416 P01HD038363 P01HD03363 P01HD034565 P01HD034565 P01HD036551 R01HD074579 R01HD074579 R01HD074579 R01HD074592 R01HD074592 R01HD074592 R01HD076592 R01HD076592 R01HD076592 | 93.837 93.837 93.837 93.837 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30,833,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 2,107,00 40,360,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,891,00 178,334,00 127,776,00 1,034,137,00 9,546,00 623,504,00 623,504,00 279,301,00 152,025,00 | 5,477.00 274,565.00 34,922.00 399,615.00 18,683,417.00 463,891.00 1,354,448.00 9,548.00 1,354,448.00 9,548.00 1,4771.00 279,301.00 196,081.00 9,954.00 9,954.00 9,954.00 75,528.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHN A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc Xenbase. The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis by Molecular signaling in uleritor receptivit Impact of Emergency Departmen Long-Term Outcomes of Interver A Cognitive Tast Battery for Bone Mineral Accretion in Young Childre Roles of STAT5b in 10-F1 Production and | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgan Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi: Sam Diego State University University of Arizone Saint Louis University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 | U24HL134763 U24HL135691 U54HL135671 Cardiovascular Disea K12HD02827 K23HD094855 K23HD094855 K23HD101416 P01HD038363 P01HD038363 P01HD034365 P1HD044565 P01HD036551 R01HD076579 R01HD074579 R01HD074579 R01HD074579 R01HD074592 | 93.837 93.837 93.837 93.837 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30,833,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,847,00 849,847,00 1,589,00 2,107,00 2,107,00 2,107,00 55,817,00 1,195,00 7,437,00 8,652,00 18,444,400 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,891,00 178,334,00 127,776,00 1,034,137,00 9,546,00 623,504,00 623,504,00 623,504,00 279,301,00 152,025,00 - - 9,954,00 93,619,00 97,050,00 954,00 | 5,477.00 274,565.00 389,615.00 18,683,417.00 463,891.00 1,354,484.00 9,584.00 9,584.00 9,564.00 9,954.00 9,954.00 9,954.00 |
| Role of Epithelial YAP in Alw Data Coordinating Genetre for PHH A cloud-based decision suppor Pediatris Heart Network Prainteiand Con Child Health Research Carser Develo Surviving and Thriving in th Exclusion and the Control Stuc Developmental Mechanisms of Trache Pediatric HIVAIDS Cohort Stuc Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis b Molecular signaling in uterine receptivit Impact of Emergency Department A Cognitive Test Battery for Bone Mineral Accretion in Troduction and Roles of Hore Charles Stressource Improving ADHD Teen Driving by Targeting 1 | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State University University of Anzone Saint Louid University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 | U24HL134763 U24HL136691 U54HL136910 U51HL135578 Cardiovascutar Disea K12HD028827 N12HD028827 N12HD028823 P01HD028303 P01HD028303 P01HD03303 P01HD03303 P01HD068524 R01HD07579 R01HD07579 R01HD07579 R01HD07579 R01HD07579 R01HD07539 R01HD07539 R01HD07539 R01HD07539 R01HD07539 R01HD07539 R01HD07539 R01HD07539 R01HD07539 | 93.837 93.837 93.837 93.837 93.857 93.865 | 30,83,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,3917,00 178,334,00 178,334,00 178,334,00 179,776,00 270,305,00 270,305,00 270,305,00 277,301,00 152,025,00 9,954,00 93,619,00 97,052,00 66,896,00 66,896,00 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 1778,334.00 1,27778.00 1,354,448.00 9,548.00 9,548.00 1,473,181.00 270,805.00 4,771.00 279,301.00 195,681.00 9,364.00 93,819.00 152,2864.00 75,528.00 416,069.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHN A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc Xenbase. The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal aregulary begartimen Image of Emergency Departmen Long-Term Outcomes of Interver A Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5b in 167-1 Production and An Intervention to Reduce SHS Exposure | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgan Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi: Sam Diego State University University of Arizone Saint Louis University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 | U24HL134763 U24HL135601 U54HL135671 Cardiovascular Diseat K12HD02827 K23HD094855 K23HD094855 K23HD101416 P01HD038363 P01HD03363 P01HD034565 P01HD034565 P01HD036551 R01HD074579 R01HD074579 R01HD074579 R01HD074592 R01HD074592 R01HD074592 R01HD076592 R01HD076592 R01HD076592 | 93.837 93.837 93.837 93.837 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 30,833,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,847,00 849,847,00 1,589,00 2,107,00 2,107,00 2,107,00 55,817,00 1,195,00 7,437,00 8,652,00 18,444,400 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 623,504,00 270,905,00 4,771,00 152,025,00 93,619,00 94,00 95,600 95,600 95,600 95,600 95,600 95,600 97,000 97,000 97,000 93,619,00 97,000 90,000 97,0000 97,0000 97,0000 97,0000 97,0000 97,0000000000 | 5,477.00 274,565.00 34,922.00 399,615.00 18,683,417.00 463,891.00 1,354,448.00 9,548.00 1,354,448.00 9,548.00 1,4771.00 279,301.00 196,081.00 9,954.00 9,954.00 9,954.00 75,528.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHN A cloud-based decision suppor Pediatric Heart Network Praineland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis by Molecular signaling in ulerine receptivit Impact of Emergency Departmen Long-Term Outcomes of Interver A Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5 in InG-1- Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRL Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davie | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgan Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State University University of Arizona Saint Louis University University of Mazachuest Boston University of Mazachuest Boston University of Instruct, en | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 | U24HL134763 U24HL136691 U54HL13691 U51HL139578 Cardiovascular Diseat K12HD028827 K23HD094855 K23HD10146 P01HD093833 P01HD103133 P41HD064566 P1HD074579 R01HD05651 R01HD05654 R01HD076189 R01HD076189 R01HD076321 R01HD076324 R01HD078592 R01HD078592 R01HD078592 R01HD078592 R01HD078592 R01HD078592 R01HD078592 | 93.837 93.837 93.837 93.837 93.865 | 30,833,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 2,107,00 2,107,00 2,107,00 2,107,00 55,817,00 1,195,00 7,437,00 8,652,00 18,444,00 18,203,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,591,00 178,334,00 127,776,00 1,034,137,00 9,548,00 623,504,00 270,305,00 4,771,00 152,025,00 9,954,00 93,616,00 94,000 94,000 94,000 94,000 94,000 94,0000000000 | 5,477.00 274,565.00 34,922.00 399,815.00 18,683,417.00 463,891.00 1,354,448.00 1,354,448.00 9,548.00 1,473,151.00 1,473,151.00 1,477,150 4,771.00 160,081.00 9,954.00 9,954.00 9,954.00 9,954.00 75,528.00 416,069.00 534,034.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHN A cloud-based decision suppor Pediatric Heart Network Praineland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis by Molecular signaling in uterine receptivit Impact of Emergency Departmen Long-Term Outcomes of Interve & Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5 in InG-F Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting 1 The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davi: | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi Sam Diago State University University of Anzone Saint Louis University University of Anzone Saint Louis University University of Anzone Saint Louis University University of Massachusets Boston University of Massachusets Boston | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 R01HD086583 R01HD086583 R01HD087363 | U24HL134763 U24HL136691 U54HL13691 U51HL139578 Cardiovascular Disea K12HD028827 K23HD04855 K23HD101416 P01HD093833 P01HD103133 P41HD064566 P1HD074576 R01HD05651 R01HD05651 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076392 R01HD076392 R01HD076392 R01HD076392 R01HD078592 R01HD078592 R01HD086011 R01HD086011 | 93.837 93.837 93.837 93.837 93.857 93.865 | 30,83,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,591,00 178,334,00 127,776,00 1,034,137,00 9,548,00 623,504,00 270,305,00 4,771,00 152,025,00 9,954,00 93,619,00 94,00 95,000 95,0000 95,0000 95,0000 95,0000000000 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 1778,334.00 1,27778.00 1,354,448.00 9,548.00 9,548.00 1,473,181.00 270,805.00 4,771.00 279,301.00 195,681.00 9,364.00 93,819.00 152,2864.00 75,528.00 416,069.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHH A cloud-based decision suppor Pediatric Heart Network Praineland Con Child Health Research Career Develo Surviving and Thriving in th Electophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis be Molecular signaling in uterrine receptivil Impact of Emergency Department A Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5 in IG-1 Froduction and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V The role of executive functions in readinç Decision-Making for Patients Born with di | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davit: | University of Cincinnat Indiana University University of Central Missour University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State University University of Arizone Saint Louis University University of Arizone Saint Louis University University of Arizone Saint Louis University University of Massacarolina-Chapa H Kennedy Kileger Institute, Inc Technion Research & Development Fi- Washington University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65888L 1(GG014633-01) 1-571918-CHMC 1580GYB180 | U24HL134763 U24HL136601 U54HL136501 U51HL155778 Cardiovascular Disear K12HD02827 P01HD028357 P01HD02833 P01HD103133 P01HD103133 P01HD103133 P01HD1034566 P11HD0765561 R01HD076579 R01HD076189 R01HD076199 R01HD076199 R01HD076322 R01HD076322 R01HD084430 R01HD084430 R01HD086583 R01HD084458 | 93.837 93.837 93.837 93.837 93.857 93.865 | 30,883,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 40,8647,00 2,107,00 40,360,00 2,107,00 40,360,00 1,155,817,00 1,155,00 7,437,00 8,852,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 18,443,00 19,443,0019,443,00 19,443,00 19,443,0019 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,317,00 463,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 270,805,00 4,7771,00 279,301,00 152,025,00 9,954,00 9,954,00 9,954,00 66,896,00 9,7,050,00 66,896,00 9,7,050,00 9,954,00 66,896,00 9,7,050,00 9,954,00 9,0000 9,0000 9,0000 9,00000000 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 463,891.00 1,354,448.00 9,548.00 9,548.00 1,473,151.00 270,805.00 4,771.00 279,301.00 196,081.00 9,954.00 9,954.00 152,867.00 152,867.00 152,867.00 554,034.00 554,034.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHN A cloud-based decision suppor Pediatric Heart Network Praineland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis by Molecular signaling in uterine receptivit Impact of Emergency Departmen Long-Term Outcomes of Interve & Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5 in InG-F Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting 1 The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davi: | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgan Children's National Medical Cente University of Mahigar Washington University Children's Hospital of Philadelphi: Sam Diego State University University of Arizone Saint Louis University University of Arizone Saint Louis University University of Nationa-Chapter Technion Research & Development For Washington University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 R01HD086583 R01HD086583 R01HD087363 | U24HL134763 U24HL136691 U54HL13691 U51HL139578 Cardiovascular Disea K12HD028827 K23HD04855 K23HD101416 P01HD093833 P01HD103133 P41HD064566 P1HD074576 R01HD05651 R01HD05651 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076392 R01HD076392 R01HD076392 R01HD076392 R01HD078592 R01HD078592 R01HD086011 R01HD086011 | 93.837 93.837 93.837 93.837 93.865 | 30,833,00 3,448,00 179,402,00 2,199,500,00 3,10,311,00 10,000,00 849,647,00 449,647,00 1,558,817,00 1,195,00 2,107,00 40,360,00 1,195,00 1,195,00 1,195,00 1,195,00 1,203,00 46,802,00 200,387,00 24,490,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,591,00 178,334,00 127,776,00 1,034,137,00 9,548,00 623,504,00 270,305,00 4,771,00 152,025,00 9,361,00 93,614,00 94,614,00 94,0000 94,0000000000 | 5,477.00 274,565.00 34,922.00 399,815.00 18,683,417.00 463,891.00 1,354,448.00 1,354,448.00 1,354,448.00 1,473,151.00 270,2065.00 4,771.00 166,081.00 195,64.00 9,954.00 9,954.00 9,954.00 9,954.00 9,5528.00 416,069.00 534,034.00 56,429.00 73,911.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHN A cloud-based decision suppor Pediatric Heart Network Praineland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis by Molecular signaling in uterine receptivit Impact of Emergency Departmen Long-Term Outcomes of Interve & Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5 in InG-F Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting 1 The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davi: | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Calgary Children's National Medical Cente University of Arabone San Diego State University University of Arabone Saint Louis University University of Arabone Children's Mercy Hospita Duke University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 R01HD086583 R01HD086583 R01HD087363 | U24HL134763 U24HL136601 U54HL136501 U51HL155778 Cardiovascular Disear K12HD02827 P01HD028357 P01HD02833 P01HD103133 P01HD103133 P01HD103133 P01HD1034566 P11HD0765561 R01HD076579 R01HD076189 R01HD076199 R01HD076199 R01HD076322 R01HD076322 R01HD084430 R01HD084430 R01HD086583 R01HD084458 | 93.837 93.837 93.837 93.837 93.857 93.865 | 30,883,00 3,448,00 179,402,00 2,199,500,00 10,000,00 849,647,00 849,647,00 40,360,00 1,1589,00 2,107,00 40,360,00 1,1589,00 2,107,00 40,360,00 1,55,817,00 1,145,00 1,247,00 1,852,00 1,852,00 1,852,00 1,852,00 1,244,00 1,249,00 2,149,00 2,140,000 2,140,000000000000000000000 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,317,00 463,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 270,805,00 4,7771,00 279,301,00 152,025,00 9,954,00 9,954,00 9,954,00 66,896,00 9,7,050,00 66,896,00 9,7,050,00 9,954,00 66,896,00 9,7,050,00 9,954,00 9,0000 9,0000 9,0000 9,00000000 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 463,891.00 1,354,448.00 9,548.00 9,548.00 9,548.00 1,473,151.00 270,805.00 4,771.00 279,301.00 196,081.00 9,954.00 9,954.00 152,867.00 152,867.00 152,867.00 554,034.00 554,034.00 554,29.00 73,911.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHH A cloud-based decision suppor Pediatric Heart Network Prainteland Con Surviving and Thriving in the Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Research Traches The Control Stur Xenbase: The Xenopus model organism HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis br Molecular signaling in uterine neceptivil Impact of Emergency Departmen Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5b in IG-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting J The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepais EHR Regis Pharmacogenetics of Oxycodone | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davi: | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diago State University University of Arizona Saint Louis University University of Arizona Saint Louis University University of Arizona Saint Louis University University of Masachusetts Bostor University of Masachusetts Bostor University of Masachusetts Bostor University of Masachusetts Bostor University of North Carolina-Chapel H Kenedy Kegendri & Development F- Washington University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 R01HD086583 R01HD086583 R01HD086583 R01HD086583 | U24HL134763 U24HL136601 U54HL136501 U51HL155778 Cardiovascular Disear K12HD02827 P01HD028357 P01HD02833 P01HD103133 P01HD103133 P01HD103133 P01HD1034566 P11HD0765561 R01HD076579 R01HD076189 R01HD076199 R01HD076199 R01HD076322 R01HD076322 R01HD076324 R01HD084430 R01HD084430 R01HD084430 | 93.837 93.837 93.837 93.837 93.857 93.865 | 30,883,00 3,448,00 179,402,00 2,199,500,00 3,10,311,00 10,000,00 849,647,00 40,8647,00 2,107,00 40,360,000 1,155,817,00 1,155,00 7,437,00 8,852,00 18,444,00 11,850,20 24,749,00 24,749,00 51,260,00 51,260,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,317,00 463,891,00 178,334,00 127,776,00 1,034,137,00 9,548,00 270,805,00 4,7771,00 279,301,00 152,025,00 9,954,00 9,954,00 9,954,00 66,896,00 9,7,050,00 66,896,00 9,7,050,00 9,954,00 66,896,00 9,7,050,00 9,954,00 9,0000 9,0000 9,0000 9,00000000 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 463,891.00 1,354,448.00 9,548.00 9,548.00 9,548.00 1,473,151.00 270,805.00 4,771.00 279,301.00 196,081.00 9,954.00 9,954.00 152,867.00 152,867.00 152,867.00 554,034.00 554,034.00 554,29.00 73,911.00 |
| Role of Epithelial YAP in Alw Data Coordinating Genetre for PHH A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Robess: The Xnoppus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis br Molecular signaling in uterine neceptivil Impact of Emergency Departmen Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5b in 167-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting N The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Calgary Children's National Medical Cente University of Arabone San Diego State University University of Arabone Saint Louis University University of Arabone Children's Mercy Hospita Duke University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312.0217179-85988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 1 0 R01HD085883 R01HD085883 R01HD085458 | U24HL134763 U24HL136601 U54HL136601 U51HL139578 Cardiovascular Disea K12HD02827 P01HD0283578 P01HD03333 P01HD103133 P01HD103133 P01HD103133 P01HD065551 R01HD074579 R01HD074579 R01HD074579 R01HD074579 R01HD074592 R01HD074592 R01HD074592 R01HD084430 R01HD084430 R01HD084430 R01HD084458 R01HD084458 R01HD084458 R01HD084458 R01HD084458 R01HD084458 R01HD084583 R01HD084583 R01HD084583 R01HD089322 R01HD089932 | 93.837 93.837 93.837 93.837 93.837 93.855 93.865 | 30,883,00 3,448,00 179,402,00 2,199,500,00 10,000,00 849,647,00 849,647,00 40,360,00 1,1589,00 2,107,00 40,360,00 1,1589,00 2,107,00 40,360,00 1,55,817,00 1,145,00 1,247,00 1,852,00 1,852,00 1,852,00 1,852,00 1,244,00 1,249,00 2,149,00 2,140,000 2,140,000000000000000000000 | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,917.00 463,891.00 178,334.00 127,776.00 1,034,137.00 9,548.00 270,805.00 270,805.00 271,905.00 9,954.00 93,619.00 97,050.00 93,619.00 97,050.00 66,896.00 370,770.00 56,420.00 56,420.00 56,420.00 56,420.00 33,71910.00 33,71910.00 33,71910.00 33,7824.00 | 5,477.00 274,565.00 34,922.00 399,615.00 18,683,417.00 463,891.00 1,354,484.00 9,584.00 1,473,151.00 270,805.00 1,473,151.00 270,805.00 1,473,151.00 270,805.00 1,473,151.00 279,301.00 196,081.00 196,081.00 152,867.00 9,954.00 9,954.00 75,528.00 75,528.00 534,034.00 534,034.00 534,034.00 534,934.00 148,430.00 49,240.00 |
| Role of Epithelial YAP in Alw Data Coordinating Genetre for PHH A cloud-based decision suppor Pediatris Heart Network Prainteiand Con Child Health Research Carser Davelo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis b Molecular signaling in uterine receptivit Impact of Emergency Department Robes of STAT bio InIGF-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors | University of Maryland Galtimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRL Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State University Mulversity of California-Davit University of Michigar Northwestern University Medical Schoc Indiana University Heatti | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State University University of Natoone Saint Louis University University of Natochart Carolina-Chapel H Kennedy Krieger Institute, Inc Technion Research & Development Fri Washington University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 R01HD086583 R01HD086583 R01HD086583 R01HD086583 | U24HL134763 U24HL136691 U54HL136691 U54HL19810 U51HL135778 Cardiovascular Disea K12HD038578 D14HD038363 P01HD03363 P01HD03363 P01HD03363 P01HD035561 R01HD05551 R01HD07619 R01HD07619 R01HD07619 R01HD07619 R01HD07619 R01HD07619 R01HD07619 R01HD07639 R01HD07639 R01HD07639 R01HD07639 R01HD08524 R01HD08524 R01HD08583 R01HD08583 R01HD08583 R01HD08583 R01HD08583 R01HD08583 R01HD08583 R01HD085932 R01HD08932 R01HD08932 R01HD08932 R01HD081347 | 93.837 93.837 93.837 93.837 93.837 93.855 93.865 | 30,83,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,517,00 463,891,00 178,334,00 127,776,00 1,034,130,00 9,548,00 270,805,00 4,777,100 279,301,00 9,564,00 93,619,00 97,71,00 668,896,00 668,896,00 668,896,00 668,896,00 668,896,00 668,896,00 73,911,00 33,710,00 73,911,00 33,710,00 73,911,00 33,710,00 73,911,00 33,7124,00 49,240,00 11,735,00 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 1778,334.00 1778,334.00 1,354,448.00 9,548.00 1,473,181.00 2,478,100 2,478,100 1,473,181.00 2,478,100 1,473,181.00 2,481,00 1,954,00 1,656,00 564,429.00 73,311.00 566,556.00 148,430.00 49,240.00 149,240.00 149,240.00 149,240.00 |
| Role of Epithelial YAP in Alw Data Coordinating Geneter for PHH A cloud-based decision suppor Pediatris Heart Network Prainteinand Con Child Health Research Carser Develo Surviving and Thriving in the Developmental Mechanisms of Trache Pediatric HIVAIDS Cohort Stuc Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis b Molecular signaling in uterine receptivit Impact of Emergency Department Bone Mineral Accretion in Froduction and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors FA DDR Pathway in Germline Integrit The Fole of Emergency Depart Development and Testing of a 1 Harnessing formis": A Systems Biology Vocacional Fit Assessment an: | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi Sam Dago State University University of Anzone Saint Louis University University of Massachusetts Booton University of Massachusetts Boot | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312.0217179-85988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 1 0 R01HD085883 R01HD085883 R01HD085458 | U24HL134763 U24HL136691 U54HL136691 U54HL19810 U51HL135578 Cardiovascular Disear K12HD028827 P01HD028363 P01HD103133 P01HD103363 P01HD103363 P01HD035651 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD086583 R01HD084958 R01HD08932 R01HD08922 R01HD08932 R01HD08932 R01HD08932 R01HD08932 R01HD08932 R01HD08932 R01HD0 | 93.837 93.837 93.837 93.837 93.857 93.865 | 30,83,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,317,00 463,891,00 178,334,00 127,776,00 623,504,00 270,805,00 4,7771,00 279,301,00 9,548,00 11,735,00 11,735,00 11,735,00 11,735,00 13,314,00 47,244,00 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 178,334.00 1,354.448.00 9,548.00 1,473,181.00 2470,805.00 4,771.00 279,301.00 195,681.00 9,964.00 9,964.00 9,964.00 152,867.00 155,28.00 75,528.00 416,069.00 534,034.00 564.29.00 73,911.00 568,560.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHH A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Developmental Mechanisms of Trache Prenatal Genetic Diagnosis b Prenatal Genetic Diagnosis b Molecular signaling in uterine receptivit Impact of Emergency Departmen Conginitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5b in 167-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenomic Predictors The Pather of Engency Depart The Effect of Emergency Depart Development and Testing of a 1 Harnessing Tomics". A Systems Biology Vocational Fit Assessment an Exploration of the genetic base | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lemer Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis VI University of Michigar Northwestern University Medical Schoo Indiana University Healti | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State University University of Natoone Saint Louis University University of Natochart Carolina-Chapel H Kennedy Krieger Institute, Inc Technion Research & Development Fri Washington University | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 1-571918-CHMC 1580GYB180 0 R01HD085853 R01HD085458 R01HD091302-03 700171-0719-00 R01HD0912474 | U24HL134763 U24HL136501 U54HL136501 U51HL155778 Cardiovascular Disea K12HD02827 Cardiovascular Disea K12HD02827 P01HD038363 P01HD038363 P01HD038363 P01HD05551 R01HD074579 R01HD074579 R01HD074579 R01HD074579 R01HD074582 R01HD074582 R01HD074582 R01HD084430 R01HD0845582 R01HD0845583 R01HD085583 R01 | 93.837 93.837 93.837 93.837 93.837 93.865 | 30,83,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,391,00 178,334,00 127,776,00 623,504,00 623,504,00 623,504,00 623,504,00 74,905,00 74,905,00 93,619,00 97,050,00 93,619,00 97,050,00 66,896,00 370,770,00 66,896,00 66,896,00 370,770,00 66,420,00 73,311,00 33,7424,00 11,735,00 11,334,00 73,241,00 73,241,00 73,241,00 | 5,477.00 274,565.00 34,922.00 399,615.00 18,683,417.00 463,891.00 1,354,448,00 1,354,448,00 9,554,00 1,473,151.00 270,805.00 4,771.00 4,771.00 196,081.00 196,081.00 152,867.00 9,954.00 9,954.00 75,528.00 416,069.00 534,034.00 554,034.00 554,034.00 554,034.00 11,735.00 73,311.00 39,110.00 39,00 30,00 |
| Role of Epithelial YAP in Alw Data Coordinating Genetre for PHH A cloud-based decision suppor Pediatist Heart Network Prainteinal Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc Xenbase: The Xanopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis by Molecular signaling in uterire receptivit Impact of Emergency Department Long-Term Outcomes of Interver A Cognitive Test Battery for Bone Mineral Accretion In Young Childre Roles of STAT5b in IGF-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting N The role of executive functions in reading Decision-Making for Patients Bons with di PED Screen: Pediatric Sepais EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis // University of Michigar Northwestern University Medical Schoo Indiana University Healt! Medical College of Wisconsir Nationwide Children's Hospita Colorado State Universit; University of Horda | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi Sam Dago State University University of Anzone Saint Louis University University of Massachusetts Booton University of Massachusetts Boot | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 1-571918-CHMC 1580GYB180 0 R01HD086583 R01HD087363 R01HD091302-03 700171-0719-00 R01HD092474 SUBK00008039 SUB00001726 | U24HL134763 U24HL136501 U54HL135678 Cardiovascular Disea K12HD02827 Cardiovascular Disea K12HD02827 P01HD03833 P01HD03455 R01HD08455 R01HD08455 R01HD074579 R01HD074579 R01HD074579 R01HD074579 R01HD074579 R01HD074592 R01HD074592 R01HD074592 R01HD074592 R01HD085924 R01HD085924 R01HD085928 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD085812 R01HD08582 R01HD085828 R01HD08588 R01HD08588 R01HD08588 R01HD08588 R01HD08588 R01HD08588 R | 93.837 93.837 93.837 93.837 93.855 93.865 | 30,83,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,391,00 178,334,00 127,776,00 1,034,137,00 9,548,00 623,504,00 623,504,00 623,504,00 152,025,00 152,025,00 152,025,00 93,619,00 97,050,00 93,619,00 97,050,00 66,896,00 66,896,00 56,429,00 73,911,00 337,024,00 48,430,00 49,240,00 11,735,00 13,314,00 73,241,00 33,124,00 13,314,00 73,241,00 33,124,00 12,024,00 13,314,00 73,241,00 33,124,00 12,024,00 12,024,00 12,024,00 12,024,00 13,314,00 12,024,00 13,024,00 13,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,00 14,024,000 14, | 5,477.00 274,565.00 34,922.00 399,615.00 18,683,417.00 463,891.00 1,354,448.00 9,554.00 1,354,448.00 9,554.00 1,277,151.00 1,277,3151.00 1,270,805.00 4,771.00 279,301.00 196,081.00 196,081.00 152,867.00 9,954.00 75,528.00 416,069.00 534,034.00 564,290.00 73,911.00 39,110.00 39,110.00 566,556.00 148,430.00 48,430.00 147,35.00 21,732.00 73,241.00 550,650.00 |
| Role of Epithelial YAP in Alw Data Coordinating Geneter for PHH A cloud-based decision suppor Pediatric Heart Network Prainteinand Con Surviving and Thriving in the Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Prenatal Genetic Diagonosis b Molecular signaling in uterine receptivil Impact of Emergency Department Roles of STAT5 in IG-1 Froduction and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors FA DDR Pathway in Germline Integrit; The Effect of Emergency Depar Decision-Making for States Biology Vocational Fit Assessment an Exploration of the genetic ba Disorder/Differences of Sex Develog CES1 Genetic Variation Influer | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis // University of Michigar Northwestern University Medical Schoc Indiana University Healt! Medical College of Wisconsir Nationwide Children's Hospita Colorado State Universit University of Michigar University of Michigar University of Michigar University of Michigar University of Michigar University of Michigar | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi Sam Dago State University University of Anzone Saint Louis University University of Massachusetts Booton University of Massachusetts Boot | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 R01HD08583 R01HD08583 R01HD087363 R01HD08458 R01HD08458 R01HD0847363 R01HD089458 | U24HL134763 U24HL136601 U54HL136601 U54HL135778 Cardiovascular Disear K12HD02827 P01HD0385778 P01HD03833 P01HD103133 P01HD103133 P01HD103133 P01HD103133 P01HD1035561 R01HD056561 R01HD056561 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076321 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084458 R01HD084458 R01HD084458 R01HD084583 R01HD084585 R01HD084585 R01HD084585 R01HD084585 R01HD084585 R01HD084585 R01HD084585 R01HD084585 R01HD084585 R01HD084585 R01HD084585 R01HD0845585 R01HD084558 R01HD08558 R | 93.837 93.837 93.837 93.837 93.857 93.865 | 30,83,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 849,647,00 | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,317.00 463,891.00 178,334.00 127,776.00 1,034,137.00 9,548.00 270,805.00 47,771.00 279,301.00 152,025.00 9,9,54.00 9,9,54.00 66,896.00 9,7,550.00 0,00 56,429.00 7,3,911.00 33,7,191.00 33,7,191.00 33,7,191.00 33,7,191.00 33,7,191.00 33,7,191.00 33,7,241.00 11,372.40 11,372.40 11,372.40 11,372.40 11,372.40 11,272.40 11,272.40 11,272.40 11,272.40 11,272.40 12,222.00 12,222.00 12,224.00 12,224.00 12,224.00 12,224.00 12,224.00 12,224.00 12,224.00 12,224.00 12,224.00 13,220.00 12,224.00 14,232.00 14,232.00 14,232.00 15,222.00 12,224.00 12,224.00 12,224.00 12,224.00 12,224.00 12,224.00 12,224.00 14,232.00 14,232.00 14,232.00 14,232.00 14,240.00 14 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 1,354.448.00 9,548.00 1,354.448.00 9,548.00 1,473,151.00 270,805.00 4,771.00 279,301.00 195,081.00 152,867.00 152,867.00 534,034.00 554,034.00 554,034.00 554,29.00 73,311.00 558,556.00 148,430.00 147,732.00 148,430.00 147,732.00 17,732.00 12,772.00 14,773.00 14 |
| Role of Epithelial YAP in Alw Data Coordinating Genete for PHH A cloud-based decision suppor Pediatric Heart Network Praineland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIVAIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis be Molecular signaling in uterine receptivit Impact of Emergency Department & Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5 in 167-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors FA DDR Pathway in Germline Integrit; The Effect of Emergency Depar Development and Testing of at Ioliology Vocational FIA Assessment and Testing Of A Diagnational FIA Assessment and CEST Genetic Variation Influent A multioner collaborative of Sex Develop | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis // University of Michigar Northwestern University Medical Schoo Indiana University Healt! Medical College of Wisconsir Nationwide Children's Hospita Colorado State Universit; University of Horda | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphia San Diego State University University of Arizona Sant Louis University Children's Hospital of Philadelphia San Diego State University University of Arizona Sant Louis University Children's Master A Development Fit Washington University CARRA Inc Children's Mercy Hospita Duke University Wake Forest University Institute for Systems Biology Baylor College of Medicine | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 1-571918-CHMC 1580GYB180 0 R01HD086583 R01HD087363 R01HD091302-03 700171-0719-00 R01HD092474 SUBK00008039 SUB00001726 | U24HL134763 U24HL136601 U54HL136601 U54HL135778 Cardiovascular Disear K12HD02827 P01HD0385778 P01HD03833 P01HD1013133 P01HD1013133 P01HD1013133 P01HD1013133 P01HD1013133 P01HD1013133 P01HD1013133 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076321 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084458 R01HD084458 R01HD084458 R01HD084583 R01HD08583 R | 93.837 93.837 93.837 93.837 93.857 93.865 93 | 30,833,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 2,107,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 40,8647,00 41,855,00 41,955,000,000,000,000,000,000,000,000,000 | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,917.00 463,891.00 178,334.00 127,776.00 1,034,137.00 9,548.00 270,805.00 470,805.00 279,301.00 152,025.00 9,954.00 66,896.00 9,954.00 66,896.00 0,000 56,429.00 7,3,911.00 337,341.00 337,324.00 11,733,424.00 11,732,41.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,223.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 63,320.00 110,128.00 44,11.00 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 1,354,448.00 9,548.00 1,354,448.00 9,548.00 1,473,151.00 2,777.00 4,771.00 2,70,805.00 4,771.00 196,081.00 195,081.00 152,867.00 195,400 75,528.00 75,528.00 534,034.00 534,034.00 534,034.00 554,290.00 73,911.00 558,556.00 148,430.00 49,241.00 50,9656.00 11,7352.00 11,7352.00 50,9650.00 11,7352.00 50,9650.00 11,7352.00 50,9650.00 11,7352.00 50,9650.00 11,7352.00 50,9650.00 11,7352.00 50,9650.00 11,7352.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHH A cloud-based decision suppor Pediatirs Heart Network Prainteiand Con Child Health Research Career Davelo Surviving and Thriving in th Electrophysiological Blomarke Developmental Mechanisms of Trache Pediatric HIV/AIDS Cohort Stuc Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis b; Molecular signaling in uterine receptivit Impact of Emergency Department Long-Term Outcomes of Interver A Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5b in ICE-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V The role of executive functions in reading Decision-Making for Patients Bon with dii PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodoms Identifying Pharmacogenomic Predictors IFA DDR Pathway in Germline Integrit; The Effect of Emergency Depar Identifying Pharmacogenomic Predictors Identifying Chartensent and Exploration of the genetic ba DibEs/Dufferences of Gak Develop Care Strophysitics of Gak Develop Care Strophysitics | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente University of California-Davit University of California-Davit University of California-Davit University of Michigar Northwestern University Medical Schoc Indiana University Healt! Medical College of Wisconsir Nationwide Children's Hospita Colorado State University University of Michigar University of Michigar University of Michigar Nationwide Children's Hospita Colorado State University University of Florida Children's National Medical Cente University of Lorida | University of Cincinnat Indiana University Columbia University University of Catifal Missour University of Calgary Children's National Medical Cente University of Calgary Children's National Medical Cente University of Ationa San Diego State University University of Atizons Sant Louis University University of Atizons University of Atizons Sant Louis University University of Atizons Sant Louis University University of Atizons Sant Louis University CARRA Inc Children's Mercy Hospita Duke University Institute for Systems Biology Baylor College of Medicine | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 R01HD085883 R01HD0858583 R01HD0858583 R01HD093458 R01HD093458 R01HD093458 R01HD093458 R01HD093458 | U24HL134763 U24HL136801 U54HL136801 U51HL136578 Cardiovascular Disea K12HD28578 K23HD01415 P01HD093363 P01HD103133 P01HD103133 P11HD04556 PL1HD10155 R01HD05551 R01HD074579 R01HD074579 R01HD076321 R01HD076321 R01HD076321 R01HD076321 R01HD07852 R01HD07852 R01HD086430 R01HD086430 R01HD086430 R01HD086430 R01HD086430 R01HD08932 R01HD08932 R01HD08932 R01HD08932 R01HD08932 R01HD08932 R01HD08932 R01HD08932 R01HD089312 R01HD089312 R01HD089312 R01HD089312 R01HD089312 R01HD089312 R01HD089312 R01HD089312 R01HD089312 R01HD089312 R01HD089312 R01HD09312 R01HD | 93.837 93.837 93.837 93.837 93.837 93.857 93.865 | 30,83,00 3,448,00 179,402,00 2,199,500,00 849,647,00 | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,517.00 1,034,137.00 1,034,137.00 270,205.00 4,777.00 279,301.00 279,301.00 279,301.00 97,650.00 93,619.00 33,719.70 0,00 | 5,477.00 274,565.00 34,922.00 399,615.00 1463.891.00 1778.334.00 1778.334.00 9,548.00 9,548.00 1,473,151.00 270,805.00 4,771.00 279,301.00 1950,81.00 9,964.00 9,964.00 9,861.00 192,2867.00 192,2867.00 192,2867.00 192,2867.00 192,2867.00 192,2867.00 192,2867.00 192,2867.00 192,528.00 416,069.00 534,034.00 508,556.00 148,430.00 49,240.00 508,556.00 110,253.00 21,732.00 21,732.00 21,732.00 21,732.00 21,732.00 21,732.00 10,2533.00,00 |
| Role of Epithelial YAP in Alw Data Coordinating Geneter for PHH A cloud-based decision suppor Pediatric Heart Network Praineland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIVAIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis be Molecular signaling in uterine receptivit Impact of Emergency Department & Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5 in 167-1 Froduction and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors FA DDR Pathway in Germline Integrit; The Effect of Emergency Depar Development and Testing of at Ioliology Vocational FIA Assessment and Testing Of Disorders/Differences of Sex Develog CES1 Genetic Variation Influence A multiterer collaborative c | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente University of California-Davit University of California-Davit University of California-Davit University of Michigar Northwestern University Medical Schoc Indiana University Healt! Medical College of Wisconsir Nationwide Children's Hospita Colorado State University University of Michigar University of Michigar University of Michigar Nationwide Children's Hospita Colorado State University University of Florida Children's National Medical Cente University of Lorida | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State University University of Natoone Saint Louis University University of Natoone Saint Louis University University of Natocal State University Washington University CARRA Inc Children's Mercy Hospita Diske University Wake Forest University Institute for Systems Biolog: Baylor College of Medicine | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 R01HD085883 R01HD0858583 R01HD0858583 R01HD093458 R01HD093458 R01HD093458 R01HD093458 R01HD093458 | U24HL134763 U24HL136601 U54HL136601 U54HL135778 Cardiovascular Disear K12HD02827 P01HD0385778 P01HD03833 P01HD1013133 P01HD1013133 P01HD1013133 P01HD1013133 P01HD1013133 P01HD1013133 P01HD1013133 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076321 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084458 R01HD084458 R01HD084458 R01HD084583 R01HD08583 R | 93.837 93.837 93.837 93.837 93.857 93.865 93 | 30,83,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 10,000,00 10,000,00 10,000,00 | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,917.00 463,891.00 178,334.00 127,776.00 1,034,137.00 9,548.00 270,805.00 470,805.00 279,301.00 152,025.00 9,954.00 66,896.00 9,954.00 66,896.00 0,000 56,429.00 7,3,911.00 337,341.00 337,324.00 11,733,424.00 11,732,41.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,241.00 73,223.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 66,323.00 110,128.00 63,320.00 110,128.00 44,11.00 | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 1,354,448.00 9,548.00 1,354,448.00 9,548.00 1,473,151.00 2,777.00 4,771.00 2,70,805.00 4,771.00 196,081.00 195,081.00 152,867.00 195,400 75,528.00 75,528.00 534,034.00 534,034.00 534,034.00 554,290.00 73,911.00 558,556.00 148,430.00 49,241.00 50,9656.00 11,7352.00 534,034.00 559,650.00 11,7352.00 53,40,04,00 73,232.00 53,90,00 12,024.00 73,232.00 53,90,00 12,024.00 73,232.00 11,028.00 14,11.00 |
| Role of Epithelial YAP in Alw Data Coordinating Center for PHH A cloud-based decision suppor Pediatric Heart Network Prainteiand Con Surviving and Thriving in the Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIVAIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis br Molecular signaling in uterine receptivit Impact of Emergency Departmen Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5 in 167-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting V The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors FA DDR Pathway in Germine Integrit The Effect of Emergency Depar Development and Testing of a I Harnessig Tomics". A Systems Biology Vocational of the genetic bactoris Disci Station of the genetic bactoris An Intervention Communication High-Intensity Interval Train Cognitive Outcome Measures is Thrombotic microangiopathy (Th | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis University of Michigar Northwestern University Medical Schoo Indiana University Healt! Medical College of Wisconsir Nationwide Children's Hospita Colorado State Universit; University of California-Davis University of California-Davis University of California-Davis University of California-Davis University of California-Davis University of California-Davis | University of Cincinnat Indiana University Columbia University University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State University University of Arizone Saint Louis University University of Arizone Saint Louis University University of Arizone Saint Louis University University of Masscaraolina-Chapel H Kennedy Kileger Institute, Inc Technior Research & Development F- Washington University CARRA Inc Children's Mercy Hospita Duke University Wake Forest University Institute for Systems Biology Baylor College of Medicine | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 1-571918-CHMC 1580GYB180 1-571918-CHMC 1580GYB180 801HD085583 R01HD085583 R01HD085583 R01HD085458 R01HD091302-03 700171-0719-00 R01HD092474 SUBK00000039 SUB0001728 30004927-01 A15446-5002 011445-02 | U24HL134763 U24HL136601 U54HL136601 U54HL135778 Cardiovascular Diseat K12HD02827 P01HD038578 P01HD038363 P01HD103133 P01HD103133 P14HD04556 P14HD045565 P14HD0455651 R01HD076579 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076321 R01HD084582 R01HD08322 R01HD084583 R01HD084583 R01HD084583 R01HD084583 R01HD089322 R01HD089322 R01HD089322 R01HD089322 R01HD089322 R01HD089322 R01HD089322 R01HD089322 R01HD089322 R01HD089374 R01HD089374 R01HD093773 | 93.837 93.837 93.837 93.837 93.837 93.857 93.865 | 30,883,00 3,448,00 179,402,00 2,199,500,00 2,199,500,00 310,311,00 10,000,00 2,107,00 40,8647,0040,00 40,8647,00 40,8647,00 40,8647,0040,00 40,8647,0040,00 40,864 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,917,00 463,891,00 178,334,00 127,776,00 439,544,00 270,805,00 270,805,00 270,805,00 271,805,00 97,551,00 97,551,00 97,551,00 97,550,00 66,896,00 370,770,00 66,896,00 370,770,00 0,00 97,551,00 97,551,00 97,550,00 93,619,00 97,550,00 93,619,00 97,351,00 97,351,00 97,351,00 97,354,00 66,896,00 337,3741,00 337,341,00 333,7824,00 11,375,00 13,314,00 73,241,00 49,240,00 11,375,00 13,314,00 73,241,00 331,773,00 11,224,00 43,241,00 43,311,00 334,310,00 735,200 43,311,00 334,310,00 735,200 43,311,00 348,308,00 736,081,00 736,081,00 736,081,00 | 5,477.00 274,565.00 34,922.00 399,615.00 16,683,417.00 176,334.00 1,354,448.00 9,584.00 270,805.00 1,473,151.00 270,805.00 1,473,151.00 270,805.00 1,473,151.00 279,301.00 196,081.00 195,081.00 195,081.00 195,081.00 152,867.00 9,954.00 75,528.00 416,069.00 534,034.00 534,034.00 534,034.00 534,034.00 534,034.00 534,034.00 11,735.00 73,241.00 508,556.00 148,430.00 49,240.00 11,732.00 73,241.00 50,566.00 12,1732.00 73,241.00 50,566.00 12,1732.00 73,241.00 50,566.00 12,1732.00 73,241.00 50,566.00 110,128.00 4,311.00 533,500.00 883,703.00 |
| Role of Epithelial YAP in Alw Data Coordinating Geneter for PHH A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIVAIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis br Molecular signaling in uterine receptivil Impact of Emergency Department Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5b in (Gr-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting J The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepais EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors FA DDR Pathway in Germline Integrit The Effect of Emergency Depar Development and Testing of a Harnessing "omics": A Systems Biology Vocational FIA Assessment and Exploration of the genetic base Disordens/Differences of Sex Develop CEST Genetic Variation Influer A mult Center colaborative ca Etglip Hensity Intervel Tarian Cegnitive Outcome Measures is Thrombolic microangiopathy (Th | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente University of California-Davit University of California-Davit University of California-Davit University of Michigar Northwestern University Medical Schoc Indiana University Healt! Medical College of Wisconsir Nationwide Children's Hospita Colorado State University University of Michigar University of Michigar University of Michigar Nationwide Children's Hospita Colorado State University University of Florida Children's National Medical Cente University of Lorida | University of Cincinnat Indiana University University of Central Missour University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State University University of Arizone Saint Louis University University of Arizone Saint Louis University University of Arizone Saint Louis University University of Masachuseths Bostor University of Masachuseths Bostor University of North Carolina-Chapel H Kennedy Kieger Institute, Inc. Technon Research & Development FW Washington University University of Mercy Hospita Duke University Wake Forest University Institute for Systems Biology Baylor College of Medicine Colorado State Universit Children's State Universit Children's State Universit Children's State Universit Children's State Universit Children's State Universit | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 R01HD085883 R01HD0858583 R01HD0858583 R01HD093458 R01HD093458 R01HD093458 R01HD093458 R01HD093458 | U24HL134763 U24HL136601 U54HL136601 U54HL139578 Cardiovascular Disea K12HD02827 P01HD0283578 P01HD028363 P01HD103133 P01HD103133 P01HD103133 P01HD1034566 P01HD035561 R01HD076579 R01HD076579 R01HD076579 R01HD076189 R01HD076189 R01HD076321 R01HD076321 R01HD084582 R01HD08430 R01HD084583 R01HD084583 R01HD084583 R01HD084588 R01HD089322 R01HD089322 R01HD08932 R01HD09453 R01HD09453 R01HD094698 R01HD094698 | 93.837 93.837 93.837 93.837 93.837 93.857 93.865 | 30,883,00 3,448,00 179,402,00 2,199,590,00 2,199,590,00 10,000,00 10,000,00 2,107,00 40,360,00 2,107,00 40,360,00 2,107,00 40,360,00 1,158,00 2,107,00 40,360,00 1,158,00 2,107,00 40,360,00 1,195,00 7,437,00 8,847,00 18,844,00 11,203,00 7,437,00 8,446,00 77,444,00 2,24,749,00 19,133,00 19,137,00, | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,917.00 463,891.00 178,334.00 127,776.00 1,034,137.00 9,548.00 270,805.00 270,805.00 271,905.00 97,050.00 97,050.00 97,050.00 97,050.00 97,050.00 97,050.00 97,050.00 93,619,00 97,050.00 93,619,00 97,050.00 93,619,00 97,050.00 93,619,00 97,3941.00 33,7844.00 49,240.00 11,735.00 33,7140.01 33,714.00 11,735.00 13,314.00 73,241.00 49,240.00 11,241.00 43,241.00 11,241.00 33,317,30 12,024.00 11,0128.00 33,311,00 33,311,00 33,110,01 33,110,01 33,110,01 33,110,00 33,110,01 34,308.00 73,241.00 43,241.00 43,311.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,00 73,241.00 34,330,00 73,241.00 34,330,00 73,241.00 34,330,00 34,3 | 5,477.00 274,565.00 34,922.00 399,615.00 18,683,417.00 176,334.00 1,354,448.00 9,584.00 270,805.00 270,805.00 279,301.00 196,081.00 195,081.00 195,081.00 195,081.00 195,081.00 195,081.00 195,081.00 534,034.00 534,034.00 534,034.00 534,034.00 534,034.00 534,034.00 11,735.00 534,034.00 534,034.00 11,735.00 73,241.00 508,556.00 148,430.00 148,240.00 11,732.00 73,241.00 50,566.00 11,128.00 12,1282.00 73,241.00 533,500.00 883,703.00 99,028.00 281,549.00 |
| Role of Epithelial YAP in Alw Data Coordinating Genetre for PHH A cloud-based decision suppor Pediatirs Heart Network Prainteinand Con Child Health Research Carser Develo Surviving and Thrving in th Electrophysiological Blomarke Developmental Mechanisms of Trache Pediatric HIVAIDS Cohort Stuc Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis b; Molecular signaling in uterine receptivit Impact of Emergency Department A Cognitive Tast Battery for Boon Mineral Accretion IV Young Childre Roles of STAT5b in IGF-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeling V Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogeneomic Predictors FA DDR Pathway in Germline Integrit The fole of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepsis EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogeneomic Predictors Exploration of the genetic ba DisorderDifferences of Sex Develop CESI Genetic Variation Influer A Stylena Filde Conservation Exploration of the genetic ba DisorderDifferences of Sex Develop CESI Genetic Variation Influer A Enty Olithoed Communication High-Intensity Interval Train Cognitive Outcome Measures i | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis University of Michigar Northwestern University Medical Schoo Indiana University Healt! Medical College of Wisconsir Nationwide Children's Hospita Colorado State Universit; University of California-Davis University of California-Davis University of California-Davis University of California-Davis University of California-Davis University of California-Davis | University of Cincinnat Indiana University Columbia University University of Cantral Missour University of Calgary Children's National Medical Cente University of Calgary Children's National Medical Cente University of Michigar Children's Hospital of Philadelphi Sam Dego State University University of Nationa Saint Louis University University of Nationates Boston University of Nationates Boston Didon's Mercy Hospita Didon State University Nate Forest University Institute for Systems Biology Baylor College of Medicine Cohorado State University University of Cincinnat | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 1-571918-CHMC 1580GYB180 1-571918-CHMC 1580GYB180 801HD085583 R01HD085583 R01HD085583 R01HD085458 R01HD091302-03 700171-0719-00 R01HD092474 SUBK00000039 SUB0001728 30004927-01 A15446-5002 011445-02 | U24HL134763 U24HL136691 U54HL136691 U54HL139578 Cardiovascular Disear K12HD028827 P01HD028363 P01HD103456 P01HD028363 P01HD103133 P14HD044566 PL1HD1013133 P14HD044566 PL1HD1013133 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076189 R01HD076321 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084430 R01HD084458 R01HD084458 R01HD084458 R01HD084583 R01HD084583 R01HD084583 R01HD084583 R01HD084583 R01HD084583 R01HD084583 R01HD084583 R01HD084583 R01HD089322 R01HD08932 R01HD085837 R01HD089327 R01HD08317 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD093173 R01HD094213 R01HD094213 R01HD094213 R01HD094213 R01HD094213 R01HD094213 R01HD094862 | 93.837 93.837 93.837 93.837 93.837 93.857 93.855 93.865 93 | 30,83,00 3,448,00 179,402,00 2,199,500,00 310,311,00 10,000,00 10,000,00 2,107,00 4,96,47,00 4,96,47,00 4,96,47,00 4,96,47,00 4,96,47,00 4,96,47,00 4,96,47,00 4,96,47,00 4,96,47,00 4,96,47,00 4,96,40,00 7,1,447,00 18,85,200 24,749,00 23,082,00 31,933,00 19,133,00 19 | 5,477,00 243,702,00 31,474,00 220,213,00 14,483,817,00 178,334,00 178,334,00 178,334,00 172,776,00 172,776,00 270,805,00 47,771,00 270,805,00 47,771,00 279,301,00 93,619,00 93,619,00 93,619,00 93,619,00 93,619,00 93,619,00 93,619,00 93,619,00 93,619,00 93,619,00 93,619,00 94,00 66,896,00 66,896,00 66,896,00 73,911,00 33,710,00 56,429,00 73,911,00 33,710,00 11,735,00 11,334,00 49,240,00 11,735,00 11,334,00 31,773,00 11,324,00 31,773,00 11,324,00 11,334,00 49,240,00 11,735,00 11,334,00 31,773,00 11,222,00 11,334,00 31,773,00 11,222,00 11,334,00 31,773,00 11,222,00 11,334,00 31,773,00 11,222,00 11,334,00 31,773,00 11,223,00 11,235,00 11,334,00 31,773,00 11,224,00 11,334,00 31,773,00 11,224,00 31,773,00 11,224,00 31,773, | 5,477.00 274,565.00 34,922.00 399,815.00 16,683,417.00 1778,334.00 1778,334.00 1,354,448.00 9,548.00 1,473,151.00 270,805.00 4,771.00 279,301.00 195,681.00 93,619.00 152,867.00 152,867.00 152,867.00 152,867.00 554,034.00 564.29.00 73,341.00 564.29.00 73,241.00 50,856.00 148,430.00 49,240.00 73,241.00 50,856.00 110,128.00 21,732.00 110,128.00 110,128.00 110,128.00 110,128.00 110,128.00 23,3150.00 53,3100.00 53,31000 |
| Role of Epithelial YAP in Alw Data Coordinating Geneter for PHH A cloud-based decision suppor Pediatric Heart Network Prainteland Con Child Health Research Career Develo Surviving and Thriving in th Electrophysiological Biomarke Developmental Mechanisms of Trache Developmental Mechanisms of Trache Pediatric HIVAIDS Cohort Stur Xenbase: The Xenopus model organisr HEAL Initiative: Antenatal Op Prenatal Genetic Diagnosis br Molecular signaling in uterine receptivil Impact of Emergency Department Cognitive Test Battery for Bone Mineral Accretion in Young Childre Roles of STAT5b in (Gr-1 Production and An Intervention to Reduce SHS Exposure Improving ADHD Teen Driving by Targeting J The role of executive functions in reading Decision-Making for Patients Born with di PED Screen: Pediatric Sepais EHR Regis Pharmacogenetics of Oxycodone Identifying Pharmacogenomic Predictors FA DDR Pathway in Germline Integrit The Effect of Emergency Depar Development and Testing of a Harnessing "omics": A Systems Biology Vocational FIA Assessment and Exploration of the genetic base Disordens/Differences of Sex Develop CEST Genetic Variation Influer A mult Center colaborative ca Etglip Hensity Intervel Tarian Cegnitive Outcome Measures is Thrombolic microangiopathy (Th | University of Maryland (Baltimore New England Research Institute: Cleveland Clin Lerner Col of Med of CWRI Harvard Medical Schoo RTI Internationa Columbia University Medical Cente Oklahoma State Universit University of California-Davis University of Michigar Northwestern University Medical Schoo Indiana University Healt! Medical College of Wisconsir Nationwide Children's Hospita Colorado State Universit; University of California-Davis University of California-Davis University of California-Davis University of California-Davis University of California-Davis University of California-Davis | University of Cincinnat Indiana University University of Central Missour University of Central Missour University of Calgary Children's National Medical Cente University of Michigar Washington University Children's Hospital of Philadelphi San Diego State University University of Arizone Saint Louis University University of Arizone Saint Louis University University of Arizone Saint Louis University University of Masachuseths Bostor University of Masachuseths Bostor University of North Carolina-Chapel H Kennedy Kieger Institute, Inc. Technon Research & Development FW Washington University University of Mercy Hospita Duke University Wake Forest University Institute for Systems Biology Baylor College of Medicine Colorado State Universit Children's State Universit Children's State Universit Children's State Universit Children's State Universit Children's State Universit | 1701192 U24HL135691 1232-Sub 117267-0184-5119274 5-312-0217179-65988L 1(GG014633-01) 1-571918-CHMC 1580GYB180 1-571918-CHMC 1580GYB180 1-571918-CHMC 1580GYB180 801HD085583 R01HD085583 R01HD085583 R01HD085458 R01HD091302-03 700171-0719-00 R01HD092474 SUBK00000039 SUB0001728 30004927-01 A15446-5002 011445-02 | U24HL134763 U24HL136601 U54HL136601 U54HL139578 Cardiovascular Disea K12HD02827 P01HD0283578 P01HD028363 P01HD103133 P01HD103133 P01HD103133 P01HD1034566 P01HD035561 R01HD076579 R01HD076579 R01HD076199 R01HD076199 R01HD076199 R01HD076199 R01HD076321 R01HD084582 R01HD08430 R01HD084583 R01HD084583 R01HD084583 R01HD084588 R01HD089322 R01HD089322 R01HD08932 R01HD09453 R01HD09453 R01HD094698 R01HD094698 | 93.837 93.837 93.837 93.837 93.837 93.857 93.865 | 30,883,00 3,448,00 179,402,00 2,199,590,00 2,199,590,00 10,000,00 10,000,00 2,107,00 40,360,00 2,107,00 40,360,00 2,107,00 40,360,00 1,158,00 2,107,00 40,360,00 1,158,00 2,107,00 40,360,00 1,195,00 7,437,00 8,847,00 18,844,00 11,203,00 7,437,00 8,446,00 77,444,00 2,24,749,00 19,133,00 19,137,00, | 5,477.00 243,702.00 31,474.00 220,213.00 14,483,917.00 463,891.00 178,334.00 127,776.00 1,034,137.00 9,548.00 270,805.00 270,805.00 271,905.00 97,050.00 97,050.00 97,050.00 97,050.00 97,050.00 97,050.00 97,050.00 93,619,00 97,050.00 93,619,00 97,050.00 93,619,00 97,050.00 93,619,00 97,3941.00 33,7844.00 49,240.00 11,735.00 33,7140.01 33,714.00 11,735.00 13,314.00 73,241.00 49,240.00 11,241.00 43,241.00 11,241.00 33,317,30 12,024.00 11,0128.00 33,311,00 33,311,00 33,110,01 33,110,01 33,110,01 33,110,00 33,110,01 34,308.00 73,241.00 43,241.00 43,311.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,01 73,241.00 33,317,30,00 73,241.00 34,330,00 73,241.00 34,330,00 73,241.00 34,330,00 34,3 | 5,477.00 274,565.00 34,922.00 399,615.00 18,683,417.00 176,334.00 1,354,448.00 9,584.00 270,805.00 270,805.00 279,301.00 196,081.00 195,081.00 195,081.00 195,081.00 195,081.00 195,081.00 195,081.00 534,034.00 534,034.00 534,034.00 534,034.00 534,034.00 534,034.00 11,735.00 534,034.00 534,034.00 11,735.00 73,241.00 508,556.00 148,430.00 148,240.00 11,732.00 73,241.00 50,566.00 11,128.00 12,1282.00 73,241.00 533,500.00 883,703.00 99,028.00 281,549.00 |

Child Health and Human Development Extramural Researc

| | Deciphening the pathophysiolo Discovery of Meculari Target Executive Function Outcome Mei Improving the Effectiveness ar Genomics of bone and body com Enhancing Nursing Care Reliab Skeletal Health and Bone Marr Integrating genomics studies o Endocannabinold Signaling dur Automated Risk Assessment for Endotypes in Children with Se Headaches and Migraines: Pube Role of Cholesterol Biosynthe: The effects of Methylphenidat Novel ie Mergaeut Larget for Integrating Dietion of CRH Expression in Rhesus Teaching Academic Success Skills t Novel therspeeut Larget for Intraversin ADAM Teaches and Care Set Mechanism-Largeted Statist to Dietion of CRH Expression in Rhesus Teaching Academic Septis-Re- Mechanism-Largeted Statist to Diving Skills of Adolescent: Prediction of Fetal Maturity i Pluripotent Stem Cell-derived live Brain organold modeling of Ga Pediatric Injury: Modules to Manag Evaluating Assessment and Mec Enhancing Academic Teatment Adhe | UCLA School of Public Health Colorado State University Children's Hospital of Philadelphi fois State University Children's Hospital Bostor University of Michigar University of Cincinnat | University of Cincinnat University of Cincinnat University of Cincinnat Dartmouth College Miami University American Academy of Pediatric: Univ of CalifDavis-Mmrrc | R01HD098389 R01HD099150-01 GRT-00000601 60077379 GENFD0001843699 SUBK00010627 011742-002 | R01HD08280 R01HD08450 R01HD089150 R01HD08975 R01HD109775 R01HD100455 R01HD100455 R01HD100455 R01HD100455 R01HD100455 R01HD103450 R01HD103450 R01HD10350 R01HD10350 R01HD10350 R01HD09789 R0 | 3 3 865 3 3 | 154,734.00 60,984.00 28,718.00 7,001.00 37,718.00 | 469 793.00 100 662.00 1144 055.00 1162 066.00 27 257.00 330,692.00 222,79.00 226,831.00 51,364.00 29,711.00 50,389.00 49,788.00 15,527.00 15,527.00 15,527.00 10,682.00 115,527.00 10,682.00 115,527.00 10,527.00 10,527.00 10,527.00 10,527.00 1163.382.00 1163.382.00 1163.382.00 127,587.00 1265.484.00 225,2484.00 225,2484.00 225,2484.00 225,2484.00 225,2484.00 225,2484.00 225,2484.00 225,2483.00 225,248 | 468, 763,00 100,662,00 144,055,00 316,800,00 27,257,00 43,624,00 22,279,00 22,6,831,00 51,364,00 29,711,00 369,00 110,772,00 81,532,00 15,527,00 15,527,00 15,527,00 15,527,00 130,00 80,397,00 16,521,00 49,626,00 27,868,00 27,868,00 27,868,00 15,527,00 132,830,00 16,271,800 15,527,00 16,271,800 16,271 |
|--|---|---|--|--|---|--|--|---|--|
| | Cincinnati Pediatric Clinical Pharma Translational medicine and mer | | University of California University of Cincinnat University of Oklahoma Health Science | e | T32HD069054 U54HD104461 | 93.865 93.865 | 206,148.00 128,327.00 14,606.00 | 37,156.00 399,404.00 | 37,156.00 859,506.00 |
| | NICHD Cooperative Multicenter Neonata | | University of Texas Southwestern | Child Health and Huma | UG1HD027853 | 93.865 | 111,021.00 - 3.248.479.00 | - 312,061.00 11,369,697,00 | 312,061.00 14.618.176.00 |
| Developmental Disabilities Basic Support and Advocacy Gran | Healthy Lifestyles for People with Disab | Ohio Dev Disabilities Counci | University of Illinois at Chicage | 17CH03FA21 | 21010HSCDD | 93.630 | 16,500.00 | 72,057.00 | 88,557.00 |
| | Identification of the genetix Development and Disease of th The role of retinoic acid sign Defining the Basis of Epithelial Defects The Role of DDX41 in Inherite Glucocoticol and circadian P Predicting Severity and Import Personalized Cystle Fibrosis 1 Critical Translational Studies in Padiatric Terminologic Dysfunction in Bi Self-Managament of Type 1 Diabete Adolescent Bariatric Surgery | | De University of Cincinnat Sanford Research North | velopmental Disabilities | Basic Support and F30DK123841 F31DK118823 F31DK120164 K01DK120164 K01DK121875 K23DK118190 P30DK078392 P30DK078392 P30DK078392 P30DK078392 R01DK064008 R01DK069486 R01DK069486 | Advocacy Grants Tota 93.847 | 16,500.00 - - - - - - - - - - - - - - - - - | 72,057.00 36,231.00 36,548.00 2,329.00 136,305.00 161,616.00 157,589.00 173,376.00 1,145,479.00 1,044,610.00 797,835.00 434,593.00 434,593.00 599,714.00 | 88,557.00 36,231.00 36,548.00 2,329.00 136,305.00 161,616.00 157,569.00 173,376.00 1,445,479.00 1,088,134.00 797,835.00 434,593.00 475.00 675,523.00 |
| | Inhibition of an Apical AMP/r The role of Hedgehog Signalin, Biological Basis of Phenotype: Genetic basis of Phenotype: Genetic basis of virus induces IPA2 receptor-containing complexes in Control of hegatic T cell res; Immunopathogenesis of non-alle after Oducity on MASH in A short cell polarit The McAnaims Regulating Renal Proy Mechanisms of genetic risk at 2p23 ir Role of Hegate RNA Silencing in Insulin | University of Arizons | The CDM Group, Inc St Jude Children's Research Hospita University of Cincinnat | 567639 | R01DK080834 R01DK083402 R01DK083781 R01DK093045 R01DK093045 R01DK093045 R01DK098222 R01DK10429 R01DK10429 R01DK10425 R01DK107520 R01DK107530 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 | 26,238.00 18,454.00 | 255,810,00 23,097,00 540,507,00 380,762,00 517,097,00 617,1384,00 217,093,00 10,801,00 336,509,00 325,454,00 386,83,00 | 274 284 00 23.097 00 540,507.00 60,302.00 617,334.00 217,097.00 10,801.00 336.509.00 325,454.00 308.663.00 |
| | Mechanistic and therapeutic r Building a functional biliary system from | University of California-Davis | University of California | R01DK107541 | R01DK107541 R01DK107553 | 93.847 93.847 93.847 | 224,240.00 | 12,280.00 135,315.00 | 12,280.00 359,555.00 |
| | Nonlinear Ultrasound: an Imaging Bior Level and timing of diabetic hypergl | University of Michigar | MedStar Health Research Institute, Ir Tufts Medical Center, Inc | 3004067897 | R01DK109032 R01DK109956 | 93.847 93.847 | 3,167.00 3,736.00 | 13,318.00 624,954.00 | 13,318.00 631,857.00 |
| | Fibrin(ogen) control of metabi Targeting IRAK1/4 in Myelodysplastii Epigenomic control of antimicrobia Host Integration of commensa Roles of circadian rhythms ir Type 2 cytokines and innate I Molecular targets in cholesta Manipulating DNA Damage-respor Surcical or Medical Treatmen | University of North Carolina University of Cincinnat | University of Cincinnat | 5116413 011798-002 | R01DK112778 R01DK113639 R01DK114123 R01DK116868 R01DK117005 R01DK117055 R01DK117266 R01DK117632 R01DK119450 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 | 5,432.00 | 21,886.00 389,908.00 301,938.00 507,831.00 12,968.00 504,788.00 364,698.00 462,695.00 288.066.00 | 21,886.00 389,908.00 307,370.00 507,831.00 12,968.00 504,788.00 364,698.00 462,695.00 558,942.00 |
| | Surgical of Medical interaintent The role of SPRV2 in the color Molecular regulation of hepa Hox Genes and Lineage Infide Retinoic acid gene regulator Regulation of functionally dir Diabetes Journey: From system Molecular mechanisms for bonr | Children's Hospital Los Angeles | University of Colorade | RGF011923-A 60052734 CCHMC | R01DK119694 R01DK120765 R01DK120842 R01DK120847 R01DK121062 R01DK121295 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 | 210,876.00 | 49,862.00 308,397.00 450,130.00 369,118.00 777,511.00 234,720.00 | 49,862.00 308,397.00 450,130.00 369,118.00 777,511.00 445,545.00 |
| | Sox Proteins Modulate Genomi Role of extracellular vesici Regulation of Niche Cell Diffe Mitochondria mediated interce Microbiota-mediated fibrotic Host and viral determinants o | Northwestern University Medical Schoc University of North Carolins Children's Hospital of Philadelphis | Vanderbilt University | 5117429 R01DK125418 | R01DK121354 R01DK123092 R01DK123181 R01DK123299 R01DK124115 R01DK124617 R01DK125418 | 93.847 93.847 93.847 93.847 93.847 93.847 | 30,559.00 - - - | 22,940.00 2478,839.00 476,511.00 116,457.00 267,830.00 11,940.00 251,149.00 | 22,940.00 247,839.00 507,070.00 116,457.00 267,830.00 11,940.00 251,149.00 |
| | Gene regulatory networks in ti Limited Competition for the C Pharmacokinetic Evaluation b Durability of Epethelial Defee Early MRI Prediction of Respor Epigenetic and functional det Enhancing effectiveness of ex | Wake Forest University Health Science | Spectrum Health Hospitals | 241-100710-553791 | R01DK125577 R01DK127208 R03DK118314 R03DK124751 R21DK124751 R21DK123691 R34DK118510 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 | - - - 5,818.00 | 369,479.00 106,805.00 82,795.00 73,218.00 123,359.00 171,286.00 69,974.00 | 369,479.00 106,805.00 82,795.00 73,218.00 123,359.00 171,286.00 78,540.00 |
| | A generalizable framework fo | | University of Minnesota University of Pittsburgh Yale University | | RC2DK122376 | 93.847 | 2,748.00 104,190.00 43,102.00 | 352,890.00 | 500,182.00 |
| | Systems Biology of Bone Marov Research Training in Pediatric Pediatric Gastroenterology an Research Training in Child Beł TODAY2 Phase 2 (T2P2): Long-Term Non Alcoholic Steatohepattii Colorado Center of Childhood I Cinical Center for Cholestal CKID IV (patient care and sai Defining the interstinal stem c Modeling diabetes using an in | Children's Hospital Bostor George Washington Universith Cleveland Clin Lerner Col of Med of CWRL University of Colorad: Children's Mercy Hospita | Baylor College of Medicine Cleveland State Universit | GENFD0001876495 2U01DK061230-13 1324-SUB FY21.220.003 18-0007 | RC2DK122533 T32DK007695 T32DK007695 T32DK063929 U01DK061230 U01DK061732 U01DK062453 U01DK062453 U01DK066143 U01DK066143 U01DK103117 U03DK119982 | 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 93.847 | 95,828.00 85,616.00 | $\begin{array}{c} 18.829.00\\ 180.856.00\\ 425.470.00\\ 266.467.00\\ 35.012.00\\ 47,4195.00\\ 47,053.00\\ 801.225.00\\ 64.223.00\\ 365.558.00\\ \end{array}$ | 18,829,00 180,856,00 425,470,00 35,012,00 174,195,00 47,053,00 601,225,00 64,223,00 461,336,00 106,772,00 |

| | Modeling diabetes using an in | | University of Illinois at Chicage Cleveland State University University of Illinois at Chicage | | UH3DK119982 | 93.847 | 21,156.00 164,366.00 239,361.00 | 877,519.00 | 1,281,246.00 |
|---|--|---|--|---|--|--|---|--|---|
| | Teen Longitudinal Assess of Bariatric Teen Longitudinal Assess of Bariatric | University of Colorado University of Cincinnat | University of minors at Unicage | FY 18.896.002 UM1DK095710 | UM1DK072493 UM1DK095710 | 93.847 93.847 | - | 253,406.00 517.858.00 | 253,406.00 517.858.00 |
| | Teen Longitudinal Assess of Banatric | University of Cincinnat | D | iabetes, Digestive, and Ki | | | 1,617,357.00 | 21,026,855.00 | 22,644,212.00 |
| Disabilities Preventior | Improving the Health of Ohioar | Ohio State University | | 60071385 | NU27DD000015-0 | 14-00 93.184 | | 41,190.00 | 41,190.00 |
| | | | | | Disab | ilities Prevention Total | - | 41,190.00 | 41,190.00 |
| Discovery and Applied Research for Technological Innovations to Imp | prov MRI Compatible Robot for Impro MRI and Deep Learning for Ear | Children's National Medical Cente | | 30004680-03 | R01EB025179 R01EB029944 | 93.286 93.286 | - | 136,358.00 300,561.00 | 136,358.00 300,561.00 |
| | Quantification of Liver Fibros | | | | R01EB030582 | 93.286 | - | 39,814.00 | 39,814.00 |
| | Development Of Hybrid Tracheas Center for Point-of-Care Techr | University of Cincinnat Johns Hopkins University | | 011164-004 U54EB007958 | R21EB025378 U54EB007958 | 93.286 93.286 | - | 14,027.00 191,590.00 | 14,027.00 191,590.00 |
| | | | Discovery and Applied Rese | earch for Technological In | novations to Impro | ove Human Health Tota | - | 682,350.00 | 682,350.00 |
| Drug Abuse and Addiction Research Program | Using Administrative and Clinica Reducing Secondhand Smoke exp | University of Cincinnat | | 011088-002 | K01DA041620 K01DA044313 | 93.279 93.279 | - | 160,470.00 6,644.00 | 160,470.00 6,644.00 |
| | Endocannabinoid Signaling during Cooperative Mechanisms of HIV | Univ of Texas Medical Branch-Galvesto | Indiana University | 20-84853-01 | R01DA006668 R01DA050530 | 93.279 93.279 | 23,056.00 | 237,947.00 36,715.00 | 261,003.00 36,715.00 |
| | Role of Siglec-1 in HIV Intera 4/5 HEAL Consortium: Establish | | University of Cincinnat | 20 01000 01 | R01DA051895 R34DA050268 | 93.279 | 10,964.00 | 407,229.00 248.168.00 | 418,193.00 |
| | Omics analysis of HIV during s | University of Cincinnat | University of Cincinnati. | 012074-003 | R61DA048439 | 93.279 93.279 | 28,918.00 | 16,372.00 | 277,086.00 16,372.00 |
| | First-In-Human Study of a Huma Ohio Valley Node-Network | University of Cincinnat University of Cincinnat | | 012264-003 009942-043 | U01DA048525 UG1DA013732 | 93.279 93.279 | | 58,295.00 38,467.00 | 58,295.00 38,467.00 |
| | | | | Drug Abus | e and Addiction Re | search Programs Tota | 62,938.00 | 1,210,307.00 | 1,273,245.00 |
| Emergency Medical Services for Childre | Pediatric Emergency Care App | | Medical College of Wisconsir Washington University | | U03MC22684 | 93.127 | 165,853.00 80,545.00 | 316,473.00 | 562,871.00 |
| | | | | Emerg | gency Medical Serv | rices for Children Total | 246,398.00 | 316,473.00 | 562,871.00 |
| Environmental Health | Genomics and geospatial analy | University of Cincinnat | | 011429-063 | P30ES006096 | 93.113 | - | 39,431.00 | 39,431.00 |
| | Early life perfluoroalkyl subs Developmental Effects of Manga | Brown University University of Kentucky | | 00001249 3200002784-20-083 | R01ES025214 R01ES026446 | 93.113 93.113 | | 142,196.00 118,278.00 | 142,196.00 118,278.00 |
| | Prenatal Exposure to Endocrine Internalizing Behaviors and Neur | Pennsylvania State Universit | University of Cincinnat | S000447-NIH | R01ES026903 R01ES027224 | 93.113 93.113 | 26,507.00 | 94,074.00 494,612.00 | 94,074.00 542,092.00 |
| | Contribution of Thirdhand Smoke | | University of Pennsylvani: San Diego St. University | | R01ES027815 | 93.113 | 20,973.00 238.189.00 | 238,264.00 | 499,721.00 |
| | Developmental neurotoxicity c | University of Cincinnat | University of Cincinnat | 011150-006 | R01ES028277 | 93.113 | 23,268.00 | 0.00 212,838.00 | 212.838.00 |
| | Longitudinal Study of Endocrir | University of Cincinnat | | 011720-002 | R01ES029133 R01ES030078 | 93.113 | - | 56,298.00 | 56,298.00 |
| | Investigating the Impact of PI Effects of DDE exposure on ad | Johns Hopkins University University of Southern California | | 2004295370 129965417 | R01ES030364 | 93.113 93.113 | - | 89,627.00 10,010.00 | 89,627.00 10,010.00 |
| | ADVOCATE: Prevalence and Clin | | San Diego St. Univ. Research Found University of Cincinnat | | R01ES030743 | 93.113 | 33,713.00 22,386.00 | 422,366.00 | 478,465.00 |
| | Epigenetics, Air Pollution, ar Longitudinal Impact of Air Po | University of Cincinnat | | 013074-002 | R01ES031054 R01ES031621 | 93.113 93.113 | : | 155,249.00 159,041.00 | 155,249.00 159,041.00 |
| | Gene-pesticide interactions ar Histone Lysine Crotonylation in Pater | | | | R01ES032270 R21ES027117 | 93.113 93.113 | - | 309,891.00 148.00 | 309,891.00 148.00 |
| | Developing and Evaluating Nov Innovative Personal Monitorin | RTI Internationa | University of Kentucky | c1-340-0217531-66041L | R21ES030092 | 93.113 93.113 | 14,615.00 | 104,686.00 80,216.00 | 119,301.00 80,216.00 |
| | Assessing Personal Exposure to Ultra | | | | R33ES024713 | 93.113 | - | 163,148.00 | 163,148.00 |
| | Validation of Cross-Species B Environmental Carcinogenesis | Litron Laboratorie: University of Cincinnat | | R44ES028163 1016232 | R44ES028163 T32ES007250 | 93.113 93.113 | - | 3,372.00 107,124.00 | 3,372.00 107,124.00 |
| | Molecular Epidemiology in Children's Mammary Carcinogenesis: puberta | University of Cincinnat Michigan State University | | 1016305 U01ES026119 | T32ES010957 U01ES026119 | 93.113 93.113 | 1 | 169,847.00 65,854.00 | 169,847.00 65,854.00 |
| | Prenatal inflammatory exposure | | Univeristy of California | | U01ES029234 | 93.113 | 268,905.00 | 426,922.00 | 695,827.00 |
| | | | | | Envir | ronmental Health Total | 648,556,00 | 3,663,492,00 | 4.312.048.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | al D Machine Learning Approach to | | | | | ronmental Health Total | 648,556.00 | 3,663,492.00 27,363.00 | 4,312,048.00 27,363.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora | | | | F31NS115447 F31NS115525 | 93.853 93.853 | 648,556.00 - - | 27,363.00 33,497.00 | 27,363.00 33,497.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromate Comparison of Hemorrhagic and | University of Cincinnat | | 012830-004 | F31NS115447 F31NS115525 R01NS028440 R01NS030678 | 93.853 93.853 93.853 93.853 93.853 | 648,556.00 - - - - | 27,363.00 33,497.00 430,862.00 277,100.00 | 27,363.00 33,497.00 430,862.00 277,100.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromate Comparison of Hemorrhagic and Roles of Gsx factors in telencephalic Study of Activity-Dependent Sympatheti | University of Cincinnat University of Cincinnat | | 012830-004 010133-007 | F31NS115447 F31NS115525 R01NS028440 R01NS030678 R01NS044080 R01NS0445594 | 93.853 93.853 93.853 93.853 93.853 93.853 | | 27,363.00 33,497.00 430,862.00 277,100.00 861.00 6,140.00 | 27,363.00 33,497.00 430,862.00 277,100.00 861.00 6,140.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic and Roles of Gsx factors in telencephalic | | University of Floridá Washington University | | F31NS115447 F31NS115525 R01NS028440 R01NS030678 R01NS044080 | 93.853 93.853 93.853 93.853 93.853 93.853 | 648,556.00 - - - - 93,231.00 26,225.00 | 27,363.00 33,497.00 430,862.00 277,100.00 861.00 | 27,363.00 33,497.00 430,862.00 277,100.00 861.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gsx factors in telencephalic Study of Activity-Dependent Sympatheti Molecular, cellular and physiologica mTOR regulation of aberrant neurons Identification and reversal o | | | | F31NS115447 F31NS115525 R01NS028440 R01NS028440 R01NS044080 R01NS045594 R01NS045594 R01NS062806 R01NS065020 | 93,853 93,853 93,853 93,853 93,853 93,853 93,853 93,853 93,853 | 93,231.00 | 27,363.00 33,497.00 430,862.00 277,100.00 6,140.00 895,374.00 183,969.00 388,035.00 | 27,363.00 33,497.00 430,862.00 277,100.00 861.00 6,140.00 988,605.00 210,194.00 388,035.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gast Ractors in telencephalic Study of Activity-Dependent Sympatheli Molecular, cellular and physiologica mTOR regulation of aberrant neurons Identification and reversal o Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua | | | | F31NS115447 F31NS115525 R01NS028440 R01NS030678 R01NS044080 R01NS044080 R01NS054594 R01NS062806 R01NS062806 R01NS069893 R01NS065391 | 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 | 93,231.00 | 27.363.00 33,497.00 430,862.00 277.100.00 6,140.00 881.00 183,969.00 388,035.00 12,167.00 135,793.00 | 27,363,00 33,497,00 430,862,00 277,100,00 6,140,00 986,605,00 210,194,00 388,035,00 12,167,00 135,793,00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gast Ractors in telencephalic Study of Activity-Dependent Sympatheli Molecular, cellular and physiologica mTOR regulation of aberrant neurons Identification and reversal o Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kw4.2 | | | | F31NS115447 F31NS115525 R01NS028440 R01NS030678 R01NS04594 R01NS04594 R01NS06594 R01NS065206 R01NS068893 R01NS068893 R01NS0885391 R01NS088529 R01NS082705 | 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 | 93,231.00 | 27,363,00 33,497,00 430,862,00 277,100,00 865,374,00 183,969,00 388,035,00 12,167,00 135,793,00 107,192,00 185,139,00 | 27,363.00 33,497.00 277,100.00 861.00 986,605.00 210,194.00 386,035.00 12,167.00 135,793.00 107,192.00 185,139.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gax factors in telencephalic Study of Activity-Dependent Sympatheli Molecular, cellular and physiologica mTOR regulation of aberrant neurons Identification and reversal o Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebra Palsy in PT | | Washington University | | F31NS115447 F31NS115225 R01NS028440 R01NS030678 R01NS045594 R01NS045594 R01NS062806 R01NS068933 R01NS088391 R01NS088391 R01NS088299 R01NS082705 R01NS092705 R01NS094200 R01NS096037 | 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 | 93,231.00 26,225.00 - - - - | 27,363.00 33,497,00 430,862.00 277,100.00 6,140.00 865,374.00 183,969.00 12,167.00 115,793.00 115,793.00 115,793.00 241,410.00 242,023.00 | 27,363.00 33,497.00 430,862.00 277,100.00 6,140.00 988,605.00 210,194.00 388,035.00 12,167.00 135,793.00 107,192.00 185,139.00 241,410.00 222,023.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gas Kators in telencephalic Study of Activity-Dependent Sympatheti Melecular, cellular and physiologica mTOR regulation of aberrant neuron Melecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate | | Washington University Phoenix Children's Hospita University of Alabama at Birminghar | | F31NS115447 F31NS115525 R01NS028440 R01NS030678 R01NS04594 R01NS054794 R01NS052806 R01NS058200 R01NS068391 R01NS088529 R01NS088529 R01NS082705 R01NS094200 | 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 | 93.231.00 26.225.00 - - - 3.438.00 2.340.00 | 27,363,00 33,497,00 430,862,00 277,100,00 861,00 865,374,00 183,969,00 388,035,00 12,167,00 107,192,00 107,192,00 185,139,00 241,410,00 | 27,363.00 33,497.00 430,862.00 277,100.00 6,140.00 988,605.00 210,194.00 388,035.00 12,167.00 135,793.00 107,192.00 185,139.00 241,410.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gax factors in telencephalic Study of Activity-Dependent Sympatheli Molecular, cellular and physiologica mTOR regulation of aberrant neurons Identification and reversal o Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebra Palsy in PT | | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Extete | | F31NS115447 F31NS115225 R01NS028440 R01NS030678 R01NS045594 R01NS045594 R01NS062806 R01NS068933 R01NS088391 R01NS088391 R01NS088299 R01NS082705 R01NS092705 R01NS094200 R01NS096037 | 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 | 93.231.00 26.225.00 - - - 3.438.00 2.340.00 10.589.00 6.187.00 | 27,363.00 33,497,00 430,862.00 277,100.00 6,140.00 865,374.00 183,969.00 12,167.00 115,793.00 115,793.00 115,793.00 241,410.00 242,023.00 | 27,363.00 33,497.00 430,862.00 277,100.00 6,140.00 988,605.00 210,194.00 388,035.00 12,167.00 135,793.00 107,192.00 185,139.00 241,410.00 222,023.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gax factors in telencephalic Study of Activity-Dependent Sympatheli Molecular, cellular and physiologica mTOR regulation of aberrant neurons Identification and reversal o Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebra Palsy in PT | | Washington University Phoenix Children's Hospita University of Alabana at Birminghar University of Exete University of Exete University of Exete | | F31NS115447 F31NS115225 R01NS028440 R01NS030678 R01NS045594 R01NS045594 R01NS062806 R01NS068933 R01NS088391 R01NS088391 R01NS088299 R01NS082705 R01NS092705 R01NS094200 R01NS096037 | 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 | 93,231.00 26,225.00 | 27,363.00 33,497,00 430,862.00 277,100.00 6,140.00 865,374.00 183,969.00 12,167.00 115,793.00 115,793.00 115,793.00 241,410.00 242,023.00 | 27,363.00 33,497.00 430,862.00 277,100.00 6,140.00 988,605.00 210,194.00 388,035.00 12,167.00 135,793.00 107,192.00 185,139.00 241,410.00 222,023.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gas Kactors in telencephalic Study of Activity-Dependent Sympatheti Molecular, cellular and physiologica mTOR regulation of aberrant neurons Identification and reversal Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig Micro/NM-meetided silency on Neonate Early Prediction of Cerebral Palsy in Pr Genetic and environmental Influences or GABAergic Sensorimotor Dysfunction | | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Extete | | F31NS115447 F31NS115525 R01NS028440 R01NS030678 R01NS04594 R01NS04594 R01NS04594 R01NS068020 R01NS068020 R01NS06803919 R01NS0680391 R01NS068037 R01NS096053 R01NS096053 | 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 | 93.231.00 26.225.00 - - - 3.438.00 2.340.00 10.589.00 6.187.00 | 27.363.00 33.497.00 430.862.00 277.100.00 6.140.00 855.374.00 183.969.00 183.969.00 16.07.102.00 16.07.102.00 16.07.102.00 241.410.00 242.02.00 383.596.00 | 27,363.00 33,497.00 277,100.00 8,840.00 286,605.00 210,194.00 388,035.00 112,167.00 107,192.00 107,192.00 242,410.00 242,410.00 242,410.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorthagic ant Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheti Molecular, callular and physiologica mTOR regulation of aberrant neurons Identification and reversal Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Cerebal Paky in PF Genetic and environmental influences or GABAergic Sensorimotor Dysfunction miR-155 and RUNX function in neuro | University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittaburg University of Tennessee Stanford University | 010133-007 | F31NS115447 F31NS115525 R01NS028440 R01NS030678 R01NS04594 R01NS04594 R01NS04594 R01NS064594 R01NS068020 R01NS068029 R01NS068027 R01NS096053 R01NS096053 R01NS096027 R01NS096027 R01NS0960207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 R01NS096207 | 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 93.853 | 93.231.00 26.225.00 | 27,363,00 33,497,00 430,662,00 277,100,00 865,374,00 183,969,00 183,969,00 183,793,00 194,140,00 244,140,00 242,023,00 383,596,00 383,596,00 383,596,00 379,942,00 379,942,00 370,942,00 | 27,363.00 33,497.00 277,100.00 6,140.00 988,605.00 210,194.00 12,167.00 138,035.00 107,192.00 107,192.00 2464,250.00 464,250.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheti Molecular, colluiar and physiologica mTOR regulation of aberrant neurons Identification and reversal of Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Cerebra Palsy in PF Genetic and environmental Influences or GABAergic Sensorimotor Dysfunction miR-155 and RUNX function in neuro Binding of Epstein Barr Virus EBNA2 Biguande Sensilivity of Gioma Sterr ICH Recovery Grant | University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittsburgh University of Tennessee | 010133-007 113091-0321 011078-014 | F31NS115447 F31NS115525 R01NS028440 R01NS030678 R01NS04594 R01NS04594 R01NS04594 R01NS054594 R01NS065200 R01NS065200 R01NS068207 R01NS0696037 R01NS0960037 R01NS0960037 R01NS0960037 R01NS096007 R01NS09607 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS097 R01NS07 R01NS07 R01NS07 R01NS07 | 93.853 | 93,231.00 26,225.00 | 27,363,00 33,497,00 430,662,00 277,100,00 865,374,00 183,969,00 12,167,03,00 135,793,00 135,793,00 135,793,00 241,4110,00 242,020,00 338,596,00 335,566,00 335,566,00 379,942,00 379,942,00 210,972,00 240,632,00 20,479,00 | 27,363.00 33,497.00 277,100.00 6,1400.00 988,605.00 210,194.00 12,167.00 135,793.00 107,192.00 145,1793.00 241,410.00 241,410.00 241,410.00 243,410.00 243,410.00 279,942.00 224,341.00 226,871.00 20,479.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorthagic ant Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheti Molecular, callular and physiologica mTOR regulation of aberrant neurons Identification and reversal o Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Cerebra Palay in PT Genetic and environmental influences or GABAergic Sensorimotor Dysfunction miR-155 and RUNX function in neuro Binding of Epstein Bar Virus EBNAC Biguande Sensilivity of Giloma Sterr ICH Recovery Grant Prevention of Cerebrospinal (C Distinct Mechanisms C Cognitive | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittaburg University of Tennessee Stanford University | 010133-007 113091-0321 011078-014 000013147-C | F31NS115447 F31NS115525 R01NS028440 R01NS030678 R01NS04594 R01NS04594 R01NS04594 R01NS065200 R01NS065201 R01NS065201 R01NS0682391 R01NS085291 R01NS085291 R01NS086207 R01NS096053 R01NS096053 R01NS096053 | 93.853 | 93.231.00 26.225.00 | 27,363,00 33,497,00 430,662,00 277,100,00 865,374,00 185,969,00 12,167,03 10,7192,00 165,139,00 165,139,00 165,139,00 216,139,00 216,139,00 338,596,00 338,596,00 379,942,00 379,942,00 210,972,00 249,632,00 20,479,00 33,782,00 534,443,00 | 27,363.00 33,497.00 277,100.00 6,140.00 988,605.00 210,194.00 12,167.00 135,793.00 107,192.00 241,410.00 241,410.00 464,250.00 379,942.00 224,341.00 226,871.00 234,749.00 33,782.00 534,843.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gas Kators in telencephalic Study of Activity-Dependent Sympatheti Melacular, callular and physiologica mTOR regulation of aberrant neurons Melacular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or GABAergic Sensorimotor Dysfunction miR-155 and RUNX function in neur Bioding of Epatein Barr Virus EBNAG Biguandie Sensitivity of Gioma Sterr ICH Recovery Grant Prevention of Cerebrospinal (C | University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittaburg University of Tennessee Stanford University | 010133-007 113091-0321 011078-014 | F31NE115447 F31NE115525 G01NE3028440 R01NE503678 R01NE504559 R01NE504559 R01NE504559 R01NE506520 R01NE506520 R01NE5068833 R01NE5068237 R01NE5096037 R01NE5096037 R01NE5096037 R01NE50960207 R01NE5096027 R01NE5096122 R01NE5096122 R01NE5096122 R01NE5096122 | 93,853 | 93.231.00 26.225.00 | 27,363,00 33,497,00 430,862,00 277,100,00 6,141,00 183,574,00 183,574,00 125,793,00 107,122,00 135,793,00 107,122,00 135,793,00 241,410,00 242,023,00 383,596,00 | 27,363.00 33,497.00 277,100.00 661.00 661.00 210,194.00 210,194.00 185,197.00 107,192.00 185,193.00 241,410.00 292,023.00 464,250.00 115,051.00 379,942.00 224,381.00 256,871.00 26,479.00 256,871.00 26,479.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic and Roles of Gas Kators in telencephalic Study of Activity-Dependent Sympatheti Melecular, cellular and physiologica mTOR regulation of aberrant neurons identification and revensal sensis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated selencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental Influences or GABAargio Sensorimotor Dysfunction mith: 155 and RINN function in neuro mith; 155 and RINN function in neuro Biguanido Sensibility of Gitoma Sterr ICH Recovery Grant Prevention of Carebrospinal (C Distinct Mechanisms of Cognitive Assessing Population-based Rac | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittaburg University of Tennessee Stanford University | 010133-007 113091-0321 011078-014 000013147-C 011815-003 | F31NS115447 F31NS115525 G01NS028440 R01NS028440 R01NS045584 R01NS045584 R01NS045594 R01NS045295 R01NS045295 R01NS045295 R01NS045293 R01NS045293 R01NS045203 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS045033 R01NS0450420 R01NS100417 R01NS100417 R01NS100427 R01NS100429 R01NS101299 R01NS101321 R01NS103244 R01NS103992 | 93,853 | 93.231.00 26.225.00 | 27,363,00 33,497,00 430,682,00 277,100,00 6,140,00 865,374,00 183,465,00 183,465,00 183,165,00 107,192,00 107,192,00 107,192,00 241,410,00 241,410,00 241,410,00 241,410,00 257,651,00 379,542,00 379,542,00 379,542,00 379,542,00 337,642,00 337,642,00 337,642,00 337,642,00 337,642,00 337,642,00 337,642,00 337,642,00 337,642,00 337,642,00 337,642,00 337,642,00 337,642,00 337,620,00 354,463,00 159,749,00 159,749,00 | 27,363.00 33,497.00 277,100.00 861.00 6,140.00 310,105.00 1210,105.00 1210,105.00 1210,105.00 1210,105.00 135,793.00 107,192.00 107,192.00 241,410.00 242,410.00 242,410.00 242,410.00 243,910.00 253,810.00 254, |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic and Roles of Gas Kators in telencephalic Study of Activity-Dependent Sympatheti Melecular, callular and physiologica mTOR regulation of aberrant neurons Identification and reversal Melecular and reversal Signaling pathways regulating to MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or Melecular and RUNA function in neuro Binding of Exertime Structure SENA Biguande Sensitivity of Giloma Sterr Prevention of Carebragainal (Distinct Mechanisms of Cognitive Assessing Population-based Rac Progranulin-X Novel Gene in Gauchen A novel samat patch for the Sensitization of developing as Targeling the Hippo signaling (| University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles University of Cincinnat New York University University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittaburg University of Tennessee Stanford University | 010133-007 113091-0321 011078-014 0000013147-C 011815-003 17-A-00-008041-01 012056-002 011818-002 | F31NE11547 F31NE115525 G01NS028440 R01NS028440 R01NS024504 R01NS045594 R01NS045594 R01NS045954 R01NS04596 R01NS0459736 R01NS04593 R01NS04593 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS04503 R01NS10421 R01NS10421 R01NS10422 R01NS10422 R01NS10422 R01NS10422 R01NS10422 R01NS10422 R01NS10422 R01NS10422 R01NS10422 R01NS105715 R01NS105787 | 93,853 | 93.231.00 26.225.00 | 27,363,00 33,497,00 430,682,00 277,100,00 6,140,00 865,374,00 183,465,00 12,165,00 12,165,00 12,165,00 12,165,00 241,410,00 241,410,00 241,410,00 241,410,00 241,410,00 241,410,00 241,410,00 241,410,00 241,420,00 379,542,00 379,542,00 379,542,00 3379,542,00 3379,542,00 3379,542,00 3379,542,00 3379,542,00 3379,542,00 3379,542,00 3379,542,00 3379,542,00 3379,542,00 3379,50,00 59,407,00 159,749,00 339,50,00 | 27,363.00 33,497.00 277,100.00 6,140.00 988,605.00 210,104.00 12,104.00 137,793.00 107,192.00 165,193.00 241,410.00 242,410.00 242,410.00 244,410.00 244,410.00 244,250.00 464,250.00 379,942.00 379,942.00 379,942.00 379,782.00 354,843.00 554,677.00 554,6 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gas Kactors in telencephalic Study of Activity-Dependent Sympatheti Melecular, collular and physiologica mTOR regulation of aberrant neurons Identification and reversals Mitocular control of neurogenesis in the Big Informations Supporting Individual MitoroRNA-mediated silencing of Kv4.2 A new Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or Binding of Epstein Barr Vinze EBNA2 Bigunide Sensitivity of Glioma Sterr IICH Recovery Grant Prevention of Carebrag I(s) Destend Brown Genetics Progranulinz Anoval Gene in Gauchen A novel Menut patholing Neurosci Ra Progranulinz Anoval Gene in Gauchen A novel semat patch for the Sensitization of developing si Targeting the Hippo signaling Targeting the Hippo signaling | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles University of Cincinnat University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittaburg University of Tennessee Stanford University | 010133-007 113091-0321 011078-014 000013147-C 011815-003 117-A0-00-080641-01 012058-002 | F31NE11547 F31NE115525 G01NS028440 R01NS030678 R01NS04594 R01NS04594 R01NS04594 R01NS04594 R01NS04594 R01NS06503 R01NS06503 R01NS06503 R01NS066037 R01NS096053 R01NS05763 R01NS105787 R01NS105787 R01NS105787 R01NS105787 R01NS105787 R01NS105787 R01NS105787 | 93,853 | 93.231.00 26.225.00 | 27.363.00 33.497.00 430,862.00 277.100.00 6.140.00 163.3630.00 163.3630.00 163.3630.00 165.574.00 165.574.00 165.139.00 241.410.00 242.023.00 383.596.00 | 27,383.00 33,497.00 277,100.00 861.00 6,140.00 988,605.00 210,144.00 135,035.00 107,192.00 107,192.00 107,192.00 107,192.00 107,192.00 241,410.00 244,410.00 244,410.00 244,410.00 244,410.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 33,762.00 33,762.00 33,762.00 33,035.00 105,508.00 105,508.00 105,508.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorthagic ant Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheli Molecular, conticular and physiologica mTOR regulation of aberrant neurons Identification and reversal Brain Mechanisms Supporting Individua Signaling pathways regulating olig A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or GABAergic Sensorimotor Dysfunction miR-155 and RUNX function in neuro Binding of Sensiti Mark Vanching ICH Recovery Grant Prevention of Carebral Palsy in Br Gassing Population-based Rat A new Modenainsen of Cognitive Assessing Population-based Rat Progenity and path for the Gasilization of developing s Targeling the Hippo signaling Targeling the Hippo signaling Crashing Sidney Sidney Sidney Sidney Sidney Basensitiking Neurostatik Functional analysis of the mix | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angelet University of Cincinnat New York University University of Cincinnat University of Cincinnat University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittaburg University of Tennessee Stanford University | 010133-007 113091-0321 113091-0321 011078-014 0000013147-C 011815-003 17-A-00-008041-01 012058-002 011818-002 R200017 GB10578.160162 | F31NS115447 F31NS115525 G01NS028440 R01NS028440 R01NS04594 R01NS04594 R01NS045954 R01NS045954 R01NS065203 R01NS065203 R01NS065203 R01NS065203 R01NS066037 R01NS096053 R01NS096053 R01NS096053 R01NS096053 R01NS096053 R01NS096053 R01NS096053 R01NS096053 R01NS096057 R01NS096057 R01NS096057 R01NS096057 R01NS096057 R01NS096057 R01NS096057 R01NS096057 R01NS097233 R01NS096057 R01NS0977 R01NS097233 R01NS096057 R01NS0977 R01NS0977 R01NS0977 R01NS0977 R01NS0977 R01NS0977 R01NS0977 R01NS0977 R01NS0977 R01NS0977 R01NS0977 R01NS077 R01NS077 R01NS077 R01NS077 R01NS10577 R01NS10577 R01NS10577 R01NS105787 R01NS105787 R01NS105787 R01NS105787 R01NS107578 R01NS107578 R01NS107578 | 93,853 | 93.231.00 26.225.00 | 27.363.00 33.497.00 430,862.00 277.100.00 6.140.00 163,3694.00 163,3694.00 163,3694.00 165,374.00 165,139.00 241,410.00 241,410.00 244,410.00 244,410.00 383,596.00 | 27,363.00 33,497.00 430,862.00 277,100.00 886.00 210,194.00 16,140.00 16,140.00 16,140.00 17,192.00 107,192.00 107,192.00 241,410.00 241,410.00 242,4381.00 242,4381.00 256,871.00 254,843.00 534,843.00 534,843.00 10,508.00 33,782.00 33,782.00 33,835.00 105,508.00 135,508.00 135,508.00 135,508.00 135,508.00 137,797.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorthagic ant Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheli Molecular, colluiar and physiologica mTOR regulation of aberrant neurons Identification and reversal Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig Micro/RN-medited silencing of Nuc2 Activity-Dependent Physiologica Micro/RN-medited silencing of Nuc2 Activity-Prediction of Cerebral Palsy in Pr Genetic and environmental influences or GABAergic Sensorimotor Dysfunction miR-155 and RUNX function in neuro Binding of Epstein Barr Virus EBNA2 Biguande Sensitivity of Giloma Sterr IICH Recovery Grant Prevention of Cerebraginal (C Distinct Mechanisms of Cognitive Assessing Population-based Rac Programilina Alvoyel Gene In Gauchet A novel smart patch for the Semilation of developing s Targeting the Hippo signaling Functional analysis of the mki Creative Transporter Deficiency Headache Assessment of Childre Spinal of collowed Start | University of Cincinnat Kennedy Krieger Research Institute University of Cincinnat Children's Hospital Los Angeles University of Cincinnat New York University University of Cincinnat University of Cincinnat University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittaburg University of Tennessee Stanford University | 010133-007 113091-0321 011078-014 000013147-C 011815-003 17-A0-00-006041-01 01208-002 011818-002 R200017 | F31NE11547 F31NE115525 G01NE328440 R01NE328440 R01NE328440 R01NE324594 R01NE324594 R01NE3045954 R01NE3045954 R01NE3085293 R01NE3085293 R01NE3085293 R01NE3085293 R01NE309605787 R01NE305 | 93,853 | 93.231.00 26.225.00 | 27.363.00 33.497.00 430,862.00 277.100.00 6.140.00 163,3690.40 163,3690.40 163,3690.40 162,103.00 107.192.00 107.192.00 241,410.00 244,410.00 244,410.00 244,410.00 244,410.00 244,620.00 379.942.00 210.972.00 244,632.00 33,762.00 33,762.00 34,660.00 360,853.00 3554,6460.00 360,853.00 355508.00 437.110.00 437.110.00 437.110.00 437.770.00 12,249.00 12,24 | 27,363.00 33,497.00 430,862.00 277,100.00 8861.00 6,140.00 988,605.00 210,194.00 115,055.00 115,055.00 115,055.00 241,410.00 242,410.00 242,410.00 242,410.00 242,431.00 244,410.00 256,871.00 256,871.00 254,447.00 33,782.00 33,782.00 33,682.00 36,653.00 36,653.00 36,655.00 36,655.00 36,655.00 37,797.00 12,2440.00 12,249.00 12 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorthagic and Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheti Molecular, colluiar and physiologica mTOR regulation of aberrant neurons Identification and reversal Molecular control of neurogenesis in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A fave Model to Identify Preterm Neonate Earler Mechanism Supporting of Kv4.2 A fave Model to Identify Preterm Neonate Earler Mechanism Supporting of Kv4.2 A fave Model to Identify Preterm Neonate Earler Control of Control of Kv4.2 Biguande Sensitivity of Gloma Sterr IICH Recovery Grant Prevention of Cerebrospinal (C Distinct Mechanisms of Cognitive Assessing Population-based Rac Programilina A Novel Gene In Gauchet A novel smart patch for the Sensitizity of the Hippo signaling Furgeling the relippo signaling Furgeling the r | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angelet University of Cincinnat New York University University of Cincinnat University of Cincinnat University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Pittaburg University of Tennessee Stanford University | 010133-007 113091-0321 113091-0321 011078-014 0000013147-C 011815-003 17-A-00-008041-01 012058-002 011818-002 R200017 GB10578.160162 | F31NS115447 F31NS115525 G01NS028440 R01NS030678 R01NS04594 R01NS04594 R01NS04594 R01NS04595 R01NS068020 R01NS068020 R01NS068020 R01NS068020 R01NS068020 R01NS096023 R01NS0628 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10329 R01NS10327 R01NS10329 R01NS10327 R01NS10329 R01NS10327 R01NS1047 R | 93,853 93 | 93.231.00 26.225.00 | 27.363.00 33.497.00 430,862.00 277.100.00 6.140.00 183.969.00 12,167.00 12,167.00 140,1762.00 140,1762.00 140,1762.00 241.410.00 242.023.00 383.596.00 383.596.00 379.942.00 379.942.00 379.942.00 33.782.00 33.782.00 33.782.00 33.782.00 33.782.00 33.782.00 33.782.00 33.782.00 33.787.00 33.787.00 33.787.00 33.797.00 33.777. | 27,363.00 33,497.00 277,100.00 861.00 6,140.00 988.605.00 210,194.00 12,167.00 12,167.00 12,167.00 12,167.00 12,167.00 242,410.00 242,410.00 242,420.00 464,250.00 464,250.00 256,871.00 256,871.00 254,463.00 59,407.00 53,463.00 59,407.00 33,782.00 33,782.00 346,053.00 155,749.00 350,653.00 360,653.00 377,797.00 12,249.00 377,797.00 12,249.00 377,977.00 12,249.00 34,340.00 34 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic and Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheti Melacular, cellular and physiological mTOR regulation of aberrant neurona identification of of insets Melanovis and the set of the set of the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or GABAergic Sensorimotor Dysfunction miR-r55 and RUNX function in neurc Bioding of Epstein Barr Virus EBNA; Biguanide Sensitivity of Gioma Sterr ICH Recovery Gran Prevention of Cerebrapian (Distinct Mechanisms of Cognitive Assessing Population-based Rat Progranulin-A Novel Gene in Gauchei A novel samat patch for th Sangting the Hippo signaling Targeting the Hippo signaling Furcention analysis of the mrin Croatine Transporter Deficiency Headache Assessment of Childre Spinal circuity for ventilati | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angelet University of Cincinnat New York University University of Cincinnat University of Cincinnat University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Chitsburgh University of Chitsburgh University of Cincinnat | 010133-007 113091-0321 113091-0321 011078-014 0000013147-C 011815-003 17-A-00-008041-01 012058-002 011818-002 R200017 GB10578.160162 | F31NE115447 F31NE115525 G01NE3028440 R01NE303678 R01NE304559 R01NE304559 R01NE304559 R01NE304559 R01NE306520 R01NE306520 R01NE3068529 R01NE3068529 R01NE3068529 R01NE3069053 R01NE3096053 R01NE3096053 R01NE3096053 R01NE3096053 R01NE3096053 R01NE3096053 R01NE3096162 R01NE3096162 R01NE3096162 R01NE3096162 R01NE3096162 R01NE3096162 R01NE3096162 R01NE3096162 R01NE3096162 R01NE31029 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE310297 R01NE3105775 R01NE3105775 R01NE3105775 R01NE3105785 R01NE3105785 R01NE3105785 R01NE31026787 R01NE3105785 R01NE31026787 R01NE3102782 R01NE3102785 R01NE3102785 R01NE310286 R01NE3086 R01NE | 93,853 93 | 93,231,00 26,225,00 26,225,00 2,240,00 10,689,00 6,187,00 57,485,00 605,00 7,239,00 7,239,00 - - - - - - - - - - - - - - - - - - | 27,363,00 33,497,00 277,100,00 6,141,00 6,141,00 183,794,00 184,0374,00 125,793,00 107,192,00 135,793,00 107,192,00 124,141,00 241,410,00 242,023,00 333,782,00 379,942,00 279,942,00 379,942,00 379,942,00 354,843,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,500,00 165,500,00 10,500 | 27,363.00 33,497.00 430,862.00 277,100.00 66,640.00 120,044.00 210,144.00 135,793.00 107,192.00 185,139.00 241,410.00 242,00 244,410.00 244,250.00 464,250.00 379,942.00 224,381.00 256,871.00 254,843.00 534,843.00 159,749.00 33,782.00 33,782.00 33,782.00 34,250.00 159,749.00 264,250.00 159,749.00 264,250.00 159,749.00 264,250.00 159,749.00 264,250.00 159,749.00 264,250.00 159,749.00 27,985.00 37,797.00 37,797.00 27,986.00 27,979.60 27,979.60 27,979.60 27,979.60 27,979.60 27,979.60 27,979.60 27,979.60 27,979.60 27,979.60 27,979.00 27,979.00 27,979.00 27,979.00 27,986.00 27,979.00 27,979.00 27,986.00 27,979.00 27,979.00 27,979.00 27,979.00 27,979.00 27,979.00 27,979.00 27,979.00 27,979.00 21,14.00 2 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic and Roles of Gas Kators in telencephalic Study of Activity-Dependent Sympatheti Molecular, cellular and physiologica mTOR regulation of aberrant neurons identification and revensal is easi in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A new Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or GABAargic Sansorimotor Dysfunction mR-155 and RUNX function in neuro Biggiang Desmis Barl Vina. EBNA Biggiang Desmis Barl Vina. Prevention of Carebragiana (Distinct Mechanisms of Cognitive Assessing Population-based Rat Progranulin-X Novel Gene in Gauchen A novel samat patch for the Sensilization of developing si Targeting the Hippo signaling Targeting the Hippo signaling Targeting the Hippo signaling Creative Sim Andri Vina Barl Herkanson of muscle afferen Bestander Assessment of Childre Sensilization of adveloping si Targeting the Hippo signaling Targeting the Hippo signaling Creative Barlson of Merkanson Heddache Assessment of Childre Sensilization of adveloping si Targeting the Hippo signaling Targeting the Hippo signaling Creative Herkanson of muscle afferen Bystander gene deletions in ca CNS in congenital DM: rpathogr | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles University of Cincinnat University of Cincinnat University of Cincinnat University of Cincinnat University of Cincinnat University of Cincinnat University of Virginis Columbia University | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Chitsburgh University of Chitsburgh University of Cincinnat | 010133-007 113091-0321 011078-014 000013147-C 011815-003 17-A-00-030041-01 01208-002 R200017 GB10578.160162 10(GG015970-01) | F31NE11547 F31NE115525 G01NE3028440 R01NE30459 R01NE30459 R01NE30459 R01NE30459 R01NE30459 R01NE306529 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306833 R01NE306833 R01NE306833 R01NE306829 R01NE306833 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE3098053 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306829 R01NE306828 R01NE306828 R01NE306787 R01NE3105787 R0 | 93,853 93 | 93,231,00 26,225,00 26,225,00 2,240,00 10,689,00 6,187,00 57,485,00 605,00 7,239,00 7,239,00 - - - - - - - - - - - - - - - - - - | 27,363,00 33,497,00 430,862,00 277,100,00 6,140,00 188,378,00 188,378,00 188,378,00 107,192,00 | 27,363.00 33,497.00 430,862.00 277,100.00 861.00 9916,604.00 3181.03 881.035.00 107,192.00 107,192.00 107,192.00 107,192.00 107,192.00 241,410.00 242,00 464,250.00 464,250.00 464,250.00 534,843.00 534,843.00 554,843.00 554,843.00 554,843.00 105,508.00 33,757.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 410,385.00 105,508.00 437,110.00 437,157.00 105,508.00 437,157.00 105,508.00 437,157.00 105,508.00 437,140.00 40 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic and Roles of Gas Kators in telencephalic Study of Activity-Dependent Sympatheti Molecular, cellular and physiologica mTOR regulation of aberrant neurons identification and reversal Signaling Pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A new Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or Binding Deptember Strapping Individual Signaling Deptember Strapping Individual Binding of Expetime Strapping Individual Binding of Expetime Strapping Individual Binding of Deptember Strapping Individual Binding Strapping Individual Individual Binding Of Deptember Strapping Individual Binding Of Deptember Strapping Individual Binding Of Deptember Strapping Individual Binding Of Deptember Strapping Indivi | University of Cincinnat Kennedy Krieger Research Institute University of Cincinnat Children's Hospital Los Angeles University of Cincinnat University of Cincinnat | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Chitsburgh University of Chitsburgh University of Cincinnat | 010133-007 113091-0321 011078-014 000013147-C 011815-003 17-A-00-008041-01 01208-002 011818-002 R200017 GB10578 160182 10(GG015970-01) R01NS115929 1580 G YB180 | F31NE11547 F31NE115525 G01NE328440 R01NE328440 R01NE328440 R01NE324594 R01NE324594 R01NE324594 R01NE326776 R01NE3089033 R01NE3089033 R01NE3089033 R01NE3089033 R01NE3089033 R01NE3096053 R01NE30957 R01NE305787 R01NE305777 R01NE305777 R01NE3057777 R01NE305777777777777777777777777777777777777 | 93,85393,853 93 | 93,231,00 26,225,00 26,225,00 2,240,00 10,689,00 6,187,00 57,485,00 605,00 7,239,00 7,239,00 - - - - - - - - - - - - - - - - - - | 27.363.00 33.497.00 433.682.00 277.100.00 6.140.00 165.00 165.578.00 125.793.00 107.192.00 10 | 27,383.00 33,497.00 430,862.00 277,100.00 861.00 6,140.00 386,605.00 12,67.00 13,793.00 107,192.00 107,192.00 107,192.00 107,192.00 241,410.00 292,023.00 464,250.00 464,250.00 370,942.00 256,871.00 256,871.00 256,871.00 357,842.00 357,842.00 353,4843.00 554,477.00 554,477.00 353,4843.00 353,4843.00 355,4871.00 355,4871.00 355,4871.00 355,4871.00 355,4871.00 355,4871.00 355,4871.00 355,4871.00 360,853.00 105,508.00 437,1797.00 12,249.00 33,785.00 33,785.00 33,855.00 105,508.00 437,110.00 447,631.00 326,565.00 326,565.00 327,575.00 324,2455.00 326,3455.00 326,3455.00 327,3455.00 337,3455.00 327,3455.0 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic and Roles of Gas Kactors in telencephalic Study of Activity-Dependent Sympatheli Molecular, collular and physiologica mTOR regulation of aberrant neurons Identification and reversal Molecular control of neurogenesis in the Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or GABAergic Sensorimotor Dysfunction miR-155 and RUNX function in neuro Binding of Epetien Bar Virus EBNA Bigunaling Deptient Bar Virus EBNA Bigunating Deptient Bar Virus EBNA Bigunating Sensibility of Glioma Sterr IDerivention Coreitoroginal (Distinct Mechanisms of Cognitive Assessing Population-based Rat Progranulin-X Novel Gene in Gauchen A novel semat patch for the Sensilization of developing si Targeling the Hippo signaling Targeling the Hippo signaling Creation analysis of the mis Creation signal of the mis Creation signal signaling Mechanisms of muscle afferen Bystante gene delations in sign Obigonastic validity and signa Mechanisms of muscle afferen Bystante gene delations in sign Obigonastic validity and signa Neuronagenetic High Frequency C Using a kteogenic die to tre s | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles University of Cincinnat University of Virginia Columbi University | Washington University Phoenix Children's Hospita University of Alabana at Birminghar University of Cape Toor University of Create University of Pitsburgh University of Cincinnat | 010133-007 113091-0321 011078-014 000013147-C 011815-003 17-A0-00-080841-01 012058-002 011818-002 R200017 GB 10578.160182 100(GG15871-01) R01NS115929 1580 G YB 180 | F31NE115447 F31NE115525 G01NE328440 R01NE328440 R01NE328440 R01NE328440 R01NE328440 R01NE328459 R01NE32859 R01NE32859 R01NE32859 R01NE32859 R01NE32859 R01NE32859 R01NE32859 R01NE32859 R01NE32857 R01NE3105787 R01NE3105777 R01NE310577 R01NE310577 R01NE3105777 R01NE310577 | 93,853 93 | 93,231,00 26,225,00 | 27.363.00 33.497.00 430,682.00 277.100.00 6,140.00 165.578.00 125.793.00 107.192.00 107.192.00 107.192.00 107.192.00 107.192.00 107.192.00 107.192.00 107.192.00 107.192.00 107.192.00 107.192.00 115.051.00 37.9542.00 20.479.00 10.3792.00 20.479.00 10.355.08.00 10.55.0 | 27,383.00 33,497.00 430,862.00 277,100.00 861.00 6,140.00 376,103.00 12,167.00 137,793.00 107,192.00 165,193.00 242,410.00 252,627.00 370,942.00 252,627.00 357,942.00 252,627.00 357,492.00 357,492.00 353,4843.00 554,497.00 554,497.00 353,4843.00 554,497.00 353,485.00 353,485.00 355,508.00 437,110.00 410,385.00 105,508.00 437,110.00 410,385.00 33,785.00 33,785.00 33,785.00 33,785.00 33,785.00 33,785.00 33,785.00 34,855.00 32,275.00 33,285.00 33,285.00 33,285.00 33,285.00 33,285.00 33,285.00 33,285.00 33,227,20 33,285.00 33,227,20 34,223.00 242,455.00 34,2233.00 34,223.00 34,223.00 34,223.00 34,2233.00 34,2233.00 34,2233.00 34,223 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheli Molecular, control of neurogenesis in the Brain Mechanisms Supporting Individual Mitogenetic Activity Dependent Sympatheli Molecular control of neurogenesis in the Brain Mechanisms Supporting Individual Mitogenetic Activity Dependent Sympatheli Mitogenetic Activity Dependent Sympatheli Mitogenetic Activity Dependent Mitogenetic Activity Activity Activity Mitogenetic Activity Activity Mitogenetic Activity Activity Mitogenetic Activity Activity Mitogenetic Activity Mitogenetic Activity Mitogenetic Activity Mitogenetic Activity A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or Anovel Sama Activity of Glioma Sterr IICH Recovery Grant Prevention of Carebraphal (6 Distant Mechanisms of Cognition Anovel Samat patch for the Sensitization of developing s Targeting the Hippo signaling Targeting the Hippo signaling Targeting the Hippo signaling Mechanisms of muscle afferen Bystander gene deletions in co CNS in congenital DM1: pathog Diagnostic validity and sately Circuit defects underlying if Aruchanisms of muscle afferen Bystander Genomics of Mamma Neuromagnelic Hipp Frequency C Using a Keepinci deit to the MEG Connectivity-Based Mappiny | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles University of Cincinnat University of Virginia Columbi University | Washington University Phoenix Children's Hospita University of Alabama at Birminghar University of Cape Towr University of Chitsburgh University of Chitsburgh University of Cincinnat | 010133-007 113091-0321 011078-014 000013147-C 011815-003 17-A0-00-080841-01 012058-002 011818-002 R200017 GB 10578.160182 100(GG15871-01) R01NS115929 1580 G YB 180 | F31NE11547 F31NE115525 G01NE328440 R01NE328440 R01NE324400 R01NE324400 R01NE324594 R01NE324594 R01NE304594 R01NE304594 R01NE3085391 R01NE3085391 R01NE308529 R01NE308529 R01NE308529 R01NE3085293 R01NE3085293 R01NE308529 R01NE3085293 R01NE3085293 R01NE3085293 R01NE308529 R01NE308529 R01NE3085293 R01NE308529 R01NE308529 R01NE3085293 R01NE308529 R01NE308529 R01NE308529 R01NE308529 R01NE308529 R01NE308529 R01NE3085783 R01NE3085783 R01NE3105787 R01NE3105783 R01NE3105783 R01NE3105783 R01NE3105783 R01NE3105783 R01NE3105783 R01NE3105783 R01NE3105783 R01NE3115829 R01NE3115829 R01NE3115829 R01NE3115827 R01N | 93,853 | 93,231,00 26,225,00 26,225,00 2,240,00 10,689,00 6,187,00 57,485,00 605,00 7,239,00 7,239,00 - - - - - - - - - - - - - - - - - - | 27.363.00 33.497.00 430,862.00 277.100.00 6.140.00 865.374.00 183,860.00 113,763.00 113,763.00 124,741.00 224,023.00 241,410.00 224,023.00 241,410.00 224,023.00 241,410.00 244,020 241,020 241,410.00 242,023.00 34,554.00 379,542.00 3715,420 240,552.00 240,552.00 353,484.00 353,486.00 155,508.00 407,5508.00 142,249.00 353,586.00 142,249.00 353,586.00 142,249.00 353,586.00 142,449.00 353,586.00 142,449.00 353,586.00 142,449.00 353,586.00 142,449.00 353,586.00 142,557.00 353,586.00 142,575.00 353,586.00 144,599.00 142,575.00 353,586.00 353,586.00 353,586.00 353,586.00 353,587.00 353,586.00 353,586.00 353,586.00 353,586.00 353,587.00 353,586.00 353,58 | 27,383.00 33,497.00 430,862.00 277,100.00 8861.00 386,400.00 380,400 10,149.00 135,793.00 107,149.00 135,793.00 107,149.00 107,149.00 107,149.00 264,1410.00 264,250.00 464,250.00 464,250.00 464,250.00 353,463.00 353,463.00 353,463.00 353,463.00 353,463.00 353,650.00 353,650.00 33,955.00 105,508.00 437,110.00 437,1377.00 12,249.00 33,855.00 105,508.00 112,249.00 33,855.00 105,508.00 133,585.00 105,508.00 133,585.00 105,508.00 133,585.00 105,508.00 122,575.00 242,418.00 260,949.00 260,949.00 260,949.00 260,969.00 260,940.00 260,940.00 260,940.00 260,940.00 260,940.00 260,940.00 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheli Molecular, collular and physiologica mTOR regulation of aberrant neurons Identification and reversale Molecular control of neurogenesis in the Bigmaling pathways pupphiling only MitroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or MitroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or Distribution of the State State Bigunaling State State State Bigunaling State State State Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or CABAergic Sensorimotor Dysfunction miR-155 and RUNX function in neuro Binding of Epstein Barr Vitus EBNA2 Bigunaling Speatim Barr Vitus EBNA2 Bigunaling Population-based Far Progranulinz-Novel Gene in Gauchen A novel semat patch for the Sensitization of developing si Targeting the Hilppo signaling Targeting the Hilppo signaling Targeting the Hilppo signaling Creative Transporter Deficienc Headache Assessment of Childre Spinal circuity for ventilat Mechanisms of muscle afferen Biystander gene deletions in c CNS in congenital DM1: pathog Diagnostic validity and astellet A wovel Role for Phospholamba Functional Genomics of Mamma Neuromagnetic High Frequency C Using a Keogenic diet tor the MEG Connectivity-Based Mapping HIV-1 Particle Capture and VCC Exploring the medicular mecha | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles University of Cincinnat University of Virginia Columbi University | Washington University Phoenix Children's Hospila University of Alabama at Birminghar University of Cape Towr University of Cincinnat University of Cincinnat The Hospila for Sick Childrer | 010133-007 113091-0321 011078-014 000013147-C 011815-003 17-A0-00-080841-01 012058-002 011818-002 R200017 GB 10578.160182 100(GG15871-01) R01NS115929 1580 G YB 180 | F31NE11547 F31NE115525 G01NE328440 R01NE328440 R01NE328440 R01NE324594 R01NE324594 R01NE324594 R01NE304594 R01NE304594 R01NE3085391 R01NE3085391 R01NE308529 R01NE308578 R01NE308578 R01NE308578 R01NE308578 R01NE308578 R01NE | 93,853 | 93.231.00 26.225.00 - - - - - - - - - - - - - - - - - - | 27.363.00 33.497.00 430,862.00 277.100.00 6.140.00 163,360.00 113,360.00 113,702.00 124,140.00 224,023.00 333,596.00 241,410.00 | 27,383.00 33,497.00 430,862.00 277,100.00 8861.00 210,194.00 386,197.00 135,793.00 107,192.00 107,192.00 107,192.00 107,192.00 107,192.00 107,192.00 107,192.00 107,192.00 264,141.00 266,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 33,955.00 105,508.00 133,787.00 12,249.00 33,955.00 105,508.00 133,585.00 105,508.00 122,575.00 242,418.00 260,949.00 34,018.00 271,949.00 34,018.00 21,337.00 20,049.00 34,018.00 21,337.00 21,347.00 21,337.00 21,34 |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic ant Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheli Molecular, control of neurogenesis in the Brain Mechanisms Supporting Individual Strong Mechanisms Supportent Individual Strong Mechanisms Composition Individual Individual Individual Individual Strong Mechanisms (Comparison Individual Indirug Of Strong Mechanisms (Comparison Indirug Of Strong Mechanisms (Comparison Indirug Of Strong Mechanisms (Comparison Indirug Of Strong Mechanisms (Comparison Indirug Of Strong Mechanisms (Comparison A rowel strong Tabath Orthol A rowel strong Tabath Orthol Strageting the Hippo signaling Targeting the Hippo signaling Targeting the Hippo signaling Mechanisms of muscle afferen Bystander gene deletions in co CNS in congenital DM1: pathog Diagnostic validity and safety Circuit defects underlying if A Novel Role for Phosphalman Functional Genomics of Mamma Functional Genomics of Mam | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles University of Cincinnat University of Virginia Columbi University | Washington University Phoenix Children's Hospila University of Alabama at Birminghar University of Cape Towr University of Cincinnat University of Cincinnat The Hospila for Sick Childrer | 010133-007 113091-0321 011078-014 000013147-C 011815-003 17-A0-00-080841-01 012058-002 011818-002 R200017 GB 10578.160182 100(GG15871-01) R01NS115929 1580 G YB 180 | F31NE115427 F31NE115525 G01NE328440 R01NE328440 R01NE328440 R01NE3264594 R01NE3264594 R01NE326594 R01NE304599 R01NE3062303 R01NE306233 R01NE306233 R01NE306233 R01NE3066233 R01NE3066237 R01NE3066237 R01NE3066237 R01NE3066237 R01NE3066237 R01NE3066237 R01NE306623 R01NE306623 R01NE306623 R01NE306623 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3067637 R01NE3106254 R01NE3106254 R01NE3106254 R01NE31057657 R01NE31057657 R01NE31057637 R01NE3115229 R01NE3115229 R01NE3115229 R01NE3115229 R01NE3115229 R01NE310533580 | 93,853 | 93.231.00 26.225.00 - - - - - - - - - - - - - - - - - - | 27.363.00 33.497.00 430,862.00 277.100.00 6.140.00 163,3630.00 133,070.00 135,793.00 145,139.00 241,410.00 241,410.00 241,410.00 241,410.00 241,410.00 241,410.00 241,410.00 241,410.00 241,410.00 241,410.00 240,622.00 240,622.00 240,622.00 240,622.00 240,622.00 240,622.00 240,622.00 240,622.00 240,622.00 240,622.00 240,625.00 33,785.00 33,785.00 33,785.00 33,785.00 33,785.00 33,785.00 34,747.00 12,249.00 33,785.00 33,785.00 33,785.00 33,785.00 33,785.00 33,785.00 12,249.00 12,249.00 12,249.00 14,344.00 241,347.00 247,300 247,300 247,300 247,300 247,300 247,300 247,300 247,300 247,300 247,300 247,300 247,300 247,300 247,300 247,300 247,300 241,440.00 3414,440.0 | 27,383.00 33,497.00 430,862.00 277,100.00 8861.00 210,194.00 135,035.00 135,035.00 135,735.00 221,141.00 222,023.00 464.250.00 464.250.00 464.250.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 256,871.00 33,762.00 33,762.00 33,762.00 33,762.00 33,762.00 33,763.00 264,472.00 33,763.00 264,473.00 264,473.00 264,473.00 264,473.00 264,473.00 279,486.00 161,314.00 338,856.00 161,314.00 272,755.00 242,263.00 272,100 29,772.00 33,855.00 122,275.00 242,263.00 222,213.00 222,213.00 20,949.00 234,018.00 21,337.00 21,337.00 21,337.00 21,341.00 21, |
| Extramural Research Programs in the Neurosciences and Neurologic | The Role of Raptor in Tempora Mitogenic Activities in Neurofibromati Comparison of Hemorrhagic and Roles of Gas factors in telencephalic Study of Activity-Dependent Sympatheti Molecular, cellular and physiological mTOR regulation of aberrant neurona identification cellular and physiological mTOR regulation of aberrant neurona identification of the sense Methods and the sense in the Brain Mechanisms Supporting Individua Signaling pathways regulating olig MicroRNA-mediated silencing of Kv4.2 A New Model to Identify Preterm Neonate Early Prediction of Carebral Palsy in Pr Genetic and environmental influences or GABAergic Sensorimotor Dysfunction miR-r55 and RUNX function in neuro Biguandie Sensitivity of Gioma Stern ICH Recovery Grant Prevention of Cerebrapiant (C Distinct Mechanisms of Cognitive Assessing Population-based Rac Progranulin-A Novel Gene in Gauchei A novel samat patch for the Sensitization of developing as Targeling the Hippo signaling Targeling the Hippo signaling Heruchonal analysis of the min Croatine Transporter Deflicienc Headache Assessment of Childre Spinal circuity for ventilat Mechanisms of muscle afferen Bystander gene deletions in c CNS in congenital DM:: pathogn Diagnostic validity and safet Circuit defects underlying in A Novel Role for Phospholamba Functional Genomics of Mamma Neuromagnoble High Frequency MEG Connectivity-Based Mapping MEC Connectivity-Based Mapping | University of Cincinnat Kennedy Krieger Research Institut University of Cincinnat Children's Hospital Los Angeles University of Cincinnat University of Virginia Columbi University | Washington University Phoenix Children's Hospila University of Alabama at Birminghar University of Cape Towr University of Cincinnat University of Cincinnat The Hospila for Sick Childrer | 010133-007 113091-0321 011078-014 000013147-C 011815-003 17-A0-00-080841-01 012058-002 011818-002 R200017 GB 10578.160182 100(GG15871-01) R01NS115929 1580 G YB 180 | F31NE115427 F31NE115525 G01NE3028440 R01NE5028440 R01NE5046704 R01NE5046704 R01NE5045704 R01NE5045704 R01NE5045704 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE5045705 R01NE510257 R01NE510577 R01NE510577 R01NE510577 R01NE510577 R01NE510577 R01NE510577 R01NE5105777 R01NE5105777 R01NE51 | 93,853 | 93.231.00 26.225.00 - - - - - - - - - - - - - - - - - - | 27, 363, 00 33,497,00 277,100,00 6,141,00 163,598,00 128,598,00 128,598,00 128,598,00 128,793,00 107,122,00 135,793,00 107,122,00 145,139,00 241,410,00 242,023,00 343,556,00 - - - 115,051,00 343,526,00 159,749,00 349,452,00 244,652,00 244,652,00 244,652,00 244,652,00 244,652,00 244,652,00 244,652,00 244,652,00 244,652,00 244,652,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 159,749,00 122,275,00 122,575,00 122,575,00 122,575,00 122,575,00 122,575,00 122,575,00 122,575,00 122,575,00 122,575,00 122,575,00 150,670,00 10,000,00 10,000,000,00 10,000,000,00 10,000,000,000,000,000,000,000,000,000, | 27,363.00 33,497.00 430,862.00 277,100.00 6,61.00 6,61.00 210,194.00 186,660.01 12,167.00 135,793.00 107,192.00 185,139.00 244,141.00 244,250.00 446,250.00 446,250.00 244,250.00 244,250.00 244,250.00 256,871.00 20,479.00 256,871.00 254,843.00 554,463.00 159,749.00 254,843.00 159,749.00 254,843.00 159,749.00 266,851.00 33,787.00 287,986.00 161,314.00 467,631.00 287,986.00 122,275.00 242,283.00 22,213.00 24,210.00 24,010.00 24,255.00 23,00 24,255.00 22,213.00 24,210.00 24,210.00 24,210.00 256,850.00 22,213.00 24,210.00 24,210.00 24,210.00 24,210.00 24,210.00 24,210.00 24,210.00 24,210.00 24,210.00 24,210.00 24,210.00 24,210.00 24,210.00 24,213.00 24,213.00 21,337.00 21,337.00 21,337.00 21,337.00 |

| | | Targeting complement 5a-media | | | | R61NS112407 | 93.853 | - | 186,341.00 | 186,341.00 |
|---|--|---|---------------------------------------|------------------------------------|------------------------|----------------------------|-----------------------|--------------|------------------------|---------------|
| Number of the state of the | | SPRINT: Signature for Pain Rec | | | R61NS114926 | R61NS114926 | 93.853 | - | 417,860.00 | 417,860.00 |
| Number of the second secon | | | | | | | | | | |
| Description in the second of the se | | Early biomarkers of Autism Spectrum | Children's Hospital Bostor | | GENFD0001563311 | U01NS082320 | 93.853 | - | 7,579.00 | 7,579.00 |
| Chronic lange of the control of the contro | | | | | | U01NS092595 U01NS092764 | 93.853 93.853 | - | 61,703.00 26,349.00 | |
| | | Cincinnati Neuroscience Clinic | University of Cincinnat | | | U24NS107200 | 93.853 | - | 151,127.00 | 151,127.00 |
| Park Querrante de la construit de | | Developmental Synaptopathies | Children's Hospital Bostor | Extramural Resear | | | | 252.346.00 | . , | . , |
| | | | | | | | | | | |
| Note of the state of the s | Food and Drug Administration_Research | | | | | | | | | |
| | | | | | | | | - | | |
| Note:::::::::::::::::::::::::::::::::::: | | | | | | | | - | | |
| | | | | | | | | - | | |
| bit bit< | | I-ACT for Children, Global Pediatric Clin | Inst For Adv Clin Trials For Children | | | | | - | | |
| | | | | | FOO | id and Drug Administr | ation_Research Totai | - | 307,983.00 | 307,983.00 |
| Ling bases best of the set of t | Grants for Training in Primary Care Medicine and Dentistry | Dental Faculty Loan Repayment Prog | | | | D87HP31252 | 93.884 | - | 112,786.00 | 112,786.00 |
| InductionNotice <td></td> <td></td> <td></td> <td></td> <td>Grants for Training in</td> <td>Primary Care Medicin</td> <td>e and Dentistry Total</td> <td>-</td> <td>112,786.00</td> <td>112,786.00</td> | | | | | Grants for Training in | Primary Care Medicin | e and Dentistry Total | - | 112,786.00 | 112,786.00 |
| InductionNotice <td>Lung Diseases Research</td> <td>Identifying Cli Regulated Tara</td> <td></td> <td></td> <td></td> <td>E20HI 142201</td> <td>02.828</td> <td></td> <td>504.00</td> <td>504.00</td> | Lung Diseases Research | Identifying Cli Regulated Tara | | | | E20HI 142201 | 02.828 | | 504.00 | 504.00 |
| | Lung Diseases Research | | | | | | | - | | |
| IndexNote <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td></td<> | | | | | | | | - | | |
| Non-water <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td></td> | | | | | | | | - | | |
| Hardway Index of the set of the se | | | | | | | | - | | |
| Index Initial initinitial initial initial initial initi | | * | | | | | | - | | |
| Regression Interpreter protocol Interpreter protocol Interpreter protocol Interpreter protocol Interpreter protocol Interpreter protocol | | | | | | | | - | | |
| Network branchesHearing divergenceHearing divergenceHearin | | | | | | | | | | |
| Notional ChandradeHerein and the set of | | | | | | | | - | | |
| Hands denote the short of t | | | | University of Washington | | | | 174,001.00 | | |
| Instant insta | | | | | | | | - | | |
| Happed ham per | | | | Politecnico di Milano-Dipartimento | | | | 20,000.00 | | |
| Under state in the interval | | | | | | | | - | | |
| Name Result of Part of Pa | | WT1 Regulation of Pulmonary Fibrosis | | | | R01HL134801 | 93.838 | | 412,540.00 | 456,559.00 |
| Genus due discussion incrementa part of the sector | | | | University of Michigan | | | | 32,793.00 | | |
| Raif BLC2/MELTYRaif BLC2Raif BL | | Pulmonary Epithelial Dynamics | University of Cincinnati | | 011283-002 | R01HL135122 | 93.838 | - | 18,679.00 | 18,679.00 |
| Transition displayment of the second seco | | Genome edited iPS cell-derived macro | | | | R01HL136721 | 93.838 | - | 158,013.00 | 158,013.00 |
| Bit damp entropies increase increase increase increase increase increase increase increase increaseEntropies increase increase increaseEntropies increase increase increaseEntropies increase increaseEntropies increase increaseEntropies increaseEntropies increaseEntropies increaseEntropies increaseEntropies increase increaseEntropies increase | | Role of EMC3/TMEM111 in Alveolar | | | | R01HL136722 | 93.838 | - | 364,744.00 | 364,744.00 |
| Markam sourcePick and Pick | | Transcriptional Regulation of Endo | | | | R01HL141174 | 93.838 | | 510,875.00 | 510,875.00 |
| FunctionFuncti | | R01- Mapping environmental con | | Erasmus MC | | R01HL141286 | 93.838 | 41,783.00 | 368,605.00 | 410,388.00 |
| Designationmeany of Channelmeany of | | Mechanisms controlling early h | Children's Hospital Los Angeles | | P2018-0376B | R01HL141856 | 93.838 | - | 7,102.00 | 7,102.00 |
| Vidency into order in field into order into order into order into order into order into order <br< td=""><td></td><td></td><td>The Lundquist Institute</td><td></td><td>CCHMC/032223-01</td><td>R01HL141856</td><td>93.838</td><td>-</td><td>20,561.00</td><td>20,561.00</td></br<> | | | The Lundquist Institute | | CCHMC/032223-01 | R01HL141856 | 93.838 | - | 20,561.00 | 20,561.00 |
| Include sets in the base of the set of Charmed in | | Development of neonatal innate | | | | R01HL142708 | 93.838 | | 485,380.00 | 485,380.00 |
| Include sets in the base of the set of Charmed in | | | | University of Cincinnati | | | 93.838 | 5.262.00 | | |
| Inveging the MaximumHunding Chronic and Large Chronic and | | | University of Cincinnati | | 012029-002 | | | - | | |
| Basise Field mean Instruction BASC MOM RNH4 1427 0.103 0.102 0.102 Pennace Devices Instruction RNH4 1405 Read | | | | University of Cincinnati | | | | 16 670 00 | | |
| Periation lowing house have have house of concaseSolition of | | | | | | | | | | |
| Material Mechanism Regular Mechanis Regular Mechanism Regular Mechanism Regular Mechanism | | Bedside Exclusion of Pulmonary | Indiana University | | 8492-CHMC | R01HL148247 | 93.838 | - | 15,226.00 | 15,226.00 |
| Material Mechanism Regular Mechanis Regular Mechanism Regular Mechanism Regular Mechanism | | Perinatal Dysbiosis, Lung Deve | | National Jewish Med & Res Cen | | R01HL149366 | 93.838 | 2,745.00 | 306,612.00 | 309,357.00 |
| Red of Asis in Pairway imaging and Mission Private imaging and Missio | | | | | | | | | | |
| Insignard Meanzar PresentRHI, 157,030.1,330.10.20,940,00ARise EFVA Insignard Forwall InsignardKing and Meanzar PresentRHI, 159,730.1,330.10.20,851,00Designard forwall InsignardKing and PresentRHI, 159,730.1,330.10.20,851,000.20,825,00Diverse signard forwall Insignard Forwall Insignard Meanzar PresentRHI, 159,1030.1,330.10.21,150,000.23,150,00Diverse signard Meanzar PresentStates States | | | Johns Hopkins School of Medicine | | 2004833966 | | 93.838 | - | | |
| | | , | | | | | | | | |
| DevelopmentUniversity of ConcinualNotil: 13074Solid: 30Solid: 30Solid: 30Solid: 30Tasser riches for IC.2 developExpensito for IC | | | | | | | | | | |
| | | | | | | | | | | |
| Tissue riches for Lisz werke R0H115001 33.83 - 133.24.00 Eigenet Regulation of Medicine 2004234609 R2H114562 33.83 - 79.967.00 Rote of IGF in pulmonary arter Johns FopLins School of Medicine 200423469 R2H114562 33.83 - 99.060.00 Rote of IGF in pulmonary arter Johns FopLins School of Medicine R8H15160 33.83 - 99.060.00 99.060.00 Comment Instation of Store R8H151610 133.84 - 99.060.00 99.060.00 Painters provide Arter R8H151610 133.84 - 99.060.00 99.060.00 Painters provide Arter R8H151610 100.111.000.00 133.84 - 99.060.00 139.440.00 Painters provide Arter R8H151610 101.111.000.00 133.88 - 159.00 159.00 159.00 Comment Order Store R8H15100 101.111.000.00 103.88 35.864.00 35.864.00 35.864.00 159.140.00 159.140.00 Editing Arealise Friedris Instation of Model Res Contraction Instation of Model Res Contraction Instation Model Res Contraction Instation Instation Model Res Contraction Instation Instation Instation Instation In | | | | University of Cincinnati | | | | 182 012 00 | | |
| Epigemetic Regulator of the Mapping School of Medicine 200423609 R0Hu 15690 93.83 - 25.155.00 Robe in Toell-mediated Javiay 200423609 R2HL 15422 93.83 - 9.09.00 9.09.00 Commercial Transition of Biom R56.115499 93.83 - 9.09.00 </td <td></td> <td></td> <td></td> <td>childrenky of childrinal</td> <td></td> <td></td> <td></td> <td>102,012.00</td> <td></td> <td></td> | | | | childrenky of childrinal | | | | 102,012.00 | | |
| Refer file Fightmanary attrime Johns Hopkins School of Medicine 200423409 R14H14542 9.838 | | | | | | | | | | |
| Riok in T del mediation d'ison Ribit In 1400 94.83 - 9.000 9.000 Commercial Translation of Bion Ribit In 14105 9.0383 - 246.050.00 27.344.0 Human gere transfer and macor Ti32H.00752 9.838 - 264.050.00 264.050.00 Pulmonary Devendopment and Dise Fight In 1291 9.838 - 264.050.00 264.050.00 ORBEX. Primary Prevendon of Asthma University of Astrona Po4.98886 UDHL 13045 9.838 - 9.091.00 9.08.00 ORBEX. Primary Prevendon of Asthma University of Astrona Po4.8886 UDHL 13045 9.838 - 9.091.00 </td <td></td> <td></td> <td>Johne Honkine School of Medicine</td> <td></td> <td>2004234600</td> <td></td> <td></td> <td>-</td> <td></td> <td></td> | | | Johne Honkine School of Medicine | | 2004234600 | | | - | | |
| Commercial Translation of Biom 8111.14205 93.333 - 244.650.00 Human gene transfer and macrop 724.1007.02 93.838 - 244.057.00 284.057.00 Cincinati Children's Summer M 1524.1007.23 93.838 - 299.050.00 284.057.00 284. | | | Source Lindking Council of Migning | | 2004204008 | | | | | |
| Human gene transfer and macrop RR1H15688 93.88 9.38 | | | | | | | | | | |
| Putnonary Dovelopment and Dide 1224-03752 93.83 224.057.00 224.057.00 Cincinard Children's Summer M Inversity of Arizona PC 43886 UDH1.13045 93.83 19.80.00 19.80.00 Editing Alveolar Progenitor Cells for Batelle Manoial Institute UDH1.13475 93.83 90.74.00 19.80.00 Boint University | | | | | | | | - | | |
| Cincinuatio Children's Summer M University of Arizona P0 43886 U01HL13045 98.383 - 19,880.00 19,880.00 ORBEX. Primary Provention of Astima University of Arizona Batele Menorial Institute 90.43886 U01HL13045 98.383 - 19,880.00 199,880.00 Editing Alvoorial Progenitor Cells for Batele Menorial Institute 124.24 372.877.00 - <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td></td<> | | | | | | | | - | | |
| ORBEX: Primary Prevention of Asthma University of Arizona P0 43886 UDIHL 13045 9.8.38 9.8.38 9.9.6.4.00 9.9.6.4.00 Editing Alveolar Progenitor Cells for Baston University Baston University 9.8.38 9.8.38 9.8.2.00 9.8.7.4.00 9.9.6.4.00 9.1.34.3.80.00 Baston University Baston University Baston University 5.8.3 9.7.8.7.00 6.6.1 5.8.2.00 Autoral Joweink Med & Res Cen 5.9.5 1.3.8.9.00 6.6.1 5.8.2.00 6.6.1 5.8.2.00 6.6.1 5.8.2.00 6.6.1 5.8.2.00 6.6.1 5.8.2.00 6.6.1 5.8.2.00 6.6.1 5.8.2.00 6.6.1 5.8.2.00 6.6.1 5.8.2.00 6.6.1 5.8.2.00 6.8.2.00 6.8.2.00 6.8.2.00 6.8.2.00 6.8.2.00 6.8.2.00 6.8.2.0.00 6.8.2 | | | | | | | | - | | |
| Editing Alveolar Progenitor Cells or Batelie Memorial Institute U01HL13473 93.838 35,864.00 396,774.00 1,134,380.00 Boston Inliversity Goston Inliversity Goston Inliversity 372,817.00 Goston 1,134,380.00 Johns Hopkis Nubresity Johns Hopkis Nubresity Johns Hopkis Nubresity 1,136.00 Goston 1,134,380.00 Johns Hopkis Nubresity Johns Hopkis Nubresity Johns Hopkis Nubresity 1,136.00 Goston 1,134,380.00 Goston Hotional Jourish Hode Stars Cent Johns Hopkis Nubresity | | | Hadrona Maria da Antonia | | DO 400000 | | | - | | |
| Boston University Boston University 372,817.00 | | | University of Arizona | | PO 438886 | | | - | | |
| Johns Hopkins University Johns Hopkins University 16,812.00 National Jowish Med. Res Cen 11,359.00 University Orensystania 2668.00.00 Washingto University 101415475 98.88 1.365.00 Preparing for a hybrid trial of Children's Hospital of Philadelphia 20110020 University 98.88 1.301.800 4.305.00 Massachusetti Schernal Hospital Scharos Mod. Codares Scharos Mod. 1.305.00 1.305.00 1.305.00 Massachusetti Schernal Hospital Scharos Mod. Codares Scharos Mod. 1.305.00 1.305.00 1.305.00 Massachusetti Schernal Hospital Scharos Mod. Codares Scharos Mod. 1.305.00 1.305.00 1.305.00 Massachusetti Schernal Hospital Scharos Mod. Scharos Mod. Scharos Mod. 1.305.00 1.305.00 1.305.00 Massachusetti Schernal Hospital Ho | | Editing Alveolar Progenitor Cells for | | Battelle Memorial Institute | | U01HL134745 | 93.838 | | 396,774.00 | 1,134,380.00 |
| National Jewish Med & Res Cen 11,580,00 - National Jewish Med & Res Cen 10,800,00 - Preparing for a hybrid trial of Children's Hospital of Philadelpha 30116020 0101H114375 93.838 - 1,855,00 1,856,00 LungMap Phase II - Building a Caras-Shinal Medical Center 0101H114365 93.838 - 1,855,00 1,856,00 Massachuset General Houspital Caras-Shinal Medical Center 0101H114865 93.838 - 1,856,00 978,265,00 The Broad Institute Inc. Enderad Institute Inc. 56,152,00 - <td< td=""><td></td><td></td><td></td><td>- ,</td><td></td><td></td><td></td><td></td><td>-</td><td></td></td<> | | | | - , | | | | | - | |
| Inversity of Pennsylvania 266,00,00 - Washington University 30110600 101L113475 30,3838 - 1,365.00 1,365.00 1,365.00 878,265.00 Preparing for a hybrid trial of Children's Hospital of Philadelpha Cedar-shinal Medical Center U01H114365 9,8388 - 1,016.00 80,785.00 878,265.00 LungMap Phase II - Building a Cedar-shinal Medical Center U01H1143865 9,8388 - 68,552.00 - 878,265.00 Massachusetts General Hospital Cedar-shinal Medical Center U2H1143865 9,8388 39,900.00 - <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td></t<> | | | | | | | | | - | |
| Washington University 320110602 U01H1143475 93.838 Preparing for a hybrid trial o Children's Hospital of Philadelphia 320110602 U01H1143475 93.838 8.01,805.00 6.01,805.00 Lung Ap Phase II - Building a Cedars-Sinai Medical Centeri UE 5.557.00 6.01 Hassachusettis General Hospital Te Road Institute Inc. 5.515.20 6.03 740,857.00 The Broad Institute Inc. 1.61.00 603,082.00 740,857.00 6.01 740,857.00 University of California UPHH113787 9.3638 9.394.00 683,052.00 740,857.00 Hydrocortisone for BPD Respirator University of California 200930081 UPHH113787 9.3638 - 38,131.00 38,131.00 Hydrocortisone for BPD Respirator Children's Hospitat of Philadelphia S20093081 UPHH1137872 9.3638 - 38,131.00 38,131.00 | | | | | | | | | - | |
| Preparing for a hybrid trial o Children's Hospital of Philadelphia 320180620 U01HL14375 93.838 1,865.00 1,365.00 LungMap Phase II - Building a Cedars-Shil Medical Center U01HL14365 93.838 10,108.00 307.8265.00 378.265.00 Massachuzetts Central Hospital The Broad Institute Inc. 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 56,152.00 | | | | | | | | | | |
| LungMap Phase II - Building a Cedars-Sinai Medical Center U01HL14885 9.8.38 13.018.00 801.538.00 878.265.00 MaschwasetIs General Hospital The Broad Institute Inc. 561.50.00 638.200 638.200 638.200 638.200 638.200 638.200 740.57.00 649.200 740.57.00 <td></td> <td></td> <td></td> <td>Washington University</td> <td></td> <td></td> <td></td> <td>33,945.00</td> <td>-</td> <td></td> | | | | Washington University | | | | 33,945.00 | - | |
| Massachusetts General Hospital 7,557.00 - The Broad Institute Inc. 56,152.00 - The LungMAP Data Coordination Research Triangle Institute Inc. 58,383 39,400.00 688,925.00 740,587.00 The Broad Institute Inc. 1,110.00 0 0 - </td <td></td> <td></td> <td>Children's Hospital of Philadelphia</td> <td></td> <td>3201160620</td> <td></td> <td></td> <td>-</td> <td></td> <td></td> | | | Children's Hospital of Philadelphia | | 3201160620 | | | - | | |
| The LungMAP Data Coordination The Broad Institute Inc. 56,152.00 - The LungMAP Data Coordination Research Triangle Institute 0,24HL148865 39,3600 638,925.00 740,587.00 The Broad Institute Inc. 1,162.00 - - - - - University of California 1,152.00 - <td< td=""><td></td><td>LungMap Phase II - Building a</td><td></td><td></td><td></td><td>U01HL148856</td><td>93.838</td><td></td><td>801,538.00</td><td>878,265.00</td></td<> | | LungMap Phase II - Building a | | | | U01HL148856 | 93.838 | | 801,538.00 | 878,265.00 |
| The LungMAP Data Coordination Research Triangle Institute U24HL148865 9.8.38 39,40.00 638,925.00 740.587.00 The Broad Institute Inc. 61,110.00 | | | | Massachusetts General Hospital | | | | 7,557.00 | - | |
| The Broad Institute Inc. 61,110.00 0 University of California 1,152.00 - Hydrocortisone for BPD Respiratory Children's Hospital of Philadelphia 3200330818 UH3HL137872 93.838 - 38,131.00 38,131.00 Lung Diseases Research Total 1,493,592.00 10,468,345.00 11,961,937.00 | | | | The Broad Institute Inc. | | | | 56,152.00 | | |
| The Broad Institute Inc. 61,110.00 0 University of California 1,152.00 - Hydrocortisone for BPD Respiratory Children's Hospital of Philadelphia 3200330818 UH3HL137872 93.838 - 38,131.00 38,131.00 Lung Diseases Research Total 1,493,592.00 10,468,345.00 11,961,937.00 | | The LungMAP Data Coordination | | Research Triangle Institute | | U24HL148865 | 93.838 | 39,400.00 | 638,925.00 | 740,587.00 |
| University of California 1,152.00 - - - - - - - - 38,131.00 - 38,131.00 - 38,131.00 - 38,131.00 38,131.00 - 38,131.00 38,131.00 - 1,452,592.00 1,468,345.00 1,961,937.00 | | | | | | | | 61,110.00 | 0 | |
| Lung Diseases Research Total 1,493,592.00 10,468,345.00 11,961,937.00 | | | | University of California | | | | 1,152.00 | - | |
| | | Hydrocortisone for BPD Respiratory | Children's Hospital of Philadelphia | | 3200930818 | UH3HL137872 | 93.838 | | 38,131.00 | 38,131.00 |
| | | | | | | Lung Dise | ases Research Total | 1,493,592.00 | 10,468,345.00 | 11,961,937.00 |
| Maternal and Child Health Federal Consolidated Programs Region V East Comprehensive Care Hemophilia Foundation of Michigan H30MC24047 H30MC24047 93.110 - \$ 21,234.00 21,234.00 | | | | | | | | | | |
| | Maternal and Child Health Federal Consolidated Programs | Region V East Comprehensive Care | Hemophilia Foundation of Michigan | | H30MC24047 | H30MC24047 | 93.110 | - \$ | 21,234.00 | 21,234.00 |
| | | | | | | | | | | |

| | Landarshin Education in Maxweller | University of Olevine of | | T70100000005 | 770100000000 | 02.440 | | 054 470 00 | 054 470 00 |
|--|---|---|-----------------------------------|--------------------------|--------------------------------|------------------|----------------------|--------------------------|--------------------------|
| | Leadership Education in Neurodev ODH Health Resources and Srv Admin | University of Cincinnati Ohio State University | University Hospitals of Cleveland | T73MC0003225 60076721 | T73MC0003225 U7AMC337160101 | 93.110 93.110 | - \$ 48,712.00 \$ | 651,473.00 122,059.00 | 651,473.00 170,771.00 |
| | Autism Intervention Research Network | Massachusetts General Hospital | University Hospitals of Cleveland | UA3MC11054 | UA3MC11054 | 93.110 | - \$ | 56,645.00 | 56,645.00 |
| | DBPNet ADHD Node | Children's Hospital of Philadelphia | | 3208960819-S1 | UA3MC20218 | 93.110 | - 3 | 52,584.00 | 52,584.00 |
| | DDI NGCADI DI NGGE | Children's Hospital of Fhiladelphia | | | Health Federal Consolidated | | 48,712.00 | 903,995.00 | 952,707.00 |
| | | | | maternal and onlid i | realth rederal consolidated | riograms rotar | 40,712.00 | 303,333.00 | 332,101.00 |
| Medical Library Assistance | Improving Intensive Care Medication | | | | R01LM012230 | 93.879 | - | 224.00 | 224.00 |
| | Personal Health Record for Youth | | | | R01LM012816 | 93.879 | - | 359,776.00 | 359,776.00 |
| | A Framework for Automated and | | | | R01LM013222 | 93.879 | - | 200,150.00 | 200,150.00 |
| | | | | | Medical Library A | ssistance Total | - | 560,150.00 | 560,150.00 |
| | | | | | | | | | |
| | Contributions of the striatal | | | | F30MH123056 | 93.242 | - | 33,657.00 | 33,657.00 |
| | A Multi-Method Investigation to Dist | | | | K23MH108603 | 93.242 | - | 54,841.00 | 54,841.00 |
| | Anomalous Sensorimotor Physiology | | | | K23MH112936 | 93.242 | - | 199,422.00 | 199,422.00 |
| | A Family Navigator Interventio | | | | K23MH125138 | 93.242 | - | 109,201.00 | 109,201.00 |
| | Molecular Mechanisms Controlli 1/2 Anomalous Motor System Phy | | University of Cincinnati | | R01MH090740 R01MH095014 | 93.242 93.242 | 52,234.00 | 566,162.00 | 618,396.00 |
| | 4/7-Collaborative genomic stud | | | | R01MH115962 | 93.242 | - | 315,938.00 92,535.00 | 315,938.00 92,535.00 |
| | Nationwide dissemination of a | | American Academy of Pediatrics | | R01MH118488 | 93.242 | 41,461.00 | 457,220.00 | 498,681.00 |
| | Patient and Provider perspecti | University of North Carolina | , monour , toutonly of r outainto | 5113985 | R01MH118955 | 93.242 | - | 44,802.00 | 44,802.00 |
| | Longitudinal Examination of SI | | | | R01MH122415 | 93.242 | - | 157,129.00 | 157,129.00 |
| | Molecular Dissection of Synapt | University of Massachusetts, Amherst | | 21-015624 A00 | R01MH122519 | 93.242 | | 8,165.00 | 8,165.00 |
| | Neuron- and microglia-specific | University of Cincinnati | | 012928-002 | R01MH123545 | 93.242 | | 53,262.00 | 53,262.00 |
| | Parsing Neurobiological Bases | | Purdue University | | R01MH123831 | 93.242 | 9,576.00 | 279,007.00 | 306,984.00 |
| | | | University of Cincinnati | | | | 18,401.00 | - | |
| | Neuroinflammation, asthma and | University of Cincinnati | | 012047-002 | R21MH117483 | 93.242 | - | 38,582.00 | 38,582.00 |
| | Improving Medication Continuity | | | | R34MH112648 | 93.242 | - | 229,388.00 | 229,388.00 |
| | Emotion coaching skills as an | | University of California | | R34MH115897 | 93.242 | 33,539.00 | 156,492.00 | 236,414.00 |
| | | | University of Georgia | | | | 46,383.00 | - | |
| | Improving Adherence in Adolesc | Case Western University | | R34 MH117206-01A1 | R34MH117206 | 93.242 | - | 20,661.00 | 20,661.00 |
| | Validation of a salivary miRNA | Quadrant Biosciences | | 1293481860000 | R42MH111347 | 93.242 | - | 36,431.00 | 36,431.00 |
| Mental Health Research Grants | (ED-STARS) Emergency Dept Screen | University of Michigan | | 3003298263 | U01MH104311 | 93.242 | - | 342.00 | 342.00 |
| | | | | | Mental Health Research | ch Grants Total | 201,594.00 | 2,853,237.00 | 3,054,831.00 |
| National Bioterrorism Hospital Preparedness Program | Eastern Great Lakes Pediatric | University Hospital of Cleveland | | U3REP190615 | U3REP190615 | 93.889 | | 58,810.00 | 58,810.00 |
| National Blotenonsm Hospital Preparedness Program | Eastern Great Lakes Pediatric | University Hospital Of Cleveland | | | orism Hospital Preparedness | | - | 58,810.00 | 58,810.00 |
| | | | | National Dioterr | onani noapitai riepareunea. | s riogram rotai | | 30,010.00 | 30,010.00 |
| National Center on Sleep Disorders Research | Circadian Clock Dysregulation | | | | K08HL148551 | 93.233 | | 140,842.00 | 140,842.00 |
| | Improving Outcomes in Pediatri | | | | K99HL144822 | 93.233 | - | 146,797.00 | 146,797.00 |
| | Sleep Restriction and the Adolescent | | | | R01HL120879 | 93.233 | - | 739.00 | 739.00 |
| | Positive airway pressure for t | Children's Hospital of Philadelphia | | 3201930820 | R61HL151253 | 93.233 | - | 160,575.00 | 160,575.00 |
| | | | | Nationa | al Center on Sleep Disorders | Research Total | - | 448,953.00 | 448,953.00 |
| | | | | | | | | | |
| National Research Service Award in Primary Care Medicine | National Research Service Award | | | | T32HP10027 | 93.186 | - | 398,475.00 | 398,475.00 |
| | | | | National Research Se | ervice Award in Primary Care | Medicine Total | - | 398,475.00 | 398,475.00 |
| | | | | | 1/001/2012000 | | | | |
| Nursing Research | Influence of Parent-Nurse Comm | | | | K23NR017396 R01NR014248 | 93.361 | - 42,639.00 | 148,395.00 | 148,395.00 |
| | A Clinic-Based Interdisciplinary Inter Self-Management in Adolescent | Loyola University Chicago | Univ of Oklahoma Health Sciences | Loyola;R01NR016235 | | 93.361 93.361 | 42,639.00 | 150,158.00 35,265.00 | 192,797.00 35,265.00 |
| | Self-Management of Adolescent | Children's Hospital of Philadelphia | | 3201511123 | R01NR017429 | 93.361 | - | 109,802.00 | 109,802.00 |
| | Peer Mentoring to Improve Self | Nationwide Children's Hospital | | 700160-0219-00 | R01NR017533 | 93.361 | | 214,141.00 | 214,141.00 |
| | Fostering medication adherence | Hatoriniao officiento hoopital | CHOC Children's Hospital | 100100 0210 00 | R01NR017794 | 93.361 | 92,052.00 | 348,296.00 | 645,021.00 |
| | | | Medical University South Carolina | | | | 74,401.00 | - | |
| | | | North Carolina State University | | | | 19,214.00 | | |
| | | | Research Inst. at Nationwide Hos | | | | 60,968.00 | | |
| | | | University of Florida | | | | 50,090.00 | - | |
| | Randomized Controlled Trial of | | University of Virginia | | R01NR019426 | 93.361 | 83,975.00 | 277,802.00 | 361,777.00 |
| | Identification of causal facto | University of Cincinnati | | 013249-002 | R01NR019531 | 93.361 | - | 17,957.00 | 17,957.00 |
| | Caregiver Self-Management Need | University of Cincinnati | | 011682-002 | R21NR016992 | 93.361 | - | 570.00 | 570.00 |
| | Improving Drug Adherence Using | | Nationwide Childrens Hospital | | R21NR017633 | 93.361 | 13,830.00 | 50,435.00 | 76,946.00 |
| | | | University of Florida | | | | 12,681.00 | - | |
| | | | | | Nursing | Research Total | 449,850.00 | 1,352,821.00 | 1,802,671.00 |
| Oral Diseases and Diseases C | | | | | 504DE000001 | 00.101 | | | 3,960.00 |
| Oral Diseases and Disorders Research | Role of the Ciliary Protein C2 | | | | F31DE030664 | 93.121 | - | 3,960.00 | |
| | Prolonger progenitor manintenance Developing Topical Fluoride He | University of Washington | | UWSC10797 | R00DE026239 R01DE026741 | 93.121 93.121 | - | 181,693.00 60,581.00 | 181,693.00 60,581.00 |
| | Mandible Development | Chiverary or wearington | | 346610/8/ | R01DE027046 | 93.121 | - | 619,690.00 | 619,690.00 |
| | Genetic Analysis of Mammalian | | | | R01DE027091 | 93.121 | - | 358,705.00 | 358,705.00 |
| | Regulation of Craniofacial Dev | | | | R01DE029417 | 93.121 | - | 442,640.00 | 442,640.00 |
| | Function and Regulation of Sem | | | | R21DE030193 | 93.121 | - | 41,363.00 | 41,363.00 |
| | Harnessing the therapeutic potential | | The Jackson Laboratory | | R35DE027557 | 93.121 | 47,094.00 | 904,762.00 | 951,856.00 |
| | Velopharyngeal insufficiency f | Phoenix Children's Hospital | | SITZMAN-20-03 | U01DE029750 | 93.121 | - | 131,289.00 | 131,289.00 |
| | Reduction of bloodstream infec | | | | UG3DE030401 | 93.121 | - | 13,771.00 | 13,771.00 |
| | | | | | Oral Diseases and Disorders | Research Total | 47,094.00 | 2,758,454.00 | 2,805,548.00 |
| | | | | | | aa | | | |
| Poison Center Support and Enhancement Grant Program | Cincinnati Drug and Poison Inf | | | | H4BHS15468 | 93.253 | - | 392,221.00 | 392,221.00 |
| | COVID-19 CARES Funding for Poison Cer | nuers | | Balana A. J. T | COVID-19 H4CHS37395 | 93.253 | - | 88,522.00 | 88,522.00 480,743.00 |
| | | | | Poison Center Sup | port and Enhancement Gran | riogram (otal | - | 480,743.00 | 480,743.00 |
| | | | | | | | | | |

| Research on Healthcare Costs, Quality and Outcomes | Family-Clinician Partnerships to Improve | | | | K08HS023827 | 93.226 | - | 13,007.00 | 13,007.00 |
|--|--|---|---|---|--|--|--|---|--|
| | Predicting Pediatric Readmission: | | | | K08HS024735 | 93.226 | - | 145,483.00 | 145,483.00 |
| | Hospital Management of Acute Resp | | | | K08HS025138 | 93.226 | - | 161,763.00 | 161,763.00 |
| | The Patient and Parent Perspec | | | | K08HS026763 | 93.226 | | 164,556.00 | 164,556.00 |
| | AHRQ Mentored Clinical Scienti | | | | K08HS026975 | 93.226 | | 191,347.00 | 191,347.00 |
| | | | | 0001050503 | | | - | | |
| | Missed Opportunities for Improving | University of Michigan | | 3004658567 | R01HS024953 | 93.226 | - | 11,385.00 | 11,385.00 |
| | Improving ADHD Behavioral Care Quality | | | | R18HS024690 | 93.226 | - | 297,720.00 | 297,720.00 |
| | Spread of Safety Interventions | Children's Hospital Boston | | RHS027401A | R18HS027401 | 93.226 | - | 70,061.00 | 70,061.00 |
| | Pediatric Hospital Care Improv | Kaiser Foundation Research Institute | | RNG210310-BUDG01- | CC U18HS025291 | 93.226 | - | 5,417.00 | 5,417.00 |
| | | | | | | y and Outcomes Total | - | 1,060,739.00 | 1,060,739.00 |
| | | | | | | | | ,, | |
| Research Related to Deafness and Communication Disorders | I diamathia an ditama dan ƙasalina in | | | | D04D0044070 | 93.173 | | 218,288.00 | 218.288.00 |
| Research Related to Deatness and Communication Disorders | Idiopathic auditory dysfunction in | | | | R01DC014078 | | - | | |
| | Prevention of Ototoxicity with | | Oregon Health & Science University | | R01DC017867 | 93.173 | 45,338.00 | 278,978.00 | 334,615.00 |
| | | | Washington University | | | | 10,299.00 | 0 | |
| | Pediatric dysphonia: Multidisc | University of South Florida | | 1219-1068-00-B | R01DC018008 | 93.173 | - | 55,311.00 | 55,311.00 |
| | Technology-assisted language i | | University of Colorado | | R01DC018550 | 93.173 | 60,377.00 | 418,269.00 | 478,646.00 |
| | Earliest predictors of languag | | University of Cincinnati | | R01DC018734 | 93.173 | 36,580.00 | 618,274.00 | 654,854.00 |
| | A Preliminary Study of the Neu | University of Cincinnati | onitionally of onitioninal | R15DC017280 | R15DC017280 | 93.173 | - | 56,179.00 | 56,179.00 |
| | | University of Cincinnati | | | | | - | | |
| | Multimodal Neuroimaging Distin | University of Cincinnati | | R21DC017393 | R21DC017393 | 93.173 | - | 36,041.00 | 36,041.00 |
| | | | | Research Related to De | afness and Communio | cation Disorders Total | 152,594.00 | 1,681,340.00 | 1,833,934.00 |
| | | | | | | | | | |
| Sickle Cell Treatment Demonstration Program | Sickle Treatment and Outcomes Res | | Children's Hosp & Clinics of Minnesot | ta | U1EMC27863 | 93.365 | 42,406.00 | 287,890.00 | 425,059.00 |
| | | | Indiana Hemophilia & Thrombosis Ctr | r Inc | | | 10,333.00 | | |
| | | | Medical College of Wisconsin | ., | | | 38,718.00 | | |
| | | | • | | | | | | |
| | | | Sanford Research | | | | 23.00 | | |
| | | | Sickle Cell Disease Assoc of America | 1 | | | 33,845.00 | | |
| | | | University of Illinois at Chicago | | | | 11,844.00 | | |
| | | | | Sickle Ce | ell Treatment Demons | tration Program Total | 137,169.00 | 287,890.00 | 425,059.00 |
| | | | | | | | | | |
| Training and Clinical Skills Improvement Projects | Enhanced Surveillance for New Vaccine | | University of Cincinnati | | U01IP001059 | 93.185 | 115,858.00 | 1,136,115.00 | 1,251,973.00 |
| Training and clinical Skills improvement Projects | COVID-19 Staat - PREVAIL COVID-19 Sup | -1 | , | U01IP001059 | COVID-19 U01IP00 | | 77,707.00 | 1,084,068.00 | 1,161,775.00 |
| | COVID-19 Staat - PREVAIL COVID-19 Sup | рі | University of Cincinnati | | | | | | |
| | | | | Training and | d Clinical Skills Improv | vement Projects Total | 193,565.00 | 2,220,183.00 | 2,413,748.00 |
| | | | | | | | | | |
| Trans-NIH Research Support | Engineering multi-organs in a | | | | DP2DK128799 | 93.310 | - | 307,341.00 | 307,341.00 |
| | Direct Epigenetic Reprogramming of T | | | | DP2GM119134 | 93.310 | - | 176.00 | 176.00 |
| | Decentralized and Reproducible | Duke University | | Duke, Brokamp | U2COD023375 | 93.310 | | 104,118.00 | 104,118.00 |
| | | - , | | | | | - | | |
| | NYU Pediatric Obesity, Metabolism and | NYU Sponsored Programs Administration | | UG30D023305 | UG3OD023305 | 93.310 | - | 41,117.00 | 41,117.00 |
| | Children's Respiratory Research and | University of Wisconsin-Madison | | UG30D023282 | UH3OD023282 | 93.310 | - | 1,104,346.00 | 1,104,346.00 |
| | Developmental Impact of NICU E | Albert Einstein College of Medicine | | 311397 | UH3OD023320 | | | 63,008.00 | |
| | | | | 31139/ | 011302023320 | 93.310 | - | 03,008.00 | 63,008.00 |
| | | | | 311397 | | 93.310 search Support Total | - | 1,620,106.00 | 1,620,106.00 |
| | | · · · · · · · · · · · · · · · · · · · | | 311397 | | | - | | |
| University Centers for Excellence in Developmental Disabilities Edu | | | | | Trans-NIH Re | search Support Total | | 1,620,106.00 | 1,620,106.00 |
| University Centers for Excellence in Developmental Disabilities Edu | catior National Training AUCD SCOPE | University of Wyoming | | 1004506-CHMC | Trans-NIH Re | search Support Total | - | 1,620,106.00 101,492.00 | 1,620,106.00 101,492.00 |
| University Centers for Excellence in Developmental Disabilities Edu | | | | 1004506-CHMC 011042-015 | Trans-NIH Re 90DDTI0042 90DDUC0013 | search Support Total 93.632 93.632 | - | 1,620,106.00 101,492.00 548,782.00 | 1,620,106.00 101,492.00 548,782.00 |
| University Centers for Excellence in Developmental Disabilities Edu | catior National Training AUCD SCOPE | University of Wyoming | University Centers for Excellence in | 1004506-CHMC 011042-015 | Trans-NIH Re 90DDTI0042 90DDUC0013 | search Support Total 93.632 93.632 | - | 1,620,106.00 101,492.00 | 1,620,106.00 101,492.00 |
| University Centers for Excellence in Developmental Disabilities Edu | catior National Training AUCD SCOPE | University of Wyoming | University Centers for Excellence in | 1004506-CHMC 011042-015 | Trans-NIH Re 90DDTI0042 90DDUC0013 Ities Education, Resea | 93.632 93.632 93.632 rch, and Service Total | - | 1,620,106.00 101,492.00 548,782.00 650,274.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 |
| University Centers for Excellence in Developmental Disabilities Edu Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE | University of Wyoming | University Centers for Excellence in | 1004506-CHMC 011042-015 | Trans-NIH Re 90DDTI0042 90DDUC0013 Ities Education, Resea | search Support Total 93.632 93.632 | | 1,620,106.00 101,492.00 548,782.00 | 1,620,106.00 101,492.00 548,782.00 |
| | catior National Training AUCD SCOPE UC University Centers for Excellen | University of Wyoming | University Centers for Excellence in | 1004506-CHMC 011042-015 I Developmental Disabili | Trans-NIH Re 90DDT10042 90DDUC0013 ities Education, Resea HHS-2019-ACL-AO | 93.632 93.632 93.632 93.632 urch, and Service Total D-PRRC-034 93.325 | - | 1,620,106.00 101,492.00 548,782.00 650,274.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 |
| | catior National Training AUCD SCOPE UC University Centers for Excellen | University of Wyoming | University Centers for Excellence in | 1004506-CHMC 011042-015 I Developmental Disabili | Trans-NIH Re 90DDT10042 90DDUC0013 ities Education, Resea HHS-2019-ACL-AO | 93.632 93.632 93.632 rch, and Service Total | - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep | University of Wyoming | | 1004506-CHMC 011042-015 I Developmental Disabili | Trans-NIH Re 90DDTI0042 90DDUC0013 titles Education, Resea HHS-2019-ACL-AO Resource Center Stat | search Support Total 93.632 93.632 Irch, and Service Total D-PRRC-03 93.325 te Pilot Program Total | - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 |
| | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in | University of Wyoming University of Cincinnati | University Centers for Excellence in Cleveland Clinic Foundation | 1004506-CHMC 011042-015 Developmental Disabili Paralysis | Trans-NIH Re 90DDT10042 90DDUC0013 tties Education, Resea HHS-2019-ACL-AO Resource Center Stat R01EY027077 | search Support Total 93.632 93.632 | - - - 225,189.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 | 1,620,106.00 101,492.00 548,782.00 656,274.00 16,582.00 16,582.00 428,522.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by | University of Wyoming | | 1004506-CHMC 011042-015 I Developmental Disabili | Trans-NIH Re 90DDT10042 90DDUC0013 tites Education, Resea HHS-2019-ACL-AO Resource Center Stat R01EY027077 R01EY027711 | search Support Total 93.632 93.632 97.61, and Service Total 0-PRRC-03 93.825 te Pilot Program Total 93.867 93.867 | - - - 225,189.00 - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 428,522.00 165,508.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel | University of Wyoming University of Cincinnati | | 1004508-CHMC 011042-015 Developmental Disabili Paralysis T750388 | Trans-NIH Re 90DDTI0042 90DDUC0013 tites Education, Resear HHS-2019-ACL-AO Resource Center Stat R01EY027077 R01EY027711 R01EY028958 | search Support Total 93.632 93.632 rch, and Service Total 0-PRRC-03 93.325 6 Pilot Program Total 93.867 93.867 93.867 | - - - 225,189.00 | 1,520,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,598.00 6,395.00 | 1,620,106.00 101,492.00 548,782.00 6650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by | University of Wyoming University of Cincinnati | | 1004506-CHMC 011042-015 Developmental Disabili Paralysis | Trans-NIH Re 90DDT10042 90DDUC0013 tites Education, Resea HHS-2019-ACL-AO Resource Center Stat R01EY027077 R01EY027711 | search Support Total 93.632 93.632 97.61, and Service Total 0-PRRC-03 93.825 te Pilot Program Total 93.867 93.867 | - - - 225,189.00 - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 428,522.00 165,508.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel | University of Wyoming University of Cincinnati | | 1004508-CHMC 011042-015 Developmental Disabili Paralysis T750388 | Trans-NIH Re 90DDTI0042 90DDUC0013 tites Education, Resear HHS-2019-ACL-AO Resource Center Stat R01EY027077 R01EY027711 R01EY028958 | search Support Total 93.632 93.632 rch, and Service Total 0-PRRC-03 93.325 6 Pilot Program Total 93.867 93.867 93.867 | - - - 225,189.00 - | 1,520,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,598.00 6,395.00 | 1,620,106.00 101,492.00 548,782.00 6650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro | University of Wyoming University of Cincinnati | Cleveland Clinic Foundation | 1004508-CHMC 011042-015 Developmental Disabili Paralysis T750388 | Trans-NH Re 90DD10042 90DDUC013 tites Education, Resea HHS-2019-ACL-AO Resource Center Stat R01EY0227077 R01EY022771 R01EY022768 R01EY022958 R01EY029427 | search Support Total 93.632 93.632 rch, and Service Total D-PRRC-03 93.325 te Pilot Program Total 93.867 93.867 93.867 93.867 | - - - 225,189.00 - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 165,582.00 428,522.00 165,508.00 6,395.00 17,440.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro | University of Wyoming University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California | 1004508-CHMC 011042-015 Developmental Disabili Paralysis T750388 | Trans-NH Re 90DD10042 90DDUC013 tites Education, Resea HHS-2019-ACL-AO Resource Center Stat R01EY0227077 R01EY022771 R01EY022768 R01EY022958 R01EY029427 | search Support Total 93.632 93.632 rch, and Service Total D-PRRC-03 93.325 te Pilot Program Total 93.867 93.867 93.867 93.867 | - - 225,189.00 - - 280.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 165,582.00 428,522.00 165,508.00 6,395.00 17,440.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro | University of Wyoming University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of California | 1004508-CHMC 011042-015 Developmental Disabili Paralysis T750388 012501-002 | Trans-NH Re 90DD10042 90DDUC013 tites Education, Resea HHS-2019-ACL-AO Resource Center Stat R01EY0227077 R01EY022771 R01EY022768 R01EY022958 R01EY029427 | search Support Total 93.632 93.632 rch, and Service Total D-PRRC-03 93.325 te Pilot Program Total 93.867 93.867 93.867 93.867 | - - - 225,188.00 - - - 280.00 164.00 56,702.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,385.00 17,440.00 245,278.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 165,582.00 428,522.00 165,508.00 6,395.00 17,440.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveitis onset in ch | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California | 1004506-CHMC 011042-015 I Developmental Disabili Paralysis T750388 012501-002 | Trans-NHR ec 90DD10042 90DD10013 Itles Education, Resear HHS-2019-ACL-AO Resource Center Stat R01EY027077 R01EY027711 R01EY027077 R01EY020521 | search Support Total 93.632 93.632 93.632 0-PRRC-03 93.825 10-PRC-03 93.867 93.867 93.867 93.867 93.867 93.867 | - - 225,189.00 - - - 280.00 164.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 428,522.00 165,508.00 6,395.00 17,440.00 336,115.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveits onset in ch | University of Wyoming University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of California | 1004508-CHMC 011042-015 Developmental Disabili Paralysis T750388 012501-002 | Trans-NH Re 90DD10042 90DD10013 Ities Education, Resear HHS-2019-ACL-AO Resource Center Stat R01EY027711 R01EY027711 R01EY029427 R01EY030521 | search Support Total 93.632 93.632 93.632 0-PRRC-03 93.325 te Pilot Program Total 93.867 93.867 93.867 93.867 93.867 | - 225,189.00 - - 280.00 164.00 56,702.00 33,691.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 - - 6,258.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveitis onset in ch | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of California | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NH Re 90DD10042 90DDUC013 title Education, Research HHS-2019-ACL-AO Roi-EV027077 R01EV027071 R01EV028958 R01EV029427 R01EV029427 R01EV029427 R01EV029427 R01EV029427 R01EV029427 | search Support Total 93.632 93.632 rch, and Service Total 0-PRRC-03 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 | - - - 225,188.00 - - - 280.00 164.00 56,702.00 | 1,520,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 245,278.00 - - 6,258.00 60,079.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveits onset in ch | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of California | 1004506-CHMC 011042-015 I Developmental Disabili Paralysis T750388 012501-002 | Trans-NH Re 90DD10042 90DD1004013 titles Education, Research HHS-2019-ACL-AO Rosever Center Stat R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY0234227 R01EY030521 | search Support Total 93.632 93.632 93.632 93.632 0-PRC-03 93.925 te Pilot Program Total 93.867 93.867 93.867 93.867 93.867 93.867 93.867 | - 225,189.00 - - 280.00 164.00 56,702.00 33,691.00 - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245.278.00 - - 6,258.00 60,079.00 95,803.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 428,522.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveitis onset in ch | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of California | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NH Re 90DD10042 90DD1004013 titles Education, Research HHS-2019-ACL-AO Rosever Center Stat R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY0234227 R01EY030521 | search Support Total 93.632 93.632 rch, and Service Total 0-PRRC-03 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 | - 225,189.00 - - 280.00 164.00 56,702.00 33,691.00 | 1,520,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 245,278.00 - - 6,258.00 60,079.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 |
| Paralysis Resource Center State Pilot Program Total | catior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveitis onset in ch | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of California | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NH Re 90DD10042 90DD1004013 titles Education, Research HHS-2019-ACL-AO Rosever Center Stat R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY0234227 R01EY030521 | search Support Total 93.632 93.632 93.632 93.632 0-PRC-03 93.925 te Pilot Program Total 93.867 93.867 93.867 93.867 93.867 93.867 93.867 | - 225,189.00 - - 280.00 164.00 56,702.00 33,691.00 - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245.278.00 - - 6,258.00 60,079.00 95,803.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 428,522.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research | Ication National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Clincinnati Wake Forest Univ School of Medicine | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NH Re 90DD10042 90DDUC0013 titles Education, Research HHS-2019-ACL-AO Ro1EY027077 R01EY027711 R01EY027721 R01EY027427 R01EY029427 R01EY029427 R01EY030521 R01EY030521 R01EY030521 R01EY032029 R42EY022545 R01HG010166 | search Support Total 93.632 93.632 93.632 93.632 93.632 0-PRC-03 93.867 93.87 | 225,189.00 - - 280.00 164.00 56,702.00 33,691.00 - - - - - - | 1,620,106.00 101,492.00 568,782.00 650,274.00 16,582.00 16,582.00 16,595.00 17,440.00 245,278.00 - - 6,258.00 60,079.00 95,803.00 800,094.00 596,616.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,116,120.00 598,616.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research | In the second se | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NH Re 90DD110042 90DD100013 titles Education, Research HHS.2019-ACL-AO Resource Center Stat R01EY027077 R01EY027711 R01EY02777 R01EY02792 R01EY02792 R01EY02792 R01EY030521 | search Support Total 93.632 93.632 93.632 93.632 0-PRC-03 93.857 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 | 225,189.00 - 280.00 164.00 56,702.00 33,691.00 - - 316,028.00 - 137,050.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 - - 6,258.00 60,079.00 95,803.00 800,034.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,116,120.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research | Icatior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveitis onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Clincinnati Wake Forest Univ School of Medicine | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NH Re 90DD110042 90DD10001013 titles Education, Research HHS-2019-ACL-AO Rosewarch Rosewarch R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY02707 R01EY0230521 R01EY031452 R01EY032029 R42EY022545 R01HG010166 | search Support Total 93.632 93.632 93.632 93.632 0-PRC-03 93.857 93.867 93.87 93.867 93.867 93.867 93.867 93.87 93.867 93.87 93.772 93.172 | 225,189.00 - - 280.00 164.00 56,702.00 33,691.00 - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 880,094.00 598,616.00 382,245.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 60,079.00 98,803.00 1,116,120.00 599,616.00 545,139.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research | Icatior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci Virus-driven human gene misreg Better Outcomes for Children: Promoting | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NH Re 90DD10042 90DD10043 title Education, Research HHS-2019-ACL-AO Ro1EY027077 R01EY027711 R01EY02777 R01EY02777 R01EY02792427 R01EY030521 R01EY031452 R01EY0302029 R42EY022545 R01HG010166 R01HG010730 U01HG000666 | search Support Total 93.632 93.632 93.632 93.632 93.632 0-PRC-03 93.325 te Pilot Program Total 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.72 | 225,189.00 - 280.00 164.00 56,702.00 33,691.00 - - 316,028.00 - 137,050.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 16,582.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 598,616.00 382,245.00 382,245.00 598,616.00 382,245.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,114,120.00 598,616.00 545,139.00 353,106.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research | Icatior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveitis onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NHR Re 90DD10042 90DD10043 1tlos Education, Research HHS-2019-ACL-AO R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY023029 R01EY031452 R01HG010160 U01HG000666 U01HG000666 U01HG001172 | search Support Total 93.632 93.632 93.632 93.632 93.632 10-PRC-030 93.325 10-PRC-030 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.72 93.72 | 225,189.00 280.00 164.00 56,702.00 33,691.00 - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 800,094.00 588,616.00 382,245.00 - 383,1076.00 483,197.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,562.00 16,562.00 428,522.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,116,120.00 596,616.00 545,139.00 353,106.00 483,197.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research | Icatior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci Virus-driven human gene misreg Better Outcomes for Children: Promoting | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NHR Re 90DD10042 90DD10043 1tlos Education, Research HHS-2019-ACL-AO R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY023029 R01EY031452 R01HG010160 U01HG000666 U01HG000666 U01HG001172 | search Support Total 93.632 93.632 93.632 93.632 93.632 0-PRC-03 93.325 te Pilot Program Total 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.72 | 225,189.00 - 280.00 164.00 56,702.00 33,691.00 - - 316,028.00 - 137,050.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 16,582.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 598,616.00 382,245.00 382,245.00 598,616.00 382,245.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,114,120.00 598,616.00 545,139.00 353,106.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research | Icatior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci Virus-driven human gene misreg Better Outcomes for Children: Promoting | University of Wyoming University of Cincinnati Emory University University of Cincinnati | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NHR Re 90DD10042 90DD10043 1tlos Education, Research HHS-2019-ACL-AO R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY023029 R01EY031452 R01HG010160 U01HG000666 U01HG000666 U01HG001172 | search Support Total 93.632 93.632 93.632 93.632 93.632 10-PRC-030 93.325 10-PRC-030 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.72 93.72 | 225,189.00 280.00 164.00 56,702.00 33,691.00 - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 800,094.00 588,616.00 382,245.00 - 383,1076.00 483,197.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,562.00 16,562.00 428,522.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,116,120.00 596,616.00 545,139.00 353,106.00 483,197.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Icatior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci Virus-driven human gene misreg Better Outcomes for Children: Promoting | University of Wyoming University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 | Trans-NHR Re 90DD10042 90DD10043 1tlos Education, Research HHS-2019-ACL-AO R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY023029 R01EY031452 R01HG010160 U01HG000666 U01HG000666 U01HG001172 | search Support Total 93.632 93.632 93.632 93.632 93.632 10-PRC-030 93.325 10-PRC-030 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.72 93.72 | 225,189.00 280.00 164.00 56,702.00 33,691.00 - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 800,094.00 588,616.00 382,245.00 - 383,1076.00 483,197.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,562.00 16,562.00 428,522.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,116,120.00 596,616.00 545,139.00 353,106.00 483,197.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research | Icatior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Theray of Corneal Dystro Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in decit Virus-driven human gene misreg Better Outcomes for Children: Promoting Polygenic Risk Scores for Heal | University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004508-CHMC 011042-015 Developmental Disabili 7750388 012501-002 013457-003 60078759 | Trans-NH Re 90DD10042 90DD10043 90DD10013 Itles Education, Research HHS-2019-ACL-AO R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY023029 R01EY031452 R01EY031452 R01EY031452 R01HG010166 R01HG010166 U01HG000666 U01HG000666 U01HG000666 U01HG000666 LU2TR001426 | search Support Total 93.632 93.632 93.632 93.632 93.632 10-PRC-030 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.72 93.75 | 225,189.00 280.00 164.00 56,702.00 33,691.00 - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 800,094.00 5580,616.00 382,245.00 - 383,1070.00 1,847,164.00 574,069.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,562.00 16,562.00 16,582.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,116,120.00 596,616.00 545,139.00 1,380,058.00 574,069.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Ication National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Comeal Dysto Predicting uveitis onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg Better Outcomes for Children: Promoting Polygenic Risk Scores for Heal Center for Clinical and Transl Disseminating Curative Biological | University of Wyoming University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 013457-003 60078759 KL2TR001426 U01TR001814 | Trans-NH Re 90DD110042 90DD1002013 titles Education, Research HHS-2019-ACL-AO R01EY027077 R01EY027771 R01EY02777 R01EY02777 R01EY02777 R01EY02777 R01EY02777 R01EY020277 R01EY031452 R01EY031452 R01HQ010166 R01HG010160 U01HG011172 Human Ge L021R001426 L01HQ01616 U01HQ016162 U01HQ016162 U01HQ016162 U01HQ016162 U01HQ016162 U01HQ016162 U01HQ016162 U01HQ016162 | search Support Total 93.632 93.632 93.632 93.632 93.632 0-PRC-03 93.325 to Pilot Program Total 93.867 93.87 93.72 93.72 93.350 93.350 | - 225,189.00 - 280.00 164.00 56,770.20 33,691.00 - - - 316,028.00 - - 137,050.00 25,844.00 - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,44.00 245,278.00 6,258.00 60,079.00 95,803.00 800,094.00 382,245.00 382,245.00 - 335,3108.00 18,317,164.00 574,069.00 124,424.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 16,588.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,603.00 1,116,120.00 598,616.00 545,139.00 353,106.00 1,980,058.00 574,069.00 124,424.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Ication National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dysto Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg Better Outcomes for Children: Promoting Polygenic Risk Scores for Heal Disseminating Curative Biological Precision Medicine in the Diag | University of Wyoming University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004506-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 013457-003 60078759 KL2TR001426 U01TR001814 5016131-SERV | Trans-NH Re 90DD10042 90DD1004013 Ities Education, Resear HHS-2019-ACL-AO Resource Center Stat R01EY027077 R01EY027077 R01EY027077 R01EY029427 R01EY030521 R01EY030521 R01EY030521 R01HG010160 R01HG0100 R01HG0100 R01HG0100 R01HG0100 R01HG0100 R01HG0100 R01HG0100 R01HG0100 R01HG0100 R01HG00 R01HG000 R01HG000 R01HG000 | search Support Total 93.632 93.632 93.632 93.632 93.632 0-PRC-03 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 1/sion Research Total 93.172 93.172 93.172 93.172 93.172 93.172 | 225,189.00 280.00 164.00 56,702.00 33,691.00 - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,0.079.00 66,0.079.00 66,0.079.00 95.803.00 880,094.00 588,616.00 382,245.00 - 353,106.00 483,197.00 1,817,164.00 574,069.00 124,424.00 81,256.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 336,115.00 6,258.00 60,079.00 95,808.00 1,116,120.00 598,616.00 545,139.00 483,197.00 483,197.00 1,980,058.00 574,069.00 574,069.00 124,424.00 81,256.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Institute Risk Scores for Children: Promoting Polygenic Risk Scores for Heal Precision Medicine in the Diag Instrumenting the Delivery Sys | University of Wyoming University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital University of Cincinnati | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 013457-003 60078759 KL2TR001426 U01TR001814 | Trans-NH Re 90DD10042 90DD10043 90DD10043 Hits-2019-ACL-AO R01EY027071 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY0200521 R01EY020427 R01EY030521 R01EY030521 R01EY030521 R01EY031452 R01HG010160 R01HG010160 R01HG010160 U01HG000666 U01HG000666 U01HG0011122 HUman Ge KL2TR001426 U01TR002471 U01TR002471 U01TR002471 | search Support Total 93.632 93.632 93.632 93.632 93.632 93.632 10-PRC-030 93.325 10-PRC-030 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.867 93.87 93.87 93.87 93.72 93.75 93.350 93.350 93.350 | 225,189.00 - - 280.00 164.00 56,702.00 33,691.00 - - - 316,028.00 - - 137,050.00 25,844.00 - - 137,050.00 25,844.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 382,245.00 333.108.00 483,197.00 1,817,164.00 574,069.00 124,424.00 81,256.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,562.00 16,562.00 16,582.00 428,522.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,603.00 17,116,120.00 598,616.00 598,616.00 598,616.00 594,5139.00 1,980,058.00 574,069.00 124,424.00 81,255.00 152,954.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Ication National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dysto Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg Better Outcomes for Children: Promoting Polygenic Risk Scores for Heal Disseminating Curative Biological Precision Medicine in the Diag | University of Wyoming University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital | 1004506-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 013457-003 60078759 KL2TR001426 U01TR001814 5016131-SERV | Trans-NH Re 90DD110042 90DD1002013 Itles Education, Research HHS-2019-ACL-AO R01EY027077 R01EY027771 R01EY02777 R01EY02777 R01EY02777 R01EY02777 R01EY02777 R01EY020277 R01EY020277 R01EY031452 R01EY031452 R01H0010160 U01H0001172 U01H0000666 U01H0001684 U01HR001884 U01HR00281 U02HR00281 | search Support Total 93.632 93.632 93.632 93.632 93.632 0-PRC-03 93.857 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 1/sion Research Total 93.172 93.172 93.172 93.172 93.172 93.172 93.172 93.172 93.350 | - 225,189.00 - 280.00 164.00 56,770.20 33,691.00 - - - 316,028.00 - - 137,050.00 25,844.00 - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,0.079.00 66,0.079.00 66,0.079.00 95.803.00 880,094.00 588,616.00 382,245.00 - 353,106.00 483,197.00 1,817,164.00 574,069.00 124,424.00 81,256.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 16,582.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 336,115.00 17,116,120.00 598,616.00 598,616.00 124,424.00 81,256.00 152,954.00 5,818.091.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Institute Risk Scores for Children: Promoting Polygenic Risk Scores for Heal Precision Medicine in the Diag Instrumenting the Delivery Sys | University of Wyoming University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital University of Cincinnati | 1004506-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 013457-003 60078759 KL2TR001426 U01TR001814 5016131-SERV | Trans-NH Re 90DD10042 90DD10043 90DD10043 Hits-2019-ACL-AO R01EY027071 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY027077 R01EY0200521 R01EY020427 R01EY030521 R01EY030521 R01EY030521 R01EY031452 R01HG010160 R01HG010160 R01HG010160 U01HG000666 U01HG000666 U01HG0011122 HUman Ge KL2TR001426 U01TR002471 U01TR002471 U01TR002471 | search Support Total 93.632 93.632 93.632 93.632 93.632 93.632 10-PRC-030 93.325 10-PRC-030 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.867 93.87 93.87 93.87 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.75 93.350 | 225,189.00 - - 280.00 164.00 56,702.00 33,691.00 - - - 316,028.00 - - 137,050.00 25,844.00 - - 137,050.00 25,844.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 382,245.00 333.108.00 483,197.00 1,817,164.00 574,069.00 124,424.00 81,256.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,562.00 16,562.00 16,582.00 428,522.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,603.00 17,116,120.00 598,616.00 598,616.00 598,616.00 594,5139.00 1,980,058.00 574,069.00 124,424.00 81,255.00 152,954.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Ication National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveitis onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg Better Outcomes for Children: Promoting Polygenic Risk Scores for Heal Center for Clinical and Transl Disseminating Curative Biological Precision Medicine in the Diag Instrumenting the Delivery Sys Data Management and Corotinal | University of Wyoming University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital University of Cincinnati | 1004506-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 013457-003 60078759 KL2TR001426 U01TR001814 5016131-SERV | Trans-NH Re 90DD110042 90DD1002013 Itles Education, Research HHS-2019-ACL-AO R01EY027077 R01EY027771 R01EY02777 R01EY02777 R01EY02777 R01EY02777 R01EY02777 R01EY020277 R01EY020277 R01EY031452 R01EY031452 R01H0010160 U01H0001172 U01H0000666 U01H0001684 U01HR001884 U01HR00281 U02HR00281 | search Support Total 93.632 93.632 93.632 93.632 93.632 10-PRC-03 93.867 93.850 93.35 | - 225,189.00 - - 280.00 164.00 56,702.00 33,691.00 - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 6,258.00 60,079.00 95,803.00 800,094.00 598,616.00 382,245.00 - 353,106.00 382,245.00 574,069.00 124,424.00 81,256.00 152,954.00 5,794,665.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 16,582.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 336,115.00 17,116,120.00 598,616.00 598,616.00 124,424.00 81,256.00 152,954.00 5,818.091.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Icatior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg Better Outcomes for Children: Promoting Polygenic Risk Scores for Heal Center for Clinical and Transl Disseminating Curative Biological Precision Medicine in the Diag Instrumenting the Delivery Sys Data Management and Coordinati Preclinical characterization o | University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital University of Cincinnati | 1004506-CHMC 011042-015 Developmental Disabili Paralysis 7750388 012501-002 013457-003 60078759 kL2TR001426 U01TR001814 S016131-SERV GENFD0001706578 | Trans-NH Re 90DD10042 90DD10043 90DD10043 HHS-2019-ACL-AO R01EY027071 R01EY027077 R01EY027077 R01EY027077 R01EY0290543 R01EY020427 R01EY020427 R01EY020427 R01EY030521 R01EY030521 R01EY031452 R01HG010166 R01HG010166 R01HG010166 R01HG010166 R01HG010162 L01HG000866 R01HG010162 L01HG0011122 Human Ge KL2TR001424 L01HG00241 U01TR00241 U01TR00241 U01TR00241 U01TR00241 U01TR00241 U03TR002612 | search Support Total 93.632 93.632 93.632 93.632 93.632 93.632 10-PRC-030 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.87 93.87 93.87 93.87 93.87 93.87 93.87 93.867 93.87 93.87 93.87 93.87 93.87 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.72 93.75 93.350 93.35 | - - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,440.00 245,278.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,562.00 16,562.00 16,582.00 428,522.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 336,115.00 17,440.00 353,106.00 483,197.00 1,286,0058.00 124,424.00 81,256.00 152,954.00 5,318,091.00 150,057.00 232,289.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Ication National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveitis onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg Better Outcomes for Children: Promoting Polygenic Risk Scores for Heal Center for Clinical and Transl Disseminating Curative Biological Precision Medicine in the Diag Instrumenting the Delivery Sys Data Management and Coordinati Preclinical characterization o Preclinical characterization o Continuing education for clini | University of Cincinnati Emory University University of Cincinnati University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital University of Cincinnati | 1004508-CHMC 011042-015 Developmental Disabili Paralysis 1750388 012501-002 013457-003 60078759 KL2TR001426 U01TR001814 5016131-SERV GENFD0001706578 | Trans-NHR Re SODDIU002 SODDIU001 Ites Education, Resear HHS-2019-ACL-AO Resource Center Star R01EY027771 R01EY027777 R01EY0277 R01EY0277 R01EY0277 R01EY0277 R01EY0277 R01EY027 | search Support Total 93.632 93.632 93.632 93.632 0-PRC-03 10-PRC-03 93.867 93.850 93.350 93. | - - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,44.00 245,278.00 6,258.00 60,079.00 995,803.00 800,094.00 598,616.00 382,245.00 - 353,106.00 382,245.00 574,069.00 124,424.00 81,256.00 132,643.00 57,40,68.00 132,643.00 57,794,665.00 132,643.00 232,289.00 232,289.00 23,538,827.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,118,120.00 598,616.00 548,139.00 1598,616.00 574,069.00 152,954.00 5,818,091.00 150,057.00 222,289.00 222,289.00 22,538,827.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Icatior National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveits onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg Better Outcomes for Children: Promoting Polygenic Risk Scores for Heal Center for Clinical and Transl Disseminating Curative Biological Precision Medicine in the Diag Instrumenting the Delivery Sys Data Management and Coordinati Preclinical characterization o | University of Cincinnati Emory University University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital University of Cincinnati | 1004508-CHMC 011042-015 Pevelopmental Disabili T750388 012501-002 013457-003 60078759 KL2TR001426 U01TR001814 5016131-SERV GENFD0001706578 | Trans-NH Re SODD10042 SODD10042 SODD1004013 Ities Education, Research Resource Center Stat Ro1EY027077 Ro1EY0277 Ro1EY0277 Ro1EY0277 Ro1EY0277 RO1EY0277 RO1EY0277 RO1EY0277 RO1EY0277 RO1EY027 | search Support Total 93.632 93.632 93.632 93.632 0-PRC-03 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.867 93.87 93.87 93.87 93.87 93.87 93.867 93.850 93.350 93. | - - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 659,274.00 16,582.00 16,582.00 16,550,274.00 203,333.00 165,508.00 6,395.00 17,744.0.00 245,278.00 6,258.00 60,079.00 95,803.00 800,0784.00 598,616.00 382,245.00 132,642.00 18,177,164.00 124,424.00 81,226.00 15,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 152,954.00 5,744,665.00 132,643.00 222,289.00 222,289.00 222,289.00 24,1957.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 98,603.00 1,116,120.00 598,616.00 546,139.00 1,980,058.00 124,424.00 81,256.00 152,954.00 152,954.00 152,954.00 153,057.00 232,289.00 41,957.00 2,538,827.00 41,957.00 |
| Paralysis Resource Center State Pilot Program Total Vision Research Human Genome Research | Ication National Training AUCD SCOPE UC University Centers for Excellen Ohio SILC UCCEDD Disaster Prep Regulation of vascular development in Regulation of eye development by Molecular Mechanism of Biallel Gene Therapy of Corneal Dystro Predicting uveitis onset in ch RNA Nanoparticles for Ocular D Light regulated vascular devel Newborn Infant Vision Test Engaging adolescents in deci: Virus-driven human gene misreg Better Outcomes for Children: Promoting Polygenic Risk Scores for Heal Center for Clinical and Transl Disseminating Curative Biological Precision Medicine in the Diag Instrumenting the Delivery Sys Data Management and Coordinati Preclinical characterization o Preclinical characterization o Continuing education for clini | University of Cincinnati Emory University University of Cincinnati University of Cincinnati University of Cincinnati Ohio State University | Cleveland Clinic Foundation Children's Hospital of Philadelphia University of California University of Cincinnati Wake Forest Univ School of Medicine Brigham and Women's Hospital University of Cincinnati | 1004508-CHMC 011042-015 Pevelopmental Disabili T750388 012501-002 013457-003 60078759 KL2TR001426 U01TR001814 5016131-SERV GENFD0001706578 | Trans-NH Re SODD10042 SODD10042 SODD1004013 Ities Education, Research Resource Center Stat Ro1EY027077 Ro1EY0277 Ro1EY0277 Ro1EY0277 Ro1EY0277 RO1EY0277 RO1EY0277 RO1EY0277 RO1EY0277 RO1EY027 | search Support Total 93.632 93.632 93.632 93.632 0-PRC-03 10-PRC-03 93.867 93.850 93.350 93. | - - - - - - - - - - - - - - - - - - - | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 203,333.00 165,508.00 6,395.00 17,44.00 245,278.00 6,258.00 60,079.00 995,803.00 800,094.00 598,616.00 382,245.00 - 353,106.00 382,245.00 574,069.00 124,424.00 81,256.00 132,643.00 57,40,68.00 132,643.00 57,794,665.00 132,643.00 232,289.00 232,289.00 23,538,827.00 | 1,620,106.00 101,492.00 548,782.00 650,274.00 16,582.00 16,582.00 16,582.00 165,508.00 6,395.00 17,440.00 336,115.00 6,258.00 60,079.00 95,803.00 1,118,120.00 598,616.00 548,139.00 1598,616.00 574,069.00 152,954.00 5,818,091.00 150,057.00 222,289.00 222,289.00 22,538,827.00 |

| | Occupational Safety and Health Program | Education and Research Center | University of Cincinnati | | 010412-094 | T42OH008432 Occupational Safety and Healt | 93.262 | - | 13,379.00 13,379.00 | 13,379.00 13,379.00 |
|--------------------------------|---|--|--|--|--------------------------|--|----------------------------|------------------------|------------------------|------------------------|
| | | | | | | Occupational Salety and Heal | ii Fiogram Totai | - | 13,379.00 | 13,379.00 |
| | Preventive Health and Health Services Block Grants | Child Injury Grant Program | Stark County (ODH) | | 07610014IC0220 | 07610014IC0220 | 93.991 | - | 2,720.00 | 2,720.00 |
| | | | | | | Occupational Safety and Healt | h Program Total | - | 2,720.00 | 2,720.00 |
| | | | | | | | | | | |
| | Research and Training in Complementary and Alternative Medicine | Using fMRI to understand response | | | | K23AT009458 | 93.213 | - | 72.00 658,467.00 | 72.00 658,467.00 |
| | | Dissecting Neural Mechanisms S Systems biology of microbe-med | University of Virginia | | R01AT010253 | R01AT010171 R01AT010253 | 93.213 93.213 | - | 50,817.00 | 50,817.00 |
| | | Mind Body Balance for Pediatr | Onversity of Virginia | University of Colorado | 10141010255 | U01AT010132 | 93.213 | 51,875.00 | 595,400.00 | 689,120.00 |
| | | | | University of Virginia | | | | 41,845.00 | | |
| | | | | Re | search and Training in | Complementary and Alternativ | e Medicine Total | 93,720.00 | 1,304,756.00 | 1,398,476.00 |
| | Health Program for Toxic Substances and Disease Registry | Pediatric Environmental Health | Univ of Illinois @ Chicago | | 17852-00 | NU61TS000296 | 93.161 | | 47,831.00 | 47,831.00 |
| | | | onno or miniolo @ onnougo | | | or Toxic Substances and Disea | | - | 47,831.00 | 47,831.00 |
| | | | | | | | | | | |
| | Healthy Start Initiative | HRSA Cradle Cincinnati | | University of Cincinnati | | H49MC27823 | 93.926 | 116,240.00 | 1,157,601.00 | 1,273,841.00 |
| | | | | | | Healthy Sta | rt Initiative Total | 116,240.00 | 1,157,601.00 | 1,273,841.00 |
| | Affordable Care Act (ACA) Family to Family Health Information Centers | Obio Family to Family Health I | | | | H84MC28443 | 93.504 | | 102,784.00 | 102,784.00 |
| | And dable care Act (ACA) Fairing to Fairing Health Information Centers | Onio Family to Family Fleature | | Afforda | able Care Act (ACA) Fa | mily to Family Health Information | | | 102,784.00 | 102,784.00 |
| | | | | | | inity to runny riouter mornate | | | 102,104.00 | 102,104.00 |
| | Rare Disorders: Research, Surveillance, Health Promotion, and Educati | iorlWoodward CDC NSBPR Registry 20 | | | | U01DD001279 | 93.315 | | 85,181.00 | 85,181.00 |
| | | | | Rare Disc | orders: Research, Surv | eillance, Health Promotion, and | Education Total | - | 85,181.00 | 85,181.00 |
| | | | | | | | | | | |
| | Blood Disorder Program: Prevention, Surveillance and Research | Community Counts: Public Health Surv | Hemophilia Foundation of Michigan | | U27DD001155 | U27DD001155 m: Prevention, Surveillance and | 93.080 | | 26,126.00 26,126.00 | 26,126.00 26,126.00 |
| | | | | | Blood Disorder Progra | m: Prevention, Surveillance and | Research Total | - | 26,126.00 | 26,126.00 |
| | Minority Health and Health Disparities Research | Linking pre- and post-natal psychosocial | | | | R01MD013006 | 93.307 | - | 572,413.00 | 572,413.00 |
| | | | | | Minori | ity Health and Health Disparities | Research Total | - | 572,413.00 | 572,413.00 |
| | | | | | | | | | | |
| | Birth Defects and Developmental Disabilities - Prevention and Surveillar | nceeyond EHDI Benchmarks in Earl | University of South Carolina | | 20-3973 | U19DD001218 | 93.073 | - | 116,648.00 | 116,648.00 |
| | | | | Birth Defe | ects and Developmenta | I Disabilities - Prevention and S | urveillance Total | - | 116,648.00 | 116,648.00 |
| | Developmental Disabilities Projects of National Significance | Center for Dignity in Healthca | | AADMD | | 90DNHC0001 | 93.631 | 86,721.00 | 178,516.00 | 478,656.00 |
| | | | | Autistic Self Advocacy Network Ind | c | | | 25,000.00 | | |
| | | | | Family Voices Inc | | | | 25,000.00 | | |
| | | | | Kennedy Krieger Institute, Inc. | | | | 19,988.00 | | |
| | | | | Rutgers, The State University | | | | 12,466.00 | | |
| | | | | University of Kentucky Vanderbilt University Medical Cent | ter | | | 99,507.00 31,458.00 | | |
| | | | | , | | sabilities Projects of National S | ignificance Total | 300,140.00 | 178,516.00 | 478,656.00 |
| | | | | | | | | | | |
| | National Research Service Awards_Health Services Research Training | PEDSnet Application | Children's Hospital of Philadelphia | | 3201350920 | K12HS026393 | 93.225 | - | 140,870.00 | 140,870.00 |
| | | | | Nation | nal Research Service A | wards_Health Services Resear | ch Training Total | - | 140,870.00 | 140,870.00 |
| | ACL National Institute on Disability, Independent Living, and Rehabilitat | in Enhancing Parenting Skills: Application | University of Oregon | | 239530A | 90DPHF0003-01-00 | 93.433 | - | 83,045.00 | 83,045.00 |
| | recentational manade on blocking, meepondont ching, and remainde | Gaining Real-life skills Over the Web | children of chegon | | 2000001 | 90IFDV0003-02-00 | 93.433 | | 94,160.00 | 94,160.00 |
| | | | | ACL National Institut | te on Disability, Indepe | ndent Living, and Rehabilitatio | n Research Total | - | 177,205.00 | 177,205.00 |
| | | | | | | | | | | |
| | Public Health Emergency Preparedness | Poison Center Bioterrorism Pre | Nationwide Children's Hospital | | 720441-0620-00 | ODH Prime Contract 342 | | - | 6,086.00 | 6,086.00 |
| | | | | | | Public Health Emergency Pre | paredness Total | - | 6,086.00 | 6,086.00 |
| | Environmental Public Health and Emergency Response | Asthma In Home | Ohio Department of Health | | | 43960 NUE1EH001385 | 93.070 | - | 35,500.00 | 35,500.00 |
| | ÷ · · | | | | Environmenta | al Public Health and Emergency | | - | 35,500.00 | 35,500.00 |
| | | | | | | | | | | |
| | Maternal & Child Health Services Block Grants | Asthma in Home | Ohio Department of Health | | | 41534 B04MC325640101 | 93.994 | - | 24,900.00 | 24,900.00 |
| | | | | | Maternal and Child | Health Services Block Grant to | the States Total | - | 24,900.00 | 24,900.00 |
| | Family Smoking Prevention and Tobacco Control Act Regulatory Resea | arcDistinguishing Exposure to Sec. | University of Cincinnati | | 013228-003 | R21ES032161 | 93.077 | - | 36.738.00 | 36.738.00 |
| | ranny choling revenuer and readers contervertegatory reader | | children of childranda | Family Sm | | Tobacco Control Act Regulator | | - | 36,738.00 | 36,738.00 |
| | | | | | | | | | • | - |
| | | | | | | Dept of Health and H | uman Serv Total | 17,439,776.00 | 161,570,901.00 | 179,010,677.00 |
| Dest of Henrice 1111 5 | Harthy Hames Taskelad Obvilas C | Data of excession data in the state | University of Obselves 11 | | 011100 | OHHHU0037-17 | 4,000 | | 04 000 00 | |
| Dept of Housing and Urban Dev | Healthy Homes Technical Studies Grants | Role of measured and observed | University of Cincinnati | | 011199 | OHHHU0037-17 Healthy Homes Technical Stud | 14.906 | - | 24,269.00 24,269.00 | 24,269.00 24,269.00 |
| | | | | | | | illo Granto I Utal | - | 27,203.00 | 27,203.00 |
| | Lead Technical Studies Grants | Analysis of Benefits of Abatem | National Center for Healthy Housing, Inc | | MDLTS000818 HL | JD_NCFMDLTS0008-18 | 14.902 | - | 29,984.00 | 29,984.00 |
| | | | | | | - Lead Technical Stud | | - | 29,984.00 | 29,984.00 |
| | | | | | | | | | | |
| | | | | | | Dept of Housing and | Urban Dev Total | - | 54,253.00 | 54,253.00 |
| Office of Personnel Management | | IPA Chepelev for Kaufman VA Me | | | | IPA Chepelev | 27.011 | _ | 27,015.00 | 27,015.00 |
| Since or reasoning management | Intergovernmental Personnel Act (IDA) Mobility Program | | | | | | | - | 21,010.00 | 21,010.00 |
| | Intergovernmental Personnel Act (IPA) Mobility Program | Role of a common leptin recept | | | | IPA Filippi | 27.011 | | 5,259.00 | 5,259.00 |
| | Intergovernmental Personnel Act (IPA) Mobility Program | • | | | | | | - | 5,259.00 28,307.00 | 5,259.00 28,307.00 |
| | Intergovernmental Personnel Act (IPA) Mobility Program | Role of a common leptin recept VA IPA - Yongbo Huang Richards VA Merit Kaufman | | | | IPA Filippi IPA Huang IPA Richards | 27.011 27.011 27.011 | - - | 28,307.00 54,803.00 | 28,307.00 54,803.00 |
| | Intergovernmental Personnel Act (IPA) Mobility Program | Role of a common leptin recept VA IPA - Yongbo Huang | | | | IPA Filippi IPA Huang | 27.011 27.011 | - - - | 28,307.00 | 28,307.00 |

| | | Tripathi VA Merit Kaufman | | | | IPA Tripathi | 27.011 | - | 72,463.00 | 72,463.00 |
|--------------------------------|--|---|--|-----------------------------------|----------------------|--|------------------|--------------------|--------------------|------------------------|
| | | Mechanisms of liver failure | | | | IPA Verma | 27.011 | - | 14,838.00 | 14,838.00 |
| | | | | | Intergovernmen | tal Personnel Act (IPA) Mobility Pro | ogram Total | - | 272,732.00 | 272,732.00 |
| | | | | | | Office of Personnel Manage | ement Total | - | 272,732.00 | 272,732.00 |
| | | | | | | Research and Developn | nent Total \$ | 17,545,822.00 \$ | 166,891,989.00 \$ | 184,437,811.00 |
| | | | | | | | | | | |
| | Medical Assistance Program | Pediatric Behavioral Health In Ohio Perinatal Quality Collabo | Ohio State University Ohio State University | Aultman Hospital | 60065930 60072430 | G-2021-05-0069 ODM202014 G-2021-05-0069:ODM202004 | 93.778 93.778 | - 971.00 | 43,935.00 | 43,935.00 35.572.00 |
| | | Onio Perinatai Quality Collabo | Onio State University | Case Western Reserve University | 60072430 | G-2021-05-0069:0DM202004 | 93.778 | 6,505.00 | - | 35,572.00 |
| | | | | Children's Hospital of Akron | | | | 2,807.00 | - | |
| | | | | Miami Valley Hospital | | | | 13,219.00 | | |
| | | | | Ohio State University | | | | 8,812.00 | | |
| | | | | University Hospitals of Cleveland | | | | 3,258.00 | | |
| | | Ohio Perinatal Quality Collabo | Ohio State University | Case Western Reserve University | 60071989 | G-2021-05-0069:ODM202010 | 93.778 | 3,245.00 | - | 13,800.00 |
| | | | | Miami Valley Hospital | | | | 9,997.00 | - | |
| | | | | University Hospitals of Cleveland | | | | 558.00 | - | |
| | | Ohio Smoke Free Families Pedia | American Academy of Pediatrics | | Carle AAP | G-2021-05-0069 | 93.778 | - | 20,400.00 | 20,400.00 |
| | | | | | Medical Ass | sistance Program/Medicaid Clu | ster Total | 49,372.00 | 64,335.00 | 113,707.00 |
| | Strengthening Public Health Sys & Svcs thru Natl Partnerships to Impro | vi Support for Early Childhood St | Assoc of Univ Center on Disabilities | | 05-21-8815 | NU38OT000280-02-02 | 93.421 | - | 41,671.00 | 41,671.00 |
| | | COVID-19 - Addressing COVID-19 vaccin | e ac Assoc of Univ Center on Disabilities | | 05-21-8815 | NU38OT000280-03-05 | 93.421 | - | 4,180.00 | 4,180.00 |
| | | COVID-19-Provider Relief Fund And American Rescue Plan (ARP) Distribution | | | | COVID-19 | 93.498 | | 42,403,258.00 | 42,403,258.00 |
| Fed Communications Commission | | COVID-19 - FCC Cares Act Telehealth Av | ward | | | COVID-19 COVID-19 | 32.006 | - | 715,854.00 | 715,854.00 |
| r eu communications commission | | State Opioid Response | ward | | | MHRSB Hamilton County | 93.788 | - | 153,813.00 | 153,813.00 |
| | | Drug and Poison Control | | | | MHRSB Hamilton County | 93.959 | - | 271,883.00 | 271,883.00 |
| | | | | | | | | | | |
| | | | | | | Grand Total all Funds | \$ | 17,595,194.00 \$ 2 | 10,546,983.00 \$ 2 | 228,142,177.00 |

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2021

1. SCOPE OF AUDIT

All federal grant operations of Cincinnati Children's are included in the scope of Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance).* Single audits under the Uniform Guidance are performed in accordance with the provisions of the Office of Management and Budget (OMB)'s Compliance Supplement for Single Audits of Higher Learning Institutions and other Non-Profit Institutions (the "Compliance Supplement"). The Department of Health and Human Services has been designated as Cincinnati Children's cognizant agency for the Single audit.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation — The accompanying Supplemental Schedule of Expenditures of Federal Awards (the "Schedule") includes the federal grant activity of Cincinnati Children's under programs of the federal government for the year ended June 30, 2021 and is presented on the accrual basis of accounting. This is consistent with the basis of accounting used in the preparation of the basic consolidated financial statements. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Guidance*. Because the Schedule presents only a selected portion of the operations of Cincinnati Children's, it is not intended to and does not present the financial position, changes in net assets or cash flows of Cincinnati Children's. Cincinnati Children's did not elect to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

Net Asset Balances — Negative amounts represent grants with deficit balances which were closed during fiscal 2021.

3. DONATED PERSONAL PROTECTIVE EQUIPMENT (UNAUDITED)

Cincinnati Children's received no donated personal protective equipment from the federal government during the year ended June 30, 2021.

4. PROVIDER RELIEF FUND TAX IDENTIFCATION NUMBER

Cincinnati Children's received COVID-19 Provider Relief funds under the 31-0833936 tax identification number only.



Deloitte & Touche LLP 50 W 5th Street Suite 200 Cincinnati, OH 45202-3789 USA

Tel: +513 784 7100 Fax: +513 784 7204 www.deloitte.com

REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS*

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees of Children's Hospital Medical Center and Affiliates Cincinnati, Ohio

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated balance sheet as of June 30, 2021, and the related consolidated statements of operations and changes in net assets and of cash flows for the year then ended, and the related notes to the consolidated financial statements which collectively comprise Children's Hospital Medical Center and Affiliates ("Cincinnati Children's") consolidated financial statements and have issued our report thereon dated September 30, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered Cincinnati Children's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of Cincinnati Children's internal control. Accordingly, we do not express an opinion on the effectiveness of Cincinnati Children's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Cincinnati Children's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results

of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Cincinnati Children's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Cincinnati Children's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte ? Touche LLP

September 30, 2021



Deloitte & Touche LLP 50 W 5th Street Suite 200 Cincinnati, OH 45202-3789 USA

Tel: +513 784 7100 Fax: +513 784 7204 www.deloitte.com

REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON THE SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE

INDEPENDENT AUDITORS' REPORT

To the Board of Trustees Children's Hospital Medical Center and Affiliates Cincinnati, Ohio

Report on Compliance for Each Major Federal Program

We have audited Children's Hospital Medical Center and Affiliates ("Cincinnati Children's") compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of Cincinnati Children's major federal programs for the year ended June 30, 2021. Cincinnati Children's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of Cincinnati Children's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principals, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Cincinnati Children's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Cincinnati Children's compliance.

Opinion on Each Major Federal Program

In our opinion, Cincinnati Children's complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2021.

Report on Internal Control Over Compliance

Management of Cincinnati Children's is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our

audit of compliance, we considered Cincinnati Children's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Cincinnati Children's internal control over compliance.

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the consolidated financial statements of Cincinnati Children's as of and for the year ended June 30, 2021, and have issued our report thereon dated September 30, 2021, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditure of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

Deloitte > Touche LLP

June 17, 2022

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2021

PART I. SUMMARY OF AUDITOR'S RESULTS

Financial Statements:

| Type of auditor's report issued: | Unmodified | |
|--|------------|----------------------|
| Internal control over financial reporting: | | |
| Material weakness(es) identified? | Yes | <u> X </u> No |
| Significant deficiency(ies) identified? | Yes | None X reported |
| Noncompliance material to financial statements noted? | Yes | <u> </u> |
| Federal Awards: | | |
| Internal control over major programs: | | |
| Material weakness(es) identified? | Yes | <u> </u> |
| Significant deficiency(ies) identified? | | N |
| | Yes | None X reported |
| Type of auditor's report issued on compliance for major programs: | Unmodified | |
| Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? | Yes | <u>X</u> No |

Identification of Major Programs:

| CFDA Number | Name of Federal Program or Cluster | | |
|-------------|---|--|--|
| Various | Research and Development* | | |
| 93.498 | COVID-19-Provider Relief Fund And American Rescue Plan (ARP) Distribution | | |

* Cincinnati Children's has determined that its entire research and development program inclusive of all research and development grant activity should be considered clustered and as such, constitutes one major program.

| Dollar threshold used to distinguish between Type A and Type B programs? | \$ 3,000,000 |
|--|-----------------|
| Research and Development program tested as a single Type A program | |

Auditee qualified as low-risk auditee?

| Х | Yes | No |
|---|-----|-------|
| | - | _ |

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2021

PART II. FINDINGS RELATED TO THE FINANCIAL STATEMENTS

None

PART III. FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

None